<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>ES2966466T3 - 
  Small cell lung cancer (SCLC) therapy with a topoisomerase-I inhibitor antibody-drug conjugate (ADC) targeting trop-2
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/ES2966466T3/en">
    <meta name="description" content="
   
    The present invention relates to the treatment of SCLC with therapeutic ADCs comprising a drug linked to an anti-Trop-2 antibody or an antigen-binding antibody fragment. Preferably, the drug is SN-38. More preferably, the antibody is an hRS7 antibody and the ADC is sacituzumab govitecan. The ADC may be administered at a dose of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12 or 16 mg/kg, most preferably 8 to 10 mg/kg. When given at specific doses and schedules, ADC can shrink solid tumors, reduce or eliminate metastases, and is effective in treating cancers resistant to standard therapies, such as radiotherapy, chemotherapy, or immunotherapy. Surprisingly, ADC is effective in treating cancers that are refractory or relapse after irinotecan or topotecan. Preferably, the ADC is administered as a combination therapy with one or more anticancer treatments, such as carboplatin or cisplatin. (Automatic translation with Google Translate, without legal value)
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Small cell lung cancer (SCLC) therapy with a topoisomerase-I inhibitor antibody-drug conjugate (ADC) targeting trop-2
 
     ">
    <meta name="DC.date" content="2018-02-21" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    The present invention relates to the treatment of SCLC with therapeutic ADCs comprising a drug linked to an anti-Trop-2 antibody or an antigen-binding antibody fragment. Preferably, the drug is SN-38. More preferably, the antibody is an hRS7 antibody and the ADC is sacituzumab govitecan. The ADC may be administered at a dose of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12 or 16 mg/kg, most preferably 8 to 10 mg/kg. When given at specific doses and schedules, ADC can shrink solid tumors, reduce or eliminate metastases, and is effective in treating cancers resistant to standard therapies, such as radiotherapy, chemotherapy, or immunotherapy. Surprisingly, ADC is effective in treating cancers that are refractory or relapse after irinotecan or topotecan. Preferably, the ADC is administered as a combination therapy with one or more anticancer treatments, such as carboplatin or cisplatin. (Automatic translation with Google Translate, without legal value)
   
 
   ">
    <meta name="citation_patent_application_number" content="ES:18758120T">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/0a/00/4e/9b4860414bfab1/ES2966466T3.pdf">
    <meta name="citation_patent_number" content="ES:2966466:T3">
    <meta name="DC.date" content="2024-04-22" scheme="issue">
    <meta name="DC.contributor" content="David M Goldenberg" scheme="inventor">
    <meta name="DC.contributor" content="Serengulam V Govindan" scheme="inventor">
    <meta name="DC.contributor" content="Immunomedics Inc" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Small cell lung cancer (SCLC) therapy with a topoisomerase-I inhibitor antibody-drug conjugate (ADC) targeting trop-2
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA671463630" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La presente invención se refiere al tratamiento de SCLC con ADC terapéuticos que comprenden un fármaco unido a un anticuerpo anti-Trop-2 o un fragmento de anticuerpo de unión a antígeno. Preferiblemente, el fármaco es SN-38. Más preferiblemente, el anticuerpo es un anticuerpo hRS7 y el ADC es sacituzumab govitecan. El ADC se puede administrar en una dosis de entre 4 mg/kg y 16 mg/kg, preferiblemente 4, 6, 8, 9, 10, 12 o 16 mg/kg, lo más preferiblemente de 8 a 10 mg/kg. Cuando se administra en dosis y horarios específicos, el ADC puede reducir el tamaño de los tumores sólidos, reducir o eliminar las metástasis y es eficaz para tratar cánceres resistentes a las terapias estándar, como la radioterapia, la quimioterapia o la inmunoterapia. Sorprendentemente, el ADC es eficaz para tratar cánceres refractarios o que recaen tras el irinotecán o el topotecán. Preferiblemente, el ADC se administra como una terapia combinada con uno o más tratamientos anticancerígenos, tales como carboplatino o cisplatino.  (Traducción automática con Google Translate, sin valor legal)</span>The present invention relates to the treatment of SCLC with therapeutic ADCs comprising a drug linked to an anti-Trop-2 antibody or an antigen-binding antibody fragment. Preferably, the drug is SN-38. More preferably, the antibody is an hRS7 antibody and the ADC is sacituzumab govitecan. The ADC may be administered at a dose of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12 or 16 mg/kg, most preferably 8 to 10 mg/kg. When given at specific doses and schedules, ADC can shrink solid tumors, reduce or eliminate metastases, and is effective in treating cancers resistant to standard therapies, such as radiotherapy, chemotherapy, or immunotherapy. Surprisingly, ADC is effective in treating cancers that are refractory or relapse after irinotecan or topotecan. Preferably, the ADC is administered as a combination therapy with one or more anticancer treatments, such as carboplatin or cisplatin. (Automatic translation with Google Translate, without legal value)</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07"><a id="link" href="#" class="style-scope state-modifier">C07</a></state-modifier>
                  <span class="description style-scope classification-tree">ORGANIC CHEMISTRY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K"><a id="link" href="#" class="style-scope state-modifier">C07K</a></state-modifier>
                  <span class="description style-scope classification-tree">PEPTIDES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/00"><a id="link" href="#" class="style-scope state-modifier">C07K16/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/18"><a id="link" href="#" class="style-scope state-modifier">C07K16/18</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C07K16/28"><a id="link" href="#" class="style-scope state-modifier">C07K16/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="C07K16/30"><a id="link" href="#" class="style-scope state-modifier">C07K16/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/13"><a id="link" href="#" class="style-scope state-modifier">A61K31/13</a></state-modifier>
                  <span class="description style-scope classification-tree">Amines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/135"><a id="link" href="#" class="style-scope state-modifier">A61K31/135</a></state-modifier>
                  <span class="description style-scope classification-tree">Amines having aromatic rings, e.g. ketamine, nortriptyline</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/137"><a id="link" href="#" class="style-scope state-modifier">A61K31/137</a></state-modifier>
                  <span class="description style-scope classification-tree">Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/185"><a id="link" href="#" class="style-scope state-modifier">A61K31/185</a></state-modifier>
                  <span class="description style-scope classification-tree">Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or&nbsp;hydroximic acids</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/19"><a id="link" href="#" class="style-scope state-modifier">A61K31/19</a></state-modifier>
                  <span class="description style-scope classification-tree">Carboxylic acids, e.g. valproic acid</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/195"><a id="link" href="#" class="style-scope state-modifier">A61K31/195</a></state-modifier>
                  <span class="description style-scope classification-tree">Carboxylic acids, e.g. valproic acid having an amino group</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/197"><a id="link" href="#" class="style-scope state-modifier">A61K31/197</a></state-modifier>
                  <span class="description style-scope classification-tree">Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/198"><a id="link" href="#" class="style-scope state-modifier">A61K31/198</a></state-modifier>
                  <span class="description style-scope classification-tree">Alpha-amino acids, e.g. alanine or edetic acid [EDTA]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/21"><a id="link" href="#" class="style-scope state-modifier">A61K31/21</a></state-modifier>
                  <span class="description style-scope classification-tree">Esters, e.g. nitroglycerine, selenocyanates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/255"><a id="link" href="#" class="style-scope state-modifier">A61K31/255</a></state-modifier>
                  <span class="description style-scope classification-tree">Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/40"><a id="link" href="#" class="style-scope state-modifier">A61K31/40</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/407"><a id="link" href="#" class="style-scope state-modifier">A61K31/407</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/41"><a id="link" href="#" class="style-scope state-modifier">A61K31/41</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/4164"><a id="link" href="#" class="style-scope state-modifier">A61K31/4164</a></state-modifier>
                  <span class="description style-scope classification-tree">1,3-Diazoles</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/4184"><a id="link" href="#" class="style-scope state-modifier">A61K31/4184</a></state-modifier>
                  <span class="description style-scope classification-tree">1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/435"><a id="link" href="#" class="style-scope state-modifier">A61K31/435</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/44"><a id="link" href="#" class="style-scope state-modifier">A61K31/44</a></state-modifier>
                  <span class="description style-scope classification-tree">Non condensed pyridines; Hydrogenated derivatives thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/445"><a id="link" href="#" class="style-scope state-modifier">A61K31/445</a></state-modifier>
                  <span class="description style-scope classification-tree">Non condensed piperidines, e.g. piperocaine</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/4523"><a id="link" href="#" class="style-scope state-modifier">A61K31/4523</a></state-modifier>
                  <span class="description style-scope classification-tree">Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/4535"><a id="link" href="#" class="style-scope state-modifier">A61K31/4535</a></state-modifier>
                  <span class="description style-scope classification-tree">Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/495"><a id="link" href="#" class="style-scope state-modifier">A61K31/495</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/505"><a id="link" href="#" class="style-scope state-modifier">A61K31/505</a></state-modifier>
                  <span class="description style-scope classification-tree">Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/513"><a id="link" href="#" class="style-scope state-modifier">A61K31/513</a></state-modifier>
                  <span class="description style-scope classification-tree">Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/395"><a id="link" href="#" class="style-scope state-modifier">A61K31/395</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/495"><a id="link" href="#" class="style-scope state-modifier">A61K31/495</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/505"><a id="link" href="#" class="style-scope state-modifier">A61K31/505</a></state-modifier>
                  <span class="description style-scope classification-tree">Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/517"><a id="link" href="#" class="style-scope state-modifier">A61K31/517</a></state-modifier>
                  <span class="description style-scope classification-tree">Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/33"><a id="link" href="#" class="style-scope state-modifier">A61K31/33</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/555"><a id="link" href="#" class="style-scope state-modifier">A61K31/555</a></state-modifier>
                  <span class="description style-scope classification-tree">Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/00"><a id="link" href="#" class="style-scope state-modifier">A61K31/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing organic active ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/70"><a id="link" href="#" class="style-scope state-modifier">A61K31/70</a></state-modifier>
                  <span class="description style-scope classification-tree">Carbohydrates; Sugars; Derivatives thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/7042"><a id="link" href="#" class="style-scope state-modifier">A61K31/7042</a></state-modifier>
                  <span class="description style-scope classification-tree">Compounds having saccharide radicals and heterocyclic rings</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/7052"><a id="link" href="#" class="style-scope state-modifier">A61K31/7052</a></state-modifier>
                  <span class="description style-scope classification-tree">Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/706"><a id="link" href="#" class="style-scope state-modifier">A61K31/706</a></state-modifier>
                  <span class="description style-scope classification-tree">Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/7064"><a id="link" href="#" class="style-scope state-modifier">A61K31/7064</a></state-modifier>
                  <span class="description style-scope classification-tree">Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K31/7068"><a id="link" href="#" class="style-scope state-modifier">A61K31/7068</a></state-modifier>
                  <span class="description style-scope classification-tree">Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6801"><a id="link" href="#" class="style-scope state-modifier">A61K47/6801</a></state-modifier>
                  <span class="description style-scope classification-tree">Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6803"><a id="link" href="#" class="style-scope state-modifier">A61K47/6803</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/00"><a id="link" href="#" class="style-scope state-modifier">A61K47/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/50"><a id="link" href="#" class="style-scope state-modifier">A61K47/50</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/51"><a id="link" href="#" class="style-scope state-modifier">A61K47/51</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/68"><a id="link" href="#" class="style-scope state-modifier">A61K47/68</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6835"><a id="link" href="#" class="style-scope state-modifier">A61K47/6835</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6851"><a id="link" href="#" class="style-scope state-modifier">A61K47/6851</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K47/6857"><a id="link" href="#" class="style-scope state-modifier">A61K47/6857</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 13 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">ES2966466T3</h2>
                  <p class="tagline style-scope patent-result">Spain</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Translation of granted European patent ( former B3)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/0a/00/4e/9b4860414bfab1/ES2966466T3.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;antibody&quot;,&quot;caf&quot;,&quot;trop&quot;,&quot;cancer&quot;,&quot;patients&quot;]" data-before="20170224"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/ES2966466T3"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2966466T3/es"><a id="link" href="#" class="style-scope state-modifier">Spanish</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="David M Goldenberg"><a id="link" href="#" class="style-scope state-modifier">David M Goldenberg</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Serengulam V Govindan"><a id="link" href="#" class="style-scope state-modifier">Serengulam V Govindan</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    Immunomedics Inc
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2018</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP7188837B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2019542544A</div>
                <div class="style-scope application-timeline">Filing date: 2018-02-21</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2018156634A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/US2018/019025</div>
                <div class="style-scope application-timeline">Filing date: 2018-02-21</div>
                <div class="style-scope application-timeline">Legal status: Application Filing</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3043766A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3043766A</div>
                <div class="style-scope application-timeline">Filing date: 2018-02-21</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PL3585442T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PL18758120.2T</div>
                <div class="style-scope application-timeline">Filing date: 2018-02-21</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RU2019124477A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">RU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: RU2019124477A</div>
                <div class="style-scope application-timeline">Filing date: 2018-02-21</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN110392580A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201880017528.6A</div>
                <div class="style-scope application-timeline">Filing date: 2018-02-21</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3585442B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP18758120.2A</div>
                <div class="style-scope application-timeline">Filing date: 2018-02-21</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2966466T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES18758120T</div>
                <div class="style-scope application-timeline">Filing date: 2018-02-21</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application ES18758120T events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline"><div date="" class="external-priority style-scope application-timeline">2017-11-22</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US10413539B2/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Priority claimed from US15/820,708</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2018-02-21</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="Immunomedics Inc"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by Immunomedics Inc</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2024-04-22</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2024-04-22</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2966466T3/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of ES2966466T3</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2038-02-21</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (6)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (2)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=ES&amp;NR=2966466T3&amp;KC=T3&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/ES/2966466/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/ES2966466T3">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES462161266" lang="EN" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIPCIÓN</span>DESCRIPTION</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Terapia del cáncer de pulmón de células pequeñas (CPCP) con un conjugado anticuerpo-fármaco inhibidor de la topoisomerasa-I (ADC) dirigido a trop-2 </span>Small cell lung cancer (SCLC) therapy with a topoisomerase-I inhibitor antibody-drug conjugate (ADC) targeting trop-2</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Campo de la invención</span>field of invention</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0001]La presente invención se relaciona con un conjugado anticuerpo-fármaco (CAF) anti-Trop-2 que comprende SN-38 conjugado con un anticuerpo anti-Trop-2, para uso en un método de tratamiento del cáncer de pulmón de células pequeñas (CPCP), y a cisplatino o carboplatino para su uso en un método de tratamiento del cáncer de pulmón de células pequeñas (CPCP). El anticuerpo puede unirse a 1-12, 1-6, 1-5, 6-8 o 7-8 copias de un resto farmacológico o un resto enlazador de fármaco por anticuerpo o fragmento. En formas de realización preferidas de la invención como se define en las reivindicaciones, la combinación de CAF y otra modalidad terapéutica exhibe un efecto sinérgico y es más eficaz para inducir la muerte de las células cancerosas que el CAF u otra modalidad terapéutica solos, o la suma de los efectos del CAF y otra modalidad terapéutica administrada individualmente. Sorprendentemente, la administración subcutánea del CAF anti-Trop-2 no da como resultado una toxicidad localizada inaceptable en el sitio de administración y en formas de realización alternativas de la invención como se define en las reivindicaciones, el CAF puede administrarse por vía intravenosa o subcutánea. </span>[0001]The present invention relates to an anti-Trop-2 antibody-drug conjugate (CAF) comprising SN-38 conjugated to an anti-Trop-2 antibody, for use in a method of treating single-cell lung cancer. (SCLC), and to cisplatin or carboplatin for use in a method of treating small cell lung cancer (SCLC). The antibody may bind 1-12, 1-6, 1-5, 6-8 or 7-8 copies of a drug moiety or a drug-linking moiety per antibody or fragment. In preferred embodiments of the invention as defined in the claims, the combination of CAF and another therapeutic modality exhibits a synergistic effect and is more effective in inducing the death of cancer cells than CAF or another therapeutic modality alone, or the sum of the effects of CAF and another individually administered therapeutic modality. Surprisingly, subcutaneous administration of the anti-Trop-2 CAF does not result in unacceptable localized toxicity at the site of administration and in alternative embodiments of the invention as defined in the claims, the CAF can be administered intravenously or subcutaneously. .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Técnica relacionada</span>Related technique</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0002]El cáncer de pulmón de células pequeñas (CPCP), que se origina a partir de células progenitoras neuroendocrinas, comprende aproximadamente el 15 % de todos los cánceres de pulmón, pero tiene una de las tasas de supervivencia a 5 años más bajas, un 6 % (Alvarado-Luna et al., 2016, Transl Lung Cancer Res 5:26-38; Siegel et al., 2017, CA Cancer J Clin 67:7-30). Esto se debe a que es muy agresivo, y alrededor de dos tercios de los pacientes tienen enfermedad metastásica en el momento del diagnóstico (Fruh et al., 2013, Ann Oncol 24(6):vi99-105). Mientras que el tratamiento de primera línea del CPCP en estadio IV es paliativo pero tiene una alta tasa de respuesta inicial del 60-75%, el resultado suele ser malo, con una mediana de supervivencia libre de progresión (SSP) de sólo 5,5 meses y una mediana de supervivencia general (SG) de &lt;10 meses (Foster et al., 2011, Cancer 117:1262-71; Wolfson et al., 2011, Int J Radiat Oncol Biol Phys 81:77-84) con quimioterapia basada en platino (Fruh et al, 2013, Ann Oncol 24(6):vi99-105). </span>[0002]Small cell lung cancer (SCLC), which originates from neuroendocrine progenitor cells, comprises approximately 15% of all lung cancers, but has one of the lowest 5-year survival rates, 6% (Alvarado-Luna et al., 2016, Transl Lung Cancer Res 5:26-38; Siegel et al., 2017, CA Cancer J Clin 67:7-30). This is because it is very aggressive, and about two-thirds of patients have metastatic disease at the time of diagnosis (Fruh et al., 2013, Ann Oncol 24(6):vi99-105). While the first-line treatment of stage IV SCLC is palliative but has a high initial response rate of 60-75%, the outcome is often poor, with a median progression-free survival (PFS) of only 5.5. months and a median overall survival (OS) of &lt;10 months (Foster et al., 2011, Cancer 117:1262-71; Wolfson et al., 2011, Int J Radiat Oncol Biol Phys 81:77-84) with chemotherapy platinum-based (Fruh et al, 2013, Ann Oncol 24(6):vi99-105).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0003]Las respuestas al tratamiento de segunda línea han sido peores, por ejemplo &lt;10%, y con una mediana de supervivencia de sólo 4 o 5 meses después de la quimioterapia de segunda o tercera línea (Hurwitz et al., 2009, Oncologist 14:986-94; Schneider, 2008, J Natl Compr Canc Netw 6:323-31), especialmente cuando hay resistencia al tratamiento de primera línea (es decir, duración de la respuesta &lt;3 meses). El único fármaco aprobado en este contexto, desde 1998, es el topotecán, indicado para pacientes recurrentes que eran sensibles (duración de la respuesta superior a 3 meses) a una terapia basada en platino (O'Brien et al., 2006, J Clin Oncol 24: 5441-7; Perez-Soler et al., 1996, J Clin Oncol 14:2785-90). Sin embargo, también se administran con frecuencia irinotecán, taxanos, vinorelbina y gemcitabina a pacientes con enfermedad recurrente quimiosensible (Furuse et al., 1996, Oncology 53:169-72; Smit et al., 1998, Br J Cancer 77:347-51); Sandler, 2001, Oncology (Williston Park) 15:11-2; van der Lee et al., 2001, Ann Oncol 12:557-61). </span>[0003]Responses to second-line treatment have been worse, for example &lt;10%, and with a median survival of only 4 or 5 months after second- or third-line chemotherapy (Hurwitz et al., 2009, Oncologist 14:986-94; Schneider, 2008, J Natl Compr Canc Netw 6:323-31), especially when there is resistance to first-line treatment (i.e. duration of response &lt;3 months). The only drug approved in this context, since 1998, is topotecan, indicated for recurrent patients who were sensitive (duration of response greater than 3 months) to a platinum-based therapy (O'Brien et al., 2006, J Clin Oncol 24: 5441-7; Perez-Soler et al., 1996, J Clin Oncol 14:2785-90). However, irinotecan, taxanes, vinorelbine, and gemcitabine are also frequently administered to patients with chemosensitive recurrent disease (Furuse et al., 1996, Oncology 53:169-72; Smit et al., 1998, Br J Cancer 77:347-72). 51); Sandler, 2001, Oncology (Williston Park) 15:11-2; van der Lee et al., 2001, Ann Oncol 12:557-61).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0004]Una revisión de ensayos clínicos aleatorizados recientes de fase II y III que incluyeron topotecán en un grupo de control mostró respuestas del 13 al 17 % en segunda línea (Inoue et al., 2008, J Clin Oncol 26:5401-6; Jotte et al., 2011, J Clin Oncol 29:287-93; Horita et al., 2015, Sci Rep 5:15437), pero con una tasa de respuesta de hasta el 20 % entre los pacientes con enfermedad quimiosensible, y solo el 4 % para aquellos que eran quimiorresistentes (von Pawel, 2003, Lung Cancer 41 (Suplemento 4): S3-8). Sin embargo, estas respuestas y/o la estabilización de la enfermedad en segunda línea no se traducen en una mejor supervivencia. Por ejemplo, Hagmann y colegas (Hagmann et al., 2015, J Cancer 6:1148-5418) informaron una respuesta del 22,5 % con topotecán y una mediana de SSP de 2,4 meses y una mediana de SG de 5 meses. En un entorno de tercera línea, no se lograron respuestas objetivas, mientras que se informó una mediana de SSP de 1,3 meses y una mediana de SG de 2,5 meses (Hagmann et al., 2015, J Cancer 6:1148-5418). Otras quimioterapias establecidas con un solo agente o el retratamiento con combinaciones de platino más etopósido también han sido decepcionantes y han producido resultados de supervivencia similares a los del topotecán solo (Hagmann et al., 2015, J Cancer 6:1148-5418). El irinotecán ha mostrado respuestas muy bajas o nulas y un tiempo medio de progresión (TTP) de 1,7 meses, mientras que también se ha informado una mediana de SG de 4,6 meses (Pallis et al., 2009, Lung Cancer 65:187-91). La gemcitabina no ha dado ninguna respuesta objetiva y dio como resultado una mediana de TTP de 6 semanas y una mediana de SG de 6,4 meses, mientras que pemetrexed logró 2 respuestas entre 43 pacientes (TRO, 4%) (Jalal et al., 2009, J Thorac Oncol 4:93-6). Por tanto, los avances en el tratamiento de los pacientes con CPCP, especialmente aquellos con enfermedad extensa, han sido decepcionantes en los últimos 20 años. Casi todos los pacientes recaen temprano y mueren dentro de un año. </span>[0004]A review of recent phase II and III randomized clinical trials that included topotecan in a control group showed responses of 13 to 17% in second line (Inoue et al., 2008, J Clin Oncol 26:5401-6; Jotte et al., 2011, J Clin Oncol 29:287-93; Horita et al., 2015, Sci Rep 5:15437), but with a response rate of up to 20% among patients with chemosensitive disease, and only 4% for those who were chemoresistant (von Pawel, 2003, Lung Cancer 41 (Supplement 4): S3-8). However, these responses and/or stabilization of the disease in the second line do not translate into better survival. For example, Hagmann and colleagues (Hagmann et al., 2015, J Cancer 6:1148-5418) reported a 22.5% response with topotecan and a median PFS of 2.4 months and a median OS of 5 months . In a third-line setting, no objective responses were achieved, while a median PFS of 1.3 months and a median OS of 2.5 months were reported (Hagmann et al., 2015, J Cancer 6:1148- 5418). Other established single-agent chemotherapies or retreatment with platinum plus etoposide combinations have also been disappointing and have produced survival outcomes similar to those of topotecan alone (Hagmann et al., 2015, J Cancer 6:1148-5418). Irinotecan has shown very low or no responses and a median time to progression (TTP) of 1.7 months, while a median OS of 4.6 months has also been reported (Pallis et al., 2009, Lung Cancer 65 :187-91). Gemcitabine did not give any objective response and resulted in a median TTP of 6 weeks and a median OS of 6.4 months, while pemetrexed achieved 2 responses among 43 patients (ORR, 4%) (Jalal et al. , 2009, J Thorac Oncol 4:93-6). Therefore, advances in the treatment of patients with SCLC, especially those with extensive disease, have been disappointing over the past 20 years. Almost all patients relapse early and die within a year.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0005]El documento US 2016/0193357 A1 está relacionado con inmunoconjugados terapéuticos que comprenden SN-38 unido a un anticuerpo anti-Trop-2. </span>[0005]US 2016/0193357 A1 relates to therapeutic immunoconjugates comprising SN-38 linked to an anti-Trop-2 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0006]Starodub A et al. (Journal of Clinical Oncology, vol. 34, n° 15, supl., 20 de mayo de 2016, págs. 8559-8559) informe sobre Trop-2 como objetivo terapéutico para el conjugado anticuerpo-fármaco (CAF) sacituzumab govitecan (IMMU-132) en pacientes con cáncer de pulmón de células pequeñas metastásico (CPCPm) previamente tratado. </span>[0006]Starodub A et al. (Journal of Clinical Oncology, vol. 34, no. 15, suppl., May 20, 2016, pp. 8559-8559) report on Trop-2 as a therapeutic target for the antibody-drug conjugate (ADF) sacituzumab govitecan (IMMU -132) in patients with previously treated metastatic small cell lung cancer (mSCLC).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0007]El documento WO 2016/172427A1 está relacionado con composiciones y métodos de uso de anticuerpos anti-Trop-2 o un fragmento de unión a antígeno de los mismos para aislar, enriquecer, detectar, diagnosticar y/o caracterizar células tumorales circulantes (CTC) de pacientes con cáncer positivo por Trop-2. </span>[0007]WO 2016/172427A1 relates to compositions and methods of using anti-Trop-2 antibodies or an antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells ( CTC) from patients with Trop-2 positive cancer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0008]Existe la necesidad de un tratamiento más eficaz para pacientes con CPCP de primera línea o en etapas posteriores. Existe la necesidad particular de mejores terapias para los pacientes que son resistentes a las quimioterapias estándar, como la quimioterapia que contiene platino, topotecán o irinotecán. </span>[0008]There is a need for more effective treatment for patients with first-line or later-stage SCLC. There is a particular need for better therapies for patients who are resistant to standard chemotherapies, such as platinum-containing chemotherapy, topotecan or irinotecan.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RESUMEN</span>SUMMARY</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0009]El problema subyacente a la presente invención es el objeto de las reivindicaciones independientes adjuntas. Se pueden tomar formas de realización preferidas de las reivindicaciones dependientes adjuntas. </span>[0009]The problem underlying the present invention is the subject of the attached independent claims. Preferred embodiments can be taken from the attached dependent claims.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0010]Más específicamente, el problema subyacente a la presente invención se resuelve en un primer aspecto mediante un conjugado anticuerpo-fármaco (CAF) anti-Trop-2 que comprende SN-38 conjugado con un anticuerpo anti-Trop-2, para uso en un método de tratamiento cáncer de pulmón de células pequeñas (CPCP), en el que el método comprende administrar a un paciente humano con CPCP (i) el conjugado anticuerpo-fármaco anti-Trop-2 (CAF) y (ii) cisplatino o carboplatino, en el que el CAF se administra como segunda línea o terapia posterior a pacientes que han recibido tratamiento oncológico previo para CPCP, en donde el anticuerpo anti-Trop-2 es un anticuerpo RS7 humanizado que comprende las secuencias CDR de cadena ligera CDR1 (KASQDVSIAVA, SEQ ID NO:1);&lt;c&gt;D&lt;r&gt;2 (SASYRYT, SEQ ID NO:2); y CDR3 (QQHYITPLT, SEQ ID NO:3) y las secuencias de CDR de cadena pesada CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) y CDR3 (GGFGSSYWYFDV, SEQ ID NO:6), y en donde hay un conector CL2A entre el SN-38 y el anticuerpo y la estructura del c Af es MAbCL2A-SN-38 </span>[0010]More specifically, the problem underlying the present invention is solved in a first aspect by an anti-Trop-2 antibody-drug conjugate (CAF) comprising SN-38 conjugated with an anti-Trop-2 antibody, for use in a method of treating small cell lung cancer (SCLC), wherein the method comprises administering to a human patient with SCLC (i) the anti-Trop-2 antibody-drug conjugate (CAF) and (ii) cisplatin or carboplatin, wherein CAF is administered as second-line or subsequent therapy to patients who have received prior oncological treatment for SCLC, wherein the anti-Trop-2 antibody is a humanized RS7 antibody comprising the CDR1 light chain CDR sequences ( KASQDVSIAVA, SEQ ID NO:1);&lt;c&gt;D&lt;r&gt;2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6), and where there is a CL2A linker between SN-38 and the antibody and the structure of the c Af is MAbCL2A-SN-38</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
[0011]El problema subyacente a la presente invención se resuelve en un segundo aspecto mediante cisplatino o carboplatino para su uso en un método para tratar el cáncer de pulmón de células pequeñas (CPCP), en donde el método comprende administrar a un paciente humano con CPCP (i) un anti-Trop-2 conjugado anticuerpo-fármaco (CAF) que comprende SN-38 conjugado con un anticuerpo anti-Trop-2 y (ii) cisplatino o carboplatino, en el que el CAF se administra como terapia de segunda línea o posterior a pacientes que han recibido tratamiento previo contra el cáncer para CPCP, en el que el anticuerpo anti-Trop-2 es un anticuerpo RS7 humanizado que comprende las secuencias CDR de cadena ligera CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); y CDR3 (QQHYITPLT, SEQ ID NO:3) y las secuencias de CDR de cadena pesada CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) y CDR3 (GGFGSSYWYFDV, SEQ ID NO:6), y en donde hay un conector CL2A entre el SN-38 y el anticuerpo y la estructura del CAF es MAb-CL2A-SN-38 </span>
[0011] The problem underlying the present invention is solved in a second aspect by cisplatin or carboplatin for use in a method for treating small cell lung cancer (SCLC), wherein the method comprises administering to a human patient with CPCP (i) an anti-Trop-2 antibody-drug conjugate (CAF) comprising SN-38 conjugated to an anti-Trop-2 antibody and (ii) cisplatin or carboplatin, in which the CAF is administered as second-line therapy line or later to patients who have received prior cancer treatment for SCLC, wherein the anti-Trop-2 antibody is a humanized RS7 antibody comprising the CDR1 light chain CDR sequences (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6), and where there is a CL2A linker between SN-38 and the antibody and the structure of the CAF is MAb-CL2A-SN-38</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
[0012]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el cáncer es metastásico (CPCPm). </span>
[0012]In an embodiment of the first aspect and in an embodiment of the second aspect, the cancer is metastatic (mSCLC).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0013]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el CAF se administra como terapia de segunda línea o posterior a pacientes que han recaído previamente o han sido resistentes al tratamiento con un agente anticancerígeno estándar. </span>[0013]In an embodiment of the first aspect and in an embodiment of the second aspect, CAF is administered as second-line or subsequent therapy to patients who have previously relapsed or been resistant to treatment with a standard anticancer agent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0014]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el paciente ha recaído previamente o ha sido resistente al tratamiento con topotecán o irinotecán. </span>[0014]In an embodiment of the first aspect and in an embodiment of the second aspect, the patient has previously relapsed or been resistant to treatment with topotecan or irinotecan.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0015]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el CPCP es resistente a la quimioterapia con agentes que contienen platino. </span>[0015]In an embodiment of the first aspect and in an embodiment of the second aspect, SCLC is resistant to chemotherapy with platinum-containing agents.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0016]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el CPCP es sensible a quimioterapia con agentes que contienen platino. </span>[0016]In an embodiment of the first aspect and in an embodiment of the second aspect, SCLC is sensitive to chemotherapy with platinum-containing agents.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0017]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el CAF se administra en una dosis de entre 6 mg/kg y 12 mg/kg. </span>[0017]In an embodiment of the first aspect and in an embodiment of the second aspect, the CAF is administered in a dose of between 6 mg/kg and 12 mg/kg.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0018]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, la dosis está entre 8 mg/kg y 10 mg/kg. </span>[0018]In an embodiment of the first aspect and in an embodiment of the second aspect, the dose is between 8 mg/kg and 10 mg/kg.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0019]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el tratamiento da como resultado una reducción del tamaño del tumor de al menos un 15 %, al menos un 20 %, al menos un 30 % o al menos un 40 %. </span>[0019]In an embodiment of the first aspect and in an embodiment of the second aspect, the treatment results in a reduction in tumor size of at least 15%, at least 20%, at least 30%. or at least 40%.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0020]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el método comprende además reducir el tamaño o eliminar las metástasis. </span>[0020]In an embodiment of the first aspect and in an embodiment of the second aspect, the method further comprises reducing the size or eliminating metastases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0021]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, hay 7-8 moléculas de SN-38 unidas a cada molécula de anticuerpo. </span>[0021]In one embodiment of the first aspect and in an embodiment of the second aspect, there are 7-8 SN-38 molecules attached to each antibody molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0022]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, la dosis de CAF se administra al sujeto humano una o dos veces por semana según un cronograma con un ciclo seleccionado del grupo que consiste en: (i) semanalmente; (ii) cada dos semanas; (iii) una semana de terapia seguida de dos, tres o cuatro semanas de descanso; (iv) dos semanas de terapia seguidas de una, dos, tres o cuatro semanas de descanso; (v) tres semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; (vi) cuatro semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; (vii) cinco semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; y (viii) mensual; preferiblemente el ciclo se repite 4, 6, 8, 10, 12, 16 o 20 veces. </span>[0022]In an embodiment of the first aspect and in an embodiment of the second aspect, the CAF dose is administered to the human subject once or twice a week according to a schedule with a cycle selected from the group consisting of: ( i) weekly; (ii) every two weeks; (iii) one week of therapy followed by two, three, or four weeks of rest; (iv) two weeks of therapy followed by one, two, three, or four weeks of rest; (v) three weeks of therapy followed by one, two, three, four, or five weeks of rest; (vi) four weeks of therapy followed by one, two, three, four, or five weeks of rest; (vii) five weeks of therapy followed by one, two, three, four, or five weeks of rest; and (viii) monthly; preferably the cycle is repeated 4, 6, 8, 10, 12, 16 or 20 times.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0023]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el CAF se administra en combinación con una o más modalidades terapéuticas seleccionadas del grupo que consiste en un anticuerpo no conjugado, un inmunoconjugado, terapia génica, quimioterapia, un péptido terapéutico, terapia con citocinas, radioterapia localizada, terapia con ARN de interferencia, un fármaco, una toxina y una citoquina, preferiblemente el fármaco, toxina o agente quimioterapéutico se selecciona del grupo que consiste en 5-fluorouracilo, afatinib, aplidina, azaribina, anastrozol, antraciclinas, axitinib, AVL-101, AVL-291, bendamustina, bleomicina, bortezomib, bosutinib, briostatina-1, busulfán, caliqueamicina, camptotecina, 10-hidroxicamptotecina, carmustina, celebrex, clorambucilo, inhibidores de la Cox-2, irinotecán (CPT-11), SN-38, cladribina, camptotecanos, ciclofosfamida, crizotinib, citarabina, dacarbazina, dasatinib, dinaciclib, docetaxel, dactinomicina, daunorrubicina, doxorrubicina, 2-pirrolinodoxorrubicina (2P-DOX), cianomorfolino doxorrubicina, glucurónido de doxorrubicina, glucurónido de epirrubicina, erlotinib, estramustina, epidofilotoxina, erlotinib, entinostat, agentes fijadores de receptores de estrógeno, etopósido (VP 16), glucurónido de etopósido, fosfato de etopósido, exemestano, fingolimod, flavopiridol, floxuridina (FUdR), 3',5'-O-dioleoil-FudR (FUdR-dO), fludarabina, flutamida, inhibidores de la farnesilproteína transferasa, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabina, hidroxiurea, ibrutinib, idarrubicina, idelalisib, ifosfamida, imatinib, L-asparaginasa, lapatinib, lenolidamida, leucovorina, LFM-A13, lomustina, mecloretamina, melfalán, mercaptopurina, 6-mercaptopurina, metotrexato, mitoxantrona, mitramicina, mitomicina, mitotano, navelbina, neratinib, nilotinib, nitrosurea, olaparib, plicomicina, procarbazina, paclitaxel, PCI-32765, pentostatina, PSI-341, raloxifeno, semustina, sorafenib, estreptozocina, SU11248, sunitinib, tamoxifeno, temazolomida (una forma acuosa de DTIC), transplatino, talidomida, tioguanina, tiotepa, tenipósido, topotecán, mostaza de uracilo, vatalanib, vinorelbina, vinblastina, vincristina, alcaloides de la vinca y ZD1839. </span>[0023]In an embodiment of the first aspect and in an embodiment of the second aspect, the CAF is administered in combination with one or more therapeutic modalities selected from the group consisting of an unconjugated antibody, an immunoconjugate, gene therapy, chemotherapy, a therapeutic peptide, cytokine therapy, localized radiotherapy, RNA interference therapy, a drug, a toxin and a cytokine, preferably the drug, toxin or chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, afatinib, aplidine ,azaribin, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan, calicheamicin, camptothecin, 10-hydroxycamptothecin, carmustine, celebrex, chlorambucil, Cox-inhibitors 2, irinotecan (CPT-11), SN-38, cladribine, camptothecans, cyclophosphamide, crizotinib, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicin (2P-DOX), cyanomorpholino doxorubicin, glucuronide doxorubicin, epirubicin glucuronide, erlotinib, estramustine, epidophyllotoxin, erlotinib, entinostat, estrogen receptor binding agents, etoposide (VP 16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, flavopiridol, floxuridine (FUdR), 3 ',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesylprotein transferase inhibitors, fostamatinib, ganatespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, L-asparaginase, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, navelbine, neratinib, nilotinib, nitrosurea, olaparib, plicomycin, procarbazine, paclitaxel, PCI-32765, pentostatin, PSI-341, raloxifene, semustine, sorafenib, streptozocin, SU11248, sunitinib, tamoxifen, temazolomide (an aqueous form of DTIC), transplatin, thalidomide, thioguanine, thiotepa, teniposide, topotecan , uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine, vinca alkaloids and ZD1839.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0024]En una forma de realización del primer aspecto y en una forma de realización del segundo aspecto, el CAF se administra al paciente humano que se ha sometido a una cirugía o que está programado para una cirugía. </span>[0024]In an embodiment of the first aspect and in an embodiment of the second aspect, the CAF is administered to the human patient who has undergone surgery or who is scheduled for surgery.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0025]La invención, tal como se define en las reivindicaciones, proporciona un tratamiento sustancialmente mejorado con respecto al estándar de atención para CPCP, con mayor eficacia y toxicidades sólo manejables cuando se usa en las dosis preferidas que se analizan en detalle a continuación. </span>[0025]The invention, as defined in the claims, provides a substantially improved treatment over the standard of care for SCLC, with increased efficacy and only manageable toxicities when used at the preferred doses discussed in detail below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0026]En diversas formas de realización de la invención como se define en las reivindicaciones, el CAF se usa solo o como una terapia combinada con una o más modalidades terapéuticas diferentes, tales como cirugía, radioterapia, quimioterapia, inmunomoduladores, citocinas, agentes quimioterapéuticos, agentes proapoptóticos, agentes antiangiogénicos, agentes citotóxicos, fármacos, toxinas, radionúclidos, ARNi, ARNip, un segundo anticuerpo o fragmento de anticuerpo, o un inmunoconjugado. En formas de realización adicionales de la invención como se define en las reivindicaciones, el CAF se administra al paciente humano que se ha sometido a una cirugía o que está programado para una cirugía. Preferiblemente, la combinación de CAF y otra modalidad terapéutica o cirugía es más eficaz que cualquiera de ellas sola o la suma de los efectos de tratamientos individuales. </span>[0026]In various embodiments of the invention as defined in the claims, CAF is used alone or as a combination therapy with one or more different therapeutic modalities, such as surgery, radiotherapy, chemotherapy, immunomodulators, cytokines, chemotherapeutic agents , proapoptotic agents, antiangiogenic agents, cytotoxic agents, drugs, toxins, radionuclides, RNAi, siRNA, a second antibody or antibody fragment, or an immunoconjugate. In further embodiments of the invention as defined in the claims, the CAF is administered to the human patient who has undergone surgery or who is scheduled for surgery. Preferably, the combination of CAF and another therapeutic modality or surgery is more effective than either alone or the sum of the effects of individual treatments.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0027]Como se define en las reivindicaciones, el anticuerpo anti-Trop-2 es un anticuerpo RS7 humanizado (véase, por ejemplo, la patente de EE. UU. n° 7.238.785), que comprende las secuencias CDR de cadena ligera CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); y CDR3 (QQHYITPLT, SEQ ID NO:3) y las secuencias de CDR de cadena pesada CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) y CDR3 (GGFGSSYWYFDV, SEQ ID NO:6). Sin embargo, como se analiza más adelante, se conocen otros anticuerpos anti-Trop-2. Según la invención, tal como se define en las reivindicaciones, el fármaco conjugado con el anticuerpo es SN-38 (véase, por ejemplo, la patente de EE. UU. n° 9.028.833). </span>[0027]As defined in the claims, the anti-Trop-2 antibody is a humanized RS7 antibody (see, for example, US Patent No. 7,238,785), which comprises the light chain CDR sequences CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6). However, as discussed below, other anti-Trop-2 antibodies are known. According to the invention, as defined in the claims, the drug conjugated to the antibody is SN-38 (see, for example, US Patent No. 9,028,833).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0028]El resto de anticuerpo puede ser un anticuerpo monoclonal, un fragmento de anticuerpo de unión a antígeno, un anticuerpo biespecífico u otro anticuerpo multivalente, u otra molécula basada en anticuerpo. El anticuerpo puede ser de diversos isotipos, preferiblemente IgG1, IgG2, IgG3 o IgG4 humana, más preferiblemente que comprende secuencias bisagra y región constante de IgG1 humana. El anticuerpo es un anticuerpo quimérico. Más preferiblemente, el anticuerpo puede diseñarse o seleccionarse para que comprenda secuencias de regiones constantes humanas que pertenecen a alotipos específicos, lo que puede dar como resultado una inmunogenicidad reducida cuando se administra el CAF a un sujeto humano. Los alotipos preferidos para la administración incluyen un alotipo distinto de G1m1 (nG1m1), tal como G1m3, G1m3,1, G1m3,2 o G 1m3, 1,2. Más preferiblemente, el alotipo se selecciona del grupo que consiste en los alotipos nG1m1, G1m3, nG1m1,2 y Km3 (Jefferies y Lefranc, 2009, mAbs 1(4): 1-7). </span>[0028]The antibody moiety may be a monoclonal antibody, an antigen-binding antibody fragment, a bispecific antibody or other multivalent antibody, or another antibody-based molecule. The antibody may be of various isotypes, preferably human IgG1, IgG2, IgG3 or IgG4, more preferably comprising human IgG1 hinge and constant region sequences. The antibody is a chimeric antibody. More preferably, the antibody can be designed or selected to comprise human constant region sequences belonging to specific allotypes, which can result in reduced immunogenicity when the CAF is administered to a human subject. Preferred allotypes for administration include an allotype other than G1m1 (nG1m1), such as G1m3, G1m3,1, G1m3,2 or G 1m3, 1,2. More preferably, the allotype is selected from the group consisting of allotypes nG1m1, G1m3, nG1m1.2 and Km3 (Jefferies and Lefranc, 2009, mAbs 1(4): 1-7).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0029]En una forma de realización de la presente invención como se define en las reivindicaciones, el fármaco que se va a conjugar con el anticuerpo o fragmento de anticuerpo se puede seleccionar del grupo que consiste en una antraciclina, una camptotecina, un inhibidor de tubulina, un maitansinoide, una caliqueamicina, una auristatina, una mostaza nitrogenada, un derivado de etilenimina, un sulfonato de alquilo, una nitrosourea, un triazeno, un análogo del ácido fólico, un taxano, un inhibidor de la COX-2, un análogo de la pirimidina, un análogo de la purina, un antibiótico, un inhibidor de enzimas, una epipodofilotoxina, un complejo de coordinación de platino, un alcaloide de la vinca, una urea sustituida, un derivado de metilhidrazina, un supresor adrenocortical, un antagonista hormonal, un antimetabolito, un agente alquilante, un antimitótico, un agente antiangiogénico, un inhibidor de la tirosina quinasa, un inhibidor de mTOR, un inhibidor de la proteína de choque térmico (HSP90), un inhibidor de proteosoma, un inhibidor de HDAC, un agente proapoptótico y una combinación de los mismos. </span>[0029]In one embodiment of the present invention as defined in the claims, the drug to be conjugated with the antibody or antibody fragment can be selected from the group consisting of an anthracycline, a camptothecin, an inhibitor of tubulin, a maytansinoid, a calicheamicin, an auristatin, a nitrogen mustard, an ethyleneimine derivative, an alkyl sulfonate, a nitrosourea, a triazene, a folic acid analog, a taxane, a COX-2 inhibitor, an analog pyrimidine, a purine analogue, an antibiotic, an enzyme inhibitor, an epipodophyllotoxin, a platinum coordination complex, a vinca alkaloid, a substituted urea, a methylhydrazine derivative, an adrenocortical suppressor, a hormone antagonist , an antimetabolite, an alkylating agent, an antimitotic, an antiangiogenic agent, a tyrosine kinase inhibitor, an mTOR inhibitor, a heat shock protein (HSP90) inhibitor, a proteasome inhibitor, an HDAC inhibitor, a proapoptotic agent and a combination thereof.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0030]Los fármacos de uso específicos pueden seleccionarse del grupo formado por 5-fluorouracilo, afatinib, aplidina, azaribina, anastrozol, antraciclinas, axitinib, AVL-101, AVL-291, bendamustina, bleomicina, bortezomib, bosutinib, briostatina-1, busulfano, caliqueamicina, camptotecina, carboplatino, 10-hidroxicamptotecina, carmustina, celecoxib, clorambucilo, cisplatino, inhibidores de la COX-2, irinotecán (CPT-11), SN-38, carboplatino, cladribina, camptotecanos, crizotinib, ciclofosfamida, citarabina, dacarbazina, dasatinib, dinaciclib, docetaxel, dactinomicina, daunorrubicina, DM1, DM3, DM4, doxorrubicina, 2-pirrolinodoxorrubicina (2-PDox), una forma profármaco de 2-PDox (pro-2-PDox), cianomorfolino doxorrubicina, glucurónido de doxorrubicina, endostatina, glucurónido de epirrubicina, erlotinib, estramustina, epidofilotoxina, erlotinib, entinostat, agentes aglutinantes del receptor de estrógeno, etopósido (VP16), glucurónido de etopósido, fosfato de etopósido, exemestano, fingolimod, floxuridina (FUdR), 3',5'-O-dioleoil-FudR (FUdR-dO), fludarabina, flutamida, inhibidores de farnesil-proteína transferasa, flavopiridol, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabina, hidroxiurea, ibrutinib, idarrubicina, idelalisib, ifosfamida, imatinib, lapatinib, lenolidamida, leucovorina, LFM-A13, lomustina, mecloretamina, melfalán, mercaptopurina, 6-mercaptopurina, metotrexato, mitoxantrona, mitramicina, mitomicina, mitotano, monometilauristatina F (MmAF), monometilauristatina D (MMAD), monometilauristatina E (MMAE), navelbina, neratinib, nilotinib, nitrosurea, olaparib, plicomicina, procarbazina, paclitaxel, PCI-32765, pentostatino, PSI-341, raloxifeno, semustina, SN-38, sorafenib, estreptozocina, SU11248, sunitinib, tamoxifen, temazolomida, transplatino, talidomida, tioguanina, tiotepa, teniposida, topotecán, mostaza de uracilo, vatalanib, vinorelbina, vinblastina, vincristina, alcaloides de la vinca y ZD1839. Preferiblemente, el fármaco es SN-38. </span>[0030]Specific drugs of use can be selected from the group consisting of 5-fluorouracil, afatinib, aplidine,azaribin, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan, calicheamicin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatin, COX-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothecans, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, DM1, DM3, DM4, doxorubicin, 2-pyrrolinodoxorubicin (2-PDox), a prodrug form of 2-PDox (pro-2-PDox), cyanomorpholino doxorubicin, doxorubicin glucuronide , endostatin, epirubicin glucuronide, erlotinib, estramustine, epidophyllotoxin, erlotinib, entinostat, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, floxuridine (FUdR), 3',5 '-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, flavopiridol, fostamatinib, ganatespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, monomethylauristatin F (MmAF), monomethylauristatin D (MMAD), monomethylauristatin E (MMAE) transplatin, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine, vinca alkaloids and ZD1839. Preferably, the drug is SN-38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0031]La dosificación óptima preferida de los CAF puede incluir una dosis de entre 4 mg/kg y 18 mg/kg, administrada preferiblemente semanalmente, dos veces por semana o cada dos semanas. El programa de dosificación óptimo puede incluir ciclos de tratamiento de dos semanas consecutivas de terapia seguidas de una, dos, tres o cuatro semanas de descanso, o semanas alternas de terapia y descanso, o una semana de terapia seguida de dos, tres o cuatro semanas de descanso, o tres semanas de terapia seguidas de una, dos, tres o cuatro semanas de descanso, o cuatro semanas de terapia seguidas de una, dos, tres o cuatro semanas de descanso, o cinco semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de reposo, o administración una vez cada dos semanas, una vez cada tres semanas o una vez al mes. El tratamiento puede extenderse durante cualquier número de ciclos, preferiblemente al menos 2, al menos 4, al menos 6, al menos 8, al menos 10, al menos 12, al menos 14 o al menos 16 ciclos. Las dosis de uso ejemplares pueden incluir 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 22 mg/kg y 24 mg/kg. Las dosis preferidas son 4, 6, 8, 9, 10, 12, 14, 16 o 18 mg/kg. Las dosis más preferidas son 6-12, 6-8, 7-8, 8-10, 10-12 u 8 12 mg/kg. La persona con experiencia ordinaria se dará cuenta de que se pueden considerar una variedad de factores, como la edad, la salud general, la función de un órgano específico o el peso, así como los efectos de la terapia previa en sistemas de órganos específicos (p. ej., la médula ósea) al seleccionar una dosis óptima de CAF, y que la dosis y/o frecuencia de administración pueden aumentarse o disminuirse durante el curso de la terapia. La dosis puede repetirse según sea necesario, observándose evidencia de reducción del tumor después de tan solo 4 a 8 dosis. Las dosis y programas de administración optimizados aquí descritos muestran una eficacia superior inesperada y una toxicidad reducida en sujetos humanos, que no podrían haberse predicho a partir de estudios en modelos animales. Sorprendentemente, la eficacia superior permite el tratamiento de tumores que previamente se consideraban resistentes a una o más terapias anticancerígenas estándar. Más sorprendentemente, se ha descubierto que el tratamiento es eficaz en tumores que anteriormente eran resistentes a las camptotecinas, como el irinotecán, el compuesto original de SN-38. </span>[0031]The preferred optimal dosage of CAFs may include a dose of between 4 mg/kg and 18 mg/kg, preferably administered weekly, twice a week or every other week. The optimal dosing schedule may include treatment cycles of two consecutive weeks of therapy followed by one, two, three, or four weeks of rest, or alternating weeks of therapy and rest, or one week of therapy followed by two, three, or four weeks of therapy. of rest, or three weeks of therapy followed by one, two, three, or four weeks of rest, or four weeks of therapy followed by one, two, three, or four weeks of rest, or five weeks of therapy followed by one, two, three, four or five weeks of rest, or administration once every two weeks, once every three weeks or once a month. The treatment may extend over any number of cycles, preferably at least 2, at least 4, at least 6, at least 8, at least 10, at least 12, at least 14 or at least 16 cycles. Exemplary use doses may include 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg. kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/ kg, 20 mg/kg, 22 mg/kg and 24 mg/kg. Preferred doses are 4, 6, 8, 9, 10, 12, 14, 16 or 18 mg/kg. The most preferred doses are 6-12, 6-8, 7-8, 8-10, 10-12 or 8 12 mg/kg. The person of ordinary experience will realize that a variety of factors may be considered, such as age, general health, specific organ function or weight, as well as the effects of prior therapy on specific organ systems ( e.g., bone marrow) when selecting an optimal dose of CAF, and that the dose and/or frequency of administration may be increased or decreased during the course of therapy. The dose can be repeated as needed, with evidence of tumor shrinkage seen after as few as 4 to 8 doses. The optimized doses and administration schedules described here show unexpected superior efficacy and reduced toxicity in human subjects, which could not have been predicted from studies in animal models. Surprisingly, the superior efficacy enables the treatment of tumors that were previously considered resistant to one or more standard anticancer therapies. More surprisingly, the treatment has been found to be effective in tumors that were previously resistant to camptothecins, such as irinotecan, the parent compound of SN-38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">BREVE DESCRIPCIÓN DE LOS DIBUJOS</span>BRIEF DESCRIPTION OF THE DRAWINGS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0032]</span>[0032]</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 1.Terapia preclínicain vivode ratones desnudos atímicos, portadores de carcinoma de páncreas humano Capan 1, con conjugados SN-38 de hRS7 (anti-Trop-2), hPAM4 (anti-MUC5ac), hMN-14 (anti-CEACAM5) o control no específico hA20 (anti-CD20). </span>FIG. 1. Preclinical in vivo therapy of athymic nude mice, carriers of Capan 1 human pancreatic carcinoma, with SN-38 conjugates of hRS7 (anti-Trop-2), hPAM4 (anti-MUC5ac), hMN-14 (anti-CEACAM5) or control non-specific hA20 (anti-CD20).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 2.Terapia preclínicain vivode ratones desnudos atímicos, portadores de carcinoma de páncreas humano BxPC3, con conjugados antiTROP2-CL2A-SN-38 en comparación con controles. </span>FIG. 2. Preclinical in vivo therapy of athymic nude mice, carriers of BxPC3 human pancreatic carcinoma, with anti-TROP2-CL2A-SN-38 conjugates compared to controls.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 3A.Estructuras de CL2-SN-38 y CL2A-SN-38. </span>FIG. 3A.Structures of CL2-SN-38 and CL2A-SN-38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 3B.Eficacia comparativa del c Af anti-Trop-2 vinculado a enlazadores CL2 frente a CL2A versus CAF hA20 y control de solución salina, utilizando adenocarcinoma de colon COLO 205. Los animales fueron tratados dos veces por semana durante 4 semanas como lo indican las flechas. Se trataron ratones COLO 205(N = 6)con 0,4 mg/kg de CAF y se midieron los tumores dos veces por semana. </span>FIG. 3B. Comparative efficacy of c Af anti-Trop-2 linked to CL2 linkers versus CL2A versus CAF hA20 and saline control, using colon adenocarcinoma COLO 205. Animals were treated twice a week for 4 weeks as indicated arrows. COLO 205 mice (N = 6) were treated with 0.4 mg/kg CAF and tumors were measured twice a week.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 3C.Eficacia comparativa del CAF anti-Trop-2 vinculado a enlazadores CL2 frente a CL2A versus CAF hA20 y control salino, utilizando adenocarcinoma de páncreas Capan-1. Los animales fueron tratados dos veces por semana durante 4 semanas como lo indican las flechas. Se trataron ratones Capan-1 (N =10)con 0,2 mg/kg de CAF y se midieron los tumores semanalmente. </span>FIG. 3C. Comparative efficacy of CAF anti-Trop-2 linked to CL2 linkers versus CL2A versus CAF hA20 and saline control, using Capan-1 pancreatic adenocarcinoma. Animals were treated twice a week for 4 weeks as indicated by arrows. Capan-1 mice (N =10) were treated with 0.2 mg/kg CAF and tumors were measured weekly.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 4A.Eficacia terapéutica del CAF hRS7-SN-38 en varios modelos de enfermedad de xenoinjerto de tumores sólidos. La eficacia del tratamiento con CAF hRS7-CL2-SN-38 y hRS7-CL2A-SN-38 se estudió en ratones portadores de xenoinjertos de tumores de pulmón de células no pequeñas, colorrectales, pancreáticos o de células escamosas humanas. Todos los CAF y los controles se administraron en las cantidades indicadas (expresadas como cantidad de SN-38 por dosis; flechas largas = inyecciones de conjugado, flechas cortas = inyecciones de irinotecán). A los ratones con tumores Calu-3 (N = 5-7) se les inyectó hRS7-CL2-SN-38 cada 4 días para un total de 4 inyecciones (q4dx4). </span>FIG. 4A. Therapeutic efficacy of CAF hRS7-SN-38 in various solid tumor xenograft disease models. The efficacy of CAF treatment with hRS7-CL2-SN-38 and hRS7-CL2A-SN-38 was studied in mice bearing xenografts of human non-small cell lung, colorectal, pancreatic, or squamous cell tumors. All CAFs and controls were administered in the indicated amounts (expressed as amount of SN-38 per dose; long arrows = conjugate injections, short arrows = irinotecan injections). Mice with Calu-3 tumors (N = 5-7) were injected with hRS7-CL2-SN-38 every 4 days for a total of 4 injections (q4dx4).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 4B.Eficacia terapéutica del CAF hRS7-SN-38 en varios modelos de enfermedad de xenoinjerto de tumores sólidos. La eficacia del tratamiento con CAF hRS7-CL2-SN-38 y hRS7-CL2A-SN-38 se estudió en ratones portadores de xenoinjertos de tumores de pulmón de células no pequeñas, colorrectales, pancreáticos o de células escamosas humanas. Todos los CAF y los controles se administraron en las cantidades indicadas (expresadas como cantidad de SN-38 por dosis; flechas largas = inyecciones de conjugado, flechas cortas = inyecciones de irinotecán). A ratones portadores de tumores COLO 205(N =5) se les inyectó 8 veces (q4dx8) el&lt;c&gt;A&lt;f&gt;o cada 2 días para un total de 5 inyecciones (q2dx5) con el MTD de irinotecán. </span>FIG. 4B.Therapeutic efficacy of CAF hRS7-SN-38 in various solid tumor xenograft disease models. The efficacy of CAF treatment with hRS7-CL2-SN-38 and hRS7-CL2A-SN-38 was studied in mice bearing xenografts of human non-small cell lung, colorectal, pancreatic, or squamous cell tumors. All CAFs and controls were administered in the indicated amounts (expressed as amount of SN-38 per dose; long arrows = conjugate injections, short arrows = irinotecan injections). COLO 205 tumor-bearing mice (N =5) were injected 8 times (q4dx8) on&lt;c&gt;A&lt;f&gt;or every 2 days for a total of 5 injections (q2dx5) with the MTD of irinotecan.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 4C.Eficacia terapéutica del CAF hRS7-SN-38 en varios modelos de enfermedad de xenoinjerto de tumores sólidos. La eficacia del tratamiento con CAF hRS7-CL2-SN-38 y hRS7-CL2A-SN-38 se estudió en ratones portadores de xenoinjertos de tumores de pulmón de células no pequeñas, colorrectales, pancreáticos o de células escamosas humanas. Todos los CAF y los controles se administraron en las cantidades indicadas (expresadas como cantidad de SN-38 por dosis; flechas largas = inyecciones de conjugado, flechas cortas = inyecciones de irinotecán). Capan-1 (N = 10) fueron tratados dos veces por semana durante 4 semanas con los agentes indicados. </span>FIG. 4C.Therapeutic efficacy of CAF hRS7-SN-38 in various solid tumor xenograft disease models. The efficacy of CAF treatment with hRS7-CL2-SN-38 and hRS7-CL2A-SN-38 was studied in mice bearing xenografts of human non-small cell lung, colorectal, pancreatic, or squamous cell tumors. All CAFs and controls were administered in the indicated amounts (expressed as amount of SN-38 per dose; long arrows = conjugate injections, short arrows = irinotecan injections). Capan-1 (N = 10) were treated twice weekly for 4 weeks with the indicated agents.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 4D.Eficacia terapéutica del CAF hRS7-SN-38 en varios modelos de enfermedad de xenoinjerto de tumores sólidos. La eficacia del tratamiento con CAF hRS7-CL2-SN-38 y hRS7-CL2A-SN-38 se estudió en ratones portadores de xenoinjertos de tumores de pulmón de células no pequeñas, colorrectales, pancreáticos o de células escamosas humanas. Todos los CAF y los controles se administraron en las cantidades indicadas (expresadas como cantidad de SN-38 por dosis; flechas largas = inyecciones de conjugado, flechas cortas = inyecciones de irinotecán). Se trataron ratones portadores de tumores BxPC-3 (N =10)dos veces por semana durante 4 semanas con los agentes indicados. </span>FIG. 4D.Therapeutic efficacy of CAF hRS7-SN-38 in various solid tumor xenograft disease models. The efficacy of CAF treatment with hRS7-CL2-SN-38 and hRS7-CL2A-SN-38 was studied in mice bearing xenografts of human non-small cell lung, colorectal, pancreatic, or squamous cell tumors. All CAFs and controls were administered in the indicated amounts (expressed as amount of SN-38 per dose; long arrows = conjugate injections, short arrows = irinotecan injections). BxPC-3 tumor-bearing mice (N =10) were treated twice a week for 4 weeks with the indicated agents.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 4E.Eficacia terapéutica del CAF hRS7-SN-38 en varios modelos de enfermedad de xenoinjerto de tumores sólidos. La eficacia del tratamiento con CAF hRS7-CL2-SN-38 y hRS7-CL2A-SN-38 se estudió en ratones portadores de xenoinjertos de tumores de pulmón de células no pequeñas, colorrectales, pancreáticos o de células escamosas humanas. Todos los CAF y los controles se administraron en las cantidades indicadas (expresadas como cantidad de SN-38 por dosis; flechas largas = inyecciones de conjugado, flechas cortas = inyecciones de irinotecán). Además del CAF administrado dos veces por semana durante 4 semanas, los ratones con tumor SK-MES-1 (N = 8) recibieron el MTD de CPT-11 (q2dx5). </span>FIG. 4E.Therapeutic efficacy of CAF hRS7-SN-38 in various solid tumor xenograft disease models. The efficacy of CAF treatment with hRS7-CL2-SN-38 and hRS7-CL2A-SN-38 was studied in mice bearing xenografts of human non-small cell lung, colorectal, pancreatic, or squamous cell tumors. All CAFs and controls were administered in the indicated amounts (expressed as amount of SN-38 per dose; long arrows = conjugate injections, short arrows = irinotecan injections). In addition to CAF administered twice weekly for 4 weeks, SK-MES-1 tumor-bearing mice (N = 8) received the MTD of CPT-11 (q2dx5).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 5A.Tolerabilidad de hRS7-CL2A-SN-38 en ratones Swiss-Webster. A cincuenta y seis ratones Swiss-Webster se les administraron 2 dosis i.p. de tampón o hRS7-CL2A-SN-38 con 3 días de diferencia (4, 8 o 12 mg/kg de SN-38 por dosis; 250, 500 o 750 mg proteína conjugada/kg por dosis). Siete y 15 días después de la última inyección, se sacrificaron 7 ratones de cada grupo y se realizaron recuentos sanguíneos y química sérica. Los gráficos muestran el porcentaje de animales en cada grupo que tenían niveles elevados de AST.FIG. 5B.Tolerabilidad de hRS7-CL2A-SN-38 en ratones Swiss-Webster. A cincuenta y seis ratones SwissWebster se les administraron 2 dosis i.p. de tampón o hRS7-CL2A-SN-38 con 3 días de diferencia (4, 8 o 12 mg/kg de SN-38 por dosis; 250, 500 o 750 mg proteína conjugada/kg por dosis). Siete y 15 días después de la última inyección, se sacrificaron 7 ratones de cada grupo y se realizaron recuentos sanguíneos y química sérica. Los gráficos muestran el porcentaje de animales en cada grupo que tenían niveles elevados de ALT.FIG. 5C.Tolerabilidad de hRS7-CL2A-SN-38 en monos Cynomolgus. A seis monos por grupo se les inyectó dos veces con 3 días de diferencia tampón (control) o hRS7-CL2A-SN-38 a 0,96 mg/kg o 1,92 mg/kg de equivalentes de SN-38 por dosis (60 y 120 mg/kg de proteína conjugada). Todos los animales se sangraron los días -1, 3 y 6. Se sangraron cuatro monos el día 11 en el grupo de 0,96 mg/kg, 3 en el grupo de 1,92 mg/kg. Cambios en el recuento de neutrófilos en monos Cynomolgus. </span>FIG. 5A.Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice. Fifty-six Swiss-Webster mice were administered 2 doses i.p. of buffer or hRS7-CL2A-SN-38 3 days apart (4, 8, or 12 mg/kg SN-38 per dose; 250, 500, or 750 mg conjugated protein/kg per dose). Seven and 15 days after the last injection, 7 mice from each group were sacrificed and blood counts and serum chemistry were performed. The graphs show the percentage of animals in each group that had elevated levels of AST.FIG. 5B. Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice. Fifty-six SwissWebster mice were administered 2 doses i.p. of buffer or hRS7-CL2A-SN-38 3 days apart (4, 8, or 12 mg/kg SN-38 per dose; 250, 500, or 750 mg conjugated protein/kg per dose). Seven and 15 days after the last injection, 7 mice from each group were sacrificed and blood counts and serum chemistry were performed. The graphs show the percentage of animals in each group that had elevated ALT levels.FIG. 5C.Tolerability of hRS7-CL2A-SN-38 in Cynomolgus monkeys. Six monkeys per group were injected twice 3 days apart with buffer (control) or hRS7-CL2A-SN-38 at 0.96 mg/kg or 1.92 mg/kg SN-38 equivalents per dose ( 60 and 120 mg/kg of conjugated protein). All animals were bled on days -1, 3 and 6. Four monkeys were bled on day 11 in the 0.96 mg/kg group, 3 in the 1.92 mg/kg group. Changes in neutrophil counts in Cynomolgus monkeys.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 5D.Tolerabilidad de hRS7-CL2A-SN-38 en monos Cynomolgus. A seis monos por grupo se les inyectó dos veces con 3 días de diferencia tampón (control) o hRS7-CL2A-SN-38 a 0,96 mg/kg o 1,92 mg/kg de equivalentes de SN-38 por dosis (60 y 120 mg/kg de proteína conjugada). Todos los animales se sangraron los días -1, 3 y 6. Se sangraron cuatro monos el día 11 en el grupo de 0,96 mg/kg, 3 en el grupo de 1,92 mg/kg. Cambios en el recuento de plaquetas en monos Cynomolgus. </span>FIG. 5D.Tolerability of hRS7-CL2A-SN-38 in Cynomolgus monkeys. Six monkeys per group were injected twice 3 days apart with buffer (control) or hRS7-CL2A-SN-38 at 0.96 mg/kg or 1.92 mg/kg SN-38 equivalents per dose ( 60 and 120 mg/kg of conjugated protein). All animals were bled on days -1, 3 and 6. Four monkeys were bled on day 11 in the 0.96 mg/kg group, 3 in the 1.92 mg/kg group. Changes in platelet count in Cynomolgus monkeys.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 6.Eficaciain vitrodel CAF anti-Trop-2-paclitaxel contra el adenocarcinoma de mama humano MDA-MB-468. </span>FIG. 6. In vitro efficacy of CAF anti-Trop-2-paclitaxel against human breast adenocarcinoma MDA-MB-468.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 7.Eficaciain vitrodel CAF anti-Trop-2-paclitaxel contra el adenocarcinoma de páncreas humano BxPC-3. </span>FIG. 7. In vitro efficacy of CAF anti-Trop-2-paclitaxel against BxPC-3 human pancreatic adenocarcinoma.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 8A.Comparación de la eficaciain vitrode los CAF anti-Trop-2 (hRS7-SN-38 versus MAB650-SN-38) en el adenocarcinoma de páncreas humano Capan-1. </span>FIG. 8A. Comparison of the in vitro efficacy of anti-Trop-2 CAFs (hRS7-SN-38 versus MAB650-SN-38) in Capan-1 human pancreatic adenocarcinoma.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 8B.Comparación de la eficaciain vitrode los CAF anti-Trop-2 (hRS7-SN-38 versus MAB650-SN-38) en el adenocarcinoma de páncreas humano BxPC-3. </span>FIG. 8B. Comparison of the in vitro efficacy of anti-Trop-2 CAFs (hRS7-SN-38 versus MAB650-SN-38) in BxPC-3 human pancreatic adenocarcinoma.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 8C.Comparación de la eficaciain vitrode los CAF anti-Trop-2 (hRS7-SN-38 versus MAB650-SN-38) en el adenocarcinoma gástrico humano NCI-N87. </span>FIG. 8C. Comparison of the in vitro efficacy of anti-Trop-2 CAFs (hRS7-SN-38 versus MAB650-SN-38) in human gastric adenocarcinoma NCI-N87.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 9A.Comparación de la citotoxicidad de los anticuerpos hRS7 desnudos o conjugados con SN-38 frente a 162-46.2 en el adenocarcinoma de páncreas humano BxPC-3. </span>FIG. 9A. Comparison of cytotoxicity of naked or SN-38-conjugated hRS7 antibodies versus 162-46.2 in BxPC-3 human pancreatic adenocarcinoma.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 9B.Comparación de la citotoxicidad de los anticuerpos hRS7 desnudos o conjugados con SN-38 versus 162-46.2 en el adenocarcinoma de mama humano MDA-M&lt;b&gt;-468. </span>FIG. 9B. Comparison of cytotoxicity of naked or SN-38-conjugated hRS7 antibodies versus 162-46.2 in human breast adenocarcinoma MDA- M&lt;b&gt;-468.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 10.Datos de IMMU-132 fase I/II para la mejor respuesta según los criterios RECIST. </span>FIG. 10.IMMU-132 phase I/II data for best response according to RECIST criteria.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 11.Datos de fase I/II de IMMU-132 para el tiempo hasta la progresión y la mejor respuesta (RECIST).FIG. 12.Terapia combinada con IMMU-132 y carboplatino o cisplatino, en comparación con IMMU-132, carboplatino o cisplatino solos, un CAF no dirigido o un control de solución salina. </span>FIG. 11.IMMU-132 phase I/II data for time to progression and best response (RECIST).FIG. 12. Combination therapy with IMMU-132 and carboplatin or cisplatin, compared to IMMU-132, carboplatin or cisplatin alone, a non-targeted CAF, or a saline control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 13.Terapia combinada con IMMU-132 más carboplatino, en comparación con IMMU-132 o caboplatino solos o control con solución salina. </span>FIG. 13. Combination therapy with IMMU-132 plus carboplatin, compared to IMMU-132 or caboplatin alone or saline control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 14.Terapia combinada con IMMU-132 más cisplatino, en comparación con IMMU-132 o cisplatino solo o control con solución salina. </span>FIG. 14. Combination therapy with IMMU-132 plus cisplatin, compared to IMMU-132 or cisplatin alone or saline control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 15.Caquexia en ratones tratados con terapia combinada con IMMU-132 y carboplatino o cisplatino, en comparación con IMMU-132, carboplatino o cisplatino solos o control con solución salina. </span>FIG. 15. Cachexia in mice treated with combination therapy with IMMU-132 and carboplatin or cisplatin, compared to IMMU-132, carboplatin or cisplatin alone or saline control.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG 16.Representación gráfica de la respuesta antitumoral y su duración en pacientes evaluables por respuesta. </span>FIG 16. Graphic representation of the antitumor response and its duration in patients evaluable for response.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(A)Mejor cambio porcentual en la suma de los diámetros de la lesión diana seleccionada y mejor descriptor de respuesta general según los criterios RECIST 1.1. Los pacientes se identifican con respecto a la dosis inicial de sacituzumab govitecan y si eran sensibles o resistentes a la terapia de primera línea previa. El paciente con respuestas parciales no confirmadas no logró mantener &gt;30 % en su siguiente evaluación por TC 4 a 6 semanas después de la primera respuesta objetiva observada. La mejor respuesta general para estos pacientes según RECIST 1.0 es una enfermedad estable.(B)Duración de la respuesta desde el inicio del tratamiento para aquellos pacientes que alcanzaron una enfermedad estable o mejor. Se muestra el momento en que la reducción del tumor alcanzó &gt;30 %, junto con la dosis inicial de sacituzumab govitecan y la sensibilidad al tratamiento de primera línea.(C)Dinámica de respuesta para pacientes que lograron una enfermedad estable o mejor. Con una línea discontinua se muestran dos pacientes con respuestas parciales confirmadas que continúan el tratamiento. </span>(A) Best percentage change in the sum of the diameters of the selected target lesion and best overall response descriptor according to the RECIST 1.1 criteria. Patients are identified with respect to the initial dose of sacituzumab govitecan and whether they were sensitive or resistant to prior first-line therapy. The patient with unconfirmed partial responses failed to maintain &gt;30% at his next CT evaluation 4 to 6 weeks after the first observed objective response. The best overall response for these patients according to RECIST 1.0 is stable disease. (B) Duration of response from the start of treatment for those patients who achieved stable disease or better. The time at which tumor shrinkage reached &gt;30% is shown, along with the initial dose of sacituzumab govitecan and sensitivity to first-line treatment. (C) Response dynamics for patients who achieved stable disease or better. Two patients with confirmed partial responses who continue treatment are shown with a dashed line.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 17. (A)Curvas de supervivencia libre de progresión y(B)generales derivadas de Kaplan-Meier para los 53 pacientes con CPCP inscritos en el ensayo de sacituzumab govitecan. </span>FIG. 17. (A) Kaplan-Meier-derived progression-free and (B) overall survival curves for the 53 SCLC patients enrolled in the sacituzumab govitecan trial.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 18.Este hombre de 64 años con diagnóstico de CPCP avanzado recibió carboplatino como tratamiento de primera línea desde julio de 2013 hasta noviembre de 2013, y se añadió etopósido en noviembre y diciembre de 2013. La enfermedad recayó en mayo de 2014. Antes de comenzar con sacituzumab govitecan, el tumor Las lesiones al inicio del estudio (mayo de 2014) incluyeron tumores de ganglio linfático subcarinal (20 mm) y de la glándula suprarrenal derecha(A)(masa suprarrenal de 43 x 34 mm de diámetro), así como múltiples lesiones no mensurables en los lóbulos derecho e izquierdo del hígado, engrosamiento. del hilio derecho, un nódulo pulmonar en el lóbulo superior izquierdo y engrosamiento esofágico. La evaluación de la respuesta después de 2 meses de terapia mostró una reducción del 50 % según RECIST 1.1(B)(la masa suprarrenal se reduce a 14 mm, el ganglio linfático subcarinal se reduce a 17 mm). En la segunda evaluación de respuesta, la masa suprarrenal ya no era visible, mientras que el ganglio subcarinal experimentó su contracción máxima ~11 meses desde el inicio del tratamiento (a 11 mm), lo que produjo una contracción máxima del 82%. El paciente experimentó una duración de respuesta de 21 meses (julio de 2014 a marzo de 2016).(C)Inmunohistología de una biopsia de la masa suprarrenal teñida para Trop-2 y puntuada como 2+, pero con escasa distribución entre las células tumorales. </span>FIG. 18.This 64-year-old man diagnosed with advanced SCLC received carboplatin as first-line treatment from July 2013 to November 2013, and etoposide was added in November and December 2013. The disease relapsed in May 2014. Before starting with sacituzumab govitecan, tumor lesions at baseline (May 2014) included subcarinal lymph node (20 mm) and right adrenal gland tumors (A)(adrenal mass 43 x 34 mm in diameter), as well as multiple non-measurable lesions in the right and left lobes of the liver, thickening. of the right hilum, a pulmonary nodule in the left upper lobe and esophageal thickening. Response evaluation after 2 months of therapy showed a 50% reduction according to RECIST 1.1(B)(adrenal mass reduced to 14 mm, subcarinal lymph node reduced to 17 mm). At the second response assessment, the adrenal mass was no longer visible, while the subcarinal ganglion experienced its maximum contraction ~11 months from the start of treatment (to 11 mm), resulting in a maximum contraction of 82%. The patient experienced a duration of response of 21 months (July 2014 to March 2016). (C) Immunohistology of a biopsy of the adrenal mass stained for Trop-2 and scored as 2+, but with poor distribution among tumor cells .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">FIG. 19.La figura muestra los efectos de la terapia IMMU-132 en un hombre de 57 años, fumador de 1 paquete/día desde los 13 años, a quien se le diagnosticó carcinoma neuroendocrino de células pequeñas metastásico en 2012 y que recibió carboplatino y etopósido como terapia de primera línea desde octubre de 2012 a enero de 2013, y en caso de recurrencia, recibió topotecán de septiembre de 2013 a noviembre de 2013 sin respuesta. Debido a la progresión de la enfermedad, el paciente pasó a una combinación de carboplatino y etopósido desde noviembre de 2013 hasta abril de 2014 y luego pasó a paclitaxel desde mayo de 2014 a junio de 2014. En septiembre de 2014, comenzó a tomar sacituzumab govitecan logrando una respuesta duradera. Se muestran imágenes de TC de 4 de las 5 lesiones diana desde el inicio y después de 2 meses de tratamiento, cuando la suma se redujo de 230 mm a 138 mm (40 % de contracción). (A) Corte axial de la masa suprarrenal derecha que mide 79 x 65 mm al inicio; (B) que muestra una reducción a 48 x 26 mm en la primera evaluación. (C) masa suprarrenal izquierda que mide 52 x 38 mm al inicio; (D) 36 x 17 mm en la primera evaluación; (E) masa axilar izquierda al inicio del estudio mostrada en el plano coronal (60 x 55 mm) y después de 2 meses de tratamiento (F), se reduce a 30 x 24 mm; (G) masa pulmonar del lóbulo superior derecho que se muestra en el plano coronal (21 x 12 mm) y se reduce a 16 x 12 mm (H). (I) Inmunohistología de una biopsia de pulmón teñida para Trop-2 con un rango de tinción de células tumorales de negativo a 3+, pero con una puntuación general de 2+. </span>FIG. 19.The figure shows the effects of IMMU-132 therapy in a 57-year-old man, a 1-pack/day smoker since age 13, who was diagnosed with metastatic small cell neuroendocrine carcinoma in 2012 and who received carboplatin and etoposide as first-line therapy from October 2012 to January 2013, and in case of recurrence, he received topotecan from September 2013 to November 2013 without response. Due to disease progression, the patient was switched to a combination of carboplatin and etoposide from November 2013 to April 2014 and then switched to paclitaxel from May 2014 to June 2014. In September 2014, he started taking sacituzumab govitecan achieving a lasting response. CT images of 4 of the 5 target lesions are shown from baseline and after 2 months of treatment, when the sum was reduced from 230 mm to 138 mm (40% contraction). (A) Axial section of the right adrenal mass measuring 79 x 65 mm at baseline; (B) showing a reduction to 48 x 26 mm on the first evaluation. (C) left adrenal mass measuring 52 x 38 mm at baseline; (D) 36 x 17 mm at first evaluation; (E) left axillary mass at baseline shown in the coronal plane (60 x 55 mm) and after 2 months of treatment (F), it is reduced to 30 x 24 mm; (G) Right upper lobe lung mass shown in the coronal plane (21 x 12 mm) and reduced to 16 x 12 mm (H). (I) Immunohistology of a lung biopsy stained for Trop-2 with a tumor cell staining range of negative to 3+, but with an overall score of 2+.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIPCIÓN DETALLADA </span>DETAILED DESCRIPTION</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Definiciones </span>Definitions</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0033] A menos que se especifique lo contrario, “un” o “una” significa uno o más. </span>[0033] Unless otherwise specified, “a” or “an” means one or more.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0034] Tal como se utiliza en el presente documento, “aproximadamente” significa más o menos 10%. Por ejemplo, “alrededor de 100” incluiría cualquier número entre 90 y 110. </span>[0034] As used herein, “approximately” means plus or minus 10%. For example, “about 100” would include any number between 90 and 110.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0035] Un anticuerpo, como se describe en el presente documento, se refiere a una molécula de inmunoglobulina de longitud completa (es decir, de origen natural o formada mediante procesos recombinatorios de fragmentos de genes de inmunoglobulina normales) (p. ej., un anticuerpo IgG) o una parte inmunológicamente activa (es decir, que se une específicamente) de una molécula de inmunoglobulina, como un fragmento de anticuerpo. </span>[0035] An antibody, as described herein, refers to a full-length immunoglobulin molecule (i.e., naturally occurring or formed by recombinational processes from fragments of normal immunoglobulin genes) (e.g., an IgG antibody) or an immunologically active (i.e. specifically binding) part of an immunoglobulin molecule, such as an antibody fragment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0036] Un fragmento de anticuerpo es una parte de un anticuerpo tal como F(ab')&lt;2&gt;, Fab', Fab, Fv, sFv y similares. Los fragmentos de anticuerpos también pueden incluir anticuerpos de dominio único y medias moléculas de IgG4, como se analiza más adelante. Independientemente de la estructura, un fragmento de anticuerpo se une al mismo antígeno que reconoce el anticuerpo de longitud completa. El término “fragmento de anticuerpo” también incluye fragmentos aislados que consisten en regiones variables de anticuerpos, tales como los fragmentos “Fv” que consisten en regiones variables de las cadenas pesada y ligera y moléculas polipeptídicas de cadena sencilla recombinantes en las que se encuentran regiones variables ligeras y pesadas conectadas por un conector peptídico (“proteínas scFv”). </span>[0036] An antibody fragment is a part of an antibody such as F(ab')&lt;2&gt;, Fab', Fab, Fv, sFv and the like. Antibody fragments may also include single domain antibodies and IgG4 half molecules, as discussed below. Regardless of the structure, an antibody fragment binds to the same antigen that the full-length antibody recognizes. The term "antibody fragment" also includes isolated fragments consisting of variable regions of antibodies, such as "Fv" fragments consisting of variable regions of the heavy and light chains and recombinant single-chain polypeptide molecules in which regions are found. light and heavy variables connected by a peptide linker (“scFv proteins”).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0037] Un anticuerpo quimérico es una proteína recombinante que contiene los dominios variables que incluyen las regiones determinantes de la complementariedad (CDR, por sus siglas en inglés) de un anticuerpo derivado de una especie, preferiblemente un anticuerpo de roedor, mientras que los dominios constantes de la molécula de anticuerpo se derivan de los de un anticuerpo humano. Para aplicaciones veterinarias, los dominios constantes del anticuerpo quimérico pueden derivarse de los de otras especies, como un gato o un perro. </span>[0037] A chimeric antibody is a recombinant protein that contains the variable domains that include the complementarity determining regions (CDR) of an antibody derived from a species, preferably a rodent antibody, while the domains Constants of the antibody molecule are derived from those of a human antibody. For veterinary applications, the constant domains of the chimeric antibody can be derived from those of other species, such as a cat or dog.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0038] Un anticuerpo humanizado es una proteína recombinante en la que las CDR de un anticuerpo de una especie; por ejemplo, un anticuerpo de roedor, se transfieren desde las cadenas variables pesada y ligera del anticuerpo de roedor a dominios variables pesados y ligeros humanos (p. ej., secuencias de regiones estructurales). Los dominios constantes de la molécula de anticuerpo se derivan de los de un anticuerpo humano. En determinadas formas de realización, se puede sustituir un número limitado de residuos de aminoácidos de la región estructural del anticuerpo original (de roedor) en las secuencias de la región estructural del anticuerpo humano. </span>[0038] A humanized antibody is a recombinant protein in which the CDRs of an antibody of one species; for example, a rodent antibody, are transferred from the heavy and light variable chains of the rodent antibody to human heavy and light variable domains (e.g., structural region sequences). The constant domains of the antibody molecule are derived from those of a human antibody. In certain embodiments, a limited number of amino acid residues from the original (rodent) antibody framework region can be substituted into the human antibody framework sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0039] Un anticuerpo humano es, por ejemplo, un anticuerpo obtenido de ratones transgénicos que han sido “diseñados” para producir anticuerpos humanos específicos en respuesta a una exposición antigénica. En esta técnica, se introducen elementos de los loci de las cadenas pesadas y ligeras humanas en cepas de ratones derivadas de líneas de células madre embrionarias que contienen alteraciones específicas de los loci de las cadenas pesadas y ligeras endógenas murinas. Los ratones transgénicos pueden sintetizar anticuerpos humanos específicos para antígenos particulares, y los ratones pueden usarse para producir hibridomas secretores de anticuerpos humanos. Green et al., Nature Genet, describen métodos para obtener anticuerpos humanos a partir de ratones transgénicos. 7:13 (1994), Lonberg et al., Nature 368:856 (1994), y Taylor et al., Int. Inmune. 6:579 (1994). También se puede construir un anticuerpo completamente humano mediante métodos de transfección genética o cromosómica, así como tecnología de presentación en fagos, todos los cuales son conocidos en la técnica. Véase, por ejemplo, McCafferty et al., Nature 348:552-553 (1990) para la producción de anticuerpos humanos y fragmentos de los mismosin vitro,a partir de repertorios de genes de dominio variable de inmunoglobulina de donantes no inmunizados. En esta técnica, los genes del dominio variable del anticuerpo se clonan en marco en un gen de la proteína de cubierta mayor o menor de un bacteriófago filamentoso y se muestran como fragmentos de anticuerpo funcionales en la superficie de la partícula del fago. Debido a que la partícula filamentosa contiene una copia de ADN monocatenario del genoma del fago, las selecciones basadas en las propiedades funcionales del anticuerpo también dan como resultado la selección del gen que codifica el anticuerpo que exhibe esas propiedades. </span>[0039] A human antibody is, for example, an antibody obtained from transgenic mice that have been “engineered” to produce specific human antibodies in response to an antigenic challenge. In this technique, elements of the human heavy and light chain loci are introduced into mouse strains derived from embryonic stem cell lines containing specific alterations of the endogenous murine heavy and light chain loci. Transgenic mice can synthesize human antibodies specific for particular antigens, and the mice can be used to produce human antibody-secreting hybridomas. Green et al., Nature Genet, describe methods for obtaining human antibodies from transgenic mice. 7:13 (1994), Lonberg et al., Nature 368:856 (1994), and Taylor et al., Immune Int. 6:579 (1994). A fully human antibody can also be constructed by genetic or chromosomal transfection methods, as well as phage display technology, all of which are known in the art. See, for example, McCafferty et al., Nature 348:552-553 (1990) for the production of human antibodies and fragments thereof in vitro, from immunoglobulin variable domain gene repertoires from non-immunized donors. In this technique, antibody variable domain genes are cloned in frame into a major or minor coat protein gene of a filamentous bacteriophage and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody that exhibits those properties.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De esta forma, el fago imita algunas de las propiedades de la célula B. La presentación en fagos se puede realizar en una variedad de formatos; para su revisión, véase, por ejemplo, Johnson y Chiswell, Current Opinion in Structural Biology 3:5564-571 (1993). Los anticuerpos humanos también pueden generarse mediante células B activadasin vitro.Véase la patente de EE. UU. Nos 5.567.610 y 5.229.275. </span>In this way, the phage mimics some of the properties of the B cell. Phage display can be performed in a variety of formats; for review, see, for example, Johnson and Chiswell, Current Opinion in Structural Biology 3:5564-571 (1993). Human antibodies can also be generated by activated B cells in vitro. See US Patent Nos. 5,567,610 and 5,229,275.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0040]Un agente terapéutico es un compuesto, molécula o átomo que se administra por separado, concurrente o secuencialmente con un resto de anticuerpo o conjugado con un resto de anticuerpo, es decir, anticuerpo o fragmento de anticuerpo, o un subfragmento, y es útil en el tratamiento de una enfermedad. Ejemplos de agentes terapéuticos incluyen anticuerpos, fragmentos de anticuerpos, fármacos, toxinas, nucleasas, hormonas, inmunomoduladores, agentes proapoptóticos, agentes antiangiogénicos, compuestos de boro, agentes fotoactivos o colorantes y radioisótopos. Los agentes terapéuticos de uso se describen con más detalle a continuación. </span>[0040]A therapeutic agent is a compound, molecule or atom that is administered separately, concurrently or sequentially with an antibody moiety or conjugated with an antibody moiety, i.e., antibody or antibody fragment, or a subfragment, and is useful in the treatment of a disease. Examples of therapeutic agents include antibodies, antibody fragments, drugs, toxins, nucleases, hormones, immunomodulators, proapoptotic agents, antiangiogenic agents, boron compounds, photoactive agents or dyes and radioisotopes. Therapeutic agents of use are described in more detail below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0041]Un inmunoconjugado es un anticuerpo, fragmento de anticuerpo o proteína de fusión conjugado con al menos un agente terapéutico y/o de diagnóstico. </span>[0041]An immunoconjugate is an antibody, antibody fragment or fusion protein conjugated to at least one therapeutic and/or diagnostic agent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0042]Un anticuerpo multiespecífico es un anticuerpo que puede unirse simultáneamente a al menos dos dianas que tienen una estructura diferente, por ejemplo, dos antígenos diferentes, dos epítopos diferentes en el mismo antígeno o un hapteno y/o un antígeno o epítopo. Los anticuerpos multiespecíficos y multivalentes son construcciones que tienen más de un sitio de unión y los sitios de unión son de diferente especificidad. </span>[0042]A multispecific antibody is an antibody that can simultaneously bind to at least two targets that have a different structure, for example, two different antigens, two different epitopes on the same antigen or a hapten and/or one antigen or epitope. Multispecific and multivalent antibodies are constructs that have more than one binding site and the binding sites are of different specificity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0043]Un anticuerpo biespecífico es un anticuerpo que puede unirse simultáneamente a dos objetivos diferentes. Los anticuerpos biespecíficos (bsAb) y los fragmentos de anticuerpos biespecíficos (bsFab) pueden tener al menos un brazo que se une específicamente a, por ejemplo, un antígeno asociado a tumor y al menos otro brazo que se une específicamente a un conjugado direccionable que porta una finalidad terapéutica o agente diagnóstico. Se puede producir una variedad de proteínas de fusión biespecíficas mediante ingeniería molecular. </span>[0043]A bispecific antibody is an antibody that can simultaneously bind to two different targets. Bispecific antibodies (bsAb) and bispecific antibody fragments (bsFab) may have at least one arm that specifically binds to, for example, a tumor-associated antigen and at least one other arm that specifically binds to a targetable conjugate carrying a therapeutic purpose or diagnostic agent. A variety of bispecific fusion proteins can be produced by molecular engineering.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos anti-T rop-2</span>Anti-T rop-2 antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0044]Según la invención, tal como se define en las reivindicaciones, el anticuerpo anti-Trop-2 es un anticuerpo RS7 humanizado (véase, por ejemplo, la patente de EE. UU. n° 7.238.785), que comprende las secuencias CDR de cadena ligera CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); y CDR3 (QQHYITPLT, SEQ ID NO:3) y las secuencias de CDR de cadena pesada CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) y CDR3 (GGFGSSYWYFDV, SEQ ID NO:6). </span>[0044]According to the invention, as defined in the claims, the anti-Trop-2 antibody is a humanized RS7 antibody (see, for example, US Patent No. 7,238,785), which comprises the CDR1 light chain CDR sequences (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0045]El anticuerpo RS7 era una IgG1 murina producida contra una preparación de membrana cruda de un carcinoma de pulmón de células escamosas primario humano. (Stein et al., Cancer Res. 50: 1330, 1990) El anticuerpo RS7 reconoce una glicoproteína de 46-48 kDa, caracterizada como grupo 13. (Stein et al., Int. J. Cancer Supp. 8:98-102, 1994) El antígeno fue designado como EGP-1 (glucoproteína epitelial-1), pero también se lo conoce como Trop-2. </span>[0045]The RS7 antibody was a murine IgG1 raised against a crude membrane preparation of a human primary squamous cell lung carcinoma. (Stein et al., Cancer Res. 50: 1330, 1990) The RS7 antibody recognizes a 46-48 kDa glycoprotein, characterized as group 13. (Stein et al., Int. J. Cancer Supp. 8:98-102 , 1994) The antigen was designated EGP-1 (epithelial glycoprotein-1), but is also known as Trop-2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0046]Trop-2 es una proteína transmembrana de tipo I y ha sido clonada a partir de células humanas (Fornaro et al., Int J Cancer 1995; 62:610-8) y de ratón (Sewedy et al., Int J Cancer 1998; 75: 324-30). Además de su papel como transductor de señales de calcio asociado a tumores (Ripani et al., Int J Cancer 1998;76:671-6), se demostró que la expresión de Trop-2 humano es necesaria para la tumorigénesis y la invasividad de las células de cáncer de colon que podría reducirse eficazmente con un anticuerpo policlonal contra el dominio extracelular de Trop-2 (Wang et al., Mol Cancer Ther 2008;7:280-5). </span>[0046]Trop-2 is a type I transmembrane protein and has been cloned from human (Fornaro et al., Int J Cancer 1995; 62:610-8) and mouse cells (Sewedy et al., Int J Cancer 1998; 75: 324-30). In addition to its role as a transducer of tumor-associated calcium signals (Ripani et al., Int J Cancer 1998;76:671-6), expression of human Trop-2 was shown to be required for tumorigenesis and invasiveness of colon cancer cells that could be effectively reduced with a polyclonal antibody against the extracellular domain of Trop-2 (Wang et al., Mol Cancer Ther 2008;7:280-5).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0047]El creciente interés en Trop-2 como diana terapéutica para cánceres sólidos (Cubas et al., Biochim Biophys Acta 2009;1796:309-14) está atestiguado por informes adicionales que documentaron la importancia clínica de Trop-2 sobreexpresado en mama (Huang et al., Clin Cancer Res 2005;11:4357-64), colorrectal (Ohmachi et al., Clin Cancer Res 2006;12:3057-63; Fang et al., Int J Colorectal Dis 2009;24:875-84) y carcinomas de células escamosas orales (Fong et al., Modern Pathol 2008;21:186-91). Es particularmente notable la evidencia más reciente de que las células basales de la próstata que expresan altos niveles de Trop-2 están enriquecidas para una actividad similar a un talloin vitroein vivo(Goldstein et al., Proc Natl Acad Sci EE. UU. 2008;105:20882-7). </span>[0047]The growing interest in Trop-2 as a therapeutic target for solid cancers (Cubas et al., Biochim Biophys Acta 2009;1796:309-14) is attested by additional reports that documented the clinical importance of overexpressed Trop-2 in breast (Huang et al., Clin Cancer Res 2005;11:4357-64), colorectal (Ohmachi et al., Clin Cancer Res 2006;12:3057-63; Fang et al., Int J Colorectal Dis 2009;24:875 -84) and oral squamous cell carcinomas (Fong et al., Modern Pathol 2008;21:186-91). Particularly noteworthy is the more recent evidence that prostate basal cells expressing high levels of Trop-2 are enriched for talloin-like activity in vitro (Goldstein et al., Proc Natl Acad Sci USA 2008; 105:20882-7).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0048]Los estudios de citometría de flujo y tinción inmunohistoquímica han demostrado que el MAb RS7 detecta antígenos en una variedad de tipos de tumores, con unión limitada al tejido humano normal (Stein et al., 1990). Trop-2 se expresa principalmente en carcinomas como los de pulmón, estómago, vejiga urinaria, mama, ovario, útero y próstata. Los estudios de localización y terapia utilizando MAb RS7 murino radiomarcado en modelos animales han demostrado eficacia terapéutica y focalización de tumores (Stein et al., 1990; Stein et al., 1991). </span>[0048]Flow cytometry and immunohistochemical staining studies have shown that MAb RS7 detects antigens in a variety of tumor types, with limited binding to normal human tissue (Stein et al., 1990). Trop-2 is mainly expressed in carcinomas such as those of the lung, stomach, urinary bladder, breast, ovary, uterus and prostate. Localization and therapy studies using radiolabeled murine MAb RS7 in animal models have demonstrated therapeutic efficacy and tumor targeting (Stein et al., 1990; Stein et al., 1991).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0049]Se ha demostrado una fuerte tinción de RS7 en tumores de pulmón, mama, vejiga, ovario, útero, estómago y próstata. (Stein et al., Int. J. Cancer 55:938, 1993) Los casos de cáncer de pulmón comprendían tanto carcinomas de células escamosas como adenocarcinomas. (Stein et al., Int. J. Cancer 55:938, 1993) Ambos tipos de células se tiñeron fuertemente, lo que indica que el anticuerpo RS7 no distingue entre clases histológicas de carcinoma de pulmón de células no pequeñas. </span>[0049]Strong RS7 staining has been demonstrated in tumors of the lung, breast, bladder, ovary, uterus, stomach, and prostate. (Stein et al., Int. J. Cancer 55:938, 1993) Lung cancer cases included both squamous cell carcinomas and adenocarcinomas. (Stein et al., Int. J. Cancer 55:938, 1993) Both cell types stained strongly, indicating that the RS7 antibody does not distinguish between histological classes of non-small cell lung carcinoma.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0050]El MAb RS7 se internaliza rápidamente en las células diana (Stein et al., 1993). La constante de tasa de intemalización para RS7 MAb es intermedia entre las constantes de tasa de intemalización de otros dos MAb de intemalización rápida, que han demostrado ser útiles para la producción de inmunotoxinas.(Id).Está bien documentado que la internalización de conjugados de inmunotoxina es un requisito para la actividad antitumoral. (Pastan et al., Cell 47:641, 1986) La internalización de inmunoconjugados de fármacos se ha descrito como un factor importante en la eficacia antitumoral. (Yang et al., Proc. Nat'l Acad. Sci. EE. UU. 85: 1189, 1988). Por tanto, el anticuerpo RS7 exhibe varias propiedades importantes para aplicaciones terapéuticas. </span>[0050]The MAb RS7 is rapidly internalized into target cells (Stein et al., 1993). The internalization rate constant for RS7 MAb is intermediate between the internalization rate constants of two other rapidly internalizing MAbs, which have been shown to be useful for the production of immunotoxins. (Id). It is well documented that the internalization of conjugates of Immunotoxin is a requirement for antitumor activity. (Pastan et al., Cell 47:641, 1986) Internalization of drug immunoconjugates has been described as an important factor in antitumor efficacy. (Yang et al., Proc. Nat'l Acad. Sci. USA 85: 1189, 1988). Therefore, the RS7 antibody exhibits several properties important for therapeutic applications.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0051]Si bien el anticuerpo hRS7 es el anticuerpo para uso según la presente invención como se define en las reivindicaciones, se conocen y/o están públicamente disponibles otros anticuerpos anti-Trop-2. Si bien se prefieren los anticuerpos humanizados o humanos por su inmunogenicidad reducida, en formas de realización alternativas puede ser útil un anticuerpo quimérico. Como se analiza más adelante, los métodos de humanización de anticuerpos son bien conocidos en la técnica y pueden utilizarse para convertir un anticuerpo murino o quimérico disponible en una forma humanizada. </span>[0051]While the hRS7 antibody is the antibody for use according to the present invention as defined in the claims, other anti-Trop-2 antibodies are known and/or publicly available. Although humanized or human antibodies are preferred for their reduced immunogenicity, in alternative embodiments a chimeric antibody may be useful. As discussed below, antibody humanization methods are well known in the art and can be used to convert an available murine or chimeric antibody into a humanized form.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0052]Los anticuerpos anti-Trop-2 están disponibles comercialmente de varias fuentes e incluyen LS-C126418, LSC178765, LS-C126416, LS-C126417 (LifeSpan BioSciences, Inc., Seattle, WA); 10428-MM01, 10428-MM02, 10428-R001, 10428-R030 (Sino Biological Inc., Beijing, China); MR54 (eBioscience, San Diego, CA); s.c.-376181, s.c.-376746, Santa Cruz Biotechnology (Santa Cruz, c A); MM0588-49D6, (Novus Biologicals, Littleton, CO); ab79976 y ab89928 (ABCAM®, Cambridge, MA). </span>[0052]Anti-Trop-2 antibodies are commercially available from various sources and include LS-C126418, LSC178765, LS-C126416, LS-C126417 (LifeSpan BioSciences, Inc., Seattle, WA); 10428-MM01, 10428-MM02, 10428-R001, 10428-R030 (Sino Biological Inc., Beijing, China); MR54 (eBioscience, San Diego, CA); s.c.-376181, s.c.-376746, Santa Cruz Biotechnology (Santa Cruz, c A); MM0588-49D6, (Novus Biologicals, Littleton, CO); ab79976 and ab89928 (ABCAM®, Cambridge, MA).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0053]En la literatura de patentes se han descrito otros anticuerpos anti-Trop-2. Por ejemplo, la publicación de EE. UU. n° 2013/0089872 divulga anticuerpos anti-Trop-2 K5-70 (n° de registro FERM BP-11251), K5-107 (n° de registro FERM BP-11252), K5-116-2-1 (n° de registro FERM BP-11253), T6-16 (n° de registro FERM BP-11346) y T5-86 (n° de registro FERM BP-11254), depositados en el Organismo Depositario Internacional de Patentes, Tsukuba, Japón. La patente de EE. UU. n° 5.840.854 desvela el anticuerpo monoclonal anti-Trop-2 BR110 (ATCC n° HB11698). La patente de EE. UU. n° 7.420.040 desvela un anticuerpo anti-Trop-2 producido por la línea celular de hibridoma AR47A6.4.2, depositado en el IDAC (Autoridad Internacional de Depósito de Canadá, Winnipeg, Canadá) con el número de acceso 141205-05. La patente de EE. UU. n° 7.420.041 desvela un anticuerpo anti-Trop-2 producido por la línea celular de hibridoma AR52A301.5, depositada en el IDAC con el número de acceso 141205-03. Publicación de EE. UU. N° 2013/0122020 divulga anticuerpos anti-Trop-23E9, 6G11, 7E6, 15E2, 18B1. Los hibridomas que codifican un anticuerpo representativo se depositaron en la Colección Americana de Cultivos Tipo (ATCC), números de acceso PTA-12871 y PTA-12872. La patente de EE. UU. n° 8.715.662 describe anticuerpos anti-Trop-2 producidos por hibridomas depositados en AID-ICLC (Génova, Italia) con números de depósito EP 08019, EP 08020 y EP 08021. Publ. de Solicitud de Patente de EE. UU. n° 20120237518 describe los anticuerpos anti-Trop-2 77220, KM4097 y KM4590. La patente de EE. UU. n° 8.309.094 (Wyeth) describe los anticuerpos A1 y A3, identificados mediante listado de secuencias. La publicación no de patente Lipinski et al. (1981, Proc Natl. Acad Sci EE. UU., 78:5147-50) describieron los anticuerpos anti-Trop-2 162-25.3 y 162 46.2. </span>[0053]Other anti-Trop-2 antibodies have been described in the patent literature. For example, US publication no. 2013/0089872 discloses anti-Trop-2 antibodies K5-70 (FERM registration no. BP-11251), K5-107 (FERM registration no. BP-11252), K5-116-2-1 (FERM registration number BP-11253), T6-16 (FERM registration number BP-11346) and T5-86 (FERM registration number BP-11254), deposited with the Agency International Patent Depository, Tsukuba, Japan. US Patent No. 5,840,854 discloses the anti-Trop-2 monoclonal antibody BR110 (ATCC No. HB11698). US Patent No. 7,420,040 discloses an anti-Trop-2 antibody produced by the hybridoma cell line AR47A6.4.2, deposited at IDAC (International Depository Authority of Canada, Winnipeg, Canada) under the number access code 141205-05. US Patent No. 7,420,041 discloses an anti-Trop-2 antibody produced by the hybridoma cell line AR52A301.5, deposited at IDAC under accession number 141205-03. US Publication No. 2013/0122020 discloses anti-Trop-23E9, 6G11, 7E6, 15E2, 18B1 antibodies. Hybridomas encoding a representative antibody were deposited in the American Type Culture Collection (ATCC), accession numbers PTA-12871 and PTA-12872. US Patent No. 8,715,662 describes anti-Trop-2 antibodies produced by hybridomas deposited at AID-ICLC (Genoa, Italy) with deposit numbers EP 08019, EP 08020 and EP 08021. Publ. US Patent Application No. 20120237518 describes anti-Trop-2 antibodies 77220, KM4097 and KM4590. US Patent No. 8,309,094 (Wyeth) describes antibodies A1 and A3, identified by sequence listing. The non-patent publication Lipinski et al. (1981, Proc Natl. Acad Sci USA, 78:5147-50) described the anti-Trop-2 antibodies 162-25.3 and 162 46.2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0054]Se conocen en la técnica y/o están disponibles públicamente numerosos anticuerpos anti-Trop-2. Como se analiza más adelante, los métodos para preparar anticuerpos contra antígenos conocidos eran rutinarios en la técnica. La secuencia de la proteína Trop-2 humana también se conocía en la técnica (véase, por ejemplo, el número de acceso de GenBank CAA54801.1). También se conocían métodos para producir anticuerpos humanizados, humanos o quiméricos. Una persona con experiencia ordinaria, leyendo la presente divulgación a la luz del conocimiento general en la técnica, habría podido producir y utilizar el género de anticuerpos anti-Trop-2 en los CAF. </span>[0054]Numerous anti-Trop-2 antibodies are known in the art and/or publicly available. As discussed below, methods for preparing antibodies against known antigens were routine in the art. The sequence of the human Trop-2 protein was also known in the art (see, for example, GenBank accession number CAA54801.1). Methods for producing humanized, human or chimeric antibodies were also known. A person of ordinary skill, reading the present disclosure in light of general knowledge in the art, would have been able to produce and use the anti-Trop-2 class of antibodies in CAFs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0055]Se ha descrito el uso de anticuerpos anti-Trop-2 para inmunoterapéuticos distintos de los CAF. El anticuerpo murino IgG2a edrecolomab (PANOREX®) se ha utilizado para el tratamiento del cáncer colorrectal, aunque el anticuerpo murino no es muy adecuado para uso clínico en humanos (Baeuerle &amp; Gires, 2007, Br. J Cancer 96:417-423). Se informó que la administración subcutánea de dosis bajas de ecrecolomab induce respuestas inmunes humorales contra el antígeno de la vacuna (Baeuerle &amp; Gires, 2007). Adecatumumab (MT201), un anticuerpo anti-Trop-2 completamente humano, se ha utilizado en el cáncer de mama metastásico y en el cáncer de próstata en etapa temprana y se informa que actúa a través de la actividad ADCC y CDC (Baeuerle &amp; Gires, 2007). MT110, una construcción de anticuerpo biespecífico monocatenario anti-Trop-2/anti-CD3, ha demostrado eficacia contra el cáncer de ovario (Baeuerle &amp; Gires, 2007). Se informó que el catumaxomab, un anticuerpo híbrido de ratón/rata con afinidad de unión por los receptores Trop-2, CD3 y Fc, es activo contra el cáncer de ovario (Baeuerle y Gires, 2007). El proxinio, una inmunotoxina que comprende un anticuerpo monocatenario anti-Trop-2 fusionado con la exotoxina de Pseudomonas, se ha probado en el cáncer de cabeza y cuello y de vejiga (Baeuerle &amp; Gires, 2007). Ninguno de estos estudios contenía ninguna divulgación sobre el uso de conjugados de fármaco y anticuerpo anti-Trop-2. </span>[0055]The use of anti-Trop-2 antibodies has been described for immunotherapeutics other than CAFs. The murine IgG2a antibody edrecolomab (PANOREX®) has been used for the treatment of colorectal cancer, although the murine antibody is not well suited for clinical use in humans (Baeuerle &amp; Gires, 2007, Br. J Cancer 96:417-423). Subcutaneous administration of low doses of ecrecolomab has been reported to induce humoral immune responses against the vaccine antigen (Baeuerle &amp; Gires, 2007). Adecatumumab (MT201), a fully human anti-Trop-2 antibody, has been used in metastatic breast cancer and early-stage prostate cancer and is reported to act through ADCC and CDC activity (Baeuerle &amp; Gires , 2007). MT110, a single-chain bispecific anti-Trop-2/anti-CD3 antibody construct, has demonstrated efficacy against ovarian cancer (Baeuerle &amp; Gires, 2007). Catumaxomab, a mouse/rat hybrid antibody with binding affinity for Trop-2, CD3, and Fc receptors, was reported to be active against ovarian cancer (Baeuerle and Gires, 2007). Proxinium, an immunotoxin comprising a single-chain anti-Trop-2 antibody fused to Pseudomonas exotoxin, has been tested in head and neck and bladder cancer (Baeuerle &amp; Gires, 2007). None of these studies contained any disclosures regarding the use of anti-Trop-2 antibody-drug conjugates.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Conjugados de camptotecina</span>Camptothecin conjugates</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0056]A continuación se describen métodos y composiciones no limitantes para preparar inmunoconjugados que comprenden un agente terapéutico de camptotecina unido a un anticuerpo o fragmento de anticuerpo de unión a antígeno. La solubilidad del fármaco se mejora colocando un resto definido de polietilenglicol (PEG) (es decir, un PEG que contiene un número definido de unidades monoméricas) entre el fármaco y el anticuerpo, en el que el PEG definido es un PEG de bajo peso molecular, que contiene preferiblemente 1-30 unidades monoméricas, que contiene más preferiblemente de 1 a 12 unidades monoméricas, lo más preferiblemente que contiene de 6 a 8 unidades monoméricas. </span>[0056]Described below are non-limiting methods and compositions for preparing immunoconjugates comprising a camptothecin therapeutic agent linked to an antigen-binding antibody or antibody fragment. The solubility of the drug is improved by placing a defined polyethylene glycol (PEG) moiety (i.e., a PEG containing a defined number of monomeric units) between the drug and the antibody, wherein the defined PEG is a low molecular weight PEG. , preferably containing 1-30 monomeric units, more preferably containing 1 to 12 monomeric units, most preferably containing 6 to 8 monomeric units.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0057]Un primer conector puede conectar el fármaco en un extremo y puede terminar con un grupo acetileno o azida en el otro extremo. Este primer conector puede comprender un resto PEG definido con un grupo azida o acetileno en un extremo y un grupo reactivo diferente, tal como ácido carboxílico o grupo hidroxilo, en el otro extremo. Dicho PEG definido bifuncional puede estar unido al grupo amino de un aminoalcohol, y el grupo hidroxilo de este último puede estar unido al grupo hidroxilo del fármaco en forma de carbonato. Alternativamente, el resto no azida (o acetileno) de dicho PEG bifuncional definido está opcionalmente unido al extremo N de un L-aminoácido o un polipéptido, con el extremo C unido al grupo amino de aminoalcohol, y el grupo hidroxi de este último está unido al grupo hidroxilo del fármaco en forma de carbonato o carbamato, respectivamente. </span>[0057]A first linker may connect the drug at one end and may terminate with an acetylene or azide group at the other end. This first linker may comprise a PEG moiety defined with an azide or acetylene group at one end and a different reactive group, such as carboxylic acid or hydroxyl group, at the other end. Said bifunctional defined PEG can be linked to the amino group of an amino alcohol, and the hydroxyl group of the latter can be linked to the hydroxyl group of the drug in carbonate form. Alternatively, the non-azide (or acetylene) moiety of said defined bifunctional PEG is optionally attached to the N-terminus of an L-amino acid or a polypeptide, with the C-terminus attached to the amino group of aminoalcohol, and the hydroxy group of the latter being attached to the hydroxyl group of the drug in the form of carbonate or carbamate, respectively.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0058]Un segundo conector, que comprende un grupo de acoplamiento de anticuerpo y un grupo reactivo complementario al grupo azida (o acetileno) del primer conector, concretamente acetileno (o azida), puede reaccionar con el conjugado fármaco-(primer conector) mediante reacción de cicloadición acetileno-azida para proporcionar un producto farmacológico bifuncional final que es útil para conjugar con anticuerpos dirigidos a enfermedades. El grupo de acoplamiento del anticuerpo es preferiblemente un tiol o un grupo reactivo con tiol. </span>[0058]A second linker, comprising an antibody coupling group and a reactive group complementary to the azide (or acetylene) group of the first linker, namely acetylene (or azide), can react with the drug-conjugate (first linker) by acetylene-azide cycloaddition reaction to provide a final bifunctional drug product that is useful for conjugation with disease-targeting antibodies. The coupling group of the antibody is preferably a thiol or a thiol-reactive group.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0059]A continuación se proporcionan métodos para la regeneración selectiva del grupo 10-hidroxilo en presencia del carbonato C-20 en preparaciones de precursores de fármaco-enlazador que implican análogos de CPT tales como SN-38. También se pueden usar otros grupos protectores para grupos hidroxilo reactivos en fármacos tales como el hidroxilo fenólico en SN-38, por ejemplo t-butildimetilsililo o t-butildifenilsililo, y estos se desprotegen mediante fluoruro de tetrabutilamonio antes de unir el fármaco derivatizado a un resto de acoplamiento de anticuerpos. El grupo 10-hidroxilo de los análogos de CPT se protege alternativamente como un éster o carbonato, distinto de 'BOC', de modo que la CPT bifuncional se conjuga con un anticuerpo sin desprotección previa de este grupo protector. El grupo protector se desprotege fácilmente en condiciones de pH fisiológico después de administrar el bioconjugado. </span>[0059]Methods are provided below for the selective regeneration of the 10-hydroxyl group in the presence of the C-20 carbonate in drug-linker precursor preparations involving CPT analogs such as SN-38. Other protecting groups can also be used for reactive hydroxyl groups in drugs such as the phenolic hydroxyl in SN-38, for example t-butyldimethylsilyl or t-butyldiphenylsilyl, and these are deprotected by tetrabutylammonium fluoride before attaching the derivatized drug to a moiety. antibody coupling. The 10-hydroxyl group of CPT analogues is alternatively protected as an ester or carbonate, other than 'BOC', so that bifunctional CPT is conjugated to an antibody without prior deprotection of this protecting group. The protecting group is easily deprotected under physiological pH conditions after administration of the bioconjugate.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0060]En el acoplamiento acetileno-azida, denominado “química de clic”, la parte de azida puede estar en L2 con la parte de acetileno en L3. Alternativamente, L2 puede contener acetileno, mientras que L3 contiene azida. La 'química de clic' se refiere a una reacción de cicloadición catalizada por cobre (+1) entre un resto de acetileno y un resto de azida (Kolb HC y Sharpless KB, Drug Discov Today 2003; 8: 1128-37), aunque se conocen formas alternativas de química de clic y pueden ser utilizadas. La química click tiene lugar en una solución acuosa en condiciones de pH casi neutrales y, por lo tanto, es adecuada para la conjugación de fármacos. La ventaja de la química click es que es quimioselectiva y complementa otras químicas de conjugación bien conocidas, como la reacción tiol-maleimida. </span>[0060]In acetylene-azide coupling, called “click chemistry”, the azide part can be in L2 with the acetylene part in L3. Alternatively, L2 may contain acetylene, while L3 contains azide. 'Click chemistry' refers to a copper(+1) catalyzed cycloaddition reaction between an acetylene moiety and an azide moiety (Kolb HC and Sharpless KB, Drug Discov Today 2003;8:1128-37), although Alternative forms of click chemistry are known and can be used. Click chemistry takes place in an aqueous solution under near-neutral pH conditions and is therefore suitable for drug conjugation. The advantage of click chemistry is that it is chemoselective and complements other well-known conjugation chemistries, such as the thiol-maleimide reaction.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0061]A continuación se muestra un ejemplo de un conjugado de un derivado de fármaco y un anticuerpo de fórmula general (1). </span>[0061]An example of a conjugate of a drug derivative and an antibody of general formula (1) is shown below.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MAb-[L2]-[L1]-[AA]m-[A']-Fármaco (1) </span>MAb-[L2]-[L1]-[AA]m-[A']-Drug (1)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">donde MAb es un anticuerpo dirigido a una enfermedad; L2 es un componente del reticulante que comprende un resto de acoplamiento de anticuerpo y uno o más grupos acetileno (o azida); L1 comprende un PEG definido con azida (o acetileno) en un extremo, complementario al resto acetileno (o azida) en L2, y un grupo reactivo tal como ácido carboxílico o grupo hidroxilo en el otro extremo;AAes un L-aminoácido; m es un número entero con valores de 0, 1, 2, 3 o 4; y A' es un espaciador adicional, seleccionado del grupo de etanolamina, alcohol 4-hidroxibencílico, alcohol 4-aminobencílico o etilendiamina sustituida o no sustituida. Los aminoácidos L de 'AA' se seleccionan entre alanina, arginina, asparagina, ácido aspártico, cisteína, glutamina, ácido glutámico, glicina, histidina, isoleucina, leucina, lisina, metionina, fenilalanina, prolina, serina, treonina, triptófano, tirosina. y valina. Si el grupo A' contiene hidroxilo, está unido al grupo hidroxilo o al grupo amino del fármaco en forma de carbonato o carbamato, respectivamente. </span>where MAb is an antibody directed at a disease; L2 is a cross-linker component comprising an antibody coupling moiety and one or more acetylene (or azide) groups; L1 comprises a PEG defined with azide (or acetylene) at one end, complementary to the acetylene (or azide) moiety in L2, and a reactive group such as carboxylic acid or hydroxyl group at the other end; AA is an L-amino acid; m is an integer with values of 0, 1, 2, 3, or 4; and A' is an additional spacer, selected from the group of ethanolamine, 4-hydroxybenzyl alcohol, 4-aminobenzyl alcohol or substituted or unsubstituted ethylenediamine. The L amino acids of 'AA' are selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine. and valine. If the A' group contains hydroxyl, it is attached to the hydroxyl group or the amino group of the drug in the form of carbonate or carbamate, respectively.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0062]En un ejemplo de fórmula 1, A' es una etanolamina sustituida derivada de un L-aminoácido, en la que el grupo ácido carboxílico del aminoácido se reemplaza por un resto hidroximetilo. A' puede derivarse de cualquiera de los siguientes laminoácidos: alanina, arginina, asparagina, ácido aspártico, cisteína, glutamina, ácido glutámico, glicina, histidina, isoleucina, leucina, lisina, metionina, fenilalanina, prolina, serina, treonina, triptófano, tirosina y valina. </span>[0062]In an example of formula 1, A' is a substituted ethanolamine derived from an L-amino acid, in which the carboxylic acid group of the amino acid is replaced by a hydroxymethyl moiety. A' can be derived from any of the following lamino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0063]En un ejemplo del conjugado de la forma de realización preferida de fórmula 1, m es 0, A' es L-valinol y el fármaco se ejemplifica mediante SN-38. En otro ejemplo de fórmula 1, m es 1 y está representado por una L-lisina derivatizada, A' es L-valinol y el fármaco está ejemplificado por SN-38. En esta forma de realización, primero se forma un enlace amida entre el ácido carboxílico de un aminoácido tal como lisina y el grupo amino de valinol, usando grupos protectores ortogonales para los grupos amino de lisina. El grupo protector en el extremo N de la lisina se elimina, manteniendo intacto el grupo protector en la cadena lateral de la lisina, y el extremo N se acopla al grupo carboxilo en el PEG definido con azida (o acetileno) en el otro extremo. A continuación, el grupo hidroxilo del valinol se une al derivado 20-cloroformiato del SN-38 protegido con 10-hidroxi, y este intermedio se acopla a un componente L2 que porta el resto de unión al anticuerpo, así como el grupo acetileno (o azida) complementario involucrado en la química de la cicloadición click. Finalmente, la eliminación de los grupos protectores tanto en la cadena lateral de lisina como en SN-38 da el producto de este ejemplo. </span>[0063]In an example of the conjugate of the preferred embodiment of formula 1, m is 0, A' is L-valinol and the drug is exemplified by SN-38. In another example of formula 1, m is 1 and is represented by a derivatized L-lysine, A' is L-valinol and the drug is exemplified by SN-38. In this embodiment, an amide bond is first formed between the carboxylic acid of an amino acid such as lysine and the amino group of valinol, using orthogonal protecting groups for the amino groups of lysine. The protecting group at the N-terminus of lysine is removed, keeping the protecting group on the lysine side chain intact, and the N-terminus is coupled to the carboxyl group in PEG defined with azide (or acetylene) on the other end. The hydroxyl group of valinol is then attached to the 10-hydroxy protected 20-chloroformate derivative of SN-38, and this intermediate is coupled to an L2 component that carries the antibody-binding moiety as well as the acetylene group (or complementary azide) involved in the chemistry of click cycloaddition. Finally, removal of the protecting groups on both the lysine side chain and SN-38 gives the product of this example.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0064]Si bien no deseamos estar ligados a ninguna teoría, el producto SN-38 de PM pequeño, a saber, carbonato de valinol-SN-38, generado después de la proteólisis intracelular, tiene la vía adicional de liberación de SN-38 intacto a través de la ciclación intramolecular que involucra al grupo amino de valinol y el carbonilo del carbonato. </span>[0064]While we do not wish to be bound by any theory, the small MW SN-38 product, namely valinol carbonate-SN-38, generated after intracellular proteolysis, has the additional pathway of SN-38 release intact through intramolecular cyclization involving the amino group of valinol and the carbonyl of the carbonate.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0065]En otro ejemplo, A' de fórmula general 1 es A-OH, donde A-OH es un resto colapsable tal como alcohol 4-aminobencílico o un alcohol 4-aminobencílico sustituido con un grupo alquilo C&lt;1&gt;-C&lt;10&gt;en la posición bencílico, y este último, a través de su grupo amino, está unido a un L-aminoácido o un polipéptido que comprende hasta cuatro restos de L-aminoácido; en el que el extremo N está unido a un reticulante que termina en el grupo de unión al anticuerpo. </span>[0065]In another example, A' of general formula 1 is A-OH, where A-OH is a collapsible moiety such as 4-aminobenzyl alcohol or a 4-aminobenzyl alcohol substituted with a C&lt;1&gt;-C&lt; alkyl group 10&gt;in the benzylic position, and the latter, through its amino group, is linked to an L-amino acid or a polypeptide comprising up to four L-amino acid residues; in which the N terminus is linked to a cross-linker that ends in the antibody binding group.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0066]En otro ejemplo, el A-OH de A' de fórmula general 1 se deriva de un alcohol 4-aminobencílico sustituido, y 'AA' está compuesto por un único L-aminoácido con m = 1 en la fórmula general 1, y el fármaco se ejemplifica con SN-38. Un solo aminoácido de AA se puede seleccionar de cualquiera de los siguientes L-aminoácidos: alanina, arginina, asparagina, ácido aspártico, cisteína, glutamina, ácido glutámico, glicina, histidina, isoleucina, leucina, lisina, metionina, fenilalanina, prolina, serina, treonina, triptófano, tirosina y valina. El sustituyente R en el resto de alcohol 4-aminobencílico (forma de realización A-OH de A') es hidrógeno o un grupo alquilo seleccionado entre grupos alquilo C&lt;1&gt;-C&lt;10&gt;. Un ejemplo de esta fórmula, en la que el único aminoácido AA es L-lisina y R = H, y el fármaco está ejemplificado por SN-38, se denomina MAb-CL2A-SN-38 (que se muestra a continuación) realizado en la presente invención, tal como se define en las reivindicaciones. La estructura difiere del conector MAbCL2-SN-38 en la sustitución de un único residuo de lisina por un dipéptido Phe-Lys que se encuentra en el conector CL2. El dipéptido Phe-Lys fue diseñado como un sitio de escisión de catepsina B para la enzima lisosomal, que se consideraba importante para la liberación intracelular del fármaco unido. Sorprendentemente, a pesar de la eliminación del sitio de escisión de catepsina, los inmunoconjugados que comprenden un conector CL2A son aparentemente más eficacesin vivoque aquellos que comprenden un conector CL2. </span>[0066]In another example, the A-OH of A' of general formula 1 is derived from a substituted 4-aminobenzyl alcohol, and 'AA' is composed of a single L-amino acid with m = 1 in general formula 1, and the drug is exemplified by SN-38. A single amino acid of AA can be selected from any of the following L-amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine , threonine, tryptophan, tyrosine and valine. The substituent R on the 4-aminobenzyl alcohol moiety (A-OH embodiment of A') is hydrogen or an alkyl group selected from C&lt;1&gt;-C&lt;10&gt;alkyl groups. An example of this formula, in which the only AA amino acid is L-lysine and R = H, and the drug is exemplified by SN-38, is called MAb-CL2A-SN-38 (shown below) made in the present invention, as defined in the claims. The structure differs from the MAbCL2-SN-38 linker in the substitution of a single lysine residue for a Phe-Lys dipeptide found in the CL2 linker. The Phe-Lys dipeptide was designed as a cathepsin B cleavage site for the lysosomal enzyme, which was considered important for the intracellular release of the bound drug. Surprisingly, despite the removal of the cathepsin cleavage site, immunoconjugates comprising a CL2A linker are apparently more effective in vivo than those comprising a CL2 linker.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
[0067]En un ejemplo, AA comprende un resto polipeptídico, preferiblemente un di, tri o tetrapéptido, que se puede escindir mediante peptidasa intracelular. Ejemplos son: Ala-Leu, Leu-Ala-Leu y Ala-Leu-Ala-Leu (SEQ ID NO: 9) (Trouet et al., 1982). </span>
[0067]In one example, AA comprises a polypeptide moiety, preferably a di, tri or tetrapeptide, which can be cleaved by intracellular peptidase. Examples are: Ala-Leu, Leu-Ala-Leu and Ala-Leu-Ala-Leu (SEQ ID NO: 9) (Trouet et al., 1982).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0068]En otro ejemplo, el componente L1 del conjugado contiene un espaciador de polietilenglicol (PEG) definido con 1-30 unidades monoméricas repetidas. En una forma de realización preferida adicional, PEG es un PEG definido con 1 12 repeticiones. unidades monoméricas. La introducción de PEG puede implicar el uso de derivados de PEG heterobifuncionalizados que están disponibles comercialmente. El PEG heterobifuncional puede contener un grupo azida o acetileno. </span>[0068]In another example, the L1 component of the conjugate contains a polyethylene glycol (PEG) spacer defined with 1-30 repeating monomeric units. In a further preferred embodiment, PEG is a defined PEG with 1 12 repeats. monomeric units. The introduction of PEG may involve the use of heterobifunctionalized PEG derivatives that are commercially available. Heterobifunctional PEG may contain an azide or acetylene group.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0069]En un ejemplo, L2 tiene una pluralidad de grupos acetileno (o azida), que varían de 2 a 40, pero preferiblemente de 2 a 20, y más preferiblemente de 2 a 5, y un único resto de unión a anticuerpo. En un ejemplo representativo, el componente 'L2' está unido a 2 grupos acetilénicos, lo que da como resultado la unión de dos moléculas de SN-38 unidas a azida. La unión al MAb puede implicar una succinimida. </span>[0069]In one example, L2 has a plurality of acetylene (or azide) groups, ranging from 2 to 40, but preferably from 2 to 20, and more preferably from 2 to 5, and a single antibody binding moiety. In a representative example, the 'L2' component is attached to 2 acetylenic groups, resulting in the attachment of two azide-linked SN-38 molecules. Binding to the MAb may involve a succinimide.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0070]Cuando el fármaco bifuncional contiene un resto reactivo con tiol como grupo de unión al anticuerpo, los tioles del anticuerpo se generan en los grupos lisina del anticuerpo utilizando un reactivo tiolante. Los métodos para introducir grupos tiol en anticuerpos mediante modificaciones de los grupos lisina de MAb son bien conocidos en la técnica (Wong en Chemistry of protein conjugation and cross-linking,&lt;c&gt;R&lt;c&gt;Press, Inc., Boca Raton, FL (1991), págs. 20-22). Alternativamente, la reducción suave de los enlaces disulfuro entre cadenas en el anticuerpo (Willner et al., Bioconjugate Chem. 4:521-527 (1993)) usando agentes reductores tales como ditiotreitol (DTT) puede generar de 7 a 10 tioles en el anticuerpo; que tiene la ventaja de incorporar múltiples restos de fármaco en la región entre cadenas del MAb alejada de la región de unión al antígeno. La unión de SN-38 a grupos disulfuro sulfhidrilo reducidos da como resultado la formación de un inmunoconjugado anticuerpo-SN-38 con 6 a 8 restos SN-38 unidos covalentemente por molécula de anticuerpo. Se conocen otros métodos para proporcionar residuos de cisteína para la unión de fármacos u otros agentes terapéuticos, como el uso de anticuerpos diseñados con cisteína (ver la patente de EE. UU. n° 7.521.541). </span>[0070]When the bifunctional drug contains a thiol-reactive moiety as an antibody-binding group, the thiols of the antibody are generated on the lysine groups of the antibody using a thiolating reagent. Methods for introducing thiol groups into antibodies by modifications of the lysine groups of MAbs are well known in the art (Wong in Chemistry of protein conjugation and cross-linking,&lt;c&gt;R&lt;c&gt;Press, Inc., Boca Raton, FL (1991), pp. 20-22). Alternatively, gentle reduction of the interchain disulfide bonds in the antibody (Willner et al., Bioconjugate Chem. 4:521-527 (1993)) using reducing agents such as dithiothreitol (DTT) can generate 7 to 10 thiols in the antibody. antibody; which has the advantage of incorporating multiple drug residues into the interchain region of the MAb away from the antigen-binding region. Binding of SN-38 to reduced disulfide sulfhydryl groups results in the formation of an antibody-SN-38 immunoconjugate with 6 to 8 covalently linked SN-38 residues per antibody molecule. Other methods of providing cysteine residues for binding of drugs or other therapeutic agents are known, such as the use of cysteine-engineered antibodies (see US Patent No. 7,521,541).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0071]Según la presente descripción que no forma parte de la presente invención como se define en las reivindicaciones, el resto quimioterapéutico se selecciona del grupo que consiste en doxorrubicina (DOX), epirrubicina, morfolinodoxorrubicina (morfolino-DOx), cianomorfolino-doxorrubicina (cianomorfolino-DOX), 2-pirrolino-doxorrubicina (2-PDOX), Pro-2PDOX, CPT, 10-hidroxicamptotecina, topotecán, lurtotecán, 9-aminocamptotecina, 9-nitrocamptotecina, taxanos, geldanamicina, ansamicinas y epotilonas. Preferiblemente, en los conjugados de las formas de realización preferidas, el anticuerpo se une a al menos una fracción quimioterapéutica; preferiblemente de 1 a aproximadamente 12 restos quimioterapéuticos; lo más preferiblemente de aproximadamente 6 a aproximadamente 8 restos quimioterapéuticos. </span>[0071] According to the present description which does not form part of the present invention as defined in the claims, the chemotherapeutic moiety is selected from the group consisting of doxorubicin (DOX), epirubicin, morpholinodoxorubicin (morpholino-DOx), cyanomorpholino-doxorubicin ( cyanomorpholino-DOX), 2-pyrrolino-doxorubicin (2-PDOX), Pro-2PDOX, CPT, 10-hydroxycamptothecin, topotecan, lurtotecan, 9-aminocamptothecin, 9-nitrocamptothecin, taxanes, geldanamycin, ansamycins and epothilones. Preferably, in the conjugates of preferred embodiments, the antibody binds to at least one chemotherapeutic moiety; preferably from 1 to about 12 chemotherapeutic residues; most preferably from about 6 to about 8 chemotherapeutic moieties.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0072]Además, el componente conector 'L2' puede comprender un grupo tiol que reacciona con un residuo reactivo con tiol introducido en uno o más grupos amino de la cadena lateral de lisina de dicho anticuerpo. En tales casos, el anticuerpo se deriva previamente con un grupo tiol reactivo tal como maleimida, vinilsulfona, bromoacetamida o yodoacetamida mediante procedimientos bien descritos en la técnica. </span>[0072]In addition, the linker component 'L2' may comprise a thiol group that reacts with a thiol-reactive residue introduced into one or more amino groups of the lysine side chain of said antibody. In such cases, the antibody is prederivatized with a reactive thiol group such as maleimide, vinylsulfone, bromoacetamide or iodoacetamide by procedures well described in the art.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0073]En el marco de este trabajo se descubrió sorprendentemente un procedimiento mediante el cual se pueden preparar enlazadores de fármacos CPT, en los que CPT presenta además un grupo 10-hidroxilo. Este proceso implica, entre otros, la protección del grupo 10-hidroxilo como un derivadode t-butiloxicarbonilo (BOC), seguido de la preparación del penúltimo intermedio del conjugado fármaco-enlazador. Por lo general, la eliminación del grupo b Oc requiere tratamiento con un ácido fuerte como el ácido trifluoroacético (TFA). En estas condiciones, el carbonato del conector CPT 20-O, que contiene grupos protectores a eliminar, también es susceptible de escisión, dando lugar así a CPT no modificado. De hecho, la razón para usar un grupo protector metoxitritilo (MMT) ligeramente eliminable para la cadena lateral de lisina de la molécula conectora, como se enuncia en la técnica, fue precisamente evitar esta posibilidad (Walkeret al.,2002). Se descubrió que la eliminación selectiva del grupo protector fenólico BOC es posible llevando a cabo reacciones de corta duración, óptimamente de 3 a 5 minutos. En estas condiciones, el producto predominante fue aquel en el que se eliminó el 'BOC' en la posición 10-hidroxilo, mientras que el carbonato en la posición '20' estaba intacto. </span>[0073]In the framework of this work, a procedure was surprisingly discovered by which CPT drug linkers can be prepared, in which CPT also has a 10-hydroxyl group. This process involves, among others, the protection of the 10-hydroxyl group as a t-butyloxycarbonyl (BOC) derivative, followed by the preparation of the penultimate intermediate of the drug-linker conjugate. Removal of the b Oc group usually requires treatment with a strong acid such as trifluoroacetic acid (TFA). Under these conditions, the carbonate of the CPT 20-O linker, which contains protecting groups to be removed, is also susceptible to cleavage, thus giving rise to unmodified CPT. In fact, the reason for using a slightly removable methoxytrityl (MMT) protecting group for the lysine side chain of the linker molecule, as stated in the art, was precisely to avoid this possibility (Walkeret al., 2002). It was found that selective removal of the BOC phenolic protecting group is possible by carrying out short-term reactions, optimally 3 to 5 minutes. Under these conditions, the predominant product was that in which the 'BOC' at the 10-hydroxyl position was removed, while the carbonate at the '20' position was intact.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0074]Un enfoque alternativo implica proteger la posición 10-hidroxi del análogo de CPT con un grupo distinto de 'BOC', de modo que el producto final esté listo para la conjugación con anticuerpos sin necesidad de desproteger el grupo protector 10-OH. El grupo protector 10-hidroxi, que convierte el 10-OH en un carbonato fenólico o un éster fenólico, se desprotege fácilmente mediante condiciones de pH fisiológico o mediante esterasas después de la administraciónin vivodel conjugado. He et al. han descrito la eliminación más rápida de un carbonato fenólico en la posición 10 frente a un carbonato terciario en la posición 20 de 10-hidroxicamptotecina en condiciones fisiológicas. (He et al., Bioorganic &amp; Medicinal Chemistry 12: 4003-4008 (2004)). Un grupo protector 10-hidroxi en SN-38 puede ser 'Co r ' donde R puede ser un alquilo sustituido tal como “N(CH&lt;3&gt;)&lt;2&gt;-(CH&lt;2&gt;)n-” donde n es 1-10 y donde el grupo amino terminal es opcionalmente en forma de una sal cuaternaria para una solubilidad acuosa mejorada, o un residuo alquilo simple tal como “CH&lt;3&gt;-(CH&lt;2&gt;)n-” donde n es 0-10, o puede ser un resto alcoxi tal como “CH&lt;3&gt;-(CH&lt;2&gt;)nO-” donde n es 0-10, o “N(CH&lt;3&gt;)&lt;2&gt;-(CH&lt;2&gt;)nO-” donde n es 2-10, o “R-iO-(CH&lt;2&gt;-CH&lt;2&gt;-O)n-CH&lt;2&gt;-CH&lt;2&gt;-O -” donde R&lt;1&gt;es etilo o metilo y n es un número entero con valores de 0-10. Estos derivados 10-hidroxi se preparan fácilmente mediante tratamiento con el cloroformiato del reactivo elegido, si el derivado final va a ser un carbonato. Normalmente, la camptotecina que contiene 10-hidroxi, tal como SN-38, se trata con un equivalente molar del cloroformiato en dimetilformamida usando trietilamina como base. En estas condiciones, la posición 20-OH no se ve afectada. Para formar 10-O-ésteres se utiliza el cloruro de ácido del reactivo elegido. </span>[0074]An alternative approach involves protecting the 10-hydroxy position of the CPT analog with a group other than 'BOC', so that the final product is ready for conjugation with antibodies without the need to deprotect the 10-OH protecting group. The 10-hydroxy protecting group, which converts 10-OH to a phenolic carbonate or phenolic ester, is easily deprotected by physiological pH conditions or by esterases after in vivo administration of the conjugate. He et al. have described the faster elimination of a 10-position phenolic carbonate versus a 20-position tertiary carbonate of 10-hydroxycamptothecin under physiological conditions. (He et al., Bioorganic &amp; Medicinal Chemistry 12: 4003-4008 (2004)). A 10-hydroxy protecting group in SN-38 can be 'Co r ' where R can be a substituted alkyl such as “N(CH&lt;3&gt;)&lt;2&gt;-(CH&lt;2&gt;)n-” where n is 1 -10 and wherein the terminal amino group is optionally in the form of a quaternary salt for improved aqueous solubility, or a simple alkyl residue such as “CH&lt;3&gt;-(CH&lt;2&gt;)n-” where n is 0-10 , or it may be an alkoxy residue such as “CH&lt;3&gt;-(CH&lt;2&gt;)nO-” where n is 0-10, or “N(CH&lt;3&gt;)&lt;2&gt;-(CH&lt;2&gt;) nO-” where n is 2-10, or “R-iO-(CH&lt;2&gt;-CH&lt;2&gt;-O)n-CH&lt;2&gt;-CH&lt;2&gt;-O -” where R&lt;1&gt;is ethyl or methyl and n is an integer with values from 0-10. These 10-hydroxy derivatives are easily prepared by treatment with the chloroformate of the chosen reagent, if the final derivative is to be a carbonate. Typically, 10-hydroxy-containing camptothecin, such as SN-38, is treated with one molar equivalent of chloroformate in dimethylformamide using triethylamine as a base. Under these conditions, the 20-OH position is not affected. To form 10-O-esters, the acid chloride of the chosen reagent is used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0075]En un proceso ejemplar de preparación de un conjugado de un derivado de fármaco y un anticuerpo de fórmula general 1, en el que los descriptores L2, L1, AA y A-X son como se describe en secciones anteriores, el resto de fármaco bifuncional, [L2]-[L1]-[AA]m-[A-X]-Fármaco se prepara primero, seguido de la conjugación del resto del fármaco bifuncional con el anticuerpo (indicado en el presente documento como “MAb”). </span>[0075]In an exemplary process of preparing a conjugate of a drug derivative and an antibody of general formula 1, in which the descriptors L2, L1, AA and A-X are as described in previous sections, the rest of bifunctional drug , [L2]-[L1]-[AA]m-[A-X]-Drug is prepared first, followed by conjugation of the rest of the bifunctional drug with the antibody (denoted herein as “MAb”).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0076]En un proceso ejemplar adicional de la preparación de un conjugado de un derivado de fármaco y un anticuerpo del fórmula general 1, en la que los descriptores L2, L1, AA y A-OH son como se describe en secciones anteriores, el resto del fármaco bifuncional se prepara uniendo primero A-OH al extremo C de AA mediante un enlace amida, seguido del acoplamiento el extremo amina de AA a un grupo ácido carboxílico de L1. Si AA está ausente (es decir, m = 0), A-OH se une directamente a L1 mediante un enlace amida. El reticulante, [L1]-[AA]m-[A-OH], se une al grupo hidroxilo o amino del fármaco, y a esto le sigue la unión al resto L1, recurriendo a la reacción entre azida (o acetileno) y grupos acetileno (o azida) en L1 y L2 mediante química de clic. </span>[0076]In a further exemplary process of preparing a conjugate of a drug derivative and an antibody of general formula 1, in which the descriptors L2, L1, AA and A-OH are as described in previous sections, the The remainder of the bifunctional drug is prepared by first attaching A-OH to the C terminus of AA via an amide bond, followed by coupling the amine terminus of AA to a carboxylic acid group of L1. If AA is absent (i.e., m = 0), A-OH binds directly to L1 via an amide bond. The cross-linker, [L1]-[AA]m-[A-OH], binds to the hydroxyl or amino group of the drug, and this is followed by binding to the L1 moiety, resorting to the reaction between azide (or acetylene) and groups acetylene (or azide) at L1 and L2 using click chemistry.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0077]En una forma de realización de la presente invención como se define en las reivindicaciones, el anticuerpo es un anticuerpo monoclonal (MAb). En otras formas de realización, el anticuerpo puede ser un MAb multivalente y/o multiespecífico. El anticuerpo puede estar en forma intacta, de fragmento (Fab, Fab', F(ab)&lt;2&gt;, F(ab')&lt;2&gt;) o de subfragmento (construcciones de cadena única), o de un isotipo IgG1, IgG2a, IgG3, IgG4, IgA o submoléculas del mismo. </span>[0077]In one embodiment of the present invention as defined in the claims, the antibody is a monoclonal antibody (MAb). In other embodiments, the antibody may be a multivalent and/or multispecific MAb. The antibody may be in intact, fragment (Fab, Fab', F(ab)&lt;2&gt;, F(ab')&lt;2&gt;) or subfragment (single chain constructs) form, or of an IgG1, IgG2a isotype. , IgG3, IgG4, IgA or submolecules thereof.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preparación de anticuerpos</span>Antibody preparation</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0078]Las técnicas para preparar anticuerpos monoclonales contra prácticamente cualquier antígeno diana, tal como Trop-2, son bien conocidas en la técnica.Véase,por ejemplo, Kohler y Milstein, Nature 256: 495 (1975), y Coligan et al. (eds.), CURRENT PROTOCOLS IN IMMUNOLOGY, VOL. 1, páginas 2.5.1-2.6.7 (John Wiley &amp; Sons 1991). Brevemente, los anticuerpos monoclonales se pueden obtener inyectando a ratones una composición que comprende un antígeno, extirpando el bazo para obtener linfocitos B, fusionando los linfocitos B con células de mieloma para producir hibridomas, clonando los hibridomas, seleccionando clones positivos que produzcan anticuerpos contra el antígeno, cultivando los clones que producen anticuerpos contra el antígeno y aislando los anticuerpos de los cultivos de hibridoma. </span>[0078]Techniques for preparing monoclonal antibodies against virtually any target antigen, such as Trop-2, are well known in the art. See, for example, Kohler and Milstein, Nature 256: 495 (1975), and Coligan et al. (eds.), CURRENT PROTOCOLS IN IMMUNOLOGY, VOL. 1, pages 2.5.1-2.6.7 (John Wiley &amp; Sons 1991). Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising an antigen, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies against the antigen, culturing the clones that produce antibodies against the antigen and isolating the antibodies from the hybridoma cultures.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0079]Los MAbs se pueden aislar y purificar a partir de cultivos de hibridomas mediante una variedad de técnicas bien establecidas. Dichas técnicas de aislamiento incluyen cromatografía de afinidad con Sefarosa de Proteína A o Proteína G, cromatografía de exclusión por tamaño y cromatografía de intercambio iónico. Véase, por ejemplo, Coligan en las páginas 2.7.1-2.7.12 y 2.9.1-2.9.3. Véase también Baines et al., “Purification of Immunoglobulin G (IgG)”, en METHODS IN MOLECULAR BIOLOGY, VOL. 10, páginas 79-104 (The Humana Press, Inc. 1992). </span>[0079]MAbs can be isolated and purified from hybridoma cultures using a variety of well-established techniques. Such isolation techniques include Protein A or Protein G Sepharose affinity chromatography, size exclusion chromatography, and ion exchange chromatography. See, for example, Coligan on pages 2.7.1-2.7.12 and 2.9.1-2.9.3. See also Baines et al., “Purification of Immunoglobulin G (IgG),” in METHODS IN MOLECULAR BIOLOGY, VOL. 10, pages 79-104 (The Humana Press, Inc. 1992).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0080]Diversas técnicas, como la producción de anticuerpos quiméricos o humanizados, pueden implicar procedimientos de clonación y construcción de anticuerpos. Las secuencias V&lt;k&gt;(cadena ligera variable) y V&lt;h&gt;(cadena pesada variable) de unión al antígeno para un anticuerpo de interés se pueden obtener mediante una variedad de procedimientos de clonación molecular, como RT-PCR, 5'-RACE y detección de bibliotecas de ADNc. Los genes V de un MAb de una célula que expresa un MAb murino pueden clonarse mediante amplificación por PCR y secuenciarse. Para confirmar su autenticidad, los genes V&lt;l&gt;y V&lt;h&gt;clonados pueden expresarse en cultivo celular como un Ab quimérico como describen Orlandi et al., (Proc. Natl. Acad. Sci, EE. UU., 86: 3833 (1989)). A partir de las secuencias del gen V, se puede diseñar y construir un MAb humanizado como describen Leung et al. (Mol. Immunol., 32: 1413 (1995)). </span>[0080]Various techniques, such as the production of chimeric or humanized antibodies, may involve antibody cloning and construction procedures. The V&lt;k&gt;(variable light chain) and V&lt;h&gt;(variable heavy chain) antigen-binding sequences for an antibody of interest can be obtained by a variety of molecular cloning procedures, such as RT-PCR, 5'- RACE and screening of cDNA libraries. The V genes of a MAb from a cell expressing a murine MAb can be cloned by PCR amplification and sequenced. To confirm their authenticity, the cloned V&lt;l&gt;and V&lt;h&gt;genes can be expressed in cell culture as a chimeric Ab as described by Orlandi et al., (Proc. Natl. Acad. Sci, USA, 86: 3833 (1989)). From the V gene sequences, a humanized MAb can be designed and constructed as described by Leung et al. (Mol. Immunol., 32: 1413 (1995)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0081]El ADNc se puede preparar a partir de cualquier línea de hibridoma conocida o línea celular transfectada que produzca un MAb murino mediante técnicas generales de clonación molecular (Sambrook et al., Molecular Cloning, A Laboratory Manual, 2a edición (1989)). La secuencia Vk del MAb puede amplificarse usando los cebadores VK1BACK y VK1FOR (Orlandiet al.,1989) o el conjunto de cebadores extendido descrito por Leung et al. (BioTechniques, 15: 286 (1993)). Las secuencias Vh se pueden amplificar usando el par de cebadores VH1BACK/VH1FOR (Orlandiet al.,1989) o los cebadores que se hibridan con la región constante de IgG murina descrita por Leung et al. (Hybridoma, 13:469 (1994)). Los genes V humanizados pueden construirse mediante una combinación de síntesis de moldes de oligonucleótidos largos y amplificación por PCR como lo describen Leung et al. (Mol. Immunol., 32: 1413 (1995)). </span>[0081]cDNA can be prepared from any known hybridoma line or transfected cell line that produces a murine MAb by general molecular cloning techniques (Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd edition (1989)) . The Vk sequence of the MAb can be amplified using the primers VK1BACK and VK1FOR (Orlandiet al., 1989) or the extended primer set described by Leung et al. (BioTechniques, 15: 286 (1993)). Vh sequences can be amplified using the VH1BACK/VH1FOR primer pair (Orlandiet al., 1989) or primers that hybridize to the murine IgG constant region described by Leung et al. (Hybridoma, 13:469 (1994)). Humanized V genes can be constructed by a combination of long oligonucleotide template synthesis and PCR amplification as described by Leung et al. (Mol. Immunol., 32: 1413 (1995)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0082]Los productos de PCR para Vk se pueden subclonar en un vector de estadificación, como un vector de estadificación basado en pBR327, VKpBR, que contiene un promotor de Ig, una secuencia de péptido señal y sitios de restricción convenientes. Los productos de&lt;p&gt;C&lt;r&gt;para V&lt;h&gt;se pueden subclonar en un vector de estadificación similar, como el VHpBS basado en pBluescript. Los casetes de expresión que contienen las secuencias VKy Vh junto con las secuencias del promotor y del péptido señal pueden escindirse de VKpBR y VHpBS y ligarse en vectores de expresión apropiados, tales como pKh y pG1g, respectivamente (Leung et al., Hybridoma, 13:469 (1994)). Los vectores de expresión pueden cotransfectarse en una célula apropiada y los fluidos sobrenadantes pueden controlarse para determinar la producción de un MAb quimérico, humanizado o humano. Alternativamente, los casetes de expresión V&lt;k&gt;y V&lt;h&gt;pueden escindirse y subclonarse en un único vector de expresión, tal como pdHL2, como describen Gillies et al. (J. Immunol. Methods 125:191 (1989) y también se muestra en Losman et al., Cancer, 80:2660 (1997)). </span>[0082]PCR products for Vk can be subcloned into a staging vector, such as a pBR327-based staging vector, VKpBR, containing an Ig promoter, a signal peptide sequence and convenient restriction sites. The&lt;p&gt;C&lt;r&gt;products for V&lt;h&gt;can be subcloned into a similar staging vector, such as the pBluescript-based VHpBS. Expression cassettes containing the VK and Vh sequences together with the promoter and signal peptide sequences can be excised from VKpBR and VHpBS and ligated into appropriate expression vectors, such as pKh and pG1g, respectively (Leung et al., Hybridoma, 13 :469 (1994)). The expression vectors can be cotransfected into an appropriate cell and the supernatant fluids can be monitored for production of a chimeric, humanized or human MAb. Alternatively, the V&lt;k&gt;and V&lt;h&gt;expression cassettes can be excised and subcloned into a single expression vector, such as pdHL2, as described by Gillies et al. (J. Immunol. Methods 125:191 (1989) and also shown in Losman et al., Cancer, 80:2660 (1997)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0083]Alternativamente, los vectores de expresión pueden transfectarse en células huésped que han sido preadaptadas para la transfección, el crecimiento y la expresión en medio libre de suero. Las líneas celulares ejemplares que pueden usarse incluyen las líneas celulares Sp/EEE, Sp/ESF y Sp/ESF-X (véanse, por ejemplo, las patentes de EE. U&lt;u&gt;. Nos 7.531.327; 7.537.930 y 7.608.425). Estas líneas celulares ejemplares se basan en la línea celular de mieloma Sp2/0, transfectadas con un gen Bcl-EEE mutante, expuestas a metotrexato para amplificar secuencias genéticas transfectadas y preadaptadas a una línea celular libre de suero para la expresión de proteínas. </span>[0083]Alternatively, expression vectors can be transfected into host cells that have been preadapted for transfection, growth and expression in serum-free medium. Exemplary cell lines that may be used include the Sp/EEE, Sp/ESF, and Sp/ESF-X cell lines (see, for example, U.S. Pat. Nos. 7,531,327; 7,537,930 and 7,608). .425). These exemplary cell lines are based on the Sp2/0 myeloma cell line, transfected with a mutant Bcl-EEE gene, exposed to methotrexate to amplify transfected genetic sequences and preadapted to a serum-free cell line for protein expression.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos quiméricos</span>Chimeric antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0084]Un anticuerpo quimérico es una proteína recombinante en la que las regiones variables de un anticuerpo humano han sido reemplazadas por las regiones variables de, por ejemplo, un anticuerpo de ratón, incluidas las regiones determinantes de la complementariedad (CDR) del anticuerpo de ratón. Los anticuerpos quiméricos exhiben una inmunogenicidad disminuida y una mayor estabilidad cuando se administran a un sujeto. Las técnicas generales para clonar dominios variables de inmunoglobulina murina se describen, por ejemplo, en Orlandi et al., Proc. Nat l Acad. Sci. EE. UU. 6: 3833 (1989). Las técnicas para construir anticuerpos quiméricos son bien conocidas por los expertos en la técnica. Como ejemplo, Leung et al., Hybridoma 13:469 (1994), produjeron una quimera LL2 combinando secuencias de ADN que codifican los dominios Vk y Vh de LL2 murino, un anticuerpo monoclonal anti-CD22, con dominios de la región constantes k e IgG&lt;1&gt;humanas respectivas. </span>[0084]A chimeric antibody is a recombinant protein in which the variable regions of a human antibody have been replaced by the variable regions of, for example, a mouse antibody, including the complementarity determining regions (CDR) of the antibody. mouse. Chimeric antibodies exhibit decreased immunogenicity and increased stability when administered to a subject. General techniques for cloning murine immunoglobulin variable domains are described, for example, in Orlandi et al., Proc. Nat l Acad. Sci. USA 6: 3833 (1989). Techniques for constructing chimeric antibodies are well known to those skilled in the art. As an example, Leung et al., Hybridoma 13:469 (1994), produced an LL2 chimera by combining DNA sequences encoding the Vk and Vh domains of murine LL2, an anti-CD22 monoclonal antibody, with k and IgG constant region domains. &lt;1&gt;respective humans.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos humanizados</span>Humanized antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0085]Los CAF pueden incluir un anticuerpo o fragmento del mismo que se une a Trop-2. Según la presente invención, como se define en las reivindicaciones, el anticuerpo anti-Trop-2 puede ser un anticuerpo RS7 humanizado (ver, por ejemplo, la Patente de EE. UU. N° 7.238.785), que comprende las secuencias CDR de cadena ligera CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO: 2); y CDR3 (QQHYITPLT, SEQ ID NO:3) y las secuencias de CDR de cadena pesada CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) y CDR3 (GGFGSSYWYFDV, SEQ ID NO:6). </span>[0085]CAFs may include an antibody or fragment thereof that binds to Trop-2. According to the present invention, as defined in the claims, the anti-Trop-2 antibody may be a humanized RS7 antibody (see, for example, US Patent No. 7,238,785), which comprises the CDR sequences light chain CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO: 2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0086]Las técnicas para producir MAb humanizados son bien conocidas en la técnica (véase, por ejemplo, Jones et al., Nature 321: 522 (1986), Riechmann et al., Nature 332: 323 (1988), Verhoeyen et al., Science 239: 1534 (1988), Carter et al., Proc. Nat'l Acad. Sci. EE. UU. 89: 4285 (1992), Sandhu, Crit. Rev. Biotech. 12: 437 (1992), y Singer et al., J. Immun. </span>[0086]Techniques for producing humanized MAbs are well known in the art (see, for example, Jones et al., Nature 321: 522 (1986), Riechmann et al., Nature 332: 323 (1988), Verhoeyen et al. ., Science 239: 1534 (1988), Carter et al., Proc. Nat'l Acad. Sci. USA 89: 4285 (1992), Sandhu, Rev. Biotech 12: 437 (1992), and Singer et al., J. Immun.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">150: 2844 (1993)). Se puede humanizar un anticuerpo monoclonal quimérico o murino transfiriendo las CDR de ratón de cadenas variables pesadas y ligeras de la inmunoglobulina de ratón en los dominios variables correspondientes de un anticuerpo humano. Las regiones estructurales (FR) de ratón en el anticuerpo monoclonal quimérico también se reemplazan con secuencias de FR humanas. Dado que la simple transferencia de CDR de ratón a FR humanas a menudo da como resultado una reducción o incluso una pérdida de la afinidad de los anticuerpos, se requieren medidas adicionales. Podría ser necesaria una modificación para restaurar la afinidad original del anticuerpo murino. Esto se puede lograr mediante la sustitución de uno o más residuos humanos en las regiones FR con sus homólogos murinos para obtener un anticuerpo que posee buena afinidad de unión con su epítopo. Véase, por ejemplo, Tempest et al., Biotechnology 9:266 (1991) y Verhoeyen y col., Science 239: 1534 (1988). Los residuos preferidos para la sustitución incluyen residuos FR que están ubicados dentro de 1, 2 o 3 Angstroms de una cadena lateral de residuo de CDR, que están ubicados adyacentes a una secuencia de CDR, o que están se predice que interactuará con un residuo de CDR. </span>150: 2844 (1993)). A chimeric or murine monoclonal antibody can be humanized by transferring the mouse CDRs of heavy and light variable chains of the mouse immunoglobulin into the corresponding variable domains of a human antibody. The mouse framework regions (FR) in the chimeric monoclonal antibody are also replaced with human FR sequences. Since simple transfer of mouse CDRs to human RFs often results in a reduction or even loss of antibody affinity, additional measures are required. Modification may be necessary to restore the original affinity of the murine antibody. This can be achieved by replacing one or more human residues in the FR regions with their murine counterparts to obtain an antibody that possesses good binding affinity to its epitope. See, for example, Tempest et al., Biotechnology 9:266 (1991) and Verhoeyen et al., Science 239: 1534 (1988). Preferred residues for substitution include FR residues that are located within 1, 2, or 3 Angstroms of a CDR residue side chain, that are located adjacent to a CDR sequence, or that are predicted to interact with a CDR residue. CDR.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos humanos</span>Human antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0087]Se conocen en la técnica métodos para producir anticuerpos completamente humanos utilizando enfoques combinatorios o animales transgénicos transformados con loci de inmunoglobulina humana(p. ej.,Mancini et al., 2004, New Microbiol. 27:315-28; Conrad y Scheller, 2005, Comb. Chem. High Throughput Screen. 8:117-26; Brekke y Loset, 2003, Curr. Opin. Pharmacol. 3:544-50). También se puede construir un anticuerpo completamente humano mediante métodos de transfección genética o cromosómica, así como tecnología de presentación en fagos, todos los cuales son conocidos en la técnica. Véase, por ejemplo, McCafferty et al., Nature 348:552-553 (1990). Se espera que tales anticuerpos completamente humanos presenten incluso menos efectos secundarios que los anticuerpos quiméricos o humanizados y funcionenin vivocomo anticuerpos humanos esencialmente endógenos. </span>[0087]Methods are known in the art to produce fully human antibodies using combinatorial approaches or transgenic animals transformed with human immunoglobulin loci (e.g., Mancini et al., 2004, New Microbiol. 27:315-28; Conrad and Scheller, 2005, Comb. Chem. High Throughput Screen 8:117-26; A fully human antibody can also be constructed by genetic or chromosomal transfection methods, as well as phage display technology, all of which are known in the art. See, for example, McCafferty et al., Nature 348:552-553 (1990). Such fully human antibodies are expected to exhibit even fewer side effects than chimeric or humanized antibodies and to function in vivo as essentially endogenous human antibodies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0088]En una alternativa, se puede usar la técnica de presentación en fagos para generar anticuerpos humanos (p. ej., Dantas-Barbosa et al., 2005, Genet. Mol. Res. 4:126-40). Los anticuerpos humanos pueden generarse a partir de humanos normales o de humanos que presentan un estado patológico particular, como el cáncer (Dantas-Barbosa et al., 2005). La ventaja de construir anticuerpos humanos a partir de un individuo enfermo es que el repertorio de anticuerpos circulantes puede estar sesgado hacia anticuerpos contra antígenos asociados a enfermedades. </span>[0088]In an alternative, the phage display technique can be used to generate human antibodies (e.g., Dantas-Barbosa et al., 2005, Genet. Mol. Res. 4:126-40). Human antibodies can be generated from normal humans or from humans presenting with a particular pathological state, such as cancer (Dantas-Barbosa et al., 2005). The advantage of constructing human antibodies from a diseased individual is that the repertoire of circulating antibodies may be biased toward antibodies against disease-associated antigens.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0089]En un ejemplo no limitante de esta metodología, Dantas-Barbosa et al. (2005) construyeron una biblioteca de presentación en fagos de fragmentos de anticuerpos Fab humanos de pacientes con osteosarcoma. Generalmente, el ARN total se obtuvo de linfocitos sanguíneos circulantes(Id.).Se clonaron Fab recombinantes a partir de los repertorios de anticuerpos de cadena m,&lt;y&gt;y&lt;k&gt;y se insertaron en una biblioteca de presentación en fagos (Id.). Los ARN se convirtieron en ADNc y se usaron para preparar bibliotecas de ADNc de Fab usando cebadores específicos contra las secuencias de inmunoglobulina de cadena pesada y ligera (Marks et al., 1991, J. Mol. Biol. 222:581-97). La construcción de la biblioteca se realizó según Andris-Widhopf et al. (2000, en: Phage Display Laboratory Manual, Barbas et al. (eds), 1.a edición, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, Nueva York, págs. 9.1 a 9.22). Los fragmentos Fab finales se digirieron con endonucleasas de restricción y se insertaron en el genoma del bacteriófago para crear la biblioteca de presentación en fagos. Dichas bibliotecas pueden seleccionarse mediante métodos estándar de presentación en fagos, como se conoce en la técnica. La presentación en fagos se puede realizar en una variedad de formatos; para su revisión, véase, por ejemplo, Johnson y Chiswell, Current Opinion in Structural Biology 3:5564-571 (1993). </span>[0089]In a non-limiting example of this methodology, Dantas-Barbosa et al. (2005) constructed a phage display library of human Fab antibody fragments from osteosarcoma patients. Generally, total RNA was obtained from circulating blood lymphocytes (Id.). Recombinant Fabs were cloned from the m,&lt;y&gt;and&lt;k&gt;chain antibody repertoires and inserted into a phage display library (Id. .). The RNAs were converted to cDNA and used to prepare Fab cDNA libraries using specific primers against the heavy and light chain immunoglobulin sequences (Marks et al., 1991, J. Mol. Biol. 222:581-97). The construction of the library was carried out according to Andris-Widhopf et al. (2000, in: Phage Display Laboratory Manual, Barbas et al. (eds), 1st edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 9.1-9.22). The final Fab fragments were digested with restriction endonucleases and inserted into the bacteriophage genome to create the phage display library. Such libraries can be selected by standard phage display methods, as is known in the art. Phage display can be performed in a variety of formats; for review, see, for example, Johnson and Chiswell, Current Opinion in Structural Biology 3:5564-571 (1993).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0090]Los anticuerpos humanos también pueden generarse mediante células B activadasin vitro.Véanse las patentes de EE. UU. nos 5.567.610 y 5.229.275. El experto en la técnica se dará cuenta de que estas técnicas son ejemplares y que se puede utilizar cualquier método conocido para preparar y seleccionar anticuerpos o fragmentos de anticuerpos humanos. </span>[0090]Human antibodies can also be generated by activated B cells in vitro. See US Patent Nos. 5,567,610 and 5,229,275. One skilled in the art will realize that these techniques are exemplary and that any known method can be used to prepare and select human antibodies or antibody fragments.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0091]En otra alternativa, se pueden usar animales transgénicos que han sido modificados genéticamente para producir anticuerpos humanos para generar anticuerpos contra esencialmente cualquier objetivo inmunogénico, usando protocolos de inmunización estándar. Green et al., Nature Genet, describen métodos para obtener anticuerpos humanos a partir de ratones transgénicos. 7:13 (1994), Lonberg et al., Nature 368:856 (1994), y Taylor et al., Int. Inmune. 6:579 (1994). Un ejemplo no limitante de dicho sistema es el XENOMOUSE® (p. ej., Green et al., 1999, J. Immunol. Methods 231:11-23) de Abgenix (Fremont, CA). En XENOMOUSE® y animales similares, los genes de anticuerpos de ratón han sido inactivados y reemplazados por genes de anticuerpos humanos funcionales, mientras que el resto del sistema inmunológico del ratón permanece intacto. </span>[0091]In another alternative, transgenic animals that have been genetically modified to produce human antibodies can be used to generate antibodies against essentially any immunogenic target, using standard immunization protocols. Green et al., Nature Genet, describe methods for obtaining human antibodies from transgenic mice. 7:13 (1994), Lonberg et al., Nature 368:856 (1994), and Taylor et al., Immune Int. 6:579 (1994). A non-limiting example of such a system is XENOMOUSE® (e.g., Green et al., 1999, J. Immunol. Methods 231:11-23) from Abgenix (Fremont, CA). In XENOMOUSE® and similar animals, the mouse antibody genes have been inactivated and replaced by functional human antibody genes, while the rest of the mouse immune system remains intact.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0092]El XENOMOUSE® se transformó con YAC (cromosomas artificiales de levadura) configurados en línea germinal que contenían porciones de los loci IgH e Igkappa humanos, incluida la mayoría de las secuencias de la región variable, junto con genes accesorios y secuencias reguladoras. El repertorio de regiones variables humanas puede usarse para generar células B productoras de anticuerpos, que pueden procesarse para dar hibridomas mediante técnicas conocidas. Un XENOMOUSE® inmunizado con un antígeno diana producirá anticuerpos humanos mediante la respuesta inmune normal, que pueden recolectarse y/o producirse mediante técnicas estándar analizadas anteriormente. Hay disponibles una variedad de cepas de XENOMOUSE®, cada una de las cuales es capaz de producir una clase diferente de anticuerpo. Se ha demostrado que los anticuerpos humanos producidos transgénicamente tienen potencial terapéutico, al tiempo que conservan las propiedades farmacocinéticas de los anticuerpos humanos normales (Green et al., 1999). El experto se dará cuenta de que las composiciones y métodos reivindicados no se limitan al uso del sistema XENOMOUSE® sino que pueden utilizar cualquier animal transgénico que haya sido modificado genéticamente para producir anticuerpos humanos. </span>[0092]XENOMOUSE® was transformed with germline configured YACs (yeast artificial chromosomes) containing portions of the human IgH and Igkappa loci, including most of the variable region sequences, along with accessory genes and regulatory sequences. The human variable region repertoire can be used to generate antibody-producing B cells, which can be processed to give hybridomas by known techniques. A XENOMOUSE® immunized with a target antigen will produce human antibodies through the normal immune response, which can be collected and/or produced by standard techniques discussed above. A variety of strains of XENOMOUSE® are available, each of which is capable of producing a different class of antibody. Transgenically produced human antibodies have been shown to have therapeutic potential, while retaining the pharmacokinetic properties of normal human antibodies (Green et al., 1999). The skilled person will realize that the claimed compositions and methods are not limited to the use of the XENOMOUSE® system but can use any transgenic animal that has been genetically modified to produce human antibodies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos conocidos y antígenos diana</span>Known antibodies and target antigens</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0093]En ciertas formas de realización de la presente invención como se define en las reivindicaciones, el cáncer diana puede expresar uno o más antígenos asociados a tumores (TAA) diana. Los anticuerpos particulares que pueden ser útiles para la terapia del cáncer incluyen, entre otros, LL1 (anti-CD74), LL2 o RFB4 (anti-CD22), veltuzumab (hA20, anti-CD20), rituxumab (anti-CD20), obinutuzumab (GA101, anti-CD20), lambrolizumab (receptor anti-EP-1), nivolumab (receptor anti-EP-1), ipilimumab (anti-CTLA-4), RS7 (glucoproteína-1 anti-epitelial (EGP-1, también conocido como Trop-2)), PAM4 o KC4 (ambos antimucina), MN-14 (antígeno anticancerígenoembrionario (CEA, también conocido como CD66e o CEACAM5), MN-15 o MN-3 (anti-CEACAM6), Mu-9 (antígeno p específico del colon), Immu 31 (una anti-alfafetoproteína), R1 (anti-IGF-1R), A19 (anti-CD19), TAG-72 (p. ej., CC49), Tn, J591 o HuJ591 (anti-PSMA (antígeno de membrana prostático específico)), AB-PG1-XG1-026 (dímero anti-PSMA), D2/B (anti-PSMA), G250 (un dímero anti carbónico anhidrasa IX MAb), L243 (anti-HLA-DR), alemtuzumab (anti-CD52), bevacizumab (anti-VEGF), cetuximab (anti-EGFR), gemtuzumab (anti-CD33), ibritumomab tiuxetan (anti-CD20); panitumumab (anti-EGFR); tositumomab (anti-CD20); PAM4 (también conocido como clivatuzumab, antimucina) y trastuzumab (anti-ErbB2). </span>[0093]In certain embodiments of the present invention as defined in the claims, the target cancer may express one or more target tumor-associated antigens (TAA). Particular antibodies that may be useful for cancer therapy include, but are not limited to, LL1 (anti-CD74), LL2 or RFB4 (anti-CD22), veltuzumab (hA20, anti-CD20), rituxumab (anti-CD20), obinutuzumab (GA101, anti-CD20), lambrolizumab (anti-EP-1 receptor), nivolumab (anti-EP-1 receptor), ipilimumab (anti-CTLA-4), RS7 (anti-epithelial glycoprotein-1 (EGP-1, also known as Trop-2)), PAM4 or KC4 (both antimucin), MN-14 (anticancer embryonic antigen (CEA, also known as CD66e or CEACAM5), MN-15 or MN-3 (anti-CEACAM6), Mu-9 (colon-specific p antigen), Immu 31 (an anti-alpha-fetoprotein), R1 (anti-IGF-1R), A19 (anti-CD19), TAG-72 (e.g., CC49), Tn, J591, or HuJ591 (anti-PSMA (prostate-specific membrane antigen)), AB-PG1-XG1-026 (anti-PSMA dimer), D2/B (anti-PSMA), G250 (an anti carbonic anhydrase IX MAb dimer), L243 (anti -HLA-DR), alemtuzumab (anti-CD52), bevacizumab (anti-VEGF), cetuximab (anti-EGFR), gemtuzumab (anti-CD33), ibritumomab tiuxetan (anti-CD20); panitumumab (anti-EGFR); tositumomab (anti-CD20); PAM4 (also known as clivatuzumab, antimucin) and trastuzumab (anti-ErbB2).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0094]Dichos anticuerpos anti-TAA son conocidos en la técnica (p. ej., Patentes de EE. UU. Nos 5.686.072; 5.874.540; 6.107.090; 6.183.744; 6.306.393; 6.653.104; 6.730.300; 6.899.864; 6.926.893; 6.962.702; 7.074.403; 7.230.084; 7.238.785; 7.238.786; 7.256.004; 7.282.567; 7.300.655; 7.312.318; 7.585.491; 7.612.180; 7.642.239; y publicación de solicitud de patente de EE. UU. n.° 20050271671; 20060193865; 20060210475; 20070087001). Los anticuerpos de uso específicos conocidos incluyen hPAM4 (Patente de EE. UU. n° 7.282.567), hA20 (Patente de EE. UU. n° 7.151.164), hA19 (Patente de EE. UU. n° 7.109.304), hIMMU-31 (Patente de EE. UU. n° 7,300,655), hLL1 (Patente de EE. UU. n° 7,312,318), hLL2 (Patente de EE. UU. n° 5.789.554), hMu-9 (Patente de EE. UU. n° 7,387,772), hL243 (Patente de EE. UU. n° 7.612.180), hMN-14 (Patente de EE. UU. n° 6.676.924), hMN-15 (Patente de EE. UU. n° 8.287.865), hR1 (Patente de EE. UU. n° 9.441.043), hRS7 (Patente de EE. UU. n° 7.238.785), hMN-3 (Patente de EE. UU. n° 7.541.440), AB-PG1-XG1-026 (Solicitud de patente de EE. UU. 11/983.372, depositada como ATCC PTA-4405 y PTA-4406) y D2/B (WO 2009/130575). </span>[0094]Such anti-TAA antibodies are known in the art (e.g., US Patent Nos. 5,686,072; 5,874,540; 6,107,090; 6,183,744; 6,306,393; 6,653,104; 6,730,300; 00,655; 7,312,318; 491; 7,612,180; Known specific antibodies of use include hPAM4 (US Patent No. 7,282,567), hA20 (US Patent No. 7,151,164), hA19 (US Patent No. 7,109,304 ), hIMMU-31 (US Patent No. 7,300,655), hLL1 (US Patent No. 7,312,318), hLL2 (US Patent No. 5,789,554), hMu-9 (US Patent US Patent No. 7,387,772), hL243 (US Patent No. 7,612,180), hMN-14 (US Patent No. 6,676,924), hMN-15 (US Patent No. No. 8,287,865), hR1 (US Patent No. 9,441,043), hRS7 (US Patent No. 7,238,785), hMN-3 (US Patent No. No. 7,541,440), AB-PG1-XG1-026 (US Patent Application 11/983,372, filed as ATCC PTA-4405 and PTA-4406) and D2/B (WO 2009/130575).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0095]Otros antígenos útiles asociados a tumores a los que se pueden dirigir incluyen anhidrasa carbónica IX, B7, CCL19, CCL21, CSAp, HER-2/neu, BrE3, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20 (p. ej., MAb C2B8, hA20, 1F5), CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L, CD44, CD45, CD46, CD47, CD52, CD54, CD55, CD59, CD64, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CEACAM5, CEACAM6, CTLA-4, alfa-fetoproteína (AFP), VEGF (p. ej., AVASTIN®, variante de empalme de fibronectina), fibronectina ED-B (p. ej., L19), EGP-1 (Trop-2), EGP-2 (p. ej., 17-1A), receptor de EGF (ErbB1) (p. ej., ERBITUX®), ErbB2, ErbB3, Factor H, FHL-1, Flt-3, receptor de folato, Ga 733,GRO-p, Hm Gb-1, factor inducible por hipoxia (HIF), HM1.24, HER-2/neu, histona H2B, histona H3, histona H4, factor de crecimiento similar a la insulina (ILGF), IFN-y, IFN-a, IFN-p, IFN-A, IL-2R, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-2, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, IGF-1R, Ia, HM1.24, gangliósidos, HCG, el antígeno HLA-DR al que se une L243, antígenos CD66, es decir, CD66a-d o una combinación de los mismos, MAGE, mCRP, MCP-1, MIP-1a , MIP-1B, factor inhibidor de la migración de macrófagos (MIF), MUC1, MUC2, MUC3, MUC4, MUC5ac, factor de crecimiento placentario (PIGF), PSA (antígeno prostático específico), PSMA, antígeno PAM4, receptor EP-1, EP-L1, NCA-95, NCA-90, A3, A33, Ep-cAM, KS-1, Le(y), mesotelina, S100, tenascina, TAC, antígeno Tn, antígenos de Thomas-Friedenreich, antígenos de necrosis tumoral, antígenos de angiogénesis tumoral, TNF-a, receptor TRAIL (R1 y R2), Trop-2, VEGFR, RANTES, T101, así como antígenos de células madre cancerosas, factores del complemento C3, C3a, C3b, C5a, C5 y un producto oncogén. </span>[0095]Other useful tumor-associated antigens that can be targeted include carbonic anhydrase IX, B7, CCL19, CCL21, CSAp, HER-2/neu, BrE3, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20 (e.g., MAb C2B8, hA20, 1F5), CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD40L , CD44, CD45, CD46, CD47, CD52, CD54, CD55, CD59, CD64, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CEACAM5, CEACAM6, CTLA-4 , alpha-fetoprotein (AFP), VEGF (e.g., AVASTIN®, fibronectin splice variant), fibronectin ED-B (e.g., L19), EGP-1 (Trop-2), EGP-2 (e.g., 17-1A), EGF receptor (ErbB1) (e.g., ERBITUX®), ErbB2, ErbB3, Factor H, FHL-1, Flt-3, folate receptor, Ga 733,GRO -p, Hm Gb-1, hypoxia-inducible factor (HIF), HM1.24, HER-2/neu, histone H2B, histone H3, histone H4, insulin-like growth factor (ILGF), IFN-y, IFN-a, IFN-p, IFN-A, IL-2R, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-2, IL-6, IL- 8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, IGF-1R, Ia, HM1.24, gangliosides, HCG, the HLA-DR antigen to which L243 binds , CD66 antigens, i.e. CD66a-d or a combination thereof, MAGE, mCRP, MCP-1, MIP-1a, MIP-1B, macrophage migration inhibitory factor (MIF), MUC1, MUC2, MUC3, MUC4, MUC5ac, placental growth factor (PIGF), PSA (prostate-specific antigen), PSMA, PAM4 antigen, EP-1 receptor, EP-L1, NCA-95, NCA-90, A3, A33, Ep-cAM, KS -1, Le(y), mesothelin, S100, tenascin, TAC, Tn antigen, Thomas-Friedenreich antigens, tumor necrosis antigens, tumor angiogenesis antigens, TNF-a, TRAIL receptor (R1 and R2), Trop-2 , VEGFR, RANTES, T101, as well as cancer stem cell antigens, complement factors C3, C3a, C3b, C5a, C5 and an oncogene product.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0096]Las células madre cancerosas, a las que se atribuye ser poblaciones de células malignas precursoras más resistentes a la terapia (Hill y Perris, J. Natl. Cancer Inst. 2007; 99:1435-40), tienen antígenos que pueden ser atacados en ciertos tipos de cáncer, como como CD133 en cáncer de próstata (Maitland et al., Ernst Schering Found. Sympos. Proc. 2006; 5:155-79), cáncer de pulmón de células no pequeñas (Donnenberg et al., J. Control Release 2007; 122(3):385-91), y glioblastoma (Beier et al., Cancer Res. 2007; 67(9):4010-5), y CD44 en cáncer colorrectal (Dalerba et al., Proc. Natl. Acad. Sci. EE. UU. 2007; 104(24)10158-63), cáncer de páncreas (Li et al., Cancer Res. 2007; 67(3): 1030-7), y en carcinoma de células escamosas de cabeza y cuello (Prince et al., Proc. Natl. Acad. Sci. EE. UU. 2007; 104(3)973-8). Otro objetivo útil para la terapia del cáncer de mama es el antígeno LIV-1 descrito por Taylor et al. (Biochem. J. 2003; 375:51-9). </span>[0096]Cancer stem cells, which are attributed to be populations of malignant precursor cells more resistant to therapy (Hill and Perris, J. Natl. Cancer Inst. 2007; 99:1435-40), have antigens that can be attacked in certain types of cancer, such as CD133 in prostate cancer (Maitland et al., Ernst Schering Found. Sympos. Proc. 2006; 5:155-79), non-small cell lung cancer (Donnenberg et al., J. Control Release 2007; 122(3):385-91), and glioblastoma (Beier et al., Cancer Res. 2007; 67(9):4010-5), and CD44 in colorectal cancer (Dalerba et al., Proc. Natl. Sci. USA 2007; 104(24)10158-63), pancreatic cancer (Li et al., Cancer Res. 2007; 67(3): 1030-7), and in carcinoma of head and neck squamous cells (Prince et al., Proc. Natl. Acad. Sci. USA 2007; 104(3)973-8). Another useful target for breast cancer therapy is the LIV-1 antigen described by Taylor et al. (Biochem. J. 2003; 375:51-9).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0097]Los anticuerpos inhibidores de puntos de control se han utilizado en la terapia del cáncer. Los puntos de control inmunológico se refieren a vías inhibidoras en el sistema inmunológico que son responsables de mantener la autotolerancia y modular el grado de respuesta del sistema inmunológico para minimizar el daño al tejido periférico. Sin embargo, las células tumorales también pueden activar puntos de control del sistema inmunológico para disminuir la eficacia de la respuesta inmune contra los tejidos tumorales. Anticuerpos inhibidores de puntos de control ejemplares contra el antígeno 4 de linfocitos T citotóxicos (CTLA4, también conocido como CD152), la proteína de muerte celular programada 1 (PD1, también conocida como CD279) y el ligando 1 de muerte celular programada 1 (EP-L1, también conocido como CD274), puede usarse en combinación con uno o más agentes para mejorar la eficacia de la respuesta inmune contra células, tejidos o patógenos patógenos. Los anticuerpos anti-PD1 ejemplares incluyen lambrolizumab (MK-3475, MERCK), nivolumab (BMS-936558, BRISTOL-MYERS SQUIBB), AMP-224 (MERCK) y pidilizumab (CT-011, CURETECH lTd .). Los anticuerpos anti-PD1 están disponibles comercialmente, por ejemplo, de ABCAM® (AB137132), BIOLEGEND® (EH12.2H7, RMP1-14) y AFFYMETRIX EBIOSCIENCE (J105, J116, MIH4). Los anticuerpos anti-EP-LI ejemplares incluyen MDX-1105 (MEDAREX), MEDI4736 (MEDIMMUNE) MPDL3280A (GENENTECH) y BMS-936559 (BRISTOL-MYERS SQUIBB). Los anticuerpos anti-EP-L1 también están disponibles comercialmente, por ejemplo de AFFYMETRIX EBIOSCIENCE (MIH1). Los anticuerpos anti-CTLA4 ejemplares incluyen ipilimumab (Bristol-Myers Squibb) y tremelimumab (PFIZER). Los anticuerpos anti-PD1 están disponibles comercialmente, por ejemplo, de ABCAM® (AB 134090), SINO BIOLOGICAL INC. (11159-H03H, 11159-H08H) y THERMO SCIENTIFIC PIERCE (PA5-29572, PA5-23967, PA5-26465, MA1-12205, MA1-35914). Ipilimumab recibió recientemente la aprobación de la FDA para el tratamiento del melanoma metastásico (Wada et al., 2013, J Transl Med 11:89). </span>[0097]Checkpoint inhibitor antibodies have been used in cancer therapy. Immune checkpoints refer to inhibitory pathways in the immune system that are responsible for maintaining self-tolerance and modulating the degree of response of the immune system to minimize damage to peripheral tissue. However, tumor cells can also activate immune system checkpoints to decrease the effectiveness of the immune response against tumor tissues. Exemplary checkpoint inhibitory antibodies against cytotoxic T lymphocyte antigen 4 (CTLA4, also known as CD152), programmed cell death protein 1 (PD1, also known as CD279), and programmed cell death 1 (EP) ligand 1 -L1, also known as CD274), can be used in combination with one or more agents to improve the effectiveness of the immune response against pathogenic cells, tissues or pathogens. Exemplary anti-PD1 antibodies include lambrolizumab (MK-3475, MERCK), nivolumab (BMS-936558, BRISTOL-MYERS SQUIBB), AMP-224 (MERCK), and pidilizumab (CT-011, CURETECH lTd.). Anti-PD1 antibodies are commercially available, for example, from ABCAM® (AB137132), BIOLEGEND® (EH12.2H7, RMP1-14) and AFFYMETRIX EBIOSCIENCE (J105, J116, MIH4). Exemplary anti-EP-LI antibodies include MDX-1105 (MEDAREX), MEDI4736 (MEDIMMUNE) MPDL3280A (GENENTECH) and BMS-936559 (BRISTOL-MYERS SQUIBB). Anti-EP-L1 antibodies are also commercially available, for example from AFFYMETRIX EBIOSCIENCE (MIH1). Exemplary anti-CTLA4 antibodies include ipilimumab (Bristol-Myers Squibb) and tremelimumab (PFIZER). Anti-PD1 antibodies are commercially available, for example, from ABCAM® (AB 134090), SINO BIOLOGICAL INC. (11159-H03H, 11159-H08H) and THERMO SCIENTIFIC PIERCE (PA5-29572, PA5-23967, PA5-26465, MA1-12205, MA1-35914). Ipilimumab recently received FDA approval for the treatment of metastatic melanoma (Wada et al., 2013, J Transl Med 11:89).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0098]El factor inhibidor de la migración de macrófagos (MIF) es un importante regulador de la inmunidad innata y adaptativa y de la apoptosis. Se ha informado que CD74 es el receptor endógeno de MIF (Leng et al., 2003, J Exp Med 197:1467-76). El efecto terapéutico de los anticuerpos anti-CD74 antagonistas sobre las vías intracelulares mediadas por MIF puede ser útil para el tratamiento de una amplia gama de enfermedades, tales como cánceres de vejiga, próstata, mama, pulmón y colon (p. ej., Meyer-Siegler et al., 2004, BMC Cancer 12:34; Shachar &amp; Haran, 2011, Leuk Lymphoma 52:1446-54). Milatuzumab (hLL1) es un anticuerpo anti-CD74 ejemplar de uso terapéutico para el tratamiento de enfermedades mediadas por MIF. </span>[0098]Macrophage migration inhibitory factor (MIF) is an important regulator of innate and adaptive immunity and apoptosis. CD74 has been reported to be the endogenous receptor for MIF (Leng et al., 2003, J Exp Med 197:1467-76). The therapeutic effect of antagonistic anti-CD74 antibodies on MIF-mediated intracellular pathways may be useful for the treatment of a wide range of diseases, such as bladder, prostate, breast, lung, and colon cancers (e.g., Meyer -Siegler et al., 2004, BMC Cancer 12:34; Shachar &amp; Haran, 2011, Leuk Lymphoma 52:1446-54). Milatuzumab (hLL1) is an exemplary anti-CD74 antibody of therapeutic use for the treatment of MIF-mediated diseases.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0099]Se conocen en la técnica varios otros anticuerpos de uso (p. ej., Patentes de EE. UU. Nos 5.686.072; 5.874.540; 6.107.090; 6.183.744; 6.306.393; 6.653.104; 6.730.300; 6.899.864; 6.926.893; 6.962.702; 7.074.403; 7.230.084; 7.238.785; 7.238.786; 7.256.004; 7.282.567; 7.300.655; 7.312.318; 7.585.491; 7.612.180; 7.642.239 y publicación de solicitud de patente de EE. UU. n° 20060193865). </span>[0099]Several other antibodies for use are known in the art (e.g., US Patent Nos. 5,686,072; 5,874,540; 6,107,090; 6,183,744; 6,306,393; 6,653,104; 6,730,300; 00,655; 7,312,318; 491; 7,612,180; 7,642,239 and US Patent Application Publication No. 20060193865).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0100]Los anticuerpos de uso pueden obtenerse comercialmente de una amplia variedad de fuentes conocidas. Por ejemplo, una variedad de líneas de hibridoma secretoras de anticuerpos están disponibles en la American Type Culture Collection (ATCC, Manassas, VA). Se ha depositado en la ATCC una gran cantidad de anticuerpos contra diversos objetivos de enfermedades, incluidos antígenos asociados a tumores, y/o se han publicado secuencias de regiones variables y están disponibles para su uso en los métodos y composiciones reivindicados. Véanse, por ejemplo, las Patentes de EE. UU. Nos 7.312.318; 7.282.567; 7.151.164; 7.074.403; 7.060.802; 7.056.509; 7.049.060; 7.045.132; 7.041.803 7.041.802 7.041.293 7.038.018 7.037.498 7.012.133 7.001.598 6.998.468 6.994.976 6.994.852 6.989.241 6.974.863 6.965.018 6.964.854 6.962.981 6.962.813 6.956.107 6.951.924 6.949.244 6.946.129 6.943.020 6.939.547 6.921.645 6.921.645 6.921.533 6.919.433 6.919.078 6.916.475 6.905.681 6.899.879 6.893.625 6.887.468 6.887.466 6.884.594 6.881.405 6.878.812 6.875.580 6.872.568 6.867.006 6.864.062 6.861.511 6.861.227 6.861.226 6.838.282 6.835.549 6.835.370 6.824.780 6.824.778 6.812.206 6.793.924 6.783.758 6.770.450 6.767.711 6.764.688 6.764.681 6.764.679 6.743.898 6.733.981 6.730.307 6.720.155 6.716.966 6.709.653 6.693.176 6.692.908 6.689.607 6.689.362 6.689.355 6.682.737 6.682.736 6.682.734 6.673.344 6.653.104 6.652.852 6.635.482 6.630.144 6.610.833 6.610.294 6.605.441 6.605.279 6.596.852 6.592.868 6.576.745 6.572;856 6.566.076 6.562.618 6.545.130 6.544.749 6.534.058 6.528.625 6.528.269 6.521.227 6.518.404 6.511.665 6.491.915 6.488.930 6.482.598 6.482.408 6.479.247 6.468.531 6.468.529 6.465.173 6.461.823 6.458.356 6.455.044 6.455.040 6.451.310 6.444.206 6.441.143 6.432.404 6.432.402 6.419.928 6.413.726 6.406.694 6.403.770 6.403.091 6.395.276 6.395.274 6.387.350 6.383.759 6.383.484 6.376.654 6.372.215 6.359.126 6.355.481 6.355.444 6.355.245 6.355.244 6.346.246 6.344.198 6.340.571 6.340.459 6.331.175 6.306.393 6.254.868 6.187.287 6.183.744 6.129.914 6.120.767 6.096.289 6.077.499 5.922.302 5.874.540 5.814.440 5.798.229 5.789.554 5.776.456 5.736.119 5.716.595 5.677.136 5.587.459 5.443.953. 5.525.338. Estos son sólo ejemplos y en la técnica se conoce una amplia variedad de otros anticuerpos y sus hibridomas. El experto en la técnica se dará cuenta de que las secuencias de anticuerpos o los hibridomas secretores de anticuerpos contra casi cualquier antígeno asociado a una enfermedad se puede obtener mediante una simple búsqueda en las bases de datos de ATCc , NCBI y/o USPTO de anticuerpos contra una diana de interés asociada a una enfermedad seleccionada. Los dominios de unión a antígeno de los anticuerpos clonados pueden amplificarse, escindirse, ligarse en un vector de expresión, transfectarse en una célula huésped adaptada y usarse para la producción de proteínas, usando técnicas estándar bien conocidas en la técnica. </span>[0100]The antibodies for use can be obtained commercially from a wide variety of known sources. For example, a variety of antibody-secreting hybridoma lines are available from the American Type Culture Collection (ATCC, Manassas, VA). A large number of antibodies against various disease targets, including tumor-associated antigens, have been deposited at the ATCC and/or variable region sequences have been published and are available for use in the claimed methods and compositions. See, for example, US Patent Nos. 7,312,318; 7,282,567; 7,151,164; 7,074,403; 7,060,802; 7,056,509; 7,049,060; 7,045,132; 7,041,803 7,041,802 7,041,293 7,038,018 7,037,498 7,012,133 7,001,598 6,998,468 6,994,976 6,994,852 6,989,241 6,974,863 6. 965,018 6,964,854 6,962,981 6,962,813 6,956. 107 6,951,924 6,949,244 6,946,129 6,943,020 6,939,547 6,921,645 6,921,645 6,921,533 6,919,433 6,919,078 6,916,475 6,905.68 1 6,899,879 6,893,625 6,887,468 6,887,466 6,884 .594 6,881,405 6,878,812 6,875,580 6,872,568 6,867,006 6,864,062 6,861,511 6,861,227 6,861,226 6,838,282 6,835,549 6,835.3 70 6,824,780 6,824,778 6,812,206 6,793,924 6,783,758 6,770,450 6,767,711 6,764,688 6,764,681 6,764,679 6,743,898 6,733,981 6,730,307 6,720,155 6,716,966 6,709,653 6. 693,176 6,692,908 6,689,607 6,689,362 6,689. 355 6,682,737 6,682,736 6,682,734 6,673,344 6,653,104 6,652,852 6,635,482 6,630,144 6,610,833 6,610,294 6,605,441 6,605.27 9 6,596,852 6,592,868 6,576,745 6,572;856 6,566 .076 6,562,618 6,545,130 6,544,749 6,534,058 6,528,625 6,528,269 6,521,227 6,518,404 6,511,665 6,491,915 6,488,930 6,482.5 98 6,482,408 6,479,247 6,468,531 6,468,529 6,465,173 6,461,823 6,458,356 6,455,044 6,455,040 6,451,310 6,444,206 6,441,143 6,432,404 6,432,402 6,419,928 6,413,726 6. 406,694 6,403,770 6,403,091 6,395,276 6,395. 274 6,387,350 6,383,759 6,383,484 6,376,654 6,372,215 6,359,126 6,355,481 6,355,444 6,355,245 6,355,244 6,346,246 6,344.19 8 6,340,571 6,340,459 6,331,175 6,306,393 6,254 .868 6,187,287 6,183,744 6,129,914 6,120,767 6,096,289 6,077,499 5,922,302 5,874,540 5,814,440 5,798,229 5,789,554 5,776.4 56 5,736,119 5,716,595 5,677,136 5,587,459 5,443,953. 5,525,338. These are only examples and a wide variety of other antibodies and their hybridomas are known in the art. One skilled in the art will realize that antibody sequences or antibody-secreting hybridomas against almost any disease-associated antigen can be obtained by a simple search of the ATCc, NCBI and/or USPTO antibody databases. against a target of interest associated with a selected disease. The antigen binding domains of the cloned antibodies can be amplified, excised, ligated into an expression vector, transfected into an adapted host cell and used for protein production, using standard techniques well known in the art.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alotipos de anticuerpos</span>Antibody allotypes</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0101]La inmunogenicidad de los anticuerpos terapéuticos se asocia con un mayor riesgo de reacciones a la infusión y una disminución de la duración de la respuesta terapéutica (Baert et al., 2003, N Engl J Med 348:602-08). El grado en que los anticuerpos terapéuticos inducen una respuesta inmune en el huésped puede estar determinado en parte por el alotipo del anticuerpo (Stickler et al., 2011, Genes and Immunity 12:213-21). El alotipo del anticuerpo está relacionado con variaciones en la secuencia de aminoácidos en ubicaciones específicas en las secuencias de la región constante del anticuerpo. Los alotipos de anticuerpos IgG que contienen una región constante de tipo&lt;y&gt;de cadena pesada se denominan alotipos Gm (1976, J Immunol 117:1056-59). </span>[0101]The immunogenicity of therapeutic antibodies is associated with an increased risk of infusion reactions and a decreased duration of therapeutic response (Baert et al., 2003, N Engl J Med 348:602-08). The degree to which therapeutic antibodies induce an immune response in the host may be determined in part by the allotype of the antibody (Stickler et al., 2011, Genes and Immunity 12:213-21). Antibody allotype is related to amino acid sequence variations at specific locations in the antibody constant region sequences. Allotypes of IgG antibodies containing a heavy chain type constant region are called Gm allotypes (1976, J Immunol 117:1056-59).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0102]Para los anticuerpos humanos IgG1 comunes, el alotipo más prevalente es G1m1 (Stickler et al., 2011, Genes and Immunity 12:213-21). Sin embargo, el alotipo G1m3 también ocurre con frecuencia en caucásicos (Stickler et al., 2011). Se ha informado que los anticuerpos G1m1 contienen secuencias alotípicas que tienden a inducir una respuesta inmune cuando se administran a receptores que no son G1m1 (nG1m1), como los pacientes con G1m3 (Stickler et al., 2011). Los anticuerpos que no son del alotipo G1m1 no son tan inmunogénicos cuando se administran a pacientes con G1m1 (Stickler et al., 2011). </span>[0102]For common human IgG1 antibodies, the most prevalent allotype is G1m1 (Stickler et al., 2011, Genes and Immunity 12:213-21). However, the G1m3 allotype also frequently occurs in Caucasians (Stickler et al., 2011). G1m1 antibodies have been reported to contain allotypic sequences that tend to induce an immune response when administered to non-G1m1 (nG1m1) recipients, such as G1m3 patients (Stickler et al., 2011). Antibodies that are not of the G1m1 allotype are not as immunogenic when administered to patients with G1m1 (Stickler et al., 2011).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0103]El alotipo humano G 1m 1 comprende los aminoácidos ácido aspártico en la posición 356 de Kabat y leucina en la posición 358 de Kabat en la secuencia CH3 de la cadena pesada IgG1. El alotipo nG1m1 comprende los aminoácidos ácido glutámico en la posición 356 de Kabat y metionina en la posición 358 de Kabat. Tanto el alotipo G1m1 como el nG1ml comprenden un residuo de ácido glutámico en la posición 357 de Kabat y los alotipos a veces se denominan alotipos DEL y EEM. A continuación se muestra un ejemplo no limitante de las secuencias de la región constante de la cadena pesada para los anticuerpos alotipos G1m1 y nG 1m 1 para los anticuerpos ejemplares rituximab (SEQ ID NO:7) y veltuzumab (SEQ ID NO:8). </span>[0103]The human allotype G 1m 1 comprises the amino acids aspartic acid at position 356 of Kabat and leucine at position 358 of Kabat in the CH3 sequence of the IgG1 heavy chain. The nG1m1 allotype comprises the amino acids glutamic acid at position 356 of Kabat and methionine at position 358 of Kabat. Both the G1m1 and nG1ml allotypes comprise a glutamic acid residue at position 357 of Kabat and the allotypes are sometimes referred to as DEL and EEM allotypes. A non-limiting example of the heavy chain constant region sequences for the G1m1 and nG 1m 1 allotype antibodies is shown below for the exemplary antibodies rituximab (SEQ ID NO:7) and veltuzumab (SEQ ID NO:8).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Secuencia de la región variable de la cadena pesada de rituximab (SEQ ID NO: 7)</span>Rituximab heavy chain variable region sequence (SEQ ID NO: 7)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA </span>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCP </span>VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCP</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV </span>PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI </span>EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN </span>SKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS </span>YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PGK </span>PGK</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Región variable de la cadena pesada de veltuzumab (SEQ ID NO:8)</span>Veltuzumab heavy chain variable region (SEQ ID NO:8)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA </span>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP </span>VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV </span>PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI </span>EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN </span>SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS </span>YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PGK </span>PGK</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0104]Jefferis y Lefranc (2009, mAbs 1:1-7) revisaron las variaciones de secuencia características de los alotipos de IgG y su efecto sobre la inmunogenicidad. Informaron que el alotipo G1m3 se caracteriza por un residuo de arginina en la posición 214 de Kabat, en comparación con un residuo de lisina en Kabat 214 en el alotipo G1m17. El alotipo nG1m1,2 se caracterizó por ácido glutámico en la posición 356 de Kabat, metionina en la posición 358 de Kabat y alanina en la posición 431 de Kabat. El alotipo G1m1,2 se caracterizó por ácido aspártico en la posición 356 de Kabat, leucina en la posición 358 de Kabat y glicina en la posición 431 de Kabat. variantes de secuencia de la región constante de la cadena, Jefferis y Lefranc (2009) informaron variantes alotípicas en la región constante de la cadena ligera kappa, con el alotipo Km1 caracterizado por valina en la posición 153 de Kabat y leucina en la posición 191 de Kabat, el alotipo Km1,2 por alanina en Kabat posición 153 y leucina en la posición 191 de Kabat, y el alotipo Km3 caracterizado por alanina en la posición 153 de Kabat y valina en la posición 191 de Kabat. </span>[0104]Jefferis and Lefranc (2009, mAbs 1:1-7) reviewed the sequence variations characteristic of IgG allotypes and their effect on immunogenicity. They reported that the G1m3 allotype is characterized by an arginine residue at position 214 of Kabat, compared to a lysine residue at Kabat 214 in the G1m17 allotype. The nG1m1,2 allotype was characterized by glutamic acid at position 356 of Kabat, methionine at position 358 of Kabat, and alanine at position 431 of Kabat. The G1m1,2 allotype was characterized by aspartic acid at position 356 of Kabat, leucine at position 358 of Kabat, and glycine at position 431 of Kabat. chain constant region sequence variants, Jefferis and Lefranc (2009) reported allotypic variants in the kappa light chain constant region, with the Km1 allotype characterized by valine at position 153 of Kabat and leucine at position 191 of Kabat, the Km1,2 allotype characterized by alanine at Kabat position 153 and leucine at position 191 of Kabat, and the Km3 allotype characterized by alanine at position 153 of Kabat and valine at position 191 of Kabat.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0105]Con respecto a los anticuerpos terapéuticos, veltuzumab y rituximab son, respectivamente, anticuerpos IgG1 humanizados y quiméricos contra CD20, de uso para la terapia de una amplia variedad de neoplasias malignas hematológicas y/o enfermedades autoinmunes. LaTabla 1compara las secuencias de alotipos de rituximab frente a veltuzumab. Como se muestra en laTabla 1,rituximab (G1m17,1) es un alotipo DEL IgG1, con una variación de secuencia adicional en la posición 214 de Kabat (CH1 de cadena pesada) de lisina en rituximab frente a arginina en veltuzumab. Se ha informado que veltuzumab es menos inmunogénico en sujetos que rituximab (ver, por ejemplo, Morchhauser et al., 2009, J Clin Oncol 27:3346-53; Goldenberg et al., 2009, Blood 113:1062-70; Robak &amp; Robak, 2011, BioDrugs 25:13-25), efecto que se ha atribuido a la diferencia entre anticuerpos humanizados y quiméricos. Sin embargo, la diferencia en los alotipos entre los alotipos EEM y DEL probablemente también explica la menor inmunogenicidad de veltuzumab. </span>[0105]With respect to therapeutic antibodies, veltuzumab and rituximab are, respectively, humanized and chimeric IgG1 antibodies against CD20, used for the therapy of a wide variety of hematological malignancies and/or autoimmune diseases. Table 1 compares the allotype sequences of rituximab versus veltuzumab. As shown in Table 1, rituximab (G1m17.1) is a DEL IgG1 allotype, with an additional sequence variation at position 214 of Kabat (CH1 heavy chain) from lysine in rituximab versus arginine in veltuzumab. Veltuzumab has been reported to be less immunogenic in subjects than rituximab (see, for example, Morchhauser et al., 2009, J Clin Oncol 27:3346-53; Goldenberg et al., 2009, Blood 113:1062-70; Robak &amp; Robak, 2011, BioDrugs 25:13-25), an effect that has been attributed to the difference between humanized and chimeric antibodies. However, the difference in allotypes between the EEM and DEL allotypes probably also explains the lower immunogenicity of veltuzumab.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 1. Alotipos de Rituximab versus Veltuzumab</span>Table 1. Allotypes of Rituximab versus Veltuzumab</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
[0106]Para reducir la inmunogenicidad de los anticuerpos terapéuticos en individuos con el genotipo nG1m1, es deseable seleccionar el alotipo del anticuerpo que corresponda al alotipo G1m3, caracterizado por arginina en Kabat 214, y al alotipo nulo nG1m1,2, caracterizado por ácido glutámico en la posición 356 de Kabat, metionina en la posición 358 de Kabat y alanina en la posición 431 de Kabat. Sorprendentemente, se encontró que la administración subcutánea repetida de anticuerpos G1m3 durante un largo período de tiempo no dio como resultado una respuesta inmune significativa. En formas de realización alternativas, la cadena pesada de IgG4 humana en común con el alotipo G1m3 tiene arginina en Kabat 214, ácido glutámico en Kabat 356, metionina en Kabat 359 y alanina en Kabat 431. Dado que la inmunogenicidad parece relacionarse al menos en parte con los residuos en esas ubicaciones, el uso de la secuencia de la región constante de la cadena pesada de IgG4 humana para anticuerpos terapéuticos también es una forma de realización preferida. Las combinaciones de anticuerpos IgG1 G1m3 con anticuerpos IgG4 también pueden ser útiles para la administración terapéutica. </span>
[0106]To reduce the immunogenicity of therapeutic antibodies in individuals with the nG1m1 genotype, it is desirable to select the antibody allotype that corresponds to the G1m3 allotype, characterized by arginine in Kabat 214, and to the nG1m1,2 null allotype, characterized by glutamic acid at position 356 of Kabat, methionine at position 358 of Kabat and alanine at position 431 of Kabat. Surprisingly, it was found that repeated subcutaneous administration of G1m3 antibodies over a long period of time did not result in a significant immune response. In alternative embodiments, the human IgG4 heavy chain in common with the G1m3 allotype has arginine at Kabat 214, glutamic acid at Kabat 356, methionine at Kabat 359, and alanine at Kabat 431. Since immunogenicity appears to be at least in part related with residues at those locations, use of the human IgG4 heavy chain constant region sequence for therapeutic antibodies is also a preferred embodiment. Combinations of IgG1 G1m3 antibodies with IgG4 antibodies may also be useful for therapeutic administration.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Nanocuerpos</span>Nanobodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0107]Los nanocuerpos son anticuerpos de dominio único de aproximadamente 12-15 kDa de tamaño (aproximadamente 110 aminoácidos de longitud). Los nanocuerpos pueden unirse selectivamente a antígenos diana, como anticuerpos de tamaño completo, y tienen afinidades similares por los antígenos. Sin embargo, debido a su tamaño mucho más pequeño, es posible que puedan penetrar mejor en tumores sólidos. El tamaño más pequeño también contribuye a la estabilidad del nanocuerpo, que es más resistente al pH y a temperaturas extremas que los anticuerpos de tamaño completo (Van Der Linden et al., 1999, Biochim Biophys Act 1431:37-46). Los anticuerpos de dominio único se desarrollaron originalmente tras el descubrimiento de que los camélidos (camellos, alpacas, llamas) poseen anticuerpos completamente funcionales sin cadenas ligeras (p. ej., Hamsen et al., 2007, Appl Microbiol Biotechnol 77:13-22). Los anticuerpos de cadena pesada constan de un único dominio variable (VHH) y dos dominios constantes (Ch2 y Ch3). Al igual que los anticuerpos, los nanocuerpos pueden desarrollarse y usarse como construcciones multivalentes y/o biespecíficas. Se están desarrollando formas humanizadas de nanocuerpos que están dirigidos a una variedad de antígenos diana, como IL-6R, vWF, TNF, RSV, RANKL, IL-17A y F e IgE (p. ej., a BlYNX®, Gante, Bélgica) con uso clínico potencial en cáncer y otros trastornos (p. ej., Saerens et al., 2008, Curr Opin Pharmacol 8:600-8; Muyldermans, 2013, Ann Rev Biochem 82:775-97; Ibanez et al., 2011, J Infect Dis 203:1063-72). </span>[0107]Nanobodies are single domain antibodies approximately 12-15 kDa in size (approximately 110 amino acids in length). Nanobodies can selectively bind to target antigens, such as full-size antibodies, and have similar affinities for the antigens. However, due to their much smaller size, they may be able to penetrate solid tumors better. The smaller size also contributes to the stability of the nanobody, which is more resistant to pH and temperature extremes than full-size antibodies (Van Der Linden et al., 1999, Biochim Biophys Act 1431:37-46). Single-domain antibodies were originally developed following the discovery that camelids (camels, alpacas, llamas) possess fully functional antibodies without light chains (e.g., Hamsen et al., 2007, Appl Microbiol Biotechnol 77:13-22 ). Heavy chain antibodies consist of a single variable domain (VHH) and two constant domains (Ch2 and Ch3). Like antibodies, nanobodies can be developed and used as multivalent and/or bispecific constructs. Humanized forms of nanobodies are being developed that target a variety of target antigens, such as IL-6R, vWF, TNF, RSV, RANKL, IL-17A and F, and IgE (e.g., BlYNX®, Ghent, Belgium ) with potential clinical use in cancer and other disorders (e.g., Saerens et al., 2008, Curr Opin Pharmacol 8:600-8; Muyldermans, 2013, Ann Rev Biochem 82:775-97; Ibanez et al., 2011, J Infect Dis 203:1063-72).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0108]La vida media plasmática de los nanocuerpos es más corta que la de los anticuerpos de tamaño completo, y su eliminación se realiza principalmente por vía renal. Debido a que carecen de una región Fc, no presentan citotoxicidad dependiente del complemento. </span>[0108]The plasma half-life of nanobodies is shorter than that of full-size antibodies, and their elimination is mainly via the kidneys. Because they lack an Fc region, they do not exhibit complement-dependent cytotoxicity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0109]Los nanocuerpos pueden producirse mediante la inmunización de camellos, llamas, alpacas o tiburones con un antígeno diana, seguido del aislamiento del ARNm, la clonación en bibliotecas y la detección de la unión al antígeno. Las secuencias de nanocuerpos pueden humanizarse mediante técnicas estándar (p. ej., Jones et al., 1986, Nature 321: 522, Riechmann et al., 1988, Nature 332: 323, Verhoeyen et al., 1988, Science 239: 1534, Carter et al., 1992, Proc. Nat'l Acad. Sci. EE. UU. 89: 4285, Sandhu, 1992, Crit. Rev. Biotech. 12: 437, Singer et al., 1993, J. Immun. 150: 2844). La humanización es relativamente sencilla debido a la alta homología entre las secuencias de FR de camélidos y humanos. </span>[0109]Nanobodies can be produced by immunizing camels, llamas, alpacas or sharks with a target antigen, followed by isolation of mRNA, cloning into libraries and detection of antigen binding. Nanobody sequences can be humanized by standard techniques (e.g., Jones et al., 1986, Nature 321: 522, Riechmann et al., 1988, Nature 332: 323, Verhoeyen et al., 1988, Science 239: 1534 , Carter et al., 1992, Proc. Nat'l Acad. Sci. USA 89: 4285, Sandhu, 1992, Crit. Rev. Biotech. 12: 437, Singer et al., 1993, J. Immun. 150: 2844). Humanization is relatively simple due to the high homology between camelid and human FR sequences.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0110]Los CAF descritos en este documento pueden comprender nanocuerpos para la administración dirigida de fármaco conjugado a células cancerosas específicas. Los nanocuerpos de uso se describen, por ejemplo, en las Patentes de EE. UU. Nos 7.807.162; 7.939.277; 8.188.223; 8.217.140; 8.372.398; 8.557.965; 8.623.361 y 8.629.244). </span>[0110]The CAFs described herein may comprise nanobodies for targeted delivery of drug conjugate to specific cancer cells. Use nanobodies are described, for example, in US Patent Nos. 7,807,162; 7,939,277; 8,188,223; 8,217,140; 8,372,398; 8,557,965; 8,623,361 and 8,629,244).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Fragmentos de anticuerpos</span>Antibody fragments</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0111]Los fragmentos de anticuerpo son porciones de un anticuerpo que se unen a antígeno, tales como F(ab')&lt;2&gt;, Fab', F(ab)&lt;2&gt;, Fab, Fv, sFv, scFv y similares. Mediante técnicas conocidas se pueden generar fragmentos de anticuerpos que reconocen epítopos específicos. Los fragmentos F(ab')&lt;2&gt;, por ejemplo, pueden producirse mediante digestión con pepsina de la molécula de anticuerpo. Estos y otros métodos se describen, por ejemplo, en Goldenberg, patente de EE.&lt;u&gt;U. Nos 4.036.945 y 4.331.647 y referencias contenidas en las mismas. Véase también Nisonoff et al., Arch Biochem. Biophys. </span>[0111]Antibody fragments are portions of an antibody that bind to antigen, such as F(ab')&lt;2&gt;, Fab', F(ab)&lt;2&gt;, Fab, Fv, sFv, scFv and the like. Antibody fragments that recognize specific epitopes can be generated by known techniques. F(ab')&lt;2&gt; fragments, for example, can be produced by pepsin digestion of the antibody molecule. These and other methods are described, for example, in Goldenberg, US Pat. Nos. 4,036,945 and 4,331,647 and references contained therein. See also Nisonoff et al., Arch Biochem. Biophys.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">89: 230 (1960); Porter, Biochem. J. 73: 119 (1959), Edelman et al., en METHODS IN ENZYMOLOGY VOL. 1, página 422 (Academic Press 1967), y Coligan en las páginas 2.8.1-2.8.10 y 2.10.- 2.10.4. Alternativamente, se pueden construir bibliotecas de expresión Fab' (Huse et al., 1989, Science, 246:1274-1281) para permitir una identificación rápida y sencilla de fragmentos Fab' monoclonales con la especificidad deseada. </span>89: 230 (1960); Porter, Biochem. J. 73: 119 (1959), Edelman et al., in METHODS IN ENZYMOLOGY VOL. 1, page 422 (Academic Press 1967), and Coligan on pages 2.8.1-2.8.10 and 2.10.- 2.10.4. Alternatively, Fab' expression libraries can be constructed (Huse et al., 1989, Science, 246:1274-1281) to allow rapid and easy identification of monoclonal Fab' fragments with the desired specificity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0112]Una molécula Fv de cadena sencilla (scFv) comprende un dominio VL y un dominio VH. Los dominios VL y VH se asocian para formar un sitio de unión objetivo. Estos dos dominios están además unidos covalentemente mediante un conector peptídico (L). Una molécula scFv se indica como VL-L-VH si el dominio VL es la parte N-terminal de la molécula scFv, o como VH-L-VL si el dominio VH es la parte N-terminal de la molécula scFv. Los métodos para preparar moléculas scFv y diseñar conectores peptídicos adecuados se describen en las patentes de EE. UU. n° 4.704.692, patente de EE. UU. N° 4.946.778, R. Raag y M. Whitlow, “Single Chain Fvs”. FASEB Vol 9:73-80 (1995) y R. E. Bird y B. W. Walker, Single Chain Antibody Variable Regions, TIBTECH, Vol 9: 132-137 (1991). </span>[0112]A single-chain Fv (scFv) molecule comprises a VL domain and a VH domain. The VL and VH domains associate to form a target binding site. These two domains are further covalently linked by a peptide linker (L). A scFv molecule is denoted as VL-L-VH if the VL domain is the N-terminal part of the scFv molecule, or as VH-L-VL if the VH domain is the N-terminal part of the scFv molecule. Methods for preparing scFv molecules and designing suitable peptide linkers are described in US Patent No. 4,704,692, US Patent No. 4,946,778, R. Raag and M. Whitlow, “Single Chain “Fvs.” FASEB Vol 9:73-80 (1995) and R. E. Bird and B. W. Walker, Single Chain Antibody Variable Regions, TIBTECH, Vol 9: 132-137 (1991).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0113]Otros fragmentos de anticuerpos, por ejemplo fragmentos de anticuerpos de dominio único, se conocen en la técnica y pueden usarse en las construcciones reivindicadas. Los anticuerpos de dominio único (VHH) pueden obtenerse, por ejemplo, de camellos, alpacas o llamas mediante técnicas de inmunización estándar. (Ver, por ejemplo, Muyldermans et al., TIBS 26:230-235, 2001; Yau et al., J Immunol Methods 281:161-75, 2003; Maass et al., J Immunol Methods 324:13-25, 2007). El VHH puede tener una potente capacidad de unión a antígeno y puede interactuar con nuevos epítopos que son inaccesibles a los pares VH-VL convencionales. (Muyldermans et al., 2001). La IgG sérica de alpaca contiene aproximadamente un 50% de anticuerpos IgG (HCAb) de cadena pesada de camélido únicamente (Maass et al., 2007). Las alpacas se pueden inmunizar con antígenos conocidos, como el TNF-a, y se pueden aislar VHH que se unen al antígeno objetivo y lo neutralizan (Maass et al., 2007). Se han identificado cebadores de PCR que amplifican prácticamente todas las secuencias codificantes de VHH de alpaca y pueden usarse para construir bibliotecas de presentación en fagos de VHH de alpaca, que pueden usarse para el aislamiento de fragmentos de anticuerpos mediante técnicas de biopanning estándar bien conocidas en la técnica (Maass et al., 2007). </span>[0113]Other antibody fragments, for example single domain antibody fragments, are known in the art and may be used in the claimed constructs. Single domain antibodies (VHH) can be obtained, for example, from camels, alpacas or llamas using standard immunization techniques. (See, for example, Muyldermans et al., TIBS 26:230-235, 2001; Yau et al., J Immunol Methods 281:161-75, 2003; Maass et al., J Immunol Methods 324:13-25, 2007). VHH may have potent antigen-binding capacity and may interact with new epitopes that are inaccessible to conventional VH-VL pairs. (Muyldermans et al., 2001). Alpaca serum IgG contains approximately 50% camelid heavy chain IgG antibodies (HCAbs) only (Maass et al., 2007). Alpacas can be immunized with known antigens, such as TNF-α, and VHHs can be isolated that bind to the target antigen and neutralize it (Maass et al., 2007). PCR primers have been identified that amplify virtually all alpaca VHH coding sequences and can be used to construct alpaca VHH phage display libraries, which can be used for the isolation of antibody fragments using standard biopanning techniques well known in the technique (Maass et al., 2007).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0114]También se puede preparar un fragmento de anticuerpo mediante hidrólisis proteolítica de un anticuerpo de longitud completa o mediante expresión en E. coli u otro huésped del ADN que codifica el fragmento. Se puede obtener un fragmento de anticuerpo mediante digestión con pepsina o papaína de anticuerpos de longitud completa mediante métodos convencionales. Por ejemplo, se puede producir un fragmento de anticuerpo mediante escisión enzimática de anticuerpos con pepsina para proporcionar un fragmento de aproximadamente 100 kD denominado F(ab')&lt;2&gt;. Este fragmento puede escindirse adicionalmente usando un agente reductor de tiol y, opcionalmente, un grupo bloqueante para los grupos sulfhidrilo resultantes de la escisión de enlaces disulfuro, para producir un fragmento monovalente Fab' de aproximadamente 50 Kd. Alternativamente, una escisión enzimática usando papaína produce directamente dos fragmentos Fab monovalentes y un fragmento Fc. </span>[0114]An antibody fragment can also be prepared by proteolytic hydrolysis of a full-length antibody or by expression in E. coli or another host of the DNA encoding the fragment. An antibody fragment can be obtained by pepsin or papain digestion of full-length antibodies by conventional methods. For example, an antibody fragment can be produced by enzymatic cleavage of antibodies with pepsin to provide an approximately 100 kD fragment designated F(ab')&lt;2&gt;. This fragment can be further cleaved using a thiol reducing agent and, optionally, a blocking group for the sulfhydryl groups resulting from the cleavage of disulfide bonds, to produce a monovalent Fab' fragment of approximately 50 Kd. Alternatively, an enzymatic cleavage using papain directly produces two monovalent Fab fragments and one Fc fragment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0115]También se pueden usar otros métodos de escisión de anticuerpos, tales como separación de cadenas pesadas para formar fragmentos de cadenas ligeras-pesadas monovalentes, escisión adicional de fragmentos u otras técnicas enzimáticas, químicas o genéticas, siempre que los fragmentos se unan al antígeno que se reconocido por el anticuerpo intacto. </span>[0115]Other methods of antibody cleavage, such as heavy chain cleavage to form monovalent light-heavy chain fragments, additional fragment cleavage, or other enzymatic, chemical or genetic techniques, may also be used, provided that the fragments are attached to the antigen that is recognized by the intact antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos biespecíficos y multiespecíficos</span>Bispecific and multispecific antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0116]Los anticuerpos biespecíficos son útiles en diversas aplicaciones biomédicas. Por ejemplo, un anticuerpo biespecífico con sitios de unión para un antígeno de superficie de células tumorales y para un receptor de superficie de células T puede dirigir la lisis de células tumorales específicas por parte de células T. Los anticuerpos biespecíficos que reconocen gliomas y el epítopo CD3 en las células T se han utilizado con éxito en el tratamiento de tumores cerebrales en pacientes humanos (Nitta, et al. Lancet. 1990; 355:368-371). Un ejemplo particular es un anticuerpo anti-CD3 X anti-Trop-2. Alternativamente, un anticuerpo anti-CD3 o fragmento del mismo puede unirse a un anticuerpo o fragmento contra un antígeno asociado a células B, tal como anti-CD3 X anti-CD19, anti-cD3 X anti-CD20, anti-CD3 X anti-CD22, anti-CD3 X anti-HLA-DR o anti-CD3 X anti-CD74. Las técnicas y composiciones para la conjugación de agentes terapéuticos descritas en el presente documento se pueden usar con anticuerpos biespecíficos o multiespecíficos como restos de dirección. </span>[0116]Bispecific antibodies are useful in various biomedical applications. For example, a bispecific antibody with binding sites for a tumor cell surface antigen and for a T cell surface receptor can direct the lysis of specific tumor cells by T cells. Bispecific antibodies that recognize gliomas and the epitope CD3 T cells have been used successfully in the treatment of brain tumors in human patients (Nitta, et al. Lancet. 1990; 355:368-371). A particular example is an anti-CD3X anti-Trop-2 antibody. Alternatively, an anti-CD3 antibody or fragment thereof may bind to an antibody or fragment against a B cell-associated antigen, such as anti-CD3X anti-CD19, anti-cD3X anti-CD20, anti-CD3X anti- CD22, anti-CD3 X anti-HLA-DR or anti-CD3 X anti-CD74. The techniques and compositions for conjugation of therapeutic agents described herein can be used with bispecific or multispecific antibodies as targeting moieties.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0117]Se conocen numerosos métodos para producir anticuerpos biespecíficos o multiespecíficos, como se describe, por ejemplo, en la patente estadounidense número 7.405.320. Los anticuerpos biespecíficos pueden producirse mediante el método del cuadroma, que implica la fusión de dos hibridomas diferentes, cada uno de los cuales produce un anticuerpo monoclonal que reconoce un sitio antigénico diferente (Milstein y Cuello, Nature, 1983; 305:537-540). </span>[0117]Numerous methods are known for producing bispecific or multispecific antibodies, as described, for example, in US patent number 7,405,320. Bispecific antibodies can be produced by the quadroma method, which involves the fusion of two different hybridomas, each of which produces a monoclonal antibody that recognizes a different antigenic site (Milstein and Cuello, Nature, 1983; 305:537-540) .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0118]Otro método para producir anticuerpos biespecíficos utiliza entrecruzadores heterobifuncionales para unir químicamente dos anticuerpos monoclonales diferentes (Staerz, et al. Nature, 1985; 314:628-631; Perez, et al. Nature, 1985; 316:354-356). También se pueden producir anticuerpos biespecíficos mediante la reducción de cada uno de los dos anticuerpos monoclonales parentales a las respectivas medias moléculas, que luego se mezclan y se dejan reoxidar para obtener la estructura híbrida (Staerz y Bevan. Proc Natl Acad Sci EE. UU. 1986; 83:1453-1457). Otra alternativa implica reticular químicamente dos o tres fragmentos Fab' purificados por separado usando enlazadores apropiados. (Ver, por ejemplo, la solicitud de patente europea 0453082). </span>[0118]Another method for producing bispecific antibodies uses heterobifunctional cross-linkers to chemically link two different monoclonal antibodies (Staerz, et al. Nature, 1985; 314:628-631; Perez, et al. Nature, 1985; 316:354-356) . Bispecific antibodies can also be produced by reducing each of the two parental monoclonal antibodies to the respective half molecules, which are then mixed and allowed to reoxidize to obtain the hybrid structure (Staerz and Bevan. Proc Natl Acad Sci USA. 1986; 83:1453-1457). Another alternative involves chemically cross-linking two or three separately purified Fab' fragments using appropriate linkers. (See, for example, European patent application 0453082).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0119]Otros métodos incluyen mejorar la eficiencia de generar hibridomas híbridos mediante la transferencia de genes de distintos marcadores seleccionables a través de vectores lanzadera derivados de retrovirus en hibridomas parentales respectivos, que se fusionan posteriormente (DeMonte, et al. Proc Natl Acad Sci EE. UU. 1990, 87:2941-2945); o transfección de una línea celular de hibridoma con plásmidos de expresión que contienen los genes de cadena pesada y ligera de un anticuerpo diferente. </span>[0119]Other methods include improving the efficiency of generating hybrid hybridomas by transferring genes of different selectable markers via retrovirus-derived shuttle vectors into respective parental hybridomas, which are subsequently fused (DeMonte, et al. Proc Natl Acad Sci EE .USA 1990, 87:2941-2945); or transfection of a hybridoma cell line with expression plasmids containing the heavy and light chain genes of a different antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0120]Los dominios Vh y Vl afines se pueden unir con un conector peptídico de composición y longitud apropiadas (que normalmente consta de más de 12 residuos de aminoácidos) para formar un Fv monocatenario (scFv) con actividad de unión. Los métodos de fabricación de scFv se describen en las patentes de EE. UU. 4.946.778 y la patente de EE. UU. n° 5.132.405. La reducción de la longitud del conector peptídico a menos de 12 residuos de aminoácidos evita el emparejamiento de los dominios V&lt;h&gt;y V&lt;l&gt;en la misma cadena y fuerza el emparejamiento de los dominios V&lt;h&gt;y V&lt;l&gt;con dominios complementarios en otras cadenas, lo que da como resultado la formación de multímeros funcionales. Las cadenas polipeptídicas de los dominios V&lt;h&gt;y V&lt;l&gt;que están unidas con conectores entre 3 y 12 residuos de aminoácidos forman predominantemente dímeros (denominados diacuerpos). Con conectores entre 0 y 2 residuos de aminoácidos, se prefieren los trímeros (denominados triacuerpos) y los tetrámeros (denominados tetracuerpos), pero los patrones exactos de oligomerización parecen depender de la composición y de la orientación de los dominios V (VH-enlazador-VL o V&lt;l&gt;-enlazador-VH), además de la longitud del enlazador. </span>[0120]The cognate Vh and Vl domains can be linked with a peptide linker of appropriate composition and length (typically consisting of more than 12 amino acid residues) to form a single-chain Fv (scFv) with binding activity. Methods of manufacturing scFv are described in US Patents 4,946,778 and US Patent No. 5,132,405. Reducing the length of the peptide linker to less than 12 amino acid residues prevents the pairing of the V&lt;h&gt;and V&lt;l&gt;domains on the same chain and forces the pairing of the V&lt;h&gt;and V&lt;l&gt;domains with complementary domains on other chains, resulting in the formation of functional multimers. The polypeptide chains of the V&lt;h&gt;and V&lt;l&gt;domains that are linked with linkers between 3 and 12 amino acid residues predominantly form dimers (termed diabodies). With linkers between 0 and 2 amino acid residues, trimers (called triabodies) and tetramers (called tetrabodies) are preferred, but the exact patterns of oligomerization appear to depend on the composition and orientation of the V (VH-linker-) domains. VL or V&lt;l&gt;-linker-VH), plus the length of the linker.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0121]Estas técnicas para producir anticuerpos multiespecíficos o biespecíficos presentan diversas dificultades en términos de bajo rendimiento, necesidad de purificación, baja estabilidad o complejidad de la técnica. Más recientemente, se ha utilizado una técnica conocida como “dock and lock” (DNL) para producir combinaciones de prácticamente cualquier anticuerpo, fragmento de anticuerpo y otras moléculas efectoras deseadas (véanse, por ejemplo, las Patentes de EE. UU. Nos 7.521.056; 7.527.787; 7.534.866; 7.550.143; 7.666.400; 7.858.070; 7.871.622; 7.906.121; 7.906.118; 8.163.291; 7.901.680; 7.981.398; 8.003.111 y 8.034.352). La técnica utiliza dominios de unión a proteínas complementarias, denominados dominios de anclaje (AD) y dominios de dimerización y acoplamiento (DDD), que se unen entre sí y permiten el ensamblaje de estructuras complejas, que van desde dímeros, trímeros, tetrámeros, quintameros y hexámeros. Estos forman complejos estables con alto rendimiento sin necesidad de una purificación extensa. La técnica DNL permite el ensamblaje de anticuerpos monoespecíficos, biespecíficos o multiespecíficos. Cualquiera de las técnicas conocidas en la técnica para preparar anticuerpos biespecíficos o multiespecíficos se puede utilizar en la práctica de los métodos actualmente reivindicados. </span>[0121]These techniques for producing multispecific or bispecific antibodies present various difficulties in terms of low yield, need for purification, low stability or complexity of the technique. More recently, a technique known as “dock and lock” (DNL) has been used to produce combinations of virtually any desired antibody, antibody fragment, and other effector molecules (see, for example, US Pat. Nos. 7,521. 056; ; 7,981,398; 8,034,352). The technique uses complementary protein binding domains, called anchoring domains (AD) and docking and dimerization domains (DDD), which bind to each other and allow the assembly of complex structures, ranging from dimers, trimers, tetramers, quintamers. and hexamers. These form stable complexes in high yield without the need for extensive purification. The DNL technique allows the assembly of monospecific, bispecific or multispecific antibodies. Any of the techniques known in the art for preparing bispecific or multispecific antibodies can be used in the practice of the currently claimed methods.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Protocolos de conjugación</span>Conjugation protocols</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0122]Los anticuerpos o fragmentos de los mismos pueden conjugarse con uno o más agentes terapéuticos o de diagnóstico. No es necesario que los agentes terapéuticos sean los mismos, sino que pueden ser diferentes, por ejemplo, un fármaco y un radioisótopo. Por ejemplo, se puede incorporar 131I en una tirosina de un anticuerpo o proteína de fusión y un fármaco unido a un grupo amino épsilon de un residuo de lisina. También se pueden unir agentes terapéuticos y de diagnóstico, por ejemplo, a grupos SH reducidos y/o a cadenas laterales de carbohidratos. En la técnica se conocen muchos métodos para preparar conjugados covalentes o no covalentes de agentes terapéuticos o de diagnóstico con anticuerpos o proteínas de fusión y se puede utilizar cualquier método conocido. </span>[0122]The antibodies or fragments thereof may be conjugated to one or more therapeutic or diagnostic agents. The therapeutic agents do not have to be the same, but can be different, for example, a drug and a radioisotope. For example, 131I can be incorporated into a tyrosine of an antibody or fusion protein and a drug attached to an epsilon amino group of a lysine residue. Therapeutic and diagnostic agents can also be attached, for example, to reduced SH groups and/or to carbohydrate side chains. Many methods are known in the art for preparing covalent or non-covalent conjugates of therapeutic or diagnostic agents with antibodies or fusion proteins and any known method can be used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0123]Se puede unir un agente terapéutico o de diagnóstico a la región bisagra de un componente de anticuerpo reducido mediante la formación de enlaces disulfuro. Alternativamente, tales agentes se pueden unir usando un reticulante heterobifuncional, tal como 3-(2-piridilditio)propionato de W-succinilo (SPDP). Yu y col., Int. J. Cancer 56: 244 (1994). Las técnicas generales para dicha conjugación son bien conocidas en la técnica. Véase, por ejemplo, Wong, CHEMISTRY OF PROTEIN CONJUGATION AND CROSS-LINKING (CRC Press 1991); Upeslaciset al.,“Modification of Antibodies by Chemical Methods”, en ANTIBODIES MONOCLONAL: PRINCIPLES AND APPLICATIONS, Birch et al. (eds.), páginas 187-230 (Wiley-Liss, Inc. 1995); Price, “Production and Characterization of Synthetic Peptide-Derived Antibodies," en MONOCLONAL ANTIBODIES: PRODUCTION, ENGINEERING AND CLINICAL APPLICATION, Ritter et al. (eds.), páginas 60-84 (Cambridge University Press 1995). Alternativamente, el agente terapéutico o de diagnóstico se puede conjugar mediante un resto carbohidrato en la región Fc del anticuerpo. El grupo carbohidrato puede usarse para aumentar la carga del mismo agente que está unido a un grupo tiol, o el resto carbohidrato puede usarse para unirse a un agente terapéutico o de diagnóstico diferente. </span>[0123]A therapeutic or diagnostic agent can be attached to the hinge region of a reduced antibody component through the formation of disulfide bonds. Alternatively, such agents can be linked using a heterobifunctional cross-linker, such as W-succinyl 3-(2-pyridyldithio)propionate (SPDP). Yu et al., Int. J. Cancer 56: 244 (1994). General techniques for such conjugation are well known in the art. See, for example, Wong, CHEMISTRY OF PROTEIN CONJUGATION AND CROSS-LINKING (CRC Press 1991); Upeslaciset al., “Modification of Antibodies by Chemical Methods”, in MONOCLONAL ANTIBODIES: PRINCIPLES AND APPLICATIONS, Birch et al. (eds.), pp. 187-230 (Wiley-Liss, Inc. 1995); Price, “Production and Characterization of Synthetic Peptide-Derived Antibodies," in MONOCLONAL ANTIBODIES: PRODUCTION, ENGINEERING AND CLINICAL APPLICATION, Ritter et al. (eds.), pages 60-84 (Cambridge University Press 1995). Alternatively, the therapeutic agent or diagnostic can be conjugated via a carbohydrate moiety in the Fc region of the antibody. The carbohydrate group can be used to increase the charge of the same agent that is attached to a thiol group, or the carbohydrate moiety can be used to bind to a therapeutic or agent. of different diagnosis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0124]Los expertos en la técnica conocen bien los métodos para conjugar péptidos con componentes de anticuerpos a través de una fracción carbohidrato de anticuerpo. Véase, por ejemplo, Shih et al., Int. J. Cancer 41: 832 (1988); Shih et al., Int. J. Cancer 46: 1101 (1990); y Shih et al., patente de Ee . UU. n° 5.057.313. El método general implica hacer reaccionar un componente de anticuerpo que tiene una parte de carbohidrato oxidada con un polímero portador que tiene al menos una función amina libre. Esta reacción da como resultado un enlace inicial de base de Schiff (imina), que puede estabilizarse mediante reducción a una amina secundaria para formar el conjugado final. </span>[0124]Methods for conjugating peptides to antibody components via an antibody carbohydrate moiety are well known to those skilled in the art. See, for example, Shih et al., Int. J. Cancer 41: 832 (1988); Shih et al., Int. J. Cancer 46: 1101 (1990); and Shih et al., US Pat. US No. 5,057,313. The general method involves reacting an antibody component having an oxidized carbohydrate moiety with a carrier polymer having at least one free amine function. This reaction results in an initial Schiff base (imine) bond, which can be stabilized by reduction to a secondary amine to form the final conjugate.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0125]La región Fc puede estar ausente si el anticuerpo usado como componente de anticuerpo del inmunoconjugado es un fragmento de anticuerpo. Sin embargo, es posible introducir un resto de carbohidrato en la región variable de cadena ligera de un anticuerpo o fragmento de anticuerpo de longitud completa. Véase, por ejemplo, Leung et al., J. Immunol. </span>[0125]The Fc region may be absent if the antibody used as the antibody component of the immunoconjugate is an antibody fragment. However, it is possible to introduce a carbohydrate residue into the light chain variable region of a full-length antibody or antibody fragment. See, for example, Leung et al., J. Immunol.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">154: 5919 (1995); Hansen et al., Patente de EE. UU. n° 5.443.953 (1995), Leung et al., Patente de EE. UU. n° 6.254.868. El resto de carbohidrato modificado se utiliza para unir el agente terapéutico o de diagnóstico. </span>154:5919 (1995); Hansen et al., US Patent No. 5,443,953 (1995), Leung et al., US Patent No. 6,254,868. The modified carbohydrate moiety is used to bind the therapeutic or diagnostic agent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0126]Un método alternativo para unir restos portadores a una molécula objetivo implica el uso de reacciones químicas de clic. El enfoque de la química del clic se concibió originalmente como un método para generar rápidamente sustancias complejas uniendo pequeñas subunidades de forma modular. (Ver, por ejemplo, Kolb et al., 2004, Angew Chem Int Ed 40:3004-31; Evans, 2007, Aust J Chem 60:384-95). Se conocen en la técnica varias formas de reacción química de clic, tales como la reacción catalizada por cobre de cicloadición 1,3-dipolar de Huisgen (Tomoe et al., 2002, J Organic Chem 67:3057-64), que a menudo se denomina “reacción de clic”. Otras alternativas incluyen reacciones de cicloadición como las de Diels-Alder, reacciones de sustitución nucleofílica (especialmente en pequeños anillos tensos como compuestos de epoxi y aziridina), formación química de carbonilo de compuestos de urea y reacciones que involucran dobles enlaces carbono-carbono, como los alquinos en reacciones de tiolino. </span>[0126]An alternative method for attaching carrier moieties to a target molecule involves the use of chemical click reactions. The click chemistry approach was originally conceived as a method to rapidly generate complex substances by linking small subunits in a modular fashion. (See, for example, Kolb et al., 2004, Angew Chem Int Ed 40:3004-31; Evans, 2007, Aust J Chem 60:384-95). Various forms of click chemical reaction are known in the art, such as the copper-catalyzed Huisgen 1,3-dipolar cycloaddition reaction (Tomoe et al., 2002, J Organic Chem 67:3057-64), which often It is called “click reaction”. Other alternatives include cycloaddition reactions such as Diels-Alder, nucleophilic substitution reactions (especially in small strained rings such as epoxy and aziridine compounds), chemical carbonyl formation of urea compounds, and reactions involving carbon-carbon double bonds, such as alkynes in thioline reactions.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0127]La reacción de cicloadición de azida alquino Huisgen utiliza un catalizador de cobre en presencia de un agente reductor para catalizar la reacción de un grupo alquino terminal unido a una primera molécula. En presencia de una segunda molécula que comprende un resto azida, la azida reacciona con el alquino activado para formar un 1,2,3-triazol 1,4-disustituido. La reacción catalizada por cobre ocurre a temperatura ambiente y es suficientemente específica como para que a menudo no sea necesaria la purificación del producto de reacción. (Rostovstev et al., 2002, Angew Chem Int Ed 41:2596; Tomoe et al., 2002, J Org Chem 67:3057). Los grupos funcionales azida y alquino son en gran medida inertes frente a biomoléculas en medio acuoso, lo que permite la reacción a ocurren en soluciones complejas. El triazol formado es químicamente estable y no está sujeto a escisión enzimática, lo que hace que el producto de química clic sea altamente estable en sistemas biológicos. Aunque el catalizador de cobre es tóxico para las células vivas, la reacción química de clic a base de cobre se puede utilizarin vitropara la formación de inmunoconjugados. </span>[0127]The Huisgen azide alkyne cycloaddition reaction uses a copper catalyst in the presence of a reducing agent to catalyze the reaction of a terminal alkyne group attached to a first molecule. In the presence of a second molecule comprising an azide moiety, the azide reacts with the activated alkyne to form a 1,4-disubstituted 1,2,3-triazole. The copper-catalyzed reaction occurs at room temperature and is specific enough that purification of the reaction product is often not necessary. (Rostovstev et al., 2002, Angew Chem Int Ed 41:2596; Tomoe et al., 2002, J Org Chem 67:3057). The azide and alkyne functional groups are largely inert to biomolecules in aqueous media, allowing the reaction to occur in complex solutions. The triazole formed is chemically stable and is not subject to enzymatic cleavage, making the click chemistry product highly stable in biological systems. Although the copper catalyst is toxic to living cells, the copper-based click chemical reaction can be used in vitro for the formation of immunoconjugates.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0128]Se ha propuesto una reacción de clic sin cobre para la modificación covalente de biomoléculas. (Ver, por ejemplo, Agard et al., 2004, J Am Chem Soc 126:15046-47). La reacción sin cobre utiliza tensión de anillo en lugar del catalizador de cobre para promover una reacción de cicloadición de [3  2] azida-alquino.(Id).Por ejemplo, el ciclooctino es una estructura de anillo de 8 carbonos que comprende un enlace alquino interno. La estructura de anillo cerrado induce una deformación sustancial del ángulo de enlace del acetileno, que es altamente reactivo con los grupos azida para formar un triazol. Por tanto, se pueden utilizar derivados de ciclooctina para reacciones de clic sin cobre(id.)</span>[0128]A copper-free click reaction has been proposed for the covalent modification of biomolecules. (See, for example, Agard et al., 2004, J Am Chem Soc 126:15046-47). The copper-free reaction uses ring tension instead of the copper catalyst to promote a [3 2]azide-alkyne cycloaddition reaction (Id). For example, cyclooctyne is an 8-carbon ring structure comprising a bond internal alkyne. The closed ring structure induces a substantial deformation of the bond angle of acetylene, which is highly reactive with azide groups to form a triazole. Therefore, cyclooctine derivatives can be used for click reactions without copper(id.)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0129]Ning et al. informaron otro tipo de reacción de clic sin cobre. (2010, Angew Chem Int Ed 49:3065-68), que implica cicloadición de alquino-nitrona promovida por cepa. Para abordar la lenta velocidad de la reacción del ciclooctino original, se unen grupos aceptores de electrones adyacentes al triple enlace(Id.).Ejemplos de tales ciclooctinos sustituidos incluyen ciclooctinos difluorados, 4-dibenzociclooctinol y azaciclooctino (Id.). Una reacción alternativa sin cobre implicó cicloadición de alquino-nitrona promovida por cepa para dar isoxazolinas N-alquiladas (Id.). Se informó que la reacción tenía una cinética de reacción excepcionalmente rápida y se usó en un protocolo de tres pasos en un solo recipiente para la modificación específica del sitio de péptidos y proteínas(Id).Las nitronas se prepararon mediante la condensación de aldehídos apropiados con A/-metilhidroxilamina y la reacción de cicloadición tuvo lugar en una mezcla de acetonitrilo y agua (Id.). Estas y otras reacciones químicas de clic conocidas pueden usarse para unir restos portadores a anticuerposin vitro.</span>[0129]Ning et al. reported another type of click reaction without copper. (2010, Angew Chem Int Ed 49:3065-68), which involves strain-promoted alkyne-nitrone cycloaddition. To address the slow reaction rate of the original cyclooctyne, electron-withdrawing groups are attached adjacent to the triple bond (Id.). Examples of such substituted cyclooctynes include difluorinated cyclooctynes, 4-dibenzocyclooctynel and azacyclooctyne (Id.). An alternative copper-free reaction involved strain-promoted alkyne-nitrone cycloaddition to give N-alkylated isoxazolines (Id.). The reaction was reported to have exceptionally fast reaction kinetics and was used in a three-step, one-pot protocol for site-specific modification of peptides and proteins (Id). Nitrones were prepared by condensation of appropriate aldehydes with A/-methylhydroxylamine and the cycloaddition reaction took place in a mixture of acetonitrile and water (Id.). These and other known click chemistry reactions can be used to attach carrier moieties to antibodies in vitro.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0130]Agard et al. (2004, J Am Chem Soc 126:15046-47) demostraron que una glicoproteína recombinante expresada en células CHO en presencia de W-azidoacetilmanosamina peracetilada dio como resultado la bioincorporación del correspondiente ácido W-azidoacetil siálico en los carbohidratos de la glicoproteína. La glicoproteína derivatizada con azido reaccionó específicamente con una ciclooctina biotinilada para formar una glicoproteína biotinilada, mientras que la glicoproteína de control sin el resto azido permaneció sin marcar(Id).Laughlin et al. (2008, Science 320:664-667) utilizaron una técnica similar para marcar metabólicamente glicanos de la superficie celular en embriones de pez cebra incubados con W-azidoacetilgalactosamina peracetilada. Los glicanos azidoderivatizados reaccionaron con reactivos de ciclooctina difluorada (DIFO) para permitir la visualización de glicanosin vivo.</span>[0130]Agard et al. (2004, J Am Chem Soc 126:15046-47) demonstrated that a recombinant glycoprotein expressed in CHO cells in the presence of peracetylated W-azidoacetylmannosamine resulted in bioincorporation of the corresponding W-azidoacetyl sialic acid into the carbohydrates of the glycoprotein. The azido-derivatized glycoprotein reacted specifically with a biotinylated cyclooctin to form a biotinylated glycoprotein, while the control glycoprotein without the azido moiety remained unlabeled(Id).Laughlin et al. (2008, Science 320:664-667) used a similar technique to metabolically label cell surface glycans in zebrafish embryos incubated with peracetylated W-azidoacetylgalactosamine. The azidoderivatized glycans were reacted with difluorinated cyclooctin (DIFO) reagents to allow visualization of live glycanosine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0131]La reacción de Diels-Alder también se ha utilizado para el marcaje de moléculasin vivo.Rossin et al. (2010, Angew Chem Int Ed 49:3375-78) informaron un rendimiento del 52 %in vivoentre un anticuerpo anti-TAG72 (CC49) localizado en un tumor que porta un resto reactivo trans-cicloocteno (TCO) y un derivado DOTA de tetrazina marcado con 111In. El anticuerpo CC49 marcado con TCO se administró a ratones portadores de xenoinjertos de cáncer de colon, seguido 1 día después por una inyección de sonda de tetrazina marcada con 111In (Id.). La reacción de la sonda radiomarcada con el anticuerpo localizado en el tumor dio como resultado una localización de radioactividad pronunciada en el tumor, como demostrado mediante imágenes SPECT de ratones vivos tres horas después de la inyección de la sonda radiomarcada, con una relación tumor-músculo de 13:1(Id.).Los resultados confirmaron la reacción químicain vivode las moléculas marcadas con TCO y tetrazina. </span>[0131]The Diels-Alder reaction has also been used for labeling molecules in vivo.Rossin et al. (2010, Angew Chem Int Ed 49:3375-78) reported a 52% yield in vivo between a tumor-localized anti-TAG72 (CC49) antibody carrying a trans-cyclooctene (TCO) reactive moiety and a tetrazine DOTA derivative. marked with 111In. TCO-labeled CC49 antibody was administered to mice bearing colon cancer xenografts, followed 1 day later by a probe injection of 111In-labeled tetrazine (Id.). Reaction of the radiolabeled probe with the tumor-localized antibody resulted in pronounced localization of radioactivity in the tumor, as demonstrated by SPECT imaging of live mice three hours after injection of the radiolabeled probe, with a tumor-to-muscle ratio of 13:1 (Id.). The results confirmed the in vivo chemical reaction of the molecules labeled with TCO and tetrazine.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0132]Los métodos alternativos de conjugación química de dichos restos con biomoléculas son bien conocidos en la técnica y se puede utilizar cualquier método conocido. Los métodos generales de formación de inmunoconjugados se describen, por ejemplo, en las Patentes de EE. UU. Nos 4.699.784; 4.824.659; 5.525.338; 5.677.427; 5.697.902; 5.716.595; 6.071.490; 6.187.284; 6.306.393; 6.548.275; 6.653.104; 6.962.702; 7.033.572; 7.147.856; y 7.259.240. </span>[0132]Alternative methods of chemical conjugation of said moieties with biomolecules are well known in the art and any known method can be used. General methods of forming immunoconjugates are described, for example, in US Patent Nos. 4,699,784; 4,824,659; 5,525,338; 5,677,427; 5,697,902; 5,716,595; 6,071,490; 6,187,284; 6,306,393; 6,548,275; 6,653,104; 6,962,702; 7,033,572; 7,147,856; and 7,259,240.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0133]El protocolo de conjugación preferido se basa en una reacción de tiol-maleimida, tiol-vinilsulfona, tiolbromoacetamida o tiol-yodoacetamida que es fácil a pH neutro o ácido. Esto evita la necesidad de condiciones de pH más altas para las conjugaciones como, por ejemplo, serían necesarias cuando se usan ésteres activos. Más detalles de protocolos de conjugación ejemplares se describen a continuación en la sección Ejemplos. </span>[0133]The preferred conjugation protocol is based on a thiol-maleimide, thiol-vinylsulfone, thiolbromoacetamide or thiol-iodoacetamide reaction that is facile at neutral or acidic pH. This avoids the need for higher pH conditions for conjugations as, for example, would be necessary when using active esters. More details of exemplary conjugation protocols are described below in the Examples section.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento terapéutico</span>Therapeutic treatment</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0134]La presente divulgación se refiere a un método para tratar a un sujeto, que comprende administrar a un sujeto una cantidad terapéuticamente eficaz de un conjugado anticuerpo-fármaco (CAF) como se describe en el presente documento. Las enfermedades que pueden tratarse con los CAF descritos en el presente documento incluyen, entre otras, neoplasias malignas de células B (p. ej., linfoma no Hodgkin, linfoma de células del manto, mieloma múltiple, linfoma de Hodgkin, linfoma difuso de células B grandes, linfoma de Burkitt, linfoma folicular), leucemia linfocítica aguda, leucemia linfocítica crónica, leucemia de células pilosas) usando, por ejemplo, un anticuerpo anti-CD22 tal como el MAb hLL2 (epratuzumab,véasela patente de EE. UU. n° 6.183.744), contra otro epítopo de CD22 (hRFB4) o anticuerpos contra otros antígenos de células B, tales como CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD74, CD80 o HLA-DR. Otras enfermedades incluyen, entre otras, adenocarcinomas de epitelios del sistema digestivo derivados del endodermo, cánceres tales como cáncer de mama y cáncer de pulmón de células no pequeñas, y otros carcinomas, sarcomas, tumores gliales, leucemias mieloides, etc. antígeno, por ejemplo, un antígeno oncofetal, producido por o asociado con un tumor sólido maligno o una neoplasia hematopoyética, por ejemplo, un antígeno gastrointestinal, de estómago, de colon, de esófago, de hígado, de mama, de páncreas, de hígado, de próstata, de ovario, de testículo, de cerebro, de hueso, se utilizan ventajosamente un tumor urotelial o linfático, un sarcoma o un melanoma. Dichas terapias se pueden administrar una o varias veces, dependiendo del estado de la enfermedad y la tolerabilidad del conjugado, y también se pueden usar opcionalmente en combinación con otras modalidades terapéuticas, radiación externa, radioinmunoterapia, inmunoterapia, quimioterapia, terapia antisentido, terapia de ARN de interferencia, terapia genética. terapia y similares. Cada combinación se adaptará al tipo de tumor, estadio, condición del paciente y terapia previa, y otros factores considerados por el médico tratante. </span>[0134]The present disclosure relates to a method of treating a subject, comprising administering to a subject a therapeutically effective amount of an antibody-drug conjugate (CAF) as described herein. Diseases that can be treated with the CAFs described herein include, but are not limited to, B-cell malignancies (e.g., non-Hodgkin lymphoma, mantle cell lymphoma, multiple myeloma, Hodgkin lymphoma, diffuse cell lymphoma). large B lymphoma, Burkitt lymphoma, follicular lymphoma), acute lymphocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia) using, for example, an anti-CD22 antibody such as MAb hLL2 (epratuzumab, see US Patent No. No. 6,183,744), against another epitope of CD22 (hRFB4) or antibodies against other B cell antigens, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD74, CD80 or HLA-DR . Other diseases include, among others, adenocarcinomas of endoderm-derived epithelia of the digestive system, cancers such as breast cancer and non-small cell lung cancer, and other carcinomas, sarcomas, glial tumors, myeloid leukemias, etc. antigen, for example, an oncofetal antigen, produced by or associated with a malignant solid tumor or a hematopoietic neoplasm, for example, a gastrointestinal, stomach, colon, esophagus, liver, breast, pancreas, liver antigen , prostate, ovarian, testicular, brain, bone, a urothelial or lymphatic tumor, a sarcoma or a melanoma are used advantageously. Such therapies can be administered once or multiple times, depending on the disease state and tolerability of the conjugate, and can also optionally be used in combination with other therapeutic modalities, external radiation, radioimmunotherapy, immunotherapy, chemotherapy, antisense therapy, RNA therapy interference, gene therapy. therapy and the like. Each combination will be tailored to the tumor type, stage, patient's condition and prior therapy, and other factors considered by the treating physician.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0135]Tal como se utiliza en el presente documento, el término “sujeto” se refiere a cualquier animal (es decir, vertebrados e invertebrados), incluidos, entre otros, mamíferos, incluidos los humanos. No se pretende que el término se limite a una edad o sexo en particular. Así, el término engloba a sujetos adultos y recién nacidos, así como a fetos, ya sean masculinos o femeninos. Las dosis indicadas en este documento son para humanos, pero pueden ajustarse al tamaño de otros mamíferos, así como de niños, de acuerdo con el peso o el tamaño del metro cuadrado. </span>[0135]As used herein, the term “subject” refers to any animal (i.e., vertebrates and invertebrates), including, but not limited to, mammals, including humans. The term is not intended to be limited to a particular age or sex. Thus, the term encompasses adult and newborn subjects, as well as fetuses, whether male or female. The doses indicated in this document are for humans, but can be adjusted to the size of other mammals, as well as children, according to weight or square meter size.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0136]Los conjugados terapéuticos que comprenden un anticuerpo anti-Trop-2 como el MAb hRS7 se pueden usar para tratar carcinomas tales como carcinomas de esófago, páncreas, pulmón, estómago, colon y recto, vejiga urinaria, mama, ovario, útero, riñón y próstata, como se describe en la patente estadounidense n° 7.238.785; 7.517.964 y 8.084.583. Un anticuerpo hRS7 es un anticuerpo humanizado que comprende secuencias de la región determinante de la complementariedad (CDR) de cadena ligera CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); y CDR3 (QQHYITPLT, SEQ ID NO:3) y secuencias de CDR de cadena pesada CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) y CDR3 (GGFGSSYWYFDV, SEQ ID NO:6) </span>[0136]Therapeutic conjugates comprising an anti-Trop-2 antibody such as MAb hRS7 can be used to treat carcinomas such as carcinomas of the esophagus, pancreas, lung, stomach, colon and rectum, urinary bladder, breast, ovary, uterus, kidney and prostate, as described in US Patent No. 7,238,785; 7,517,964 and 8,084,583. An hRS7 antibody is a humanized antibody comprising CDR1 light chain complementarity determining region (CDR) sequences (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and CDR1 heavy chain CDR sequences (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0137]Los anticuerpos que pueden usarse en el tratamiento de enfermedades humanas son versiones de anticuerpos humanos o humanizados (injertados con CDR); aunque se pueden utilizar versiones murinas y quiméricas de anticuerpos. Se prefieren principalmente moléculas de IgG de la misma especie como agentes de administración para minimizar las respuestas inmunitarias. Esto es particularmente importante cuando se considera repetir tratamientos. Para los humanos, es menos probable que un anticuerpo IgG humano o humanizado genere una respuesta inmune anti-IgG en los pacientes. Los anticuerpos como hLL1 y hLL2 se internalizan rápidamente después de unirse al antígeno de internalización en las células diana, lo que significa que el fármaco quimioterapéutico que se transporta también se internaliza rápidamente en las células. Sin embargo, también se pueden utilizar anticuerpos que tienen tasas de internalización más lentas para efectuar una terapia selectiva. </span>[0137]Antibodies that can be used in the treatment of human diseases are versions of human or humanized (CDR-grafted) antibodies; although murine and chimeric versions of antibodies can be used. IgG molecules of the same species are mainly preferred as delivery agents to minimize immune responses. This is particularly important when considering repeat treatments. For humans, a human or humanized IgG antibody is less likely to generate an anti-IgG immune response in patients. Antibodies such as hLL1 and hLL2 are rapidly internalized after binding to the internalizing antigen on target cells, which means that the chemotherapeutic drug being transported is also rapidly internalized into the cells. However, antibodies that have slower internalization rates can also be used to effect selective therapy.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0138]En otra forma de realización preferida de la presente invención como se define en las reivindicaciones, un agente terapéutico usado en combinación con el CAF puede comprender uno o más isótopos. Los isótopos radiactivos útiles para tratar tejido enfermo incluyen, entre otros: 111In, 177Lu, 212Bi, 213Bi, 211At, 62Cu, 67Cu, 90Y, 125I, 131I, 32P, 33P, 47Sc, 111Ag, 67Ga, 142Pr, 153Sm, 161Tb, 166Dy, 166Ho, 186Re, 188Re, 189Re, 212Pb, 223Ra, 225Ac, 59Fe, 75Se, 77As, 89Sr, 99Mo, 105Rh, 109Pd, 143Pr, 149Pm, 169Er, 194Ir, 198Au, 199Au, 227Th y 211Pb. El radionucleido terapéutico tiene preferentemente una energía de desintegración en el intervalo de 20 a 6.000 keV, preferentemente en el intervalo de 60 a 200 keV para un emisor Auger, de 100 a 2.500 keV para un emisor beta y de 4.000 a 6.000 keV para un emisor alfa. Las energías máximas de desintegración de los nucleidos emisores de partículas beta útiles son preferentemente de 20 a 5.000 keV, más preferentemente de 100 a 4.000 keV y lo más preferentemente de 500 a 2.500 keV. También se prefieren los radionucleidos que se desintegran sustancialmente con partículas emisoras de Auger. Por ejemplo, Co-58, Ga-67, Br-80m, Tc-99m, Rh-103m, Pt-109, In-111, Sb-119, I-125, Ho-161, Os-189m e Ir-192. Las energías de desintegración de los nucleidos emisores de partículas beta útiles son preferentemente &lt;1.000 keV, más preferentemente &lt;100 keV y lo más preferentemente &lt;70 keV. También se prefieren radionucleidos que se desintegran sustancialmente con la generación de partículas alfa. Dichos radionucleidos incluyen, entre otros: Dy-152, At-211, Bi-212, Ra-223, Rn-219, Po-215, Bi-211, Ac-225, Fr-221, At-217, Bi-213, Th-227 y Fm-255. Las energías de desintegración de los radionucleidos emisores de partículas alfa útiles son preferentemente de 2.000 a 10.000 keV, más preferentemente de 3.000 a 8.000 keV y lo más preferentemente de 4.000 a 7.000 keV. Otros posibles radioisótopos de uso incluyen 11C, 13N, 15O, 75Br, 198Au, 224Ac, 126I, 133I, 77Br, 113mIn, 95Ru, 97Ru, 103Ru, 105Ru, 107Hg, 203Hg, 121mTe, 122mTe, 125mTe, 165Tm, 167Tm, 168Tm, 197Pt, 109Pd, 105Rh, 142Pr, 143Pr, 161Tb, 166Ho, 199Au, 57Co, 58Co, 51Cr, 59Fe, 75Se, 201Tl, 225Ac, 76Br, 169Yb y similares. </span>[0138]In another preferred embodiment of the present invention as defined in the claims, a therapeutic agent used in combination with the CAF may comprise one or more isotopes. Radioactive isotopes useful for treating diseased tissue include, but are not limited to: 111In, 177Lu, 212Bi, 213Bi, 211At, 62Cu, 67Cu, 90Y, 125I, 131I, 32P, 33P, 47Sc, 111Ag, 67Ga, 142Pr, 153Sm, , 166Dy , 166Ho, 186Re, 188Re, 189Re, 212Pb, 223Ra, 225Ac, 59Fe, 75Se, 77As, 89Sr, 99Mo, 105Rh, 109Pd, 143Pr, 149Pm, 169Er, 194Ir, 198Au, 99Au, 227Th and 211Pb. The therapeutic radionuclide preferably has a decay energy in the range of 20 to 6,000 keV, preferably in the range of 60 to 200 keV for an Auger emitter, from 100 to 2,500 keV for a beta emitter and from 4,000 to 6,000 keV for an alpha. The maximum decay energies of useful beta particle-emitting nuclides are preferably 20 to 5,000 keV, more preferably 100 to 4,000 keV, and most preferably 500 to 2,500 keV. Also preferred are radionuclides that decay substantially with Auger emitting particles. For example, Co-58, Ga-67, Br-80m, Tc-99m, Rh-103m, Pt-109, In-111, Sb-119, I-125, Ho-161, Os-189m and Ir-192 . The decay energies of useful beta particle emitting nuclides are preferably &lt;1,000 keV, more preferably &lt;100 keV and most preferably &lt;70 keV. Also preferred are radionuclides that substantially decay with the generation of alpha particles. Such radionuclides include, but are not limited to: Dy-152, At-211, Bi-212, Ra-223, Rn-219, Po-215, Bi-211, Ac-225, Fr-221, At-217, Bi-213 , Th-227 and Fm-255. The decay energies of useful alpha-emitting radionuclides are preferably 2,000 to 10,000 keV, more preferably 3,000 to 8,000 keV and most preferably 4,000 to 7,000 keV. Other possible radioisotopes of use include 11C, 13N, 15O, 75Br, 198Au, 224Ac, 126I, 133I, 77Br, 113mIn, 95Ru, 97Ru, 103Ru, 105Ru, 107Hg, 203Hg, 121mTe, 122mTe, mTe, 165Tm, 167Tm, 168Tm, 197Pt, 109Pd, 105Rh, 142Pr, 143Pr, 161Tb, 166Ho, 199Au, 57Co, 58Co, 51Cr, 59Fe, 75Se, 201Tl, 225Ac, 76Br, 169Yb and similar.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0139]Se pueden administrar radionucleidos y otros metales, por ejemplo, utilizando grupos quelantes unidos a un anticuerpo o conjugado. Los quelatos macrocíclicos como NOTA, DOTA y TETA son útiles con una variedad de metales y radiometales, más particularmente con radionúclidos de galio, itrio y cobre, respectivamente. Tales complejos de quelato de metal pueden hacerse muy estables adaptando el tamaño del anillo al metal de interés. Se pueden usar otros quelatos de tipo anillo, tales como poliéteres macrocíclicos para formar complejos con 223Ra. </span>[0139]Radionuclides and other metals can be administered, for example, using chelating groups attached to an antibody or conjugate. Macrocyclic chelates such as NOTA, DOTA and TETA are useful with a variety of metals and radiometals, most particularly with gallium, yttrium and copper radionuclides, respectively. Such metal chelate complexes can be made very stable by tailoring the ring size to the metal of interest. Other ring-type chelates, such as macrocyclic polyethers, can be used to form complexes with 223Ra.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0140]Los agentes terapéuticos de uso en la presente invención como se define en las reivindicaciones también incluyen, por ejemplo, fármacos quimioterapéuticos tales como alcaloides de la vinca, antraciclinas, epidofilotoxinas, taxanos, antimetabolitos, inhibidores de tirosina quinasa, agentes alquilantes, antibióticos, inhibidores de Cox-2, agentes antimitóticos, antiangiogénicos y proapoptóticos, particularmente doxorrubicina, metotrexato, taxol, otras camptotecinas y otros de estas y otras clases de agentes anticancerígenos y similares. Otros fármacos quimioterapéuticos contra el cáncer incluyen mostazas nitrogenadas, alquilsulfonatos, nitrosoureas, triazenos, análogos del ácido fólico, análogos de pirimidina, análogos de purina, complejos de coordinación de platino, hormonas y similares. Los agentes quimioterapéuticos adecuados se describen en REMINGTON'S PHARMACEUTICAL SCIENCES, 19a Ed. (Mack Publishing Co. 1995), y en GOODMAN AND GII,MAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTIC, 7a Ed. (MacMillan Publishing Co. 1985), así como ediciones revisadas de estas publicaciones. Los expertos en la técnica conocen otros agentes quimioterapéuticos adecuados, tales como fármacos experimentales. </span>[0140]Therapeutic agents of use in the present invention as defined in the claims also include, for example, chemotherapeutic drugs such as vinca alkaloids, anthracyclines, epidophyllotoxins, taxanes, antimetabolites, tyrosine kinase inhibitors, alkylating agents, antibiotics , Cox-2 inhibitors, antimitotic, antiangiogenic and proapoptotic agents, particularly doxorubicin, methotrexate, taxol, other camptothecins and others of these and other classes of anticancer agents and the like. Other anticancer chemotherapeutic drugs include nitrogen mustards, alkylsulfonates, nitrosoureas, triazenes, folic acid analogues, pyrimidine analogues, purine analogues, platinum coordination complexes, hormones and the like. Suitable chemotherapeutic agents are described in REMINGTON'S PHARMACEUTICAL SCIENCES, 19th Ed. (Mack Publishing Co. 1995), and in GOODMAN AND GII, MAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTIC, 7th Ed. (MacMillan Publishing Co. 1985), as well as revised editions. of these publications. Other suitable chemotherapeutic agents, such as experimental drugs, are known to those skilled in the art.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0141]Los fármacos de uso ejemplares incluyen, entre otros, 5-fluorouracilo, afatinib, aplidina, azaribina, anastrozol, antraciclinas, axitinib, AVL-101, AVL-291, bendamustina, bleomicina, bortezomib, bosutinib, briostatina-1, busulfán, caliqueamicina, camptotecina, carboplatino, 10-hidroxicamptotecina, carmustina, celecoxib, clorambucilo, cisplatino (CDDP), inhibidores de la Cox-2, irinotecán (CPT-11), SN-38, carboplatino, cladribina, camptotecanos, crizotinib, ciclofosfamida, citarabina, dacarbazina, dasatinib, dinaciclib, docetaxel, dactinomicina, daunorrubicina, doxorrubicina, 2-pirrolinodoxorrubicina (2P-DOX), cianomorfolino doxorrubicina, glucurónido de doxorrubicina, glucurónido de epirrubicina, erlotinib, estramustina, epidofilotoxina, erlotinib, entinostat, agentes de unión al receptor de estrógeno, etopósido (VP16), glucurónido de etopósido, fosfato de etopósido, exemestano, fingolimod, floxuridina (FUdR), 3',5'-O-dioleoil-FudR (FUdR-dO), fludarabina, flutamida, inhibidores de farnesil-proteína transferasa, flavopiridol, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabina, hidroxiurea, ibrutinib, idarrubicina, idelalisib, ifosfamida, imatinib, L-asparaginasa, lapatinib, lenolidamida, leucovorina, LFM-A13, lomustina, mecloretamina, melfalán, mercaptopurina, 6-mercaptopurina, metotrexato, mitoxantrona, mitramicina, mitomicina, mitotano, navelbina, neratinib, nilotinib, nitrosurea, olaparib, plicomicina, procarbazina, paclitaxel, PCI-32765, pentostatina, PSI-341, raloxifeno, semustina, sorafenib, estreptozocina, SU11248, sunitinib, tamoxi pantano, temazolomida (una forma acuosa de DTIC), transplatino, talidomida, tioguanina, tiotepa, tenipósido, topotecán, mostaza de uracilo, vatalanib, vinorelbina, vinblastina, vincristina, alcaloides de vinca y ZD1839. Dichos agentes pueden ser parte de los conjugados descritos en el presente documento o, alternativamente, pueden administrarse en combinación con los conjugados descritos, ya sea antes, simultáneamente o después del conjugado. Alternativamente, se pueden usar uno o más anticuerpos terapéuticos desnudos conocidos en la técnica en combinación con los conjugados descritos. Los anticuerpos desnudos terapéuticos ejemplares se describen anteriormente. </span>[0141]Exemplary drugs of use include, but are not limited to, 5-fluorouracil, afatinib, aplidine,azaribin, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan , calicheamicin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatin (CDDP), Cox-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothecans, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicin (2P-DOX), cyanomorpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, erlotinib, estramustine, epidophyllotoxin, erlotinib, entinostat, agents of union to estrogen receptor, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl inhibitors -protein transferase, flavopiridol, fostamatinib, ganatespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, L-asparaginase, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, navelbine, neratinib, nilotinib, nitrosurea, olaparib, plycomycin, procarbazine, paclitaxel, PCI-32765, pentostatin, PSI-341, raloxifene, semustine, sorafenib, streptozocin, SU11248, sunitinib, tamoxi marsh, temazolomide (an aqueous form of DTIC), transplatin, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine, vinca alkaloids, and ZD1839. Such agents may be part of the conjugates described herein or, alternatively, may be administered in combination with the conjugates described, either before, simultaneously or after the conjugate. Alternatively, one or more naked therapeutic antibodies known in the art may be used in combination with the conjugates described. Exemplary therapeutic naked antibodies are described above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0142]En formas de realización preferidas de la invención como se define en las reivindicaciones, un agente terapéutico para usar en combinación con el CAF que es un conjugado de anticuerpo que rompe el ADN es un inhibidor de microtúbulos, tal como un alcaloide de la vinca, un taxano, un maitansinoide o una auristatina. Los inhibidores de microtúbulos conocidos a modo de ejemplo incluyen paclitaxel, vincristina, vinblastina, mertansina, epotilona, docetaxel, discodermolida, combrestatina, podofilotoxina, CI-980, fenilahistinas, esteganacinas, curacinas, 2-metoxiestradiol, E7010, metoxibencenosuflonamidas, vinorelbina, vinflunina, vindesina, dolastatinas, espongistatina, rizoxina, tasidotina, halicondrinas, hemiasterlinas, criptoficina 52, MMAE y mesilato de eribulina. </span>[0142] In preferred embodiments of the invention as defined in the claims, a therapeutic agent for use in combination with CAF which is a DNA cleaving antibody conjugate is a microtubule inhibitor, such as an alkaloid of the vinca, a taxane, a maytansinoid or an auristatin. Exemplary known microtubule inhibitors include paclitaxel, vincristine, vinblastine, mertansine, epothilone, docetaxel, discodermolide, combrestatin, podophyllotoxin, CI-980, phenylahistines, steganazines, curacins, 2-methoxyestradiol, E7010, methoxybenzenesuflonamides, vinorelbine, vinflunine, vindesine, dolastatins, spongistatin, rhizoxin, tasidotin, halichondrins, hemiasterlins, cryptophycin 52, MMAE and eribulin mesylate.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0143]En una forma de realización alternativa preferida de la invención como se define en las reivindicaciones, un agente terapéutico para usar en combinación con el CAF que es un CAF que rompe el ADN, es un inhibidor de PARP, tal como olaparib, talazoparib (BMN-673), rucaparib, veliparib, CEP 9722, MK 4827, BGB-290, ABT-888, AG014699, BSI-201, CEP-8983 o 3-aminobenzamida. </span>[0143]In an alternative preferred embodiment of the invention as defined in the claims, a therapeutic agent for use in combination with the CAF which is a DNA-cleaving CAF, is a PARP inhibitor, such as olaparib, talazoparib (BMN-673), rucaparib, veliparib, CEP 9722, MK 4827, BGB-290, ABT-888, AG014699, BSI-201, CEP-8983, or 3-aminobenzamide.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0144]En otra alternativa de la invención como se define en las reivindicaciones, un agente terapéutico usado en combinación con el CAF es un inhibidor de tirosina quinasa, tal como ibrutinib (PCI-32765), PCI-45292, CC-292 (AVL-292), ONO-4059, GDC-0834, LFM-A13 o RN486. </span>[0144] In another alternative of the invention as defined in the claims, a therapeutic agent used in combination with CAF is a tyrosine kinase inhibitor, such as ibrutinib (PCI-32765), PCI-45292, CC-292 (AVL -292), ONO-4059, GDC-0834, LFM-A13 or RN486.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0145]En otra alternativa más de la invención como se define en las reivindicaciones, un agente terapéutico usado en combinación con el CAF es un inhibidor de PI3K, tal como idelalisib, Wortmanina, demetoxiviridina, perifosina, PX-866, IPI-145 (duvelisib), BAY 80-6946, BEZ235, RP6530, TGR1202, SF1126, INK1117, GDC-0941, BKM120, XL147, XI,765, Palomid 529, GSK1059615, ZSTK474, PWT33597, IC87114, TG100-115, CAL263, PI -103, GNE477, CUDC-907, AEZS-136 o LY294002. </span>[0145] In yet another alternative of the invention as defined in the claims, a therapeutic agent used in combination with CAF is a PI3K inhibitor, such as idelalisib, Wortmannin, demethoxyviridine, perifosine, PX-866, IPI-145 ( duvelisib), BAY 80-6946, BEZ235, RP6530, TGR1202, SF1126, INK1117, GDC-0941, BKM120, XL147, 15, CAL263, PI -103 , GNE477, CUDC-907, AEZS-136 or LY294002.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0146]Los agentes terapéuticos que pueden usarse junto con conjugados de camptotecina también pueden comprender toxinas conjugadas con restos diana. Las toxinas que pueden usarse a este respecto incluyen ricina, abrina, ribonucleasa (RNasa), DNasa I, ranpirnasa, enterotoxina estafilocócica A, proteína antiviral de hierba carmín, gelonina, toxina diftérica, exotoxina dePseudomonasy endotoxina dePseudomonas.(Véase, por ejemplo, Pastan. et al., Cell (1986), 47:641, y Sharkey y Goldenberg, CA Cancer J Clin. 2006 julio-agosto;56(4):226-43). Toxinas adicionales adecuadas para su uso aquí son conocidas por los expertos en la técnica y se describen en el documento US 6.077.499. </span>[0146]Therapeutic agents that may be used in conjunction with camptothecin conjugates may also comprise toxins conjugated to target moieties. Toxins that may be used in this regard include ricin, abrin, ribonuclease (RNase), DNase I, ranpirnase, staphylococcal enterotoxin A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin. (See, for example, Pastan . et al., Cell (1986), 47:641, and Sharkey and Goldenberg, CA Cancer J Clin 2006 July-August;56(4):226-43). Additional toxins suitable for use herein are known to those skilled in the art and are described in US 6,077,499.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0147]Aún otra clase de agente terapéutico puede comprender uno o más inmunomoduladores. Los inmunomoduladores de uso pueden seleccionarse entre una citoquina, un factor de crecimiento de células madre, una linfotoxina, un factor hematopoyético, un factor estimulante de colonias (CSF), un interferón (IFN), eritropoyetina, trombopoyetina y una combinación de los mismos. Específicamente útiles son linfotoxinas tales como factor de necrosis tumoral (TNF), factores hematopoyéticos, tales como interleucina (IL), factor estimulante de colonias, tal como factor estimulante de colonias de granulocitos (G-CSF) o factor estimulante de colonias de granulocitos y macrófagos (GM-CSF), interferón, tal como interferones a, p, y o A, y factor de crecimiento de células madre, tal como el denominado “factor S1”. Entre las citoquinas se incluyen hormonas del crecimiento tales como la hormona del crecimiento humana, la hormona del crecimiento humana N-metionil y la hormona del crecimiento bovino; hormona paratiroidea; tiroxina; insulina; proinsulina; relaxina; prorelaxina; hormonas glicoproteicas tales como hormona estimulante del folículo (FSH), hormona estimulante de la tiroides (TSH) y hormona luteinizante (LH); factor de crecimiento hepático; prostaglandina, factor de crecimiento de fibroblastos; prolactina; lactógeno placentario, proteína OB; factor de necrosis tumoral a y p; sustancia inhibidora de Muller; péptido asociado a gonadotropina de ratón; inhibina; activina; factor de crecimiento vascular endotelial; integrina; trombopoyetina (TPO); factores de crecimiento nervioso tales como NGF-p; factor de crecimiento plaquetario; factores de crecimiento transformantes (TGF) tales como TGF-a y TGF-p; factores de crecimiento similares a la insulina I y II; eritropoyetina (EPO); factores osteoinductivos; interferones tales como interferón a, p,&lt;y&gt;y A; factores estimulantes de colonias (CSF) tales como macrófagos-CSF (MCSF); interleucinas (IL) como IL-1, IL-1 a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-25, LIF, ligando kit o FLT-3, angiostatina, trombospondina, endostatina, necrosis tumoral factor y linfotoxina (LT). Tal como se utiliza en el presente documento, el término citocina incluye proteínas de fuentes naturales o de cultivos celulares recombinantes y equivalentes biológicamente activos de las citocinas de secuencia nativa. </span>[0147]Still another class of therapeutic agent may comprise one or more immunomodulators. The immunomodulators for use can be selected from a cytokine, a stem cell growth factor, a lymphotoxin, a hematopoietic factor, a colony stimulating factor (CSF), an interferon (IFN), erythropoietin, thrombopoietin and a combination thereof. Specifically useful are lymphotoxins such as tumor necrosis factor (TNF), hematopoietic factors, such as interleukin (IL), colony-stimulating factor, such as granulocyte colony-stimulating factor (G-CSF) or granulocyte colony-stimulating factor and macrophages (GM-CSF), interferon, such as interferons a, p, and or A, and stem cell growth factor, such as the so-called “S1 factor”. Cytokines include growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH) and luteinizing hormone (LH); liver growth factor; prostaglandin, fibroblast growth factor; prolactin; placental lactogen, OB protein; tumor necrosis factor a and p; Muller's inhibitory substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF-p; platelet growth factor; transforming growth factors (TGF) such as TGF-a and TGF-p; insulin-like growth factors I and II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon a, p,&lt;y&gt;and A; colony stimulating factors (CSF) such as macrophage-CSF (MCSF); interleukins (IL) such as IL-1, IL-1 a, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-25, LIF, kit ligand or FLT-3, angiostatin, thrombospondin, endostatin, tumor necrosis factor and lymphotoxin (LT). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell cultures and biologically active equivalents of native sequence cytokines.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0148]Las quimiocinas de uso incluyen RANTES, MCAF, MIP1-alfa, MIP1-Beta e IP-10. </span>[0148]Chemokines of use include RANTES, MCAF, MIP1-alpha, MIP1-Beta and IP-10.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0149]El experto habitual se dará cuenta de que, de acuerdo con la invención, tal como se define en las reivindicaciones, el CAF puede usarse en combinación con uno o más agentes terapéuticos diferentes, tales como un segundo anticuerpo, un segundo fragmento de anticuerpo, un segundo inmunoconjugado, un radionucleido, una toxina, fármaco, agente quimioterapéutico, radioterapia, quimiocina, citocina, inmunomodulador, enzima, hormona, oligonucleótido, ARNi o ARNip. Dichos agentes terapéuticos adicionales pueden administrarse por separado, en combinación o unidos a los inmunoconjugados anticuerpo-fármaco en cuestión. </span>[0149]The ordinary person skilled in the art will realize that, according to the invention, as defined in the claims, CAF can be used in combination with one or more different therapeutic agents, such as a second antibody, a second fragment of antibody, a second immunoconjugate, a radionuclide, a toxin, drug, chemotherapeutic agent, radiotherapy, chemokine, cytokine, immunomodulator, enzyme, hormone, oligonucleotide, RNAi or siRNA. Said additional therapeutic agents can be administered separately, in combination or linked to the antibody-drug immunoconjugates in question.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Formulación y Administración</span>Formulation and Administration</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0150]Las vías de administración adecuadas de los conjugados para su uso de acuerdo con la presente invención como se define en las reivindicaciones incluyen, sin limitación, administración oral, parenteral, subcutánea, rectal, transmucosa, intestinal, intramuscular, intramedular, intratecal, intraventricular directa, intravenosa, intravítrea, inyecciones intraperitoneales, intranasales o intraoculares. Las vías de administración preferidas son parenterales. Alternativamente, se puede administrar el compuesto de manera local en lugar de sistémica, por ejemplo, mediante inyección del compuesto directamente en un tumor sólido. </span>[0150]Suitable routes of administration of the conjugates for use in accordance with the present invention as defined in the claims include, without limitation, oral, parenteral, subcutaneous, rectal, transmucosal, intestinal, intramuscular, intramedullary, intrathecal, direct intraventricular, intravenous, intravitreal, intraperitoneal, intranasal or intraocular injections. The preferred routes of administration are parenteral. Alternatively, the compound may be administered locally rather than systemically, for example, by injecting the compound directly into a solid tumor.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0151]Los inmunoconjugados se pueden formular según métodos conocidos para preparar composiciones farmacéuticamente útiles, mediante las cuales el inmunoconjugado se combina en una mezcla con un excipiente farmacéuticamente adecuado. La solución salina tamponada con fosfato estéril es un ejemplo de excipiente farmacéuticamente adecuado. Otros excipientes adecuados son bien conocidos por los expertos en la técnica. Véase, por ejemplo, Ansel et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5.a edición (Lea &amp; Febiger 1990), y Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18.a edición (Mack Publishing Company 1990), y ediciones revisadas del mismo. </span>[0151]Immunoconjugates can be formulated according to known methods for preparing pharmaceutically useful compositions, whereby the immunoconjugate is combined in a mixture with a pharmaceutically suitable excipient. Sterile phosphate buffered saline is an example of a pharmaceutically suitable excipient. Other suitable excipients are well known to those skilled in the art. See, for example, Ansel et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th edition (Lea &amp; Febiger 1990), and Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18th edition (Mack Publishing Company 1990) , and revised editions thereof.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0152]En una forma de realización preferida de la invención como se define en las reivindicaciones, el inmunoconjugado se formula en tampón biológico de Good (pH 6-7), usando un tampón seleccionado del grupo que consiste en ácido N-(2-acetamido)-2-aminoetanosulfónico (ACES); ácido N-(2-acetamido)iminodiacético (ADA); ácido N,N-bis(2-hidroxietil)-2-aminoetanosulfónico (BES); ácido 4-(2-hidroxietil)piperazina-1-etanosulfónico (HEPES); ácido 2-(N-morfolino)etanosulfónico (MES); ácido 3-(Nmorfolino)propanosulfónico (MOPS); ácido 3-(N-morfolinil)-2-hidroxipropanosulfónico (MOPSO); y piperazina N,N'-bis(ácido 2-etanosulfónico) [Tuberías]. Los tampones más preferidos son MES o MOPS, preferentemente en el intervalo de concentración de 20 a 100 mM, más preferentemente aproximadamente 25 mM. El más preferido es MES 25 mM, pH 6,5. La formulación puede comprender además trehalosa 25 mM y polisorbato 80 al 0,01 % v/v como excipientes, modificándose la concentración final del tampón a 22,25 mM como resultado de la adición de excipientes. El método de almacenamiento preferido es una formulación liofilizada de los conjugados, almacenada en un rango de temperatura de -20 °C a 2 °C, siendo el almacenamiento más preferido entre 2 °C y 8 °C. </span>[0152]In a preferred embodiment of the invention as defined in the claims, the immunoconjugate is formulated in Good's biological buffer (pH 6-7), using a buffer selected from the group consisting of N-(2- acetamido)-2-aminoethanesulfonic acid (ACES); N-(2-acetamido)iminodiacetic acid (ADA); N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES); 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES); 2-(N-morpholino)ethanesulfonic acid (MES); 3-(Nmorpholino)propanesulfonic acid (MOPS); 3-(N-morpholinyl)-2-hydroxypropanesulfonic acid (MOPSO); and piperazine N,N'-bis(2-ethanesulfonic acid) [Pipelines]. Most preferred buffers are MES or MOPS, preferably in the concentration range of 20 to 100 mM, more preferably about 25 mM. Most preferred is 25 mM MES, pH 6.5. The formulation may further comprise 25 mM trehalose and 0.01% v/v polysorbate 80 as excipients, with the final concentration of the buffer being modified to 22.25 mM as a result of the addition of excipients. The preferred storage method is a lyophilized formulation of the conjugates, stored at a temperature range of -20°C to 2°C, with the most preferred storage being between 2°C and 8°C.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0153]El inmunoconjugado puede formularse para administración intravenosa mediante, por ejemplo, inyección en bolo, infusión lenta o infusión continua. Preferiblemente, el anticuerpo de la presente invención se infunde durante un período de menos de aproximadamente 4 horas, y más preferiblemente, durante un período de menos de aproximadamente 3 horas. Por ejemplo, los primeros 25 a 50 mg se podrían infundir en 30 minutos, preferiblemente incluso 15 minutos, y el resto se podría infundir durante las siguientes 2 a 3 horas. Las formulaciones para inyección pueden presentarse en forma de dosificación unitaria, por ejemplo, en ampollas o en recipientes multidosis, con un conservante añadido. Las composiciones pueden tomar formas tales como suspensiones, soluciones o emulsiones en vehículos oleosos o acuosos, y pueden contener agentes de formulación tales como agentes de suspensión, estabilizantes y/o dispersantes. Alternativamente, el ingrediente activo puede estar en forma de polvo para su constitución con un vehículo adecuado, por ejemplo, agua estéril libre de pirógenos, antes de su uso. </span>[0153]The immunoconjugate may be formulated for intravenous administration by, for example, bolus injection, slow infusion or continuous infusion. Preferably, the antibody of the present invention is infused over a period of less than about 4 hours, and more preferably, over a period of less than about 3 hours. For example, the first 25 to 50 mg could be infused over 30 minutes, preferably even 15 minutes, and the remainder could be infused over the next 2 to 3 hours. Formulations for injection may be presented in unit dosage form, for example, in ampoules or multidose containers, with an added preservative. The compositions may take forms such as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending agents, stabilizers and/or dispersants. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0154]Se pueden emplear métodos farmacéuticos adicionales para controlar la duración de la acción del conjugado terapéutico. Se pueden preparar preparaciones de liberación controlada mediante el uso de polímeros para complejar o adsorber el inmunoconjugado. Por ejemplo, los polímeros biocompatibles incluyen matrices de poli(etileno-co-acetato de vinilo) y matrices de un copolímero de polianhídrido de un dímero de ácido esteárico y ácido sebácico. Sherwood y col., Bio/Technology 10: 1446 (1992). La velocidad de liberación de un inmunoconjugado de dicha matriz depende del peso molecular del inmunoconjugado, la cantidad de inmunoconjugado dentro de la matriz y el tamaño de las partículas dispersas. Saltzman y col., Biophys. J. 55: 163 (1989); Sherwood y otros,supra.Otras formas de dosificación sólidas se describen en Ansel et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5a edición (Lea &amp; Febiger 1990), y Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18a edición (Mack Publishing Company 1990), y ediciones revisadas de los mismos. </span>[0154]Additional pharmaceutical methods may be employed to control the duration of action of the therapeutic conjugate. Controlled release preparations can be prepared by using polymers to complex or adsorb the immunoconjugate. For example, biocompatible polymers include poly(ethylene-co-vinyl acetate) matrices and matrices of a polyanhydride copolymer of a dimer of stearic acid and sebacic acid. Sherwood et al., Bio/Technology 10: 1446 (1992). The rate of release of an immunoconjugate from such a matrix depends on the molecular weight of the immunoconjugate, the amount of immunoconjugate within the matrix, and the size of the dispersed particles. Saltzman et al., Biophys. J. 55: 163 (1989); Sherwood et al., supra. Other solid dosage forms are described in Ansel et al., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, 5th edition (Lea &amp; Febiger 1990), and Gennaro (ed.), REMINGTON'S PHARMACEUTICAL SCIENCES, 18th edition ( Mack Publishing Company 1990), and revised editions thereof.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0155]Generalmente, la dosis de un inmunoconjugado administrado para humanos variará dependiendo de factores tales como la edad, el peso, la altura, el sexo, el estado médico general y el historial médico previo del paciente. Puede ser deseable proporcionar al receptor una dosis de inmunoconjugado que esté en el intervalo de aproximadamente 1 mg/kg a 24 mg/kg como una única infusión intravenosa, aunque también se puede administrar una dosis más baja o más alta según lo dicten las circunstancias. Una dosis de 1 a 20 mg/kg para un paciente de 70 kg, por ejemplo, es de 70 a 1.400 mg, o de 41 a 824 mg/m2 para un paciente de 1,7 m. La dosis se puede repetir según sea necesario, por ejemplo, una vez por semana durante 4 a 10 semanas, una vez por semana durante 8 semanas o una vez por semana durante 4 semanas. También se puede administrar con menos frecuencia, como cada dos semanas durante varios meses, o mensualmente o trimestralmente durante muchos meses, según sea necesario en una terapia de mantenimiento. Las dosis preferidas pueden incluir, entre otras, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 22 mg/kg y 24 mg/kg. Puede usarse cualquier cantidad en el intervalo de 1 a 24 mg/kg. Sin embargo, en formas de realización preferidas, el rango de dosificación puede ser de 4 a 16 mg/kg, de 6 a 12 mg/kg o de 8 a 10 mg/kg. </span>[0155]Generally, the dose of an immunoconjugate administered for humans will vary depending on factors such as the patient's age, weight, height, sex, general medical condition, and previous medical history. It may be desirable to provide the recipient with a dose of immunoconjugate that is in the range of about 1 mg/kg to 24 mg/kg as a single intravenous infusion, although a lower or higher dose may also be administered as circumstances dictate. A dose of 1 to 20 mg/kg for a 70 kg patient, for example, is 70 to 1,400 mg, or 41 to 824 mg/m2 for a 1.7 m patient. The dose may be repeated as needed, for example, once a week for 4 to 10 weeks, once a week for 8 weeks, or once a week for 4 weeks. It may also be given less frequently, such as every two weeks for several months, or monthly or quarterly for many months, as needed in maintenance therapy. Preferred doses may include, but are not limited to, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 11 mg/kg, 12 mg/kg, 13 mg/kg, 14 mg/kg, 15 mg/kg, 16 mg/kg, 17 mg/kg, 18 mg/kg, 19 mg/kg, 20 mg/kg, 22 mg/kg and 24 mg/kg. Any amount in the range of 1 to 24 mg/kg can be used. However, in preferred embodiments, the dosage range may be 4 to 16 mg/kg, 6 to 12 mg/kg or 8 to 10 mg/kg.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0156]La dosis se administra preferiblemente varias veces, una o dos veces por semana. Puede usarse un programa de dosificación mínimo de 4 semanas, más preferiblemente 8 semanas, más preferiblemente 16 semanas o más. El programa de administración puede comprender la administración una o dos veces por semana, en un ciclo seleccionado del grupo que consiste en: (i) semanalmente; (ii) cada dos semanas; (iii) una semana de terapia seguida de dos, tres o cuatro semanas de descanso; (iv) dos semanas de terapia seguidas de una, dos, tres o cuatro semanas de descanso; (v) tres semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; (vi) cuatro semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; (vii) cinco semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; y (viii) mensualmente. El ciclo puede repetirse 4, 6, 8, 10, 12, 16 o 20 veces o más. </span>[0156]The dose is preferably administered several times, once or twice a week. A minimum dosing schedule of 4 weeks, more preferably 8 weeks, more preferably 16 weeks or more may be used. The administration schedule may comprise administration once or twice a week, in a cycle selected from the group consisting of: (i) weekly; (ii) every two weeks; (iii) one week of therapy followed by two, three, or four weeks of rest; (iv) two weeks of therapy followed by one, two, three, or four weeks of rest; (v) three weeks of therapy followed by one, two, three, four, or five weeks of rest; (vi) four weeks of therapy followed by one, two, three, four, or five weeks of rest; (vii) five weeks of therapy followed by one, two, three, four, or five weeks of rest; and (viii) monthly. The cycle can be repeated 4, 6, 8, 10, 12, 16 or 20 times or more.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0157]Alternativamente, se puede administrar un inmunoconjugado en una dosis cada 2 o 3 semanas, repetida hasta un total de al menos 3 dosis. O dos veces por semana durante 4 a 6 semanas. Si la dosis se reduce a aproximadamente 200-300 mg/m2 (340 mg por dosis para un paciente de 1,7 m, o 4,9 mg/kg para un paciente de 70 kg), se puede administrar una o incluso dos veces por semana durante 4 a 10 semanas. Alternativamente, se puede reducir la pauta posológica, es decir, cada 2 o 3 semanas durante 2 o 3 meses. Sin embargo, se ha determinado que se pueden administrar dosis incluso más altas, como 12 mg/kg una vez a la semana o una vez cada 2-3 semanas mediante infusión intravenosa lenta, para ciclos de dosificación repetidos. Opcionalmente, el programa de dosificación se puede repetir en otros intervalos y la dosis se puede administrar a través de varias vías parenterales, con el ajuste apropiado de la dosis y el programa. </span>[0157]Alternatively, an immunoconjugate may be administered in a dose every 2 or 3 weeks, repeated for a total of at least 3 doses. Or twice a week for 4 to 6 weeks. If the dose is reduced to approximately 200-300 mg/m2 (340 mg per dose for a 1.7 m patient, or 4.9 mg/kg for a 70 kg patient), it can be administered once or even twice per week for 4 to 10 weeks. Alternatively, the dosage regimen can be reduced, i.e. every 2 to 3 weeks for 2 to 3 months. However, it has been determined that even higher doses, such as 12 mg/kg once weekly or once every 2-3 weeks by slow intravenous infusion, can be administered for repeated dosing cycles. Optionally, the dosing schedule may be repeated at other intervals and the dose may be administered via various parenteral routes, with appropriate adjustment of the dose and schedule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0158]Los inmunoconjugados descritos en el presente documento pero no sujetos a la invención tal como se definen en las reivindicaciones son útiles para la terapia del cáncer. Los ejemplos de cánceres incluyen, entre otros, carcinoma, linfoma, glioblastoma, melanoma, sarcoma y leucemia, mieloma o neoplasias malignas linfoides. A continuación se indican ejemplos más particulares de tales cánceres e incluyen: cáncer de células escamosas (p. ej., cáncer de células escamosas epiteliales), sarcoma de Ewing, tumor de Wilms, astrocitomas, cáncer de pulmón que incluye cáncer de pulmón de células pequeñas, cáncer de pulmón de células no pequeñas, adenocarcinoma del pulmón y el carcinoma escamoso de pulmón, el cáncer de peritoneo, el cáncer gástrico o de estómago, incluido el cáncer gastrointestinal, el cáncer de páncreas, el glioblastoma multiforme, el cáncer de cuello uterino, el cáncer de ovario, el cáncer de hígado, el cáncer de vejiga, el hepatoma, el carcinoma hepatocelular, los tumores neuroendocrinos, la tiroides medular cáncer, carcinoma diferenciado de tiroides, cáncer de mama, cáncer de ovario, cáncer de colon, cáncer de recto, cáncer de endometrio o carcinoma uterino, carcinoma de glándulas salivales, cáncer de riñón o renal, cáncer de próstata, cáncer de vulva, carcinoma anal, carcinoma de pene, así como cáncer de cabeza. y cáncer de cuello. El término “cáncer” incluye células o tumores malignos primarios (p. ej., aquellos cuyas células no han migrado a sitios en el cuerpo del sujeto distintos del sitio de la malignidad o tumor original) y células o tumores malignos secundarios (p. ej., aquellos que surgen de metástasis, la migración de células malignas o tumorales a sitios secundarios que son diferentes del sitio del tumor original). </span>[0158]The immunoconjugates described herein but not subject to the invention as defined in the claims are useful for cancer therapy. Examples of cancers include, but are not limited to, carcinoma, lymphoma, glioblastoma, melanoma, sarcoma and leukemia, myeloma or lymphoid malignancies. More particular examples of such cancers are listed below and include: squamous cell cancer (e.g., epithelial squamous cell cancer), Ewing sarcoma, Wilms tumor, astrocytomas, lung cancer including squamous cell lung cancer. small cell lung cancer, adenocarcinoma of the lung and squamous cell carcinoma of the lung, cancer of the peritoneum, gastric or stomach cancer, including gastrointestinal cancer, pancreatic cancer, glioblastoma multiforme, neck cancer uterine, ovarian cancer, liver cancer, bladder cancer, hepatoma, hepatocellular carcinoma, neuroendocrine tumors, medullary thyroid cancer, differentiated thyroid carcinoma, breast cancer, ovarian cancer, colon cancer, rectal cancer, endometrial cancer or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulvar cancer, anal carcinoma, penile carcinoma, as well as head cancer. and neck cancer. The term “cancer” includes primary malignant cells or tumors (e.g., those whose cells have not migrated to sites in the subject's body other than the site of the original malignancy or tumor) and secondary malignant cells or tumors (e.g. ., those arising from metastasis, the migration of malignant or tumor cells to secondary sites that are different from the original tumor site).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0159]Otros ejemplos de cánceres o neoplasias malignas incluyen, entre otros: leucemia linfoblástica aguda infantil, leucemia linfoblástica aguda, leucemia linfocítica aguda, leucemia mieloide aguda, carcinoma suprarrenocortical, cáncer hepatocelular (primario) en adultos, cáncer de hígado (primario) en adultos, leucemia linfocítica aguda en adultos, leucemia mieloide aguda en adultos, linfoma de Hodgkin en adultos, leucemia linfocítica en adultos, linfoma no Hodgkin en adultos, cáncer primario de hígado en adultos, sarcoma de tejido blando en adultos, linfoma relacionado con el SIDA, neoplasias malignas relacionadas con el SIDA, cáncer anal, astrocitoma, cáncer de vías biliares, cáncer de vejiga, cáncer de huesos, glioma del tronco encefálico, tumores cerebrales, cáncer de mama, cáncer de pelvis renal y uréter, linfoma del sistema nervioso central (primario), linfoma del sistema nervioso central, astrocitoma cerebeloso, astrocitoma cerebral, cáncer de cuello uterino, cáncer hepatocelular infantil (primario), cáncer de hígado infantil (primario), leucemia linfoblástica aguda infantil, leucemia mieloide aguda infantil, glioma del tronco encefálico infantil, astrocitoma cerebeloso infantil, astrocitoma cerebral infantil, tumores extracraneales de células germinales infantiles, enfermedad de Hodgkin infantil, linfoma de Hodgkin infantil, glioma hipotalámico y de las vías visuales infantil, leucemia linfoblástica infantil, meduloblastoma infantil, linfoma no Hodgkin infantil, tumores neuroectodérmicos primitivos supratentoriales y pineales infantiles, cáncer de hígado primario infantil, rabdomiosarcoma infantil, sarcoma de tejido blando infantil, glioma hipotalámico y de las vías visuales infantil, leucemia linfocítica crónica, leucemia mielógena crónica, cáncer de colon, linfoma cutáneo de células T, carcinoma endocrino de células de los islotes de páncreas, cáncer de endometrio, ependimoma, cáncer epitelial, cáncer de esófago, enfermedad de Ewing Sarcoma y tumores relacionados, cáncer de páncreas exocrino, tumor extracraneal de células germinales, tumor extragonadal de células germinales, cáncer de vías biliares extrahepáticas, cáncer ocular, cáncer de mama femenino, enfermedad de Gaucher, cáncer de vesícula biliar, cáncer gástrico, tumor carcinoide gastrointestinal, tumores gastrointestinales, tumores de células germinales, tumor trofoblástico gestacional, leucemia de células pilosas, cáncer de cabeza y cuello, cáncer hepatocelular, linfoma de Hodgkin, hipergammaglobulinemia, cáncer de hipofaringe, cánceres intestinales, melanoma intraocular, carcinoma de células de los islotes, cáncer de páncreas de células de los islotes, sarcoma de Kaposi, cáncer de riñón, cáncer de laringe, labio y cáncer de cavidad oral, cáncer de hígado, cáncer de pulmón, trastornos linfoproliferativos, macroglobulinemia, cáncer de mama masculino, mesotelioma maligno, timoma maligno, meduloblastoma, melanoma, mesotelioma, cáncer escamoso primario oculto metastásico de cuello, cáncer escamoso primario metastásico de cuello, cáncer escamoso primario metastásico de cuello, mieloma múltiple, mieloma múltiple/neoplasia de células plasmáticas, síndrome mielodisplásico, leucemia mielógena, leucemia mieloide, trastornos mieloproliferativos, cáncer de cavidad nasal y de senos paranasales, cáncer nasofaríngeo, neuroblastoma, linfoma no Hodgkin, cáncer de piel no melanoma, cáncer de pulmón de células no pequeñas, cáncer escamoso de cuello metastásico primario oculto, cáncer de orofaringe, osteosarcoma fibroso/maligno, osteosarcoma/histiocitoma fibroso maligno, osteosarcoma/histiocitoma fibroso maligno de hueso, cáncer epitelial de ovario, tumor de células germinales de ovario, tumor de ovario de bajo potencial maligno, cáncer de páncreas, paraproteinemias, policitemia vera, cáncer de paratiroides, cáncer de pene, feocromocitoma, tumor hipofisario, linfoma primario del sistema nervioso central, cáncer primario de hígado, cáncer de próstata, cáncer de recto, cáncer de células renales, cáncer de pelvis renal y de uréter, retinoblastoma, rabdomiosarcoma, cáncer de glándulas salivales, sarcomas de sarcoidosis, síndrome de Sézary, cáncer de piel, cáncer de pulmón de células pequeñas, cáncer de intestino delgado, sarcoma de tejido blando, cáncer de cuello escamoso, cáncer de estómago, tumores neuroectodérmicos y pineales primitivos supratentoriales, linfoma de células T, cáncer testicular, timoma, cáncer de tiroides, cáncer de células transicionales de pelvis renal y de uréter, cáncer de pelvis renal y de uréter de transición, tumores trofoblásticos, cáncer de células de uréter y de pelvis renal, cáncer de uretra, cáncer de útero, sarcoma uterino, cáncer de vagina, glioma de las vías visuales y hipotalámico, cáncer de vulva, macroglobulinemia de Waldenstrom, tumor de Wilms, y cualquier otra enfermedad hiperproliferativa, además de la neoplasia, localizada en un sistema de órganos enumerado anteriormente. </span>[0159]Other examples of cancers or malignancies include, but are not limited to: childhood acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, adrenocortical carcinoma, hepatocellular cancer (primary) in adults, liver cancer (primary) in adults, adult acute lymphocytic leukemia, adult acute myeloid leukemia, adult Hodgkin lymphoma, adult lymphocytic leukemia, adult non-Hodgkin lymphoma, adult primary liver cancer, adult soft tissue sarcoma, AIDS-related lymphoma , AIDS-related malignancies, anal cancer, astrocytoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumors, breast cancer, renal pelvis and ureter cancer, central nervous system lymphoma (primary), central nervous system lymphoma, cerebellar astrocytoma, brain astrocytoma, cervical cancer, childhood hepatocellular cancer (primary), childhood liver cancer (primary), childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, brainstem glioma childhood, childhood cerebellar astrocytoma, childhood brain astrocytoma, childhood extracranial germ cell tumors, childhood Hodgkin disease, childhood Hodgkin lymphoma, childhood hypothalamic and visual pathway glioma, childhood lymphoblastic leukemia, childhood medulloblastoma, childhood non-Hodgkin lymphoma, neuroectodermal tumors childhood supratentorial and pineal primitives, childhood primary liver cancer, childhood rhabdomyosarcoma, childhood soft tissue sarcoma, childhood hypothalamic and visual pathway glioma, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, cutaneous T-cell lymphoma, endocrine carcinoma pancreatic islet cell cancer, endometrial cancer, ependymoma, epithelial cancer, esophageal cancer, Ewing disease Sarcoma and related tumors, exocrine pancreatic cancer, extracranial germ cell tumor, extragonadal germ cell tumor, bile duct cancer extrahepatic, eye cancer, female breast cancer, Gaucher disease, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal tumors, germ cell tumors, gestational trophoblastic tumor, hairy cell leukemia, head and neck cancer, cancer hepatocellular, Hodgkin lymphoma, hypergammaglobulinemia, hypopharyngeal cancer, intestinal cancers, intraocular melanoma, islet cell carcinoma, islet cell pancreatic cancer, Kaposi sarcoma, kidney cancer, laryngeal cancer, lip and oral cavity, liver cancer, lung cancer, lymphoproliferative disorders, macroglobulinemia, male breast cancer, malignant mesothelioma, malignant thymoma, medulloblastoma, melanoma, mesothelioma, metastatic occult primary squamous neck cancer, metastatic primary squamous neck cancer, squamous cancer primary metastatic neck cancer, multiple myeloma, multiple myeloma/plasma cell neoplasm, myelodysplastic syndrome, myelogenous leukemia, myeloid leukemia, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-hodgkin lymphoma melanoma, non-small cell lung cancer, occult primary metastatic squamous neck cancer, oropharyngeal cancer, fibrous/malignant osteosarcoma, osteosarcoma/malignant fibrous histiocytoma, osteosarcoma/malignant fibrous histiocytoma of bone, epithelial ovarian cancer, germ cell tumor ovarian, ovarian tumor of low malignant potential, pancreatic cancer, paraproteinemias, polycythemia vera, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor, primary lymphoma of the central nervous system, primary liver cancer, prostate cancer, cancer rectum, renal cell cancer, renal pelvis and ureter cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoidosis sarcomas, Sézary syndrome, skin cancer, small cell lung cancer, small intestine cancer, sarcoma soft tissue, squamous neck cancer, stomach cancer, supratentorial primitive neuroectodermal and pineal tumors, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, renal pelvic cancer and transitional ureter, trophoblastic tumors, ureteral and renal pelvic cell cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, visual tract and hypothalamic glioma, vulvar cancer, Waldenstrom's macroglobulinemia, tumor Wilms disease, and any other hyperproliferative disease, in addition to neoplasia, located in an organ system listed above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0160]Los métodos y composiciones divulgados en el presente documento, pero no sujetos a la invención, tal como se define en las reivindicaciones, pueden usarse para tratar afecciones malignas o premalignas y para prevenir la progresión a un estado neoplásico o maligno, incluidos, entre otros, los trastornos descritos anteriormente. Dichos usos están indicados en condiciones conocidas o sospechadas de progresión previa a neoplasia o cáncer, en particular, donde se ha producido un crecimiento de células no neoplásicas que consiste en hiperplasia, metaplasia o, más particularmente, displasia (para una revisión de dichas condiciones de crecimiento anormal, ver Robbins y Angell, Basic Pathology, 2a ed., W. B. Saunders Co., Filadelfia, págs. 68-79 (1976)). </span>[0160]The methods and compositions disclosed herein, but not subject to the invention, as defined in the claims, can be used to treat malignant or premalignant conditions and to prevent progression to a neoplastic or malignant state, including, among others, the disorders described above. Such uses are indicated in conditions known or suspected of prior progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia or, more particularly, dysplasia has occurred (for a review of such conditions of abnormal growth, see Robbins and Angell, Basic Pathology, 2nd ed., W. B. Saunders Co., Philadelphia, pp. 68-79 (1976).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0161]La displasia es frecuentemente un precursor del cáncer y se encuentra principalmente en los epitelios. Es la forma más desordenada de crecimiento celular no neoplásico, que implica una pérdida en la uniformidad celular individual y en la orientación arquitectónica de las células. La displasia ocurre característicamente cuando existe irritación o inflamación crónica. Los trastornos displásicos que pueden tratarse incluyen, entre otros, displasia ectodérmica anhidrótica, displasia anterofacial, displasia torácica asfixiante, displasia auriculodigital, displasia broncopulmonar, displasia cerebral, displasia cervical, displasia condroectodérmica, displasia cleidocraneal, displasia ectodérmica congénita, displasia craneodiafisaria, displasia craneocarpotarsiana, displasia craneometafisaria, displasia dentinaria, displasia diafisaria, displasia ectodérmica, displasia del esmalte, displasia encefalo-oftálmica, displasia epifisaria hemimelia, displasia epifisaria múltiple, displasia epifisaria punctata, displasia epitelial, displasia faciodigitogenital, displasia fibrosa familiar de las mandíbulas, displasia familiar de pliegue blanco, displasia fibromuscular, displasia fibrosa del hueso, displasia ósea florida, displasia renal-retiniana hereditaria, displasia ectodérmica hidrótica, displasia ectodérmica hipohidrótica, displasia tímica linfopénica, displasia mamaria, displasia mandibulofacial, displasia metafisaria, displasia de Mondini, displasia fibrosa monostótica, displasia mucoepitelial, displasia epifisaria múltiple, displasia oculoauriculovertebral, displasia oculodentodigital, displasia oculovertebral, displasia odontogénica, displasia oftalmomandibulomelica, displasia cementaria periapical, displasia fibrosa poliostótica, displasia espondiloepifisaria pseudoacondroplásica, displasia retiniana, displasia septoóptica, displasia espondiloepifisaria y displasia ventriculoradial. </span>[0161]Dysplasia is frequently a precursor to cancer and is mainly found in epithelia. It is the most disordered form of non-neoplastic cell growth, which involves a loss in individual cellular uniformity and in the architectural orientation of the cells. Dysplasia characteristically occurs when there is chronic irritation or inflammation. Dysplastic disorders that can be treated include, but are not limited to, anhydrotic ectodermal dysplasia, anterofacial dysplasia, asphyxiating thoracic dysplasia, auriculodigital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondroectodermal dysplasia, cleidocranial dysplasia, congenital ectodermal dysplasia, craniodiaphyseal dysplasia, craniocarpotarsal dysplasia, craniometaphyseal dysplasia, dentinal dysplasia, diaphyseal dysplasia, ectodermal dysplasia, enamel dysplasia, encephalo-ophthalmic dysplasia, hemimelia epiphyseal dysplasia, multiple epiphyseal dysplasia, punctate epiphyseal dysplasia, epithelial dysplasia, faciodigitogenital dysplasia, familial fibrous dysplasia of the jaws, familial fold dysplasia white, fibromuscular dysplasia, fibrous dysplasia of bone, florid bone dysplasia, hereditary renal-retinal dysplasia, hydrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia, lymphopenic thymic dysplasia, mammary dysplasia, mandibulofacial dysplasia, metaphyseal dysplasia, Mondini dysplasia, monostotic fibrous dysplasia, dysplasia mucoepithelial, multiple epiphyseal dysplasia, oculoauriculovertebral dysplasia, oculodentodigital dysplasia, oculovertebral dysplasia, odontogenic dysplasia, ophthalmomandibulomelic dysplasia, periapical cemental dysplasia, polyostotic fibrous dysplasia, pseudoachondroplastic spondyloepiphyseal dysplasia, retinal dysplasia, septooptic dysplasia, spondyloepiphyseal dysplasia and ventriculoradial dysplasia ial.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0162]Los trastornos preneoplásicos adicionales que pueden tratarse incluyen, entre otros, trastornos disproliferativos benignos (p. ej., tumores benignos, afecciones fibroquísticas, hipertrofia tisular, pólipos o adenomas intestinales y displasia esofágica), leucoplasia, queratosis, enfermedad de Bowen, piel de granjero, queilitis solar y queratosis solar. En formas de realización preferidas, el método de la invención se usa para inhibir el crecimiento, la progresión y/o la metástasis de cánceres, en particular los enumerados anteriormente. </span>[0162]Additional preneoplastic disorders that may be treated include, but are not limited to, benign dysproliferative disorders (e.g., benign tumors, fibrocystic conditions, tissue hypertrophy, intestinal polyps or adenomas, and esophageal dysplasia), leukoplakia, keratosis, Bowen's disease, farmer's skin, solar cheilitis and solar keratosis. In preferred embodiments, the method of the invention is used to inhibit the growth, progression and/or metastasis of cancers, particularly those listed above.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0163]Enfermedades, trastornos y/o afecciones hiperproliferativas adicionales incluyen, entre otras, progresión y/o metástasis de neoplasias malignas y trastornos relacionados tales como leucemia (incluidas leucemias agudas; por ejemplo, leucemia linfocítica aguda, leucemia mielocítica aguda [incluidas leucemia mieloblástica, promielocítica, mielomonocítica, monocítica y eritroleucemia]) y leucemias crónicas (p. ej., leucemia mielocítica crónica [granulocítica] y leucemia linfocítica crónica leucemia), policitemia vera, linfomas (p. ej., enfermedad de Hodgkin y enfermedad no Hodgkin), mieloma múltiple, macroglobulinemia de Waldenstrom, enfermedad de cadenas pesadas y tumores sólidos que incluyen, entre otros, sarcomas y carcinomas tales como fibrosarcoma, mixosarcoma, liposarcoma, cordrosarcoma, sarcoma osteogénico, acordoma, angiosarcoma, endoteliosarcoma, linfangiosarcoma, linfangioendoteliosarcoma, sinovioma, mesotelioma, tumor de Ewing, leiomiosarcoma, rabdomiosarcoma, carcinoma de colon, cáncer de páncreas, cáncer de mama, cáncer de ovario, cáncer de próstata, carcinoma de células escamosas, carcinoma de células basales, adenocarcinoma, carcinoma de glándulas sudoríparas, carcinoma de glándulas sebáceas, carcinoma papilar, adenocarcinomas papilares, cistadenocarcinoma, carcinoma medular, carcinoma broncogénico, carcinoma de células renales, hepatoma, carcinoma de vías biliares, coriocarcinoma, seminoma, carcinoma embrionario, tumor de Wilm, cáncer de cuello uterino, tumor testicular, pulmón carcinoma, carcinoma de pulmón de células pequeñas, carcinoma de vejiga, carcinoma epitelial, glioma, astrocitoma, meduloblastoma, craneofaringioma, ependimoma, pinealoma, emangioblastoma, neuroma acústico, oligodendroglioma, meningioma, melanoma, neuroblastoma y retinoblastoma. </span>[0163]Additional hyperproliferative diseases, disorders and/or conditions include, but are not limited to, progression and/or metastasis of malignant neoplasms and related disorders such as leukemia (including acute leukemias; for example, acute lymphocytic leukemia, acute myelocytic leukemia [including myeloblastic leukemia , promyelocytic, myelomonocytic, monocytic, and erythroleukemia]) and chronic leukemias (e.g., chronic myelocytic [granulocytic] leukemia and chronic lymphocytic leukemia), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease) , multiple myeloma, Waldenstrom macroglobulinemia, heavy chain disease and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, cordrosarcoma, osteogenic sarcoma, accordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma , Ewing tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma , papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, carcinoma small cell lung, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, emangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma and retinoblastoma.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0164]Las enfermedades autoinmunes que pueden tratarse con inmunoconjugados pueden incluir trombocitopenias inmunitarias agudas y crónicas, dermatomiositis, corea de Sydenham, miastenia gravis, lupus eritematoso sistémico, nefritis lúpica, fiebre reumática, síndromes poliglandulares, penfigoide ampolloso, diabetes mellitus, púrpura de Henoch-Schonlein, nefritis estreptocócica, eritema nudoso, arteritis de Takayasu, vasculitis asociada a ANCA, enfermedad de Addison, artritis reumatoide, esclerosis múltiple, sarcoidosis, colitis ulcerosa, eritema multiforme, nefropatía por IgA, poliarteritis nudosa, espondilitis anquilosante, síndrome de Goodpasture, tromboangitis obliterante, síndrome de Sjogren, primario cirrosis biliar, tiroiditis de Hashimoto, tirotoxicosis, esclerodermia, hepatitis crónica activa, polimiositis/dermatomiositis, policondritis, penfigoide ampolloso, pénfigo vulgar, granulomatosis de Wegener, nefropatía membranosa, esclerosis lateral amiotrófica, tabes dorsal, arteritis/polimialgia de células gigantes, anemia perniciosa, rápidamente progresiva glomerulonefritis, psoriasis o alveolitis fibrosante. </span>[0164]Autoimmune diseases that can be treated with immunoconjugates may include acute and chronic immune thrombocytopenias, dermatomyositis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes, bullous pemphigoid, diabetes mellitus, Henoch's purpura -Schonlein, streptococcal nephritis, erythema nodosum, Takayasu arteritis, ANCA-associated vasculitis, Addison's disease, rheumatoid arthritis, multiple sclerosis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture syndrome, thromboangiitis obliterans, Sjogren's syndrome, primary biliary cirrhosis, Hashimoto's thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis, polychondritis, bullous pemphigoid, pemphigus vulgaris, Wegener's granulomatosis, membranous nephropathy, amyotrophic lateral sclerosis, tabes dorsalis, arteritis /giant cell polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis, psoriasis or fibrosing alveolitis.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Kits</span>Kits</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0165]También se describen en el presente documento, pero no están sujetos a la invención como se define en las reivindicaciones, kits que contienen componentes adecuados para tratar el cáncer en un paciente. Los kits ejemplares pueden contener al menos un anticuerpo conjugado con fármaco como se describe en el presente documento. Si la composición que contiene componentes para administración no está formulada para administración a través del tubo digestivo, tal como administración oral, se puede incluir un dispositivo capaz de administrar los componentes del kit a través de alguna otra ruta. Un tipo de dispositivo, para aplicaciones tales como administración parenteral, es una jeringa que se usa para inyectar la composición en el cuerpo de un sujeto. También se pueden utilizar dispositivos de inhalación. </span>[0165]Also described herein, but not subject to the invention as defined in the claims, are kits containing components suitable for treating cancer in a patient. Exemplary kits may contain at least one drug-conjugated antibody as described herein. If the composition containing components for administration is not formulated for administration through the digestive tract, such as oral administration, a device capable of administering the components of the kit through some other route may be included. One type of device, for applications such as parenteral administration, is a syringe that is used to inject the composition into the body of a subject. Inhalation devices can also be used.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0166]Los componentes del kit pueden empaquetarse juntos o separarse en dos o más contenedores. En algunas formas de realización, los recipientes pueden ser viales que contienen formulaciones liofilizadas estériles de una composición que son adecuadas para la reconstitución. Un kit también puede contener uno o más tampones adecuados para la reconstitución y/o dilución de otros reactivos. Otros recipientes que pueden usarse incluyen, entre otros, una bolsa, bandeja, caja, tubo o similares. Los componentes del kit se pueden empaquetar y mantener de forma estéril dentro de los contenedores. Otro componente que se puede incluir son instrucciones para una persona que utilice un kit para su uso. </span>[0166]The kit components may be packaged together or separated into two or more containers. In some embodiments, the containers may be vials containing sterile lyophilized formulations of a composition that are suitable for reconstitution. A kit may also contain one or more buffers suitable for reconstitution and/or dilution of other reagents. Other containers that may be used include, but are not limited to, a bag, tray, box, tube or the like. Kit components can be packaged and maintained sterile within containers. Another component that may be included is instructions for a person using a kit to use.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EJEMPLOS</span>EXAMPLES</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 1. Terapia dirigida de cánceres gastrointestinales con IMMU-132 (Sacituzumab Govitecan), un conjugado de fármaco-anticuerpo anti-Trop-2-SN-38 (CAF)</span>Example 1. Targeted therapy of gastrointestinal cancers with IMMU-132 (Sacituzumab Govitecan), an anti-Trop-2-SN-38 (CAF) antibody-drug conjugate</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0167]Trop-2 es una glicoproteína asociada a tumores muy prevalente en muchos cánceres epiteliales. Su elevada expresión se ha relacionado con una enfermedad más agresiva y un mal pronóstico. Un mAb humanizado que se une al dominio extracelular de Trop-2 se conjugó con SN-38 (IMMU-132; relación promedio fármaco:mAb = 7,6), el principio activo de CPT-11. Después de una potente actividad en xenoinjertos de tumores humanos, se inició un ensayo de fase I/II en pacientes con diversos tumores sólidos, incluidos cánceres gastrointestinales. </span>[0167]Trop-2 is a tumor-associated glycoprotein highly prevalent in many epithelial cancers. Its high expression has been related to a more aggressive disease and a poor prognosis. A humanized mAb that binds to the extracellular domain of Trop-2 was conjugated to SN-38 (IMMU-132; average drug:mAb ratio = 7.6), the active ingredient of CPT-11. Following potent activity in human tumor xenografts, a Phase I/II trial was initiated in patients with various solid tumors, including gastrointestinal cancers.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0168] Métodos: Se inscribieron pacientes con cánceres metastásicos después del fracaso de la terapia estándar, comenzando con una dosis de 8,0 mg/kg administrada los días 1 y 8 de un ciclo de 3 semanas. Se determinó que la MTD era 12 mg/kg; se eligieron niveles de dosis de 8 y 10 mg/kg para las pruebas de Fase II. </span>[0168] Methods: Patients with metastatic cancers were enrolled after failure of standard therapy, starting with a dose of 8.0 mg/kg administered on days 1 and 8 of a 3-week cycle. The MTD was determined to be 12 mg/kg; Dose levels of 8 and 10 mg/kg were chosen for Phase II testing.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0169] Resultados: Se inscribieron sesenta pacientes con cánceres gastrointestinales avanzados en un ensayo de fase I/II. En 29 pacientes con CCR (9 tratados con 10 mg/kg, 20 con 8 mg/kg), 1 tuvo una RP (respuesta parcial) y 14 tuvieron EE (enfermedad estable) como la mejor respuesta según RECIST, con un tiempo hasta la progresión (Tt P) de 50+ semanas para los pacientes RP (-65%) y una mediana de 21+ semanas para los pacientes EE (5 continuando). Trece pacientes con CCR tenían mutaciones enKRAS,7 mostraron EE con una mediana de TTP de 19,1+ semanas (rango, 12,0-34,0; 3 continuaron). De 15 pacientes con cáncer de páncreas que fueron tratados (5 con 8, 7 con 10 y 3 con 12 mg/kg), 7 tuvieron EE como mejor respuesta para una mediana de TTP de 15,0 semanas. Entre 11 pacientes con cáncer de esófago (9 comenzaron a las 8, 1 a las 10 y 1 a 18 mg/kg), 8 tuvieron una evaluación por TC, mostrando 1 RP con un TTP de 30+ semanas y 4 con una EE de 17,4+, 21,9, 26,3 y 29,9 semanas. De 5 pacientes con cáncer gástrico (2 a 8 y 3 a 10 mg/kg), sólo a 3 se les ha realizado valoración por T&lt;c&gt;, todos con EE (1 con una reducción del 19% de la lesión diana y un TTP continuo de más de 29 semanas). </span>[0169] Results: Sixty patients with advanced gastrointestinal cancers were enrolled in a phase I/II trial. In 29 patients with CRC (9 treated with 10 mg/kg, 20 with 8 mg/kg), 1 had a PR (partial response) and 14 had EE (stable disease) as the best response according to RECIST, with a time to progression (Tt P) of 50+ weeks for RP patients (-65%) and a median of 21+ weeks for EE patients (5 continuing). Thirteen CRC patients had KRAS mutations,7 showed EE with a median TTP of 19.1+ weeks (range, 12.0-34.0; 3 continued). Of 15 pancreatic cancer patients who were treated (5 with 8, 7 with 10, and 3 with 12 mg/kg), 7 had EE as best response for a median TTP of 15.0 weeks. Among 11 patients with esophageal cancer (9 started at 8, 1 at 10, and 1 at 18 mg/kg), 8 had a CT evaluation, showing 1 PR with a TTP of 30+ weeks and 4 with an EE of 17.4+, 21.9, 26.3 and 29.9 weeks. Of 5 patients with gastric cancer (2 to 8 and 3 to 10 mg/kg), only 3 have undergone T&lt;c&gt; assessment, all with EE (1 with a 19% reduction of the target lesion and one Continuous TTP of more than 29 weeks).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0170] La neutropenia fue la principal toxicidad limitante de la dosis, junto con fatiga, diarrea, náuseas y vómitos como otras toxicidades comúnmente reportadas. Sin embargo, el perfil de toxicidad de 75 pacientes en el ensayo completo mostró sólo un 17,3% y un 2,7% de neutropenia de grado 3 y 4, respectivamente, y sólo un 6,7% de diarrea de grado 3. </span>[0170] Neutropenia was the main dose-limiting toxicity, along with fatigue, diarrhea, nausea and vomiting as other commonly reported toxicities. However, the toxicity profile of 75 patients in the full trial showed only 17.3% and 2.7% grade 3 and 4 neutropenia, respectively, and only 6.7% grade 3 diarrhea.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0171] Conclusiones: IMMU-132 mostró un alto índice terapéutico en pacientes con diversos cánceres gastrointestinales metastásicos recidivantes. Tiene un fármaco moderadamente tóxico conjugado con un mAb internalizante y selectivo para el cáncer, que puede administrarse repetidamente durante muchos meses una vez a la semana x 2 en un ciclo de 21 días. </span>[0171] Conclusions: IMMU-132 showed a high therapeutic index in patients with various recurrent metastatic gastrointestinal cancers. It has a moderately toxic drug conjugated to an internalizing and cancer-selective mAb, which can be administered repeatedly over many months once a week x 2 in a 21-day cycle.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 2. Producción y uso de conjugado anticuerpo-fármaco anti-Trop-2-SN-38 </span>Example 2. Production and use of anti-Trop-2-SN-38 antibody-drug conjugate</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0172] El anticuerpo anti-Trop-2 RS7 humanizado (hRS7) se produjo como se describe en la patente de EE. UU. n° 7.238.785. Se produjo SN-38 unido a un conector CL2A y se conjugó con anticuerpos hRS7 (anti-Trop-2), hPAM4 (anti-MLTCSac), hA20 (anti-CD20) o hMN-14 (anti-CEACAM5) según la patente estadounidense 7.999.083. El protocolo de conjugación dio como resultado una proporción de aproximadamente 6 moléculas de SN-38 unidas por molécula de anticuerpo. </span>[0172] Humanized anti-Trop-2 RS7 antibody (hRS7) was produced as described in US Patent No. 7,238,785. SN-38 linked to a CL2A linker was produced and conjugated with antibodies hRS7 (anti-Trop-2), hPAM4 (anti-MLTCSac), hA20 (anti-CD20), or hMN-14 (anti-CEACAM5) according to the US patent 7,999,083. The conjugation protocol resulted in a ratio of approximately 6 bound SN-38 molecules per antibody molecule.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0173] Se trataron ratones desnudos atímicos (hembras) inmunocomprometidos, portadores de xenoinjertos de tumores de colon o páncreas humanos subcutáneos, con conjugado CL2A-SN-38 específico o con conjugado de control, o se dejaron sin tratar. Se observaron las eficacias terapéuticas de los conjugados específicos. FIG. 1 muestra un modelo de tumor pancreático Capan 1, en el que los conjugados CL2A-SN-38 específicos de anticuerpos hRS7 (anti-Trop-2), hPAM4 (anti-MUC-5ac) y hMN-14 (anti-cEACAM5) mostraron mejores eficacias que el conjugado de control hA20-CL2A-SN-38 (anti-CD20) y control sin tratar. De manera similar, en un modelo BXPC3 de cáncer de páncreas humano, el hRS7-CL2A-SN-38 específico mostró una mejor eficacia terapéutica que los tratamientos de control (FIG. 2). </span>[0173] Immunocompromised athymic nude mice (females), carrying subcutaneous human colon or pancreas tumor xenografts, were treated with specific CL2A-SN-38 conjugate or control conjugate, or left untreated. The therapeutic efficacies of the specific conjugates were observed. FIG. 1 shows a Capan 1 pancreatic tumor model, in which the antibody-specific CL2A-SN-38 conjugates hRS7 (anti-Trop-2), hPAM4 (anti-MUC-5ac) and hMN-14 (anti-cEACAM5) showed better efficacies than the control conjugate hA20-CL2A-SN-38 (anti-CD20) and untreated control. Similarly, in a BXPC3 model of human pancreatic cancer, the specific hRS7-CL2A-SN-38 showed better therapeutic efficacy than control treatments (FIG. 2).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 3. Eficacia del CAF anti-Trop-2-SN-38 contra diversos cánceres epitelialesin vivo</span>Example 3. Efficacy of CAF anti-Trop-2-SN-38 against various epithelial cancers in vivo</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resumen</span>Summary</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0174] El propósito de este estudio fue evaluar la eficacia de un CAF SN-38-anti-Trop-2 (hRS7) contra varios tipos de tumores sólidos humanos, y evaluar su tolerabilidad en ratones y monos, estos últimos con reactividad cruzada tisular a hRS7 similar a los humanos. Se conjugaron dos derivados de SN-38, CL2-SN-38 y CL2A-SN-38, con el anticuerpo humanizado anti-Trop-2, hRS7. Los inmunoconjugados se caracterizaronin vitropor su estabilidad, unión y citotoxicidad. La eficacia se ensayó en cinco modelos diferentes de xenoinjertos de tumores sólidos humanos que expresaban el antígeno Trop-2. La toxicidad se evaluó en ratones y monos Cynomolgus. </span>[0174] The purpose of this study was to evaluate the efficacy of a CAF SN-38-anti-Trop-2 (hRS7) against various types of human solid tumors, and to evaluate its tolerability in mice and monkeys, the latter with tissue cross-reactivity. to hRS7 similar to humans. Two SN-38 derivatives, CL2-SN-38 and CL2A-SN-38, were conjugated to the humanized anti-Trop-2 antibody, hRS7. The immunoconjugates were characterized in vitro for their stability, binding and cytotoxicity. Efficacy was tested in five different human solid tumor xenograft models expressing the Trop-2 antigen. Toxicity was evaluated in mice and Cynomolgus monkeys.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0175] Los conjugados hRS7 de los dos derivados de SN-38 fueron equivalentes en sustitución de fármacos (~6), unión celular(Kd ~1,2 nmol/L), citotoxicidad (CI&lt;50&gt;~ 2,2 nmol/L) y estabilidad séricain vitro(t/A~20 horas). La exposición de las células al CAF demostró vías de señalización que conducen a la escisión de PARP, pero se observaron diferencias frente al SN-38 libre en la regulación positiva de p53 y p21. hRS7-SN-38 produjo efectos antitumorales significativos en dosis no tóxicas en ratones con tumores Calu-3(P&lt; 0,05), Capan-1 (P &lt;0,018), BxPC-3 (P &lt;0,005) y COLO 205 (P &lt; 0,033) en comparación con los CAF de control no dirigidos. Los ratones toleraron una dosis de 2 * 12 mg/kg (equivalentes de SN-38) con elevaciones de corta duración en los niveles de enzimas hepáticas ALT y AST. Los monos Cynomolgus a los que se les administró 2 x 30,96 mg/kg mostraron sólo disminuciones transitorias en los recuentos sanguíneos, aunque, lo que es más importante, los valores no cayeron por debajo de los rangos normales. </span>[0175] The hRS7 conjugates of the two SN-38 derivatives were equivalent in drug substitution (~6), cell binding (Kd ~1.2 nmol/L), cytotoxicity (IC&lt;50&gt;~ 2.2 nmol/ L) and serum stability in vitro (t/A~20 hours). Exposure of cells to CAF demonstrated signaling pathways leading to PARP cleavage, but differences versus free SN-38 were observed in the upregulation of p53 and p21. hRS7-SN-38 produced significant antitumor effects at non-toxic doses in mice with Calu-3 (P &lt; 0.05), Capan-1 (P &lt; 0.018), BxPC-3 (P &lt; 0.005), and COLO 205 (P &lt; 0.033) compared to untargeted control CAFs. Mice tolerated a dose of 2 * 12 mg/kg (SN-38 equivalents) with short-lived elevations in ALT and AST liver enzyme levels. Cynomolgus monkeys given 2 x 30.96 mg/kg showed only transient decreases in blood counts, although, importantly, values did not fall below normal ranges.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0176] En resumen, el CAF anti-Trop-2 hRS7-CL2A-SN-38 proporcionó efectos antitumorales significativos y específicos contra una variedad de tipos de tumores sólidos humanos. Fue bien tolerado en monos, con una expresión tisular de Trop-2 similar a la de los humanos, en dosis clínicamente relevantes. </span>[0176] In summary, the anti-Trop-2 CAF hRS7-CL2A-SN-38 provided significant and specific antitumor effects against a variety of human solid tumor types. It was well tolerated in monkeys, with tissue expression of Trop-2 similar to that in humans, at clinically relevant doses.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0177] El tratamiento exitoso con irinotecán de pacientes con tumores sólidos ha sido limitado, debido en gran parte a la baja tasa de conversión del profármaco CPT-11 en el metabolito activo SN-38. Otros han examinado formas no dirigidas de SN-38 como un medio para evitar la necesidad de esta conversión y administrar SN-38 de forma pasiva a los tumores. Conjugamos SN-38 covalentemente a un anticuerpo anti-Trop-2 humanizado, hRS7. Este conjugado anticuerpo-fármaco tiene efectos antitumorales específicos en una variedad de modelos de xenoinjerto de cáncer humano s.c., incluidos el carcinoma de pulmón de células no pequeñas, el carcinoma de pulmón de células no pequeñas, el páncreas, el colorrectal y el carcinoma de pulmón de células escamosas, todos en dosis no tóxicas (p. ej., &lt;3,2 mg/kg de dosis equivalente de SN-38 acumulativo). Trop-2 se expresa ampliamente en muchos cánceres epiteliales, pero también en algunos tejidos normales y, por lo tanto, se realizó un estudio de aumento de dosis en monos Cynomolgus para evaluar la seguridad clínica de este conjugado. Los monos toleraron 24 mg de equivalentes de SN-38/kg con sólo toxicidades menores y reversibles. Dado su perfil de seguridad y de focalización en tumores, hRS7-SN-38 proporciona una mejora significativa en el tratamiento de tumores sólidos que responden al irinotecán. </span>[0177] Successful treatment with irinotecan of patients with solid tumors has been limited, due in large part to the low conversion rate of the prodrug CPT-11 to the active metabolite SN-38. Others have examined nontargeting forms of SN-38 as a means to circumvent the need for this conversion and deliver SN-38 passively to tumors. We covalently conjugated SN-38 to a humanized anti-Trop-2 antibody, hRS7. This antibody-drug conjugate has specific antitumor effects in a variety of human s.c. cancer xenograft models, including non-small cell lung carcinoma, pancreatic, colorectal, and lung carcinoma. of squamous cells, all at non-toxic doses (e.g., &lt;3.2 mg/kg cumulative SN-38 equivalent dose). Trop-2 is widely expressed in many epithelial cancers but also in some normal tissues and therefore a dose escalation study was performed in Cynomolgus monkeys to evaluate the clinical safety of this conjugate. Monkeys tolerated 24 mg SN-38 equivalents/kg with only minor and reversible toxicities. Given its safety and tumor targeting profile, hRS7-SN-38 provides a significant improvement in the treatment of solid tumors that respond to irinotecan.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Material y métodos</span>Material and methods</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0178] Líneas celulares, anticuerpos y quimioterapéuticos: todas las líneas celulares de cáncer humano utilizadas en este estudio se adquirieron de la Colección Estadounidense de Cultivos Tipo. Estos incluyen Calu-3 (carcinoma de pulmón de células no pequeñas), SK-MES-1 (carcinoma de pulmón de células escamosas), COLO 205 (adenocarcinoma de colon), Capan-1 y BxPC-3 (adenocarcinomas de páncreas) y PC-3 (adenocarcinomas de próstata). La IgG RS7 humanizada y los anticuerpos anti-CD20 (IgG hA20, veltuzumab) y anti-CD22 (IgG hLL2, epratuzumab) humanizados de control se prepararon en Immunomedics, Inc. El irinotecán (20 mg/ml) se obtuvo de Hospira, Inc. </span>[0178] Cell lines, antibodies and chemotherapeutics: All human cancer cell lines used in this study were purchased from the American Type Culture Collection. These include Calu-3 (non-small cell lung carcinoma), SK-MES-1 (squamous cell lung carcinoma), COLO 205 (colon adenocarcinoma), Capan-1 and BxPC-3 (pancreatic adenocarcinomas), and PC-3 (prostate adenocarcinomas). Humanized IgG RS7 and control humanized anti-CD20 (IgG hA20, veltuzumab) and anti-CD22 (IgG hLL2, epratuzumab) antibodies were prepared from Immunomedics, Inc. Irinotecan (20 mg/ml) was obtained from Hospira, Inc. .</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0179] Inmunoconjugados SN-38 y aspectosin vitro: la síntesis de CL2-SN-38 se ha descrito previamente (Moon et al., 2008, J Med Chem 51:6916-26). Su conjugación con hRS7 IgG y la estabilidad sérica se realizaron como se describe (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61). Se realizaron preparaciones de CL2ASN-38 (PM 1480) y su conjugado hRS7, y estudios de estabilidad, unión y citotoxicidad como se describe en los ejemplos anteriores. </span>[0179] SN-38 immunoconjugates and in vitro aspects: The synthesis of CL2-SN-38 has been described previously (Moon et al., 2008, J Med Chem 51:6916-26). Its conjugation with hRS7 IgG and serum stability were performed as described (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61). Preparations of CL2ASN-38 (PM 1480) and its conjugate hRS7, and stability, binding and cytotoxicity studies were performed as described in the previous examples.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0180] Estudios terapéuticosin vivo:para todos los estudios en animales, las dosis de inmunoconjugados SN-38 e irinotecán se muestran en equivalentes de SN-38. Basado en una relación media de sustitución SN-38/IgG de 6, una dosis de 500 |jg de CAF para un ratón de 20 g (25 mg/kg) contiene 0,4 mg/kg de SN-38. Las dosis de irinotecán también se muestran como equivalentes de SN-38 (es decir, 40 mg de irinotecán/kg equivalen a 24 mg/kg de SN-38). </span>[0180] In vivo therapeutic studies: For all animal studies, doses of SN-38 immunoconjugates and irinotecan are shown in SN-38 equivalents. Based on an average SN-38/IgG substitution ratio of 6, a 500 μg dose of CAF for a 20 g mouse (25 mg/kg) contains 0.4 mg/kg of SN-38. Irinotecan doses are also shown as SN-38 equivalents (i.e., 40 mg irinotecan/kg is equivalent to 24 mg/kg SN-38).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0181] Se compraron ratones NCr hembra atímicos desnudos(nu/nu),de 4 a 8 semanas de edad, y ratones macho Swiss-Webster, de 10 semanas de edad, de Taconic Farms. SNBL USA, Ltd realizó estudios de tolerabilidad en monos Cynomolgus(Macaca fascicularis;2,5-4 kg, macho y hembra). </span>[0181] Female NCr nude mice, 4 to 8 weeks old, and male Swiss-Webster mice, 10 weeks old, were purchased from Taconic Farms. SNBL USA, Ltd conducted tolerability studies in Cynomolgus monkeys (Macaca fascicularis; 2.5-4 kg, male and female).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0182] A los animales se les implantaron por vía subcutánea diferentes líneas celulares de cáncer humano. El volumen del tumor (TV) se determinó mediante mediciones en 2 dimensiones utilizando calibradores, con volúmenes definidos como:Lxw2/2, dondeLes la dimensión más larga del tumor y w es la más corta. Los tumores oscilaban en tamaño entre 0,10 y 0,47 cm3 cuando comenzó la terapia. Los regímenes de tratamiento, las dosis y el número de animales en cada experimento se describen en los Resultados. El hRS7-CL2A-SN-38 liofilizado y el CAF de control se reconstituyeron y diluyeron según fue necesario en solución salina estéril. Todos los reactivos se administraron por vía intraperitoneal (0,1 ml), excepto el irinotecán, que se administró por vía intravenosa. El régimen de dosificación estuvo influenciado por nuestras investigaciones previas, donde el CAF se administró cada 4 días o dos veces por semana durante períodos de tiempo variables (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61). Esta frecuencia de dosificación reflejó una consideración de la vida media sérica del conjugadoin vitro,para permitir una exposición más continua al CAF. </span>[0182] The animals were implanted subcutaneously with different human cancer cell lines. Tumor volume (TV) was determined by 2-dimensional measurements using calipers, with volumes defined as:Lxw2/2, whereLes the longest dimension of the tumor and w is the shortest. The tumors ranged in size from 0.10 to 0.47 cm3 when therapy began. The treatment regimens, doses, and number of animals in each experiment are described in the Results. Lyophilized hRS7-CL2A-SN-38 and control CAF were reconstituted and diluted as necessary in sterile saline. All reagents were administered intraperitoneally (0.1 ml), except irinotecan, which was administered intravenously. The dosing regimen was influenced by our previous investigations, where CAF was administered every 4 days or twice a week for varying periods of time (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al. , 2009, Clin Chem Res 15:6052-61). This dosing frequency reflected a consideration of the serum half-life of the conjugate in vitro, to allow for more continuous exposure to CAF.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0183] Estadísticas: las curvas de crecimiento se muestran como cambio porcentual en el TV inicial a lo largo del tiempo. El análisis estadístico del crecimiento tumoral se basó en el área bajo la curva (AUC). Los perfiles de crecimiento de tumores individuales se obtuvieron mediante modelado de curvas lineales. Se empleó una pruebafpara determinar la igualdad de la varianza entre los grupos antes del análisis estadístico de las curvas de crecimiento. Se utilizó una pruebatde dos colas para evaluar la significación estadística entre los diversos grupos de tratamiento y controles, excepto para el control de solución salina, donde se utilizó una pruebatde una cola (significancia enP&lt; 0,05). Las comparaciones estadísticas del AUC se realizaron solo hasta el momento en que el primer animal dentro de un grupo fue sacrificado debido a la progresión. </span>[0183] Statistics: Growth curves are shown as percentage change in baseline TV over time. Statistical analysis of tumor growth was based on the area under the curve (AUC). Growth profiles of individual tumors were obtained by linear curve modeling. An f-test was used to determine equality of variance between groups prior to statistical analysis of the growth curves. A two-tailed t-test was used to evaluate statistical significance between the various treatment groups and controls, except for the saline control, where a one-tailed t-test was used (significance at P &lt; 0.05). Statistical comparisons of AUC were performed only up to the time the first animal within a group was euthanized due to progression.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0184] Farmacocinética y biodistribución: se inyectaron hRS7-CL2A-SN-38 y hRS7 IgG radiomarcadas con 111In en ratones desnudos que portaban tumores s.c. SK-MES-1 (~ 0,3 cm3). A un grupo se le inyectaron por vía intravenosa 20 jC i (250 jg de proteína) de 111In-hRS7-CL2A-SN-38, mientras que otro grupo recibió 20 jC i (250 jg de proteína) de 111InhRS7 IgG. En varios momentos, los ratones (5 por momento) fueron anestesiados, sangrados mediante punción intracardíaca y luego sacrificados. Se extirparon, pesaron y contaron tumores y diversos tejidos mediante centelleo y para determinar el porcentaje de dosis inyectada por gramo de tejido (% ID/g). A un tercer grupo se le inyectaron 250 jg de hRS7-CL2A-SN-38 sin marcar 3 días antes de la administración de 111In-hRS7-CL2A-SN-38 y también se le realizó la necropsia. Se utilizó una prueba t de dos colas para comparar la captación de hRS7-CL2A-SN-38 y hRS7 IgG después de determinar la igualdad de varianza utilizando la pruebaf.El análisis farmacocinético del aclaramiento de la sangre se realizó utilizando el software WinNonLin (Parsight Corp.). </span>[0184] Pharmacokinetics and biodistribution: 111In-radiolabeled hRS7-CL2A-SN-38 and hRS7 IgG were injected into tumor-bearing nude mice s.c. SK-MES-1 (~ 0.3 cm3). One group was injected intravenously with 20 jC i (250 jg protein) of 111In-hRS7-CL2A-SN-38, while another group received 20 jC i (250 jg protein) of 111InhRS7 IgG. At various time points, mice (5 per time point) were anesthetized, bled by intracardiac puncture, and then sacrificed. Tumors and various tissues were removed, weighed and counted by scintillation and to determine the percentage of injected dose per gram of tissue (%ID/g). A third group was injected with 250 μg of unlabeled hRS7-CL2A-SN-38 3 days before 111In-hRS7-CL2A-SN-38 administration and also underwent necropsy. A two-tailed t test was used to compare the uptake of hRS7-CL2A-SN-38 and hRS7 IgG after determining equality of variance using the f-test. Pharmacokinetic analysis of blood clearance was performed using WinNonLin software (Parsight Corp.).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0185] Tolerabilidad en ratones Swiss-Webster y monos Cynomolgus: brevemente, los ratones se clasificaron en 4 grupos cada uno para recibir inyecciones i.p. de 2 ml de un control de tampón de acetato de sodio o 3 dosis diferentes de hRS7-CL2A-SN-38 (4, 8, o 12 mg/kg de SN-38) los días 0 y 3 seguido de recolección de sangre y suero, como se describe en Resultados. A monos Cynomolgus (3 machos y 3 hembras; 2,5-4,0 kg) se les administraron 2 dosis diferentes de hRS7-CL2A-SN-38. Las dosis, los tiempos y el número de monos sangrados para la evaluación de posibles toxicidades hematológicas y la química sérica se describen en los Resultados. </span>[0185] Tolerability in Swiss-Webster mice and Cynomolgus monkeys: Briefly, mice were classified into 4 groups each to receive i.p. injections. of 2 ml of a sodium acetate buffer control or 3 different doses of hRS7-CL2A-SN-38 (4, 8, or 12 mg/kg SN-38) on days 0 and 3 followed by blood collection and serum, as described in Results. Cynomolgus monkeys (3 males and 3 females; 2.5-4.0 kg) were administered 2 different doses of hRS7-CL2A-SN-38. Doses, times, and numbers of monkeys bled for evaluation of potential hematologic toxicities and serum chemistry are described in the Results.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0186] Estabilidad y potencia de hRS7-CL2A-SN-38: se usaron dos enlaces diferentes para conjugar SN-38 con hRS7 IgG (FIG. 3A). El primero se denomina CL2-SN-38 y se ha descrito previamente (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61). Se utilizó un cambio en la síntesis de CL2 para eliminar el resto de fenilalanina dentro del conector para producir el conector CL2A. Este cambio simplificó la síntesis, pero no afectó el resultado de la conjugación (p. ej., tanto CL2-SN-38 como CL2A-SN-38 incorporaron ~6 SN-38 por molécula de IgG). Las comparaciones lado a lado no encontraron diferencias significativas en la estabilidad sérica, la unión al antígeno o la citotoxicidadin vitro.Este resultado fue sorprendente, ya que el residuo de fenilalanina en CL2 es parte de un sitio de escisión diseñado para la catepsina B, una proteasa lisosomal. </span>[0186] Stability and potency of hRS7-CL2A-SN-38: Two different linkers were used to conjugate SN-38 to hRS7 IgG (FIG. 3A). The first is called CL2-SN-38 and has been described previously (Moon et al., 2008, J Med Chem 51:6916-26; Govindan et al., 2009, Clin Chem Res 15:6052-61). A change in CL2 synthesis was used to remove the phenylalanine residue within the linker to produce the CL2A linker. This change simplified the synthesis, but did not affect the outcome of the conjugation (e.g., both CL2-SN-38 and CL2A-SN-38 incorporated ~6 SN-38 per IgG molecule). Side-by-side comparisons found no significant differences in serum stability, antigen binding, or cytotoxicity in vitro. This result was surprising, since the phenylalanine residue in CL2 is part of a cleavage site designed for cathepsin B, a lysosomal protease.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0187] Para confirmar que el cambio en el conector SN-38 de CL2 a CL2A no afectó la potenciain vivo,se compararon hRS7-CL2A y hRS7-CL2-SN-38 en ratones que portaban tumores COLO 205 (FIG. 3B) o Capan-1. (FIG. 3C), usando 0,4 mg o 0,2 mg/kg de SN-38 dos veces por semana durante x 4 semanas, respectivamente, y con tumores iniciales de 0,25 cm3 de tamaño en ambos estudios. Tanto los conjugados hRS7-CL2A como CL2-SN-38 inhibieron significativamente el crecimiento tumoral en comparación con los no tratados (AUC-MdíasP&lt;0,002 frente a solución salina en el modelo COLO 205; AUC&lt;21&gt;díasP&lt;0,001 frente a solución salina en el modelo Capan-1), y un anti-CD20 no dirigido CAF de control, hA20-CL2A-SN-38 (AUC-MdíasP&lt;0,003 en el modelo COLO-205; AUC&lt;35&gt;días:P&lt;0,002 en el modelo Capan-1). Al final del estudio (día 140) en el modelo Capan-1, el 50% de los ratones tratados con hRS7-CL2A-SN-38 y el 40% de los ratones hRS7-CL2-SN-38 estaban libres de tumores, mientras que sólo el 20% de los animales tratados con hA20-CAF no tenían signos visibles de enfermedad. Como se demuestra en la FIG. 3, el conector CL2A resultó en una eficacia algo mayor en comparación con CL2. </span>[0187] To confirm that the change in the SN-38 linker from CL2 to CL2A did not affect potency in vivo, hRS7-CL2A and hRS7-CL2-SN-38 were compared in mice bearing COLO 205 tumors (FIG. 3B) or Capan-1. (FIG. 3C), using 0.4 mg or 0.2 mg/kg SN-38 twice a week for x 4 weeks, respectively, and with initial tumors of 0.25 cm3 in size in both studies. Both hRS7-CL2A and CL2-SN-38 conjugates significantly inhibited tumor growth compared to untreated (AUC-MdaysP&lt;0.002 vs. saline in the COLO 205 model; AUC&lt;21&gt;daysP&lt;0.001 vs. saline in the Capan-1 model), and a control non-CAF-targeted anti-CD20, hA20-CL2A-SN-38 (AUC-MdaysP&lt;0.003 in the COLO-205 model; AUC&lt;35&gt;days:P&lt;0.002 in the Capan-1 model). At the end of the study (day 140) in the Capan-1 model, 50% of the hRS7-CL2A-SN-38-treated mice and 40% of the hRS7-CL2-SN-38 mice were tumor-free, while that only 20% of the animals treated with hA20-CAF had no visible signs of disease. As demonstrated in FIG. 3, the CL2A connector resulted in somewhat higher efficiency compared to CL2.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0188] Mecanismo de acción: los estudios de citotoxicidadin vitrodemostraron que hRS7-CL2A-SN-38 tenía valores de CI&lt;50&gt;en el rango de nmol/L frente a varias líneas de tumores sólidos diferentes (Tabla 2). La CI&lt;50&gt;con SN-38 libre fue menor que la del conjugado en todas las líneas celulares. Aunque no hubo una correlación aparente entre la expresión de Trop-2 y la sensibilidad a hRS7-CL2ASN-38, la relación CI&lt;50&gt;del CAF versus SN-38 libre fue menor en las células con mayor expresión de Trop-2, lo que probablemente refleja la mayor capacidad para internalizar el fármaco cuando hay más antígeno presente. </span>[0188] Mechanism of action: In vitro cytotoxicity studies demonstrated that hRS7-CL2A-SN-38 had IC values &lt;50&gt; in the nmol/L range against several different solid tumor lines (Table 2). The IC&lt;50&gt;with free SN-38 was lower than that of the conjugate in all cell lines. Although there was no apparent correlation between Trop-2 expression and sensitivity to hRS7-CL2ASN-38, the IC&lt;50&gt;ratio of CAF versus free SN-38 was lower in cells with higher Trop-2 expression, indicating which probably reflects the greater ability to internalize the drug when more antigen is present.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0189] Se sabe que SN-38 activa varias vías de señalización en las células, lo que conduce a la apoptosis (p. ej., Cusack et al., 2001, Cancer Res 61:3535-40; Liu et al. 2009, Cancer Lett 274:47-53; Lagadec et al. al., 2008, Br J Cancer 98:335-44). Nuestros estudios iniciales examinaron la expresión de 2 proteínas involucradas en eventos de señalización temprana (p21Waf1/Cip1 y p53) y 1 evento apoptótico tardío [escisión de poli-ADP-ribosa polimerasa (PARP)]in vitro(no mostrado). En BxPC-3, SN-38 produjo un aumento de 20 veces en la expresión de p21Waf1/Cip1 (no mostrado), mientras que hRS7-CL2A-SN-38 resultó en solo un aumento de 10 veces (no mostrado), un hallazgo consistente con la mayor actividad con SN-38 libre en esta línea celular (Tabla 2). Sin embargo, hRS7-CL2ASN-38 aumentó la expresión de p21Waf1/Cip1 en Calu-3 más del doble que SN-38 libre (no se muestra). </span>[0189] SN-38 is known to activate several signaling pathways in cells, leading to apoptosis (e.g., Cusack et al., 2001, Cancer Res 61:3535-40; Liu et al. 2009 , Cancer Lett 274:47-53; Lagadec et al., 2008, Br J Cancer 98:335-44). Our initial studies examined the expression of 2 proteins involved in early signaling events (p21Waf1/Cip1 and p53) and 1 late apoptotic event [poly-ADP-ribose polymerase (PARP) cleavage] in vitro (not shown). In BxPC-3, SN-38 resulted in a 20-fold increase in p21Waf1/Cip1 expression (not shown), whereas hRS7-CL2A-SN-38 resulted in only a 10-fold increase (not shown), a finding consistent with the highest activity with free SN-38 in this cell line (Table 2). However, hRS7-CL2ASN-38 increased the expression of p21Waf1/Cip1 in Calu-3 more than twice that of free SN-38 (not shown).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0190] Se observó una mayor disparidad entre los eventos de señalización mediados por hRS7-CL2A-SN-38 y SN-38 libre en la expresión de p53 (no se muestra). Tanto en BxPC-3 como en Calu-3, la regulación positiva de p53 con SN-38 libre no fue evidente hasta las 48 horas, mientras que hRS7-CL2A-SN-38 aumentó la regulación de p53 en 24 horas (no se muestra). Además, la expresión de p53 en células expuestas al CAF fue mayor en ambas líneas celulares en comparación con SN-38 (no mostrado). Curiosamente, aunque hRS7 IgG no tuvo un efecto apreciable sobre la expresión de p21Waf1/Cip1, sí indujo la regulación positiva de p53 tanto en BxPC-3 como en Calu-3, pero solo después de una exposición de 48 horas (no se muestra). En términos de eventos apoptóticos posteriores, la escisión de PARP fue evidente en ambas líneas celulares cuando se incubaron con SN-38 o el conjugado (no mostrado). La presencia de PARP escindida fue mayor a las 24 horas en BxPC-3 (no mostrado), lo que se correlaciona con una alta expresión de p21 y su CI&lt;50&gt;más baja. El mayor grado de escisión con SN-38 libre sobre el CAF fue consistente con los hallazgos de citotoxicidad. </span>[0190] A greater disparity between hRS7-CL2A-SN-38 and free SN-38-mediated signaling events was observed in p53 expression (not shown). In both BxPC-3 and Calu-3, upregulation of p53 with free SN-38 was not evident until 48 hours, whereas hRS7-CL2A-SN-38 upregulated p53 at 24 hours (not shown ). Furthermore, p53 expression in cells exposed to CAF was higher in both cell lines compared to SN-38 (not shown). Interestingly, although hRS7 IgG had no appreciable effect on p21Waf1/Cip1 expression, it did induce p53 upregulation in both BxPC-3 and Calu-3, but only after a 48-h exposure (not shown). . In terms of subsequent apoptotic events, PARP cleavage was evident in both cell lines when incubated with SN-38 or the conjugate (not shown). The presence of cleaved PARP was greater at 24 hours in BxPC-3 (not shown), which correlates with high p21 expression and its lower IC&lt;50&gt;. The greater degree of cleavage with free SN-38 on the CAF was consistent with the cytotoxicity findings.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0191] Eficacia de hRS7-SN-38: debido a que Trop-2 se expresa ampliamente en varios carcinomas humanos, se realizaron estudios en varios modelos diferentes de cáncer humano, que comenzaron usando el enlace hRS7-CL2-SN-38, pero luego se utilizaron conjugados con enlaces CL2A. Los ratones desnudos portadores de Calu-3 que recibieron 0,04 mg de SN-38/kg de hRS7-CL2-SN-38 cada 4 días tuvieron una respuesta significativamente mejor en comparación con los animales a los que se les administró la cantidad equivalente de hLL2-CL2-SN-38 no dirigido (TV = 0,14 ± 0,22 cm3 frente a 0,80 ± 0,91 cm3, respectivamente; AUC&lt;42&gt;díasP &lt;0,026;FIG. 4A). Se observó una dosis-respuesta cuando la dosis se aumentó a 0,4 mg/kg de SN-38 (FIG. 4A). Con este nivel de dosis más alto, todos los ratones que recibieron el conjugado hRS7 específico se “curaron” en 28 días y permanecieron libres de tumores hasta el final del estudio el día 147, mientras que los tumores volvieron a crecer en los animales tratados con el CAF irrelevante (específico vs. irrelevante AUCgedías:P= 0,05). En ratones que recibieron la mezcla de hRS7 IgG y SN-38, los tumores progresaron &gt;4,5 veces en el día 56 (TV = 1,10 ± 0,88 cm3; AUCgedíasP&lt; 0,006 frente a hRS7-CL2-SN-38) (FIG. 4A). </span>[0191] Efficacy of hRS7-SN-38: Because Trop-2 is widely expressed in several human carcinomas, studies were performed in several different human cancer models, starting using the hRS7-CL2-SN-38 linker, but then conjugates with CL2A bonds were used. Calu-3-bearing nude mice given 0.04 mg SN-38/kg hRS7-CL2-SN-38 every 4 days had a significantly better response compared to animals given the equivalent amount of non-targeted hLL2-CL2-SN-38 (TV = 0.14 ± 0.22 cm3 vs. 0.80 ± 0.91 cm3, respectively; AUC&lt;42&gt;daysP &lt;0.026; FIG. 4A). A dose-response was observed when the dose was increased to 0.4 mg/kg SN-38 (FIG. 4A). At this higher dose level, all mice receiving the specific hRS7 conjugate were “cured” within 28 days and remained tumor-free until the end of the study on day 147, while tumors regrew in animals treated with the irrelevant CAF (specific vs. irrelevant AUCgedias:P= 0.05). In mice receiving the mixture of hRS7 IgG and SN-38, tumors progressed &gt;4.5-fold at day 56 (TV = 1.10 ± 0.88 cm3; AUCgediasP &lt; 0.006 vs. hRS7-CL2-SN-38 ) (FIG. 4A).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0192]También se examinó la eficacia en xenoinjertos de tumores de colon humano (COLO 205) y páncreas (Capan-1). En animales portadores de tumores COLO 205,(FIG. 4Bhttp://clincancerres.aacriournals.org/content/17/10/3157.long - F3), hRS7-CL2-SN-38 (0,4 mg/kg, q4dx8) previno el crecimiento del tumor durante el período de tratamiento de 28 días con tumores significativamente más pequeños en comparación con el control CAF anti-CD20 (hA20-CL2-SN-38) o hRS7 IgG (TV = 0,16 ± 0,09 cm3, 1,19 ± 0,59 cm3 y 1,77 ± 0,93 cm3, respectivamente; AUC&lt;28&gt;díasP&lt; 0,016). </span>[0192]Efficacy was also examined in human colon (COLO 205) and pancreas (Capan-1) tumor xenografts. In animals carrying COLO 205 tumors, (FIG. 4Bhttp://clincancerres.aacriournals.org/content/17/10/3157.long - F3), hRS7-CL2-SN-38 (0.4 mg/kg, q4dx8 ) prevented tumor growth over the 28-day treatment period with significantly smaller tumors compared to control CAF anti-CD20 (hA20-CL2-SN-38) or hRS7 IgG (TV = 0.16 ± 0.09 cm3, 1.19 ± 0.59 cm3 and 1.77 ± 0.93 cm3, respectively; AUC&lt;28&gt;daysP&lt; 0.016).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 2. Expresión de la citotoxicidadin vitrode Trop-2 de SN-38 y hRS7-SN-38 en diversas líneas de tumores sólidos</span>Table 2. Expression of in vitro cytotoxicity of Trop-2 of SN-38 and hRS7-SN-38 in various solid tumor lines.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Expresión de Trop-2 mediante FACS Resultados de citotoxicidad Línea Fluorescencia Porcentaje SN-38 IC 95% hRS7-SN- IC 95% Relación celular media (fondo) positivo 38 ADC/SN-38 libre CI&lt;50&gt;CI50 CI50 CI50 </span>Expression of Trop-2 by FACS Cytotoxicity results Line Fluorescence Percentage SN-38 95% CI hRS7-SN- 95% CI Mean cell ratio (background) positive 38 ADC/free SN-38 CI&lt;50&gt;IC50 CI50 CI50</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">(nmol/L) (nmol/L) (nmol/L) (nmol/L) </span>(nmol/L) (nmol/L) (nmol/L) (nmol/L)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Calu-3 282,2 (4,7) 99,6% 7,19 5,77-8,95 9,97 8,12-12,25 1,39 </span>Calu-3 282.2 (4.7) 99.6% 7.19 5.77-8.95 9.97 8.12-12.25 1.39</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">COLO 205 141,5 (4,5) 99,5% 1,02 0,66-1,57 1,95 1,26-3,01 1,91 </span>COLO 205 141.5 (4.5) 99.5% 1.02 0.66-1.57 1.95 1.26-3.01 1.91</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Capan-1 100,0 (5,0) 94,2% 3,50 2,17-5,65 6,99 5,02-9,72 2,00 </span>Capan-1 100.0 (5.0) 94.2% 3.50 2.17-5.65 6.99 5.02-9.72 2.00</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PC-3 46,2 (5,5) 73,6% 1,86 1,16-2,99 4,24 2,99-6,01 2,28 </span>PC-3 46.2 (5.5) 73.6% 1.86 1.16-2.99 4.24 2.99-6.01 2.28</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SK-MES-1 44,0 (3,5) 91,2% 8,61 6,30-11,76 23,14 17,98-29,78 2,69 </span>SK-MES-1 44.0 (3.5) 91.2% 8.61 6.30-11.76 23.14 17.98-29.78 2.69</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">BxPC-3 26,4 (3,1) 98,3% 1,44 1,04-2,00 4,03 3,25-4,98 2,80 </span>BxPC-3 26.4 (3.1) 98.3% 1.44 1.04-2.00 4.03 3.25-4.98 2.80</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0193]La MTD de irinotecán (24 mg de SN-38/kg, cada 2 días x 5) fue tan efectiva como hRS7-CL2-SN-38 en células COLO 205, porque el suero de ratón puede convertir más eficientemente el irinotecán en SN-38 (Morton et al., 2000, Cancer Res 60:4206-10) que el suero humano, pero la dosis de SN-38 en irinotecán (2400 |jg acumulativos) fue 37,5 veces mayor que con el conjugado (64 jg en total). </span>[0193]The MTD of irinotecan (24 mg SN-38/kg, every 2 days x 5) was as effective as hRS7-CL2-SN-38 in COLO 205 cells, because mouse serum can more efficiently convert irinotecan in SN-38 (Morton et al., 2000, Cancer Res 60:4206-10) than human serum, but the dose of SN-38 in irinotecan (2400 |jg cumulative) was 37.5 times higher than with the conjugate (64 jg in total).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0194]Los animales que portaban Capan-1 (FIG. 4C)no mostraron una respuesta significativa al irinotecán solo cuando se les administró una dosis de SN-38 equivalente al conjugado hRS7-CL2-SN-38 (p. ej., el día 35, el tamaño promedio del tumor fue 0,04 ± 0,05 cm3 en animales que recibieron 0,4 mg de SN-38/kg hRS7-SN-38 frente a 1,78 ± 0,62 cm3 en animales tratados con irinotecán que recibieron 0,4 mg/kg de SN-38 (AUCdía&lt;35&gt;P&lt; 0,001;FIG. 4C). Cuando la dosis de irinotecán se aumentó 10 veces a 4 mg/kg de SN-38, la respuesta mejoró, pero aún no fue tan significativa como la del conjugado al nivel de dosis de 0,4 mg/kg de SN-38 (TV = 0,17 ± 0,18 cm3 vs, 1,69 ± 0,47 cm3, AUCdía&lt;49&gt;P&lt; 0,001) (FIG.</span>[0194]Animals carrying Capan-1 (FIG. 4C) did not show a significant response to irinotecan alone when administered a dose of SN-38 equivalent to the hRS7-CL2-SN-38 conjugate (e.g., the Day 35, the average tumor size was 0.04 ± 0.05 cm3 in animals receiving 0.4 mg SN-38/kg hRS7-SN-38 versus 1.78 ± 0.62 cm3 in animals treated with irinotecan who received 0.4 mg/kg SN-38 (AUCday&lt;35&gt;P&lt; 0.001; FIG. 4C). When the dose of irinotecan was increased 10-fold to 4 mg/kg SN-38, the response improved, but it was still not as significant as that of the conjugate at the 0.4 mg/kg dose level of SN-38 (TV = 0.17 ± 0.18 cm3 vs, 1.69 ± 0.47 cm3, AUCday &lt;49 &gt;P&lt; 0.001) (FIG.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4C). Una dosis igual de hA20-CL2-SN-38 no dirigido también tuvo un efecto antitumoral significativo en comparación con los animales tratados con irinotecán, pero el conjugado específico de hRS7 fue significativamente mejor que el CAF irrelevante (TV = 0,17 ± 0,18 cm3 frente a 0,80 ± 0,68 cm3, AUCdía&lt;49&gt;P&lt; 0,018) (FIG. 4C). </span>4C). An equal dose of non-targeted hA20-CL2-SN-38 also had a significant antitumor effect compared to irinotecan-treated animals, but the hRS7-specific conjugate was significantly better than the irrelevant CAF (TV = 0.17 ± 0. 18 cm3 vs. 0.80 ± 0.68 cm3, AUCday&lt;49&gt;P&lt; 0.018) (FIG. 4C).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0195]A continuación, los estudios con el CAF hRS7-CL2A-SN-38 se ampliaron a otros dos modelos de cánceres epiteliales humanos. En ratones que portaban tumores pancreáticos humanos BxPC-3 (FIG. 4D), hRS7-CL2A-SN-38 nuevamente inhibió significativamente el crecimiento tumoral en comparación con ratones de control tratados con solución salina o una cantidad equivalente de hA20-CL2A-SN-38 no dirigido (TV = 0,24 ± 0,11 cm3 frente a 1,17 ± 0,45 cm3 y 1,05 ± 0,73 cm3, respectivamente; AUC&lt;21&gt;díasP&lt; 0,001), o irinotecán administrado a una dosis equivalente de SN-38 10 veces mayor (TV = 0,27 ± 0,18 cm3 frente a 0,90 ± 0,62 cm3, respectivamente; AUCdía&lt;25&gt;P&lt; 0,004) (FIG.4D). Curiosamente, en ratones portadores de tumores de pulmón de células escamosas humanas SK-MES-1 tratados con 0,4 mg/kg de CAF (FIG. 4E), la inhibición del crecimiento tumoral fue superior a la IgG hRS7 salina o no conjugada (TV = 0,36 ± 0,25 cm3 vs. 1,02 ± 0,70 cm3 y 1,30 ± 1,08 cm3, respectivamente; AUC&lt;28&gt;días,P&lt; 0,043), pero el hA20-CL2A-SN-38 no dirigido o la MTD del irinotecán proporcionaron los mismos efectos antitumorales que el conjugado específico hRS7-SN-38 (FIG. 5E). </span>[0195]The studies with the CAF hRS7-CL2A-SN-38 were then extended to two other models of human epithelial cancers. In mice bearing BxPC-3 human pancreatic tumors (FIG. 4D), hRS7-CL2A-SN-38 again significantly inhibited tumor growth compared to control mice treated with saline or an equivalent amount of hA20-CL2A-SN-38. 38 non-targeted (TV = 0.24 ± 0.11 cm3 vs. 1.17 ± 0.45 cm3 and 1.05 ± 0.73 cm3, respectively; AUC&lt;21&gt;daysP&lt; 0.001), or irinotecan administered to a equivalent dose of SN-38 10 times higher (TV = 0.27 ± 0.18 cm3 vs. 0.90 ± 0.62 cm3, respectively; AUCday&lt;25&gt;P&lt; 0.004) (FIG.4D). Interestingly, in mice bearing SK-MES-1 human squamous cell lung tumors treated with 0.4 mg/kg CAF (FIG. 4E), tumor growth inhibition was superior to saline or unconjugated hRS7 IgG ( TV = 0.36 ± 0.25 cm3 vs. 1.02 ± 0.70 cm3 and 1.30 ± 1.08 cm3, respectively; AUC&lt;28&gt;days, P&lt; 0.043), but the hA20-CL2A-SN Non-targeted -38 or the MTD of irinotecan provided the same antitumor effects as the specific hRS7-SN-38 conjugate (FIG. 5E).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0196]En todos los estudios murinos, el CAF hRS7-SN-38 fue bien tolerado en términos de pérdida de peso corporal (no mostrado). </span>[0196]In all murine studies, CAF hRS7-SN-38 was well tolerated in terms of body weight loss (not shown).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0197]Biodistribución de hRS7-CL2A-SN-38: se compararon las biodistribuciones de hRS7-CL2A-SN-38 o hRS7 IgG no conjugada en ratones portadores de xenoinjertos de carcinoma de pulmón de células escamosas humanas SK-MES-1 (no mostrado), utilizando los respectivos sustratos etiquetados con 111In. Se realizó un análisis farmacocinético para determinar la eliminación de hRS7-CL2A-SN-38 en relación con hRS7 no conjugado (no mostrado). El CAF se eliminó más rápido que la cantidad equivalente de hRS7 no conjugado, y el CAF exhibió una vida media y un tiempo de residencia medio aproximadamente un 40 % más cortos. No obstante, esto tuvo un impacto mínimo en la captación del tumor (no se muestra). Aunque hubo diferencias significativas a las 24 y 48 horas, a las 72 horas (captación máxima) las cantidades de ambos agentes en el tumor eran similares. Entre los tejidos normales, las diferencias hepáticas y esplénicas fueron las más llamativas (no mostradas). A las 24 horas posteriores a la inyección, había &gt;2 veces más hRS7-CL2ASN-38 en el hígado que hRS7 IgG (no se muestra). Por el contrario, en el bazo había 3 veces más IgG hRS7 parental presente en el pico de absorción (punto de tiempo de 48 horas) que hRS7-CL2A-SN-38 (no se muestra). La captación y eliminación en el resto de los tejidos generalmente reflejaron diferencias en la concentración sanguínea (no mostradas). </span>[0197]Biodistribution of hRS7-CL2A-SN-38: The biodistributions of hRS7-CL2A-SN-38 or unconjugated hRS7 IgG were compared in mice bearing human squamous cell lung carcinoma SK-MES-1 xenografts (not shown), using the respective substrates labeled with 111In. Pharmacokinetic analysis was performed to determine the clearance of hRS7-CL2A-SN-38 relative to unconjugated hRS7 (not shown). CAF was eliminated faster than the equivalent amount of unconjugated hRS7, and CAF exhibited an approximately 40% shorter half-life and mean residence time. However, this had minimal impact on tumor uptake (not shown). Although there were significant differences at 24 and 48 hours, at 72 hours (maximum uptake) the amounts of both agents in the tumor were similar. Among normal tissues, hepatic and splenic differences were the most striking (not shown). At 24 hours postinjection, there was &gt;2-fold more hRS7-CL2ASN-38 in the liver than hRS7 IgG (not shown). In contrast, in the spleen there was 3 times more parental hRS7 IgG present at the peak absorption (48 hour time point) than hRS7-CL2A-SN-38 (not shown). Uptake and elimination in the remaining tissues generally reflected differences in blood concentration (not shown).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0198] Debido a que se administraron dosis dos veces por semana para la terapia, se examinó la captación tumoral en un grupo de animales que recibieron por primera vez una predosis de 0,2 mg/kg (250 |jg de proteína) del CAF hRS7 3 días antes de la inyección del anticuerpo marcado con 111In. La absorción tumoral de 111In-hRS7-CL2A-SN-38 en ratones predosificados se redujo sustancialmente en cada momento en comparación con los animales que no recibieron la dosis previa (p. ej., a las 72 horas, la absorción tumoral predosificada fue del 12,5 % ± 3,8 % ID/g vs 25,4% 6 8,1% ID/g en animales a los que no se les administró la predosis;P= 0,0123; no se muestra http://clincancerres.aacNournals.org/content/17/10/3157.long - F4). La predosificación no tuvo un impacto apreciable en el aclaramiento de sangre o la absorción de tejido (no se muestra). Estos estudios sugieren que en algunos modelos tumorales, la acumulación tumoral del anticuerpo específico puede reducirse con las dosis anteriores, lo que probablemente explica por qué la especificidad de una respuesta terapéutica podría disminuir al aumentar las dosis de CAF y por qué no es indicado un mayor aumento de la dosis. </span>[0198] Because twice-weekly dosing was administered for therapy, tumor uptake was examined in a group of animals that first received a predose of 0.2 mg/kg (250 μg protein) of CAF. hRS7 3 days before injection of the 111In-labeled antibody. Tumor uptake of 111In-hRS7-CL2A-SN-38 in predosed mice was substantially reduced at each time point compared to unpredosed animals (e.g., at 72 hours, predosed tumor uptake was 12.5% ± 3.8% ID/g vs 25.4% 6 8.1% ID/g in animals that were not predose;P= 0.0123; not shown http:// clincancerres.aacNournals.org/content/17/10/3157.long - F4). Predosing had no appreciable impact on blood clearance or tissue absorption (not shown). These studies suggest that in some tumor models, tumor accumulation of specific antibody may be reduced with earlier doses, which likely explains why the specificity of a therapeutic response could decrease with increasing doses of CAF and why a higher dose is not indicated. dose increase.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0199] Tolerabilidad de hRS7-CL2A-SN-38 en ratones Swiss-Webster y monos Cynomolgus. Los ratones Swiss-Webster toleraron 2 dosis durante 3 días, cada una de 4, 8 y 12 mg de SN-38/kg de hRS7-CL2A-SN-38, con pérdida de peso transitoria mínima (no se muestra). No se produjo toxicidad hematopoyética y las químicas séricas solo revelaron niveles elevados de aspartato transaminasa (AST, FIG. 5A) y alanina transaminasa (ALT, FIG. 5B). Siete días después del tratamiento, la AST aumentó por encima de los niveles normales (&gt;298 U/L) en los 3 grupos de tratamiento (FIG. 5A), estando la mayor proporción de ratones en el grupo de 2 x 8 mg/kg. Sin embargo, 15 días después del tratamiento, la mayoría de los animales estaban dentro del rango normal. Los niveles de ALT también estaban por encima del rango normal (&gt;77 U/L) dentro de los 7 días de tratamiento (FIG. 5B) y con evidencia de normalización el día 15. Los hígados de todos estos ratones no mostraron evidencia histológica de daño tisular (no mostrado). En cuanto a la función renal, sólo los niveles de glucosa y cloro estaban algo elevados en los grupos tratados. Con 2 x 8 mg/kg, 5 de 7 ratones tenían niveles de glucosa ligeramente elevados (rango de 273-320 mg/dL, límite superior de lo normal 263 mg/dL) que volvieron a la normalidad 15 días después de la inyección. De manera similar, los niveles de cloruro estaban ligeramente elevados, oscilando entre 116 y 127 mmol/L (extremo superior del rango normal 115 mmol/L) en los 2 grupos de dosis más altas (57% en el grupo de 2,3,8 mg/kg y 100% del grupo de ratones en el grupo de 2 x 12 mg/kg), y permaneció elevado hasta 15 días después de la inyección. Esto también podría ser indicativo de toxicidad gastrointestinal, porque la mayor parte del cloruro se obtiene mediante absorción en el intestino; sin embargo, al finalizar, no hubo evidencia histológica de daño tisular en ningún sistema de órganos examinado (no se muestra). </span>[0199] Tolerability of hRS7-CL2A-SN-38 in Swiss-Webster mice and Cynomolgus monkeys. Swiss-Webster mice tolerated 2 doses for 3 days, each of 4, 8, and 12 mg SN-38/kg hRS7-CL2A-SN-38, with minimal transient weight loss (not shown). No hematopoietic toxicity occurred and serum chemistries only revealed elevated levels of aspartate transaminase (AST, FIG. 5A) and alanine transaminase (ALT, FIG. 5B). Seven days after treatment, AST increased above normal levels (&gt;298 U/L) in all 3 treatment groups (FIG. 5A), with the highest proportion of mice in the 2 x 8 mg/kg group. . However, 15 days after treatment, most animals were within the normal range. ALT levels were also above the normal range (&gt;77 U/L) within 7 days of treatment (FIG. 5B) and with evidence of normalization by day 15. The livers of all of these mice showed no histological evidence of tissue damage (not shown). Regarding kidney function, only glucose and chloride levels were somewhat elevated in the treated groups. At 2 x 8 mg/kg, 5 of 7 mice had slightly elevated glucose levels (range 273-320 mg/dL, upper limit of normal 263 mg/dL) that returned to normal 15 days after injection. Similarly, chloride levels were slightly elevated, ranging from 116 to 127 mmol/L (upper end of the normal range 115 mmol/L) in the 2 highest dose groups (57% in the 2.3, 8 mg/kg and 100% of the mice group in the 2 x 12 mg/kg group), and remained elevated up to 15 days after injection. This could also be indicative of gastrointestinal toxicity, because most of the chloride is obtained through absorption in the intestine; however, upon completion, there was no histologic evidence of tissue damage in any organ system examined (not shown).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0200] Debido a que los ratones no expresan Trop-2 identificado por hRS7, se requirió un modelo más adecuado para determinar el potencial del conjugado de hRS7 para uso clínico. Los estudios de inmunohistología revelaron unión en múltiples tejidos tanto en humanos como en monos Cynomolgus (mama, ojo, tracto gastrointestinal, riñón, pulmón, ovario, trompas de Falopio, páncreas, paratiroides, próstata, glándula salival, piel, timo, tiroides, amígdala, uréter, sistema urinario, vejiga y útero; no se muestran). Sobre la base de esta reactividad cruzada, se realizó un estudio de tolerabilidad en monos. </span>[0200] Because mice do not express Trop-2 identified by hRS7, a more suitable model was required to determine the potential of the hRS7 conjugate for clinical use. Immunohistology studies revealed binding in multiple tissues in both humans and Cynomolgus monkeys (breast, eye, gastrointestinal tract, kidney, lung, ovary, fallopian tubes, pancreas, parathyroid, prostate, salivary gland, skin, thymus, thyroid, tonsil , ureter, urinary system, bladder and uterus not shown). Based on this cross-reactivity, a tolerability study was performed in monkeys.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0201] El grupo que recibió 2 x 0,96 mg de SN-38/kg de hRS7-CL2A-SN-38 no tuvo eventos clínicos significativos después de la infusión ni hasta la finalización del estudio. La pérdida de peso no superó el 7,3 % y volvió a los pesos de aclimatación el día 15. Se observaron disminuciones transitorias en la mayoría de los datos del recuento sanguíneo (los datos de neutrófilos y plaquetas se muestran en la FIG. 5C y la FIG. 5D), pero los valores no cayeron por debajo de los rangos normales. No se encontraron valores anormales en la química del suero. La histopatología de los animales sometidos a necropsia el día 11 (8 días después de la última inyección) mostró cambios microscópicos en los órganos hematopoyéticos (timo, ganglios linfáticos mandibulares y mesentéricos, bazo y médula ósea), órganos gastrointestinales (estómago, duodeno, yeyuno, íleon, ciego, colon y recto), los órganos reproductores femeninos (ovario, útero y vagina) y en el lugar de la inyección. Estos cambios variaron de mínimos a moderados y se revirtieron completamente al final del período de recuperación (día 32) en todos los tejidos, excepto en el timo y el tracto gastrointestinal, que tendían a una recuperación completa en este último momento (no mostrado). </span>[0201] The group receiving 2 x 0.96 mg SN-38/kg hRS7-CL2A-SN-38 had no significant clinical events after infusion or until completion of the study. Weight loss did not exceed 7.3% and returned to acclimatization weights on day 15. Transient decreases were observed in most blood count data (neutrophil and platelet data are shown in FIG. 5C and FIG. 5D), but the values did not fall below normal ranges. No abnormal values were found in serum chemistry. Histopathology of necropsied animals on day 11 (8 days after the last injection) showed microscopic changes in hematopoietic organs (thymus, mandibular and mesenteric lymph nodes, spleen and bone marrow), gastrointestinal organs (stomach, duodenum, jejunum , ileum, cecum, colon and rectum), the female reproductive organs (ovary, uterus and vagina) and at the injection site. These changes ranged from minimal to moderate and were completely reversed by the end of the recovery period (day 32) in all tissues except the thymus and gastrointestinal tract, which trended toward complete recovery at the latter time point (not shown).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0202] Con el nivel de dosis de 2 * 1,92 mg de SN-38/kg del conjugado, hubo 1 muerte derivada de complicaciones gastrointestinales y supresión de la médula ósea, y otros animales dentro de este grupo mostraron eventos adversos similares, pero más graves, que los de 2 * 30,96 mg/kg grupo (no mostrado). Estos datos indican que las toxicidades limitantes de la dosis fueron idénticas a las del irinotecán; a saber, intestinal y hematológico. Por lo tanto, la DMT para hRS7-CL2A-SN-38 se encuentra entre 2 x 0,96 y 1,92 mg de SN-38/kg, lo que representa una dosis humana equivalente de 2 x 0,3 a 0,6 mg/kg de SN-38. </span>[0202] At the dose level of 2 * 1.92 mg SN-38/kg conjugate, there was 1 death resulting from gastrointestinal complications and bone marrow suppression, and other animals within this group showed similar adverse events, but more severe, than those in the 2 * 30.96 mg/kg group (not shown). These data indicate that dose-limiting toxicities were identical to those of irinotecan; namely, intestinal and hematological. Therefore, the MTD for hRS7-CL2A-SN-38 is between 2 x 0.96 and 1.92 mg SN-38/kg, which represents an equivalent human dose of 2 x 0.3 to 0. 6 mg/kg of SN-38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Discusión</span>Discussion</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0203] Trop-2 es una proteína expresada en muchos tumores epiteliales, incluidos los cánceres de pulmón, mama, colorrectal, páncreas, próstata y ovario, lo que la convierte en un objetivo potencialmente importante para la administración de agentes citotóxicos (Ohmachi et al., 2006, Clin Cancer Res 12: 3057-63; Fong et al., 2008, Br J Cancer 99:1290-95; Cubas et al., 2009, Biochim Biophys Acta 1796:309-14). El anticuerpo RS7 se internaliza cuando se une a Trop-2 (Shih et al., 1995, Cancer Res 55:5857s-63s), lo que permite la administración intracelular directa de citotóxicos. </span>[0203] Trop-2 is a protein expressed in many epithelial tumors, including lung, breast, colorectal, pancreatic, prostate and ovarian cancers, making it a potentially important target for the delivery of cytotoxic agents (Ohmachi et al ., 2006, Clin Cancer Res 12: 3057-63; Fong et al., 2008, Br J Cancer 99:1290-95; The RS7 antibody is internalized when it binds to Trop-2 (Shih et al., 1995, Cancer Res 55:5857s-63s), allowing direct intracellular delivery of cytotoxics.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0204] SN-38 es un potente inhibidor de la topoisomerasa I, con valores de CI&lt;50&gt;en el rango nanomolar en varias líneas celulares. Es la forma activa del profármaco irinotecán, que se utiliza para el tratamiento del cáncer colorrectal y que también tiene actividad en los cánceres de pulmón, mama y cerebro. Razonamos que un SN-38 dirigido directamente, en forma de CAF, sería un tratamiento terapéutico significativamente mejorado con respecto al CPT-11, al superar la baja y variable bioconversión de este último a SN-38 activo (Mathijssen et al., 2001), Clin Cancer Res 7:2182-94). </span>[0204] SN-38 is a potent inhibitor of topoisomerase I, with IC values &lt;50&gt; in the nanomolar range in several cell lines. It is the active form of the prodrug irinotecan, which is used for the treatment of colorectal cancer and also has activity in lung, breast, and brain cancers. We reasoned that a directly targeted SN-38, in the form of CAF, would be a significantly improved therapeutic treatment over CPT-11, by overcoming the low and variable bioconversion of the latter to active SN-38 (Mathijssen et al., 2001). , Clin Cancer Res 7:2182-94).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0205] El péptido Phe-Lys insertado en el derivado CL2 original permitió una posible escisión mediante catepsina B. Para simplificar el proceso sintético, en CL2A se eliminó la fenilalanina y, por lo tanto, se eliminó el sitio de escisión de la catepsina B. Curiosamente, este producto tenía un perfil cromatográfico mejor definido en comparación con el perfil amplio obtenido con CL2 (no mostrado), pero lo más importante es que este cambio no tuvo impacto en la unión, estabilidad o potencia del conjugado en las pruebas en paralelo. Estos datos sugieren que SN-38 en CL2 se liberó del conjugado principalmente por la escisión en el enlace de carbonato de bencilo sensible al pH al anillo de lactona de SN-38 y no por el sitio de escisión de la catepsina B. </span>[0205] The Phe-Lys peptide inserted into the original CL2 derivative allowed for possible cleavage by cathepsin B. To simplify the synthetic process, in CL2A the phenylalanine was removed and therefore the cathepsin B cleavage site was eliminated Interestingly, this product had a better defined chromatographic profile compared to the broad profile obtained with CL2 (not shown), but importantly this change had no impact on the binding, stability or potency of the conjugate in parallel tests. . These data suggest that SN-38 in CL2 was released from the conjugate primarily by cleavage at the pH-sensitive benzyl carbonate bond to the lactone ring of SN-38 and not by the cathepsin B cleavage site.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0206] Citotoxicidadin vitrode hRS7 CAF contra una variedad de líneas celulares de tumores sólidos tuvo consistentemente valores de CI&lt;50&gt;en el rango de nmol/l. Sin embargo, las células expuestas al SN-38 libre demostraron un valor de CI&lt;50&gt;más bajo en comparación con el CAF. Esta disparidad entre SN-38 libre y conjugado también se informó para ENZ-2208 (Sapra et al., 2008, Clin Cancer Res 14:1888-96, Zhao et al., 2008, Bioconjug Chem 19:849-59) y NK012 (Koizumi et al., 2006, Cancer Res 66:10048-56). ENZ-2208 utiliza un PEG ramificado para unir aproximadamente de 3,5 a 4 moléculas de SN-38 por PEG, mientras que NK012 es una nanopartícula micelar que contiene un 20 % de SN-38 en peso. Con nuestro CAF, esta disparidad (es decir, la relación de potencia con SN-38 libre versus conjugado) disminuyó a medida que aumentaron los niveles de expresión de Trop-2 en las células tumorales, lo que sugiere una ventaja para la administración dirigida del fármaco. En términos de estabilidad séricain vitro,las formas CL2- y CL2A-SN-38 de hRS7-SN-38 produjeron una t/A de aproximadamente 20 horas, en contraste con la t/A corta, de 12,3 minutos. reportado para ENZ-2208 (Zhao et al., 2008, Bioconjug Chem 19:849-59), pero similar a la liberación del 57 % de SN-38 de NK012 en condiciones fisiológicas después de 24 horas (Koizumi et al., 2006, Cancer Res 66:10048-56). </span>[0206] In vitro cytotoxicity of hRS7 CAF against a variety of solid tumor cell lines consistently had IC values &lt;50&gt; in the nmol/L range. However, cells exposed to free SN-38 demonstrated a lower IC&lt;50&gt;value compared to CAF. This disparity between free and conjugated SN-38 was also reported for ENZ-2208 (Sapra et al., 2008, Clin Cancer Res 14:1888-96, Zhao et al., 2008, Bioconjug Chem 19:849-59) and NK012 (Koizumi et al., 2006, Cancer Res 66:10048-56). ENZ-2208 uses a branched PEG to bind approximately 3.5 to 4 molecules of SN-38 per PEG, while NK012 is a micellar nanoparticle containing 20% SN-38 by weight. With our CAF, this disparity (i.e., potency ratio with free versus conjugated SN-38) decreased as Trop-2 expression levels in tumor cells increased, suggesting an advantage for targeted delivery of the drug. In terms of in vitro serum stability, the CL2- and CL2A-SN-38 forms of hRS7-SN-38 produced a t/A of approximately 20 hours, in contrast to the short t/A of 12.3 minutes. reported for ENZ-2208 (Zhao et al., 2008, Bioconjug Chem 19:849-59), but similar to the release of 57% of SN-38 from NK012 under physiological conditions after 24 hours (Koizumi et al., 2006 , Cancer Res 66:10048-56).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0207] El tratamiento de ratones portadores de tumores con hRS7-SN-38 (ya sea con CL2-SN-38 o CL2A-SN-38) inhibió significativamente el crecimiento del tumor en 5 modelos de tumores diferentes. En 4 de ellos, se observaron regresiones tumorales y, en el caso de Calu-3, todos los ratones que recibieron la dosis más alta de hRS7-SN-38 estaban libres de tumores al finalizar el estudio. A diferencia de lo que ocurre en los seres humanos, el irinotecán se convierte de manera muy eficiente en SN-38 mediante una esterasa plasmática en ratones, con una tasa de conversión superior al 50 %, y produce una mayor eficacia en ratones que en humanos (Morton et al., 2000, Cancer Res 60: 4206-10; Furman et al., 1999, J Clin Oncol 17:1815-24). Cuando se administró irinotecán a niveles de SN-38 10 veces superiores o equivalentes, hRS7-SN-38 fue significativamente mejor en el control del crecimiento tumoral. Sólo cuando se administró irinotecán a su DMT de 24 mg/kg cada 2 días x 5 (37,5 veces más SN-38) igualó la eficacia de hRS7-SN-38. En los pacientes, esperaríamos que esta ventaja favoreciera aún más a hRS7-CL2A-SN-38, porque la bioconversión de irinotecán sería sustancialmente menor. </span>[0207] Treatment of tumor-bearing mice with hRS7-SN-38 (either CL2-SN-38 or CL2A-SN-38) significantly inhibited tumor growth in 5 different tumor models. In 4 of them, tumor regressions were observed and, in the case of Calu-3, all mice that received the highest dose of hRS7-SN-38 were tumor-free at the end of the study. Unlike in humans, irinotecan is very efficiently converted to SN-38 by a plasma esterase in mice, with a conversion rate greater than 50%, and produces greater efficacy in mice than in humans. (Morton et al., 2000, Cancer Res 60: 4206-10; Furman et al., 1999, J Clin Oncol 17:1815-24). When irinotecan was administered at 10-fold or equivalent SN-38 levels, hRS7-SN-38 was significantly better at controlling tumor growth. Only when irinotecan was administered at its MTD of 24 mg/kg every 2 days x 5 (37.5 times more SN-38) did it match the efficacy of hRS7-SN-38. In patients, we would expect this advantage to further favor hRS7-CL2A-SN-38, because the bioconversion of irinotecan would be substantially lower.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0208] También demostramos en algunas líneas celulares que expresan antígenos, como SK-MES-1, que el uso de un CAF que se une a antígenos no garantiza mejores respuestas terapéuticas que un conjugado irrelevante y que no se une. Este no es un hallazgo inusual o inesperado. De hecho, los conjugados SN-38 no vinculantes mencionados anteriormente mejoran la actividad terapéutica en comparación con el irinotecán, por lo que se espera que un conjugado IgG-SN-38 irrelevante tenga cierta actividad. Esto está relacionado con el hecho de que los tumores tienen vasos inmaduros y con fugas que permiten el paso de macromoléculas mejor que los tejidos normales (Jain, 1994, Sci Am 271:58-61). Con nuestro conjugado, el 50% del SN-38 se liberará en aproximadamente 13 horas cuando el pH se reduce a un nivel que imita los niveles lisosomales (p. ej., pH 5,3 a 37 °C; datos no mostrados), mientras que al pH neutro de suero, la tasa de liberación se reduce casi 2 veces. Si un conjugado irrelevante ingresa a un microambiente tumoral ácido, se espera que libere algo de SN-38 localmente. Otros factores, como la fisiología del tumor y las sensibilidades innatas al fármaco, también desempeñarán un papel en la definición de esta actividad “base”. Sin embargo, un conjugado específico con un tiempo de residencia más largo debería tener una potencia mejorada con respecto a esta respuesta inicial siempre que haya suficiente antígeno para capturar el anticuerpo específico. Los estudios de biodistribución en el modelo SK-MES-1 también mostraron que si el antígeno tumoral se satura como consecuencia de dosis sucesivas, la absorción tumoral del conjugado específico se reduce, lo que produce resultados terapéuticos similares a los encontrados con un conjugado irrelevante. </span>[0208] We also demonstrate in some antigen-expressing cell lines, such as SK-MES-1, that the use of an antigen-binding CAF does not guarantee better therapeutic responses than an irrelevant, non-binding conjugate. This is not an unusual or unexpected finding. Indeed, the non-binding SN-38 conjugates mentioned above improve therapeutic activity compared to irinotecan, so an irrelevant IgG-SN-38 conjugate is expected to have some activity. This is related to the fact that tumors have immature and leaky vessels that allow the passage of macromolecules better than normal tissues (Jain, 1994, Sci Am 271:58-61). With our conjugate, 50% of the SN-38 will be released in approximately 13 hours when the pH is reduced to a level that mimics lysosomal levels (e.g., pH 5.3 at 37 °C; data not shown), while at neutral serum pH, the release rate is reduced almost 2 times. If an irrelevant conjugate enters an acidic tumor microenvironment, it is expected to release some SN-38 locally. Other factors, such as tumor physiology and innate drug sensitivities, will also play a role in defining this “base” activity. However, a specific conjugate with a longer residence time should have improved potency over this initial response as long as there is sufficient antigen to capture the specific antibody. Biodistribution studies in the SK-MES-1 model also showed that if the tumor antigen is saturated as a consequence of successive doses, tumor uptake of the specific conjugate is reduced, producing therapeutic results similar to those found with an irrelevant conjugate.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0209] Aunque es un desafío hacer comparaciones directas entre nuestro CAF y los informes publicados de otros agentes dispensadores de SN-38, se pueden hacer algunas observaciones generales. En nuestros estudios de terapia, la dosis individual más alta fue de 0,4 mg/kg de SN-38. En el modelo Calu-3, solo se administraron 4 inyecciones para una dosis acumulativa total de 1,6 mg/kg de SN-38 o 32 mg de SN-38 en un ratón de 20 g. Se realizaron múltiples estudios con ENZ-2208 utilizando su MTD de 10 mg/kg x 5 (Sapra et al., 2008, Clin Cancer Res 14:1888-96; Pastorini et al., 2010, Clin Cancer Res 16:4809-21), y los estudios preclínicos con NK012 involucraron su DMT de 30 mg/kg x 3 (Koizumi et al., 2006, Cancer Res 66:10048-56). Por lo tanto, se obtuvieron efectos antitumorales significativos con hRS7-SN-38 a 30 veces y 55 veces menos equivalentes de SN-38 que las dosis informadas en ENZ-2208 y NK012, respectivamente. Incluso con 10 veces menos CAF de hRS7 (0,04 mg/kg), se observaron efectos antitumorales significativos, mientras que no se presentaron dosis más bajas de ENZ-2208, y cuando la dosis de NK012 se redujo 4 veces a 7,5 mg/kg, la eficacia fue menor. perdido (Koizumi et al., 2006, Cancer Res 66:10048-56). Los ratones normales no mostraron toxicidad aguda con una dosis acumulada durante 1 semana de 24 mg/kg de SN-38 (1500 mg/kg del conjugado), lo que indica que la MTD era mayor. Por lo tanto, los animales con tumores fueron tratados eficazmente con cantidades de 7,5 a 15 veces menores de equivalentes de SN-38. </span>[0209] Although it is challenging to make direct comparisons between our CAF and published reports of other SN-38 delivery agents, some general observations can be made. In our therapy studies, the highest individual dose was 0.4 mg/kg SN-38. In the Calu-3 model, only 4 injections were administered for a total cumulative dose of 1.6 mg/kg SN-38 or 32 mg SN-38 in a 20 g mouse. Multiple studies were conducted with ENZ-2208 using its MTD of 10 mg/kg x 5 (Sapra et al., 2008, Clin Cancer Res 14:1888-96; Pastorini et al., 2010, Clin Cancer Res 16:4809-21 ), and preclinical studies with NK012 involved its DMT of 30 mg/kg x 3 (Koizumi et al., 2006, Cancer Res 66:10048-56). Therefore, significant antitumor effects were obtained with hRS7-SN-38 at 30-fold and 55-fold lower SN-38 equivalents than the doses reported in ENZ-2208 and NK012, respectively. Even with 10 times less CAF of hRS7 (0.04 mg/kg), significant antitumor effects were observed, while lower doses of ENZ-2208 were not present, and when the dose of NK012 was reduced 4 times to 7.5 mg/kg, the efficacy was lower. lost (Koizumi et al., 2006, Cancer Res 66:10048-56). Normal mice showed no acute toxicity at a 1-week cumulative dose of 24 mg/kg SN-38 (1500 mg/kg conjugate), indicating that the MTD was higher. Therefore, tumor-bearing animals were effectively treated with 7.5- to 15-fold lower amounts of SN-38 equivalents.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0210] Los estudios de biodistribución revelaron que hRS7-CL2A-SN-38 tuvo una absorción tumoral similar a la hRS7 IgG parental, pero se eliminó sustancialmente más rápido con una absorción hepática 2 veces mayor, lo que puede deberse a la hidrofobicidad de SN-38. Dado que el CAF se elimina a través del hígado, se esperaba que las toxicidades hepáticas y gastrointestinales limitaran la dosis. Aunque los ratones tenían evidencia de aumento de las transaminasas hepáticas, la toxicidad gastrointestinal fue, en el mejor de los casos, leve, con solo una pérdida transitoria de peso y no se observaron anomalías en el examen histopatológico. Curiosamente, no se observó toxicidad hematológica. Sin embargo, los monos mostraron un perfil de toxicidad idéntico al esperado para el irinotecán, siendo la toxicidad gastrointestinal y hematológica la dosis limitante. </span>[0210] Biodistribution studies revealed that hRS7-CL2A-SN-38 had similar tumor uptake as the parental hRS7 IgG, but was cleared substantially faster with 2-fold higher hepatic uptake, which may be due to the hydrophobicity of SN. -38. Since CAF is eliminated through the liver, hepatic and gastrointestinal toxicities were expected to be dose limiting. Although the mice had evidence of increased hepatic transaminases, gastrointestinal toxicity was mild at best, with only transient weight loss and no abnormalities noted on histopathological examination. Interestingly, no hematological toxicity was observed. However, the monkeys showed a toxicity profile identical to that expected for irinotecan, with gastrointestinal and hematological toxicity being the limiting dose.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0211] Debido a que Trop-2 reconocido por hRS7 no se expresa en ratones, era importante realizar estudios de toxicidad en monos que tienen una expresión tisular de Trop-2 similar a la de los humanos. Los monos toleraron 0,96 mg/kg/dosis (~ 12 mg/m2) con una toxicidad leve y reversible, que se extrapola a una dosis humana de ~0,3 mg/kg/dosis (~11 mg/m2). En un ensayo clínico de Fase I de NK012, los pacientes con tumores sólidos toleraron 28 mg/m2 de SN-38 cada 3 semanas con neutropenia de Grado 4 como toxicidad limitante de la dosis (DLT; Hamaguchi et al., 2010, Clin Cancer Res 16:5058 -66). De manera similar, los ensayos clínicos de Fase I con ENZ-2208 revelaron neutropenia febril limitante de dosis, con una recomendación de administrar 10 mg/m2 cada 3 semanas o 16 mg/m2 si a los pacientes se les administró G-CSF (Kurzrock et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 15-19 de noviembre de 2009; Boston, MA; Poster No C216; Patnaik et al, Conferencia internacional AACR-NCIEORTC sobre objetivos moleculares y terapias contra el cáncer; 15-19 de noviembre de 2009; Boston, MA; póster n.° C221). Debido a que los monos toleraron una dosis equivalente humana acumulada de 22 mg/m2, parece que aunque hRS7 se une a varios tejidos normales, la DMT para un único tratamiento del CAF de hRS7 podría ser similar a la de otros agentes SN-38 no dirigidos. De hecho, la especificidad del anticuerpo anti-Trop-2 no pareció desempeñar un papel en la definición de la DLT, porque el perfil de toxicidad era similar al del irinotecán. Más importante aún, si se puede lograr actividad antitumoral en humanos como en ratones que respondieron con una dosis equivalente humana de solo 0,03 mg de equivalentes de SN-38/kg/dosis, entonces se pueden obtener respuestas antitumorales significativas desde el punto de vista clínico. </span>[0211] Because Trop-2 recognized by hRS7 is not expressed in mice, it was important to perform toxicity studies in monkeys that have tissue expression of Trop-2 similar to that in humans. Monkeys tolerated 0.96 mg/kg/dose (~12 mg/m2) with mild, reversible toxicity, which extrapolates to a human dose of ~0.3 mg/kg/dose (~11 mg/m2). In a Phase I clinical trial of NK012, patients with solid tumors tolerated 28 mg/m2 SN-38 every 3 weeks with Grade 4 neutropenia as a dose-limiting toxicity (DLT; Hamaguchi et al., 2010, Clin Cancer Res 16:5058 -66). Similarly, Phase I clinical trials with ENZ-2208 revealed dose-limiting febrile neutropenia, with a recommendation to administer 10 mg/m2 every 3 weeks or 16 mg/m2 if patients were administered G-CSF (Kurzrock et al., AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 15-19, 2009; Boston, MA; Poster No C216; cancer; November 15-19, 2009; Boston, MA; poster #C221). Because the monkeys tolerated a cumulative human equivalent dose of 22 mg/m2, it appears that although hRS7 binds to various normal tissues, the MTD for a single CAF treatment of hRS7 may be similar to that of other non-SN-38 agents. directed. In fact, the specificity of the anti-Trop-2 antibody did not appear to play a role in defining DLT, because the toxicity profile was similar to that of irinotecan. More importantly, if antitumor activity can be achieved in humans as in mice that responded with a human equivalent dose of only 0.03 mg SN-38 equivalents/kg/dose, then potentially significant antitumor responses can be obtained. clinical view.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0212] En conclusión, los estudios de toxicología en monos, combinados con modelos de xenoinjertos de cáncer humanoin vivoen ratones, han indicado que este CAF dirigido a Trop-2 es una terapéutica eficaz en varios tumores de diferente origen epitelial. </span>[0212] In conclusion, toxicology studies in monkeys, combined with in vivo human cancer xenograft models in mice, have indicated that this CAF targeting Trop-2 is an effective therapeutic in several tumors of different epithelial origin.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 4. CAF anti-Trop-2 que comprende hRS7 y paclitaxel </span>Example 4. Anti-Trop-2 CAF comprising hRS7 and paclitaxel</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0213] Se preparó un nuevo conjugado anticuerpo-fármaco (CAF) conjugando paclitaxel (TAXOL®) con el anticuerpo hRS7 anti-Trop-2 humano (hRS7-paclitaxel). El producto final tenía una relación media de sustitución de fármaco a anticuerpo de 2,2. Este CAF se ensayóin vitroutilizando dos líneas celulares positivas para Trop-2 diferentes como objetivos: BxPC-3 (adenocarcinoma de páncreas humano) y MDA-MB-468 (carcinoma de mama humano triple negativo). Un día antes de agregar el CAF, se recogieron células del cultivo de tejidos y se sembraron en placas de 96 pocillos a razón de 2000 células por pocillo. Al día siguiente, las células se expusieron a paclitaxel libre (6,1 x 3 x 10'11 a 4 x 3 x 10' 6 M) o al fármaco equivalente de hRS7-paclitaxel. A modo de comparación, también se probaron hRS7-SN-38 y SN-38 libre en un rango de 3,84 x 10‘12 a 2,5 x 3 x 10‘7 M. Las placas se incubaron a 37°C durante 96 h. Después de este período de incubación, se añadió un sustrato MTS a todas las placas y se leyó el desarrollo del color a intervalos de media hora hasta que los pocillos de control no tratados tuvieron una lectura de Do a 492 nm de aproximadamente 1,0. La inhibición del crecimiento se midió como un porcentaje del crecimiento en relación con las células no tratadas utilizando el software Microsoft Excel y Prism (regresión no lineal para generar curvas sigmoidales de respuesta a la dosis que producen valores de CI&lt;50&gt;). </span>[0213] A new antibody-drug conjugate (CAF) was prepared by conjugating paclitaxel (TAXOL®) with the hRS7 anti-human Trop-2 antibody (hRS7-paclitaxel). The final product had a mean drug-to-antibody substitution ratio of 2.2. This CAF was tested in vitro using two different Trop-2 positive cell lines as targets: BxPC-3 (human pancreatic adenocarcinoma) and MDA-MB-468 (triple negative human breast carcinoma). One day before adding CAF, tissue culture cells were harvested and seeded into 96-well plates at 2000 cells per well. The next day, cells were exposed to free paclitaxel (6.1 x 3 x 10'11 to 4 x 3 x 10'6 M) or the equivalent drug hRS7-paclitaxel. For comparison, hRS7-SN-38 and free SN-38 were also tested in a range of 3.84 x 10.12 to 2.5 x 3 x 10.7 M. Plates were incubated at 37°C for 96 hours. After this incubation period, an MTS substrate was added to all plates and color development was read at half-hour intervals until the untreated control wells had a Do reading at 492 nm of approximately 1.0. Growth inhibition was measured as a percentage of growth relative to untreated cells using Microsoft Excel and Prism software (nonlinear regression to generate sigmoidal dose response curves yielding IC&lt;50&gt; values).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0214] El CAF hRS7-paclitaxel exhibió actividad citotóxica en la línea celular de mama MDA-MB-468 (FIG. 6), con un valor de CI&lt;50&gt;aproximadamente 4,5 veces mayor que hRS7-SN-38. El paclitaxel libre era mucho más potente que el SN-38 libre (FIG. 6). Mientras que la CI&lt;50&gt;para SN-38 libre fue 1,54 x 10‘9 M, la CI&lt;50&gt;para paclitaxel libre fue inferior a 6,1 x 10‘ 11 M. Se obtuvieron resultados similares para la línea celular pancreática BxPC-3 (FIG. 7) en la que el hRS7-paclitaxel CAF tenía un valor de CI&lt;50&gt;aproximadamente 2,8 veces mayor que el CAF hRS7-SN-38. Estos resultados muestran la eficacia del paclitaxel conjugado con anti-Trop-2in vitro,con valores de CI&lt;50&gt;en el rango nanomolar, similar al CAF hRS7-SN-38. </span>[0214] The CAF hRS7-paclitaxel exhibited cytotoxic activity in the breast cell line MDA-MB-468 (FIG. 6), with an IC value &lt;50&gt; approximately 4.5 times higher than hRS7-SN-38. Free paclitaxel was much more potent than free SN-38 (FIG. 6). While the IC&lt;50&gt;for free SN-38 was 1.54 x 10'9 M, the IC&lt;50&gt;for free paclitaxel was less than 6.1 x 10'11 M. Similar results were obtained for the cell line pancreatic BxPC-3 (FIG. 7) in which the hRS7-paclitaxel CAF had an IC value &lt;50&gt; approximately 2.8 times higher than the CAF hRS7-SN-38. These results show the efficacy of paclitaxel conjugated with anti-Trop-2 in vitro, with IC values &lt;50&gt; in the nanomolar range, similar to CAF hRS7-SN-38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 5. Ensayo de unión celular de anticuerpos anti-Trop-2 </span>Example 5. Cellular binding assay of anti-Trop-2 antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0215] Se obtuvieron dos anticuerpos monoclonales murinos diferentes contra Trop-2 humano para la conjugación con CAF. El primero, 162-46.2, se purificó a partir de un hibridoma (ATCC, HB-187) cultivado en botellas giratorias. Se adquirió un segundo anticuerpo, MAB650, de R&amp;D Systems (Minneapolis, MN). Para comparar la unión, se utilizó como diana el carcinoma gástrico humano Trop-2 positivo, NCI-N87. Las células (1,5 x 105/pocillo) se sembraron en placas de 96 pocillos el día antes del ensayo de unión. A la mañana siguiente, se generó una curva dosis/respuesta con 162-46,2, MAB650 y RS7 murino (0,03 a 66 nM). Estos anticuerpos primarios se incubaron con las células durante 1,5 h a 4°C. Se lavaron los pocillos y se añadió un anticuerpo secundario anti-HRP de ratón a todos los pocillos durante 1 hora a 4°C. Los pocillos se lavan nuevamente y luego se agrega un sustrato luminiscente. Las placas se leyeron utilizando el lector de placas Envision y los valores se informan como unidades luminiscentes relativas. </span>[0215] Two different murine monoclonal antibodies against human Trop-2 were obtained for conjugation with CAF. The first, 162-46.2, was purified from a hybridoma (ATCC, HB-187) grown in roller bottles. A second antibody, MAB650, was purchased from R&amp;D Systems (Minneapolis, MN). To compare binding, Trop-2 positive human gastric carcinoma, NCI-N87, was used as a target. Cells (1.5 x 105/well) were seeded in 96-well plates the day before the binding assay. The next morning, a dose/response curve was generated with 162-46.2, MAB650, and murine RS7 (0.03 to 66 nM). These primary antibodies were incubated with the cells for 1.5 h at 4°C. The wells were washed and a secondary anti-mouse HRP antibody was added to all wells for 1 hour at 4°C. The wells are washed again and then a luminescent substrate is added. Plates were read using the Envision plate reader and values are reported as relative luminescent units.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0216] Los tres anticuerpos tenían valores deKdsimilares de 0,57 nM para RS7, 0,52 nM para 162-46,2 y 0,49 nM para MAB650. Sin embargo, al comparar la unión máxima (Bmax) de 162-46,2 y MAB650 con RS7, se redujeron en un 25% y un 50%, respectivamente (BMax 11.250 para RS7, 8.471 para 162-46.2 y 6.018 para MAB650), lo que indica diferentes propiedades de unión en comparación con RS7. </span>[0216] All three antibodies had similar Kd values of 0.57 nM for RS7, 0.52 nM for 162-46.2, and 0.49 nM for MAB650. However, when comparing the maximum binding (Bmax) of 162-46.2 and MAB650 with RS7, they were reduced by 25% and 50%, respectively (BMax 11,250 for RS7, 8,471 for 162-46.2 and 6,018 for MAB650) , indicating different binding properties compared to RS7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 6. C itotoxicidad del CAF Anti-Trop-2 (MAB650-SN-38) </span>Example 6. Cytotoxicity of CAF Anti-Trop-2 (MAB650-SN-38)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0217] Se preparó un nuevo CAF anti-Trop-2 con SN-38 y MAB650, lo que produjo una relación media de sustitución de fármaco por anticuerpo de 6,89. Se realizaron ensayos de citotoxicidad para comparar los CAF MAB650-SN-38 y hRS7-SN-38 utilizando dos líneas celulares de adenocarcinoma de páncreas humano diferentes (BxPC-3 y Capan-1) y una línea celular de carcinoma de mama triple negativo humano (MDA-MB-468) como objetivos. </span>[0217] A new anti-Trop-2 CAF was prepared with SN-38 and MAB650, yielding an average drug-to-antibody substitution ratio of 6.89. Cytotoxicity assays were performed to compare MAB650-SN-38 and hRS7-SN-38 CAFs using two different human pancreatic adenocarcinoma cell lines (BxPC-3 and Capan-1) and one human triple-negative breast carcinoma cell line. (MDA-MB-468) as objectives.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0218] Un día antes de agregar los CAF, se recogieron células del cultivo de tejidos y se sembraron en placas de 96 pocillos. Al día siguiente, las células se expusieron a hRS7-SN-38, MAB650-SN-38 y SN-38 libre en un rango de fármaco de 3,84 x 10'12 a 2,5 x 10'7 M. Se usó MAB650 no conjugado como control en dosis equivalentes de proteína como el MAB650-SN-38. Las placas se incubaron a 37°C durante 96 h. Después de este período de incubación, se añadió un sustrato MTS a todas las placas y se leyó para desarrollo del color a intervalos de media hora hasta que se alcanzó una DO&lt;492&gt;nm de aproximadamente 1,0 para las células no tratadas. La inhibición del crecimiento se midió como un porcentaje del crecimiento en relación con las células no tratadas utilizando el software Microsoft Excel y Prism (regresión no lineal para generar curvas sigmoideas de respuesta a la dosis que producen valores de CI&lt;50&gt;). </span>[0218] One day before adding the CAFs, tissue culture cells were harvested and seeded into 96-well plates. The next day, cells were exposed to hRS7-SN-38, MAB650-SN-38, and free SN-38 in a drug range of 3.84 x 10.12 to 2.5 x 10.7 M. Unconjugated MAB650 as control at equivalent doses of protein as MAB650-SN-38. The plates were incubated at 37°C for 96 h. After this incubation period, an MTS substrate was added to all plates and read for color development at half-hour intervals until an OD&lt;492&gt;nm of approximately 1.0 was reached for untreated cells. Growth inhibition was measured as a percentage of growth relative to untreated cells using Microsoft Excel and Prism software (nonlinear regression to generate sigmoidal dose response curves yielding IC&lt;50&gt; values).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0219] Como se muestra en la FIG. 8, hRS7-SN-38 y MAB650-SN-38 tuvieron efectos inhibidores del crecimiento similares con valores de CI&lt;50&gt;en el rango bajo de nM, que es típico de los SN-38-CAF en estas líneas celulares. En la línea celular de adenocarcinoma de páncreas humano Capan-1 (FIG. 8A), el CAF hRS7-SN-38 mostró una CI&lt;50&gt;de 3,5 nM, en comparación con 4,1 nM para el CAF MAB650-SN-38 y 1,0 nM para SN-38 libre. En la línea celular de adenocarcinoma de páncreas humano BxPC-3 (FIG.8B), el CAF hRS7-SN-38 mostró una CI&lt;50&gt;de 2,6 nM, en comparación con 3,0 nM para el Ca F MAB650-SN-38 y 1,0 nM para SN-38 libre. En la línea celular de adenocarcinoma gástrico NCI-N87 humano (FIG. 8C), el CAF hRS7-SN-38 mostró una CI&lt;50&gt;de 3,6 nM, en comparación con 4,1 nM para el CAF MAB650-SN-38 y 4,3 nM para S&lt;n&gt;-38 libre. </span>[0219] As shown in FIG. 8, hRS7-SN-38 and MAB650-SN-38 had similar growth inhibitory effects with IC values &lt;50&gt; in the low nM range, which is typical of SN-38-CAFs in these cell lines. In the human pancreatic adenocarcinoma cell line Capan-1 (FIG. 8A), the hRS7-SN-38 CAF showed an IC&lt;50&gt; of 3.5 nM, compared to 4.1 nM for the MAB650-SN CAF -38 and 1.0 nM for free SN-38. In the human pancreatic adenocarcinoma cell line BxPC-3 (FIG.8B), CAF hRS7-SN-38 showed an IC&lt;50&gt; of 2.6 nM, compared to 3.0 nM for CaF MAB650- SN-38 and 1.0 nM for free SN-38. In the human NCI-N87 gastric adenocarcinoma cell line (FIG. 8C), the hRS7-SN-38 CAF showed an IC&lt;50&gt; of 3.6 nM, compared to 4.1 nM for the MAB650-SN-CAF. 38 and 4.3 nM for free S&lt;n&gt;-38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0220] En resumen, en estos ensayosin vitro,los conjugados SN-38 de dos anticuerpos anti-Trop-2, hRS7 y MAB650, mostraron eficacias iguales contra varias líneas de células tumorales, que fue similar a la del SN-38 libre. Debido a que la función de direccionamiento de los anticuerpos anti-Trop-2 sería un factor mucho más significativoin vivoquein vitro,los datos respaldan que los CAF anti-Trop-2-SN-38 como clase serían muy eficacesin vivo,como se ha demostrado en los ejemplos anteriores para hRS7-SN-38. </span>[0220] In summary, in these in vitro assays, SN-38 conjugates of two anti-Trop-2 antibodies, hRS7 and MAB650, showed equal efficacies against various tumor cell lines, which was similar to that of free SN-38. Because the targeting function of anti-Trop-2 antibodies would be a much more significant factor in vivo than in vitro, the data support that anti-Trop-2-SN-38 CAFs as a class would be very effective in vivo, as has been shown in the examples above for hRS7-SN-38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 7. C itotoxicidad del CAF Anti-Trop-2 (162-46.2-SN-38) </span>Example 7. Cytotoxicity of CAF Anti-Trop-2 (162-46.2-SN-38)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0221] Se preparó un nuevo CAF anti-Trop-2 con SN-38 y 162-46,2, lo que produjo una relación de sustitución de fármaco por anticuerpo de 6,14. Se realizaron ensayos de citotoxicidad para comparar los CAF 162-46.2-SN-38 y hRS7-SN-38 utilizando dos líneas celulares positivas para Trop-2 diferentes como objetivos, el adenocarcinoma de páncreas humano BxPC-3 y el carcinoma de mama negativo triple humano MDA-MB-468. </span>[0221] A new anti-Trop-2 CAF was prepared with SN-38 and 162-46.2, yielding a drug-to-antibody substitution ratio of 6.14. Cytotoxicity assays were performed to compare CAFs 162-46.2-SN-38 and hRS7-SN-38 using two different Trop-2-positive cell lines as targets, human pancreatic adenocarcinoma BxPC-3 and triple-negative breast carcinoma. human MDA-MB-468.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0222] Un día antes de agregar el CAF, se recogieron células del cultivo de tejidos y se sembraron en placas de 96 pocillos a razón de 2000 células por pocillo. Al día siguiente, las células se expusieron a hRS7-SN-38, 162-46.2-SN-38 o SN-38 libre en un rango de fármaco de 3,84 x 10'12 a 2,5 x 10'7 M. 162-46.2 y hRS7 no conjugados. se utilizaron como controles con las mismas dosis equivalentes de proteína que 162-46.2-SN-38 y hRS7-SN-38, respectivamente. Las placas se incubaron a 37°C durante 96 h. Después de este período de incubación, se añadió un sustrato MTS a todas las placas y se leyó el desarrollo del color a intervalos de media hora hasta que los pocillos de control no tratados tuvieron una lectura de DO492 nm de aproximadamente 1,0. La inhibición del crecimiento se midió como un porcentaje del crecimiento en relación con las células no tratadas utilizando el software Microsoft Excel y Prism (regresión no lineal para generar curvas sigmoidales de respuesta a la dosis que producen valores de CI&lt;50&gt;). </span>[0222] One day before adding the CAF, tissue culture cells were harvested and seeded into 96-well plates at 2000 cells per well. The next day, cells were exposed to hRS7-SN-38, 162-46.2-SN-38, or free SN-38 in a drug range of 3.84 x 10.12 to 2.5 x 10.7 M. 162-46.2 and hRS7 not conjugated. were used as controls with the same equivalent protein doses as 162-46.2-SN-38 and hRS7-SN-38, respectively. The plates were incubated at 37°C for 96 h. After this incubation period, an MTS substrate was added to all plates and color development was read at half-hour intervals until the untreated control wells had an OD492 nm reading of approximately 1.0. Growth inhibition was measured as a percentage of growth relative to untreated cells using Microsoft Excel and Prism software (nonlinear regression to generate sigmoidal dose response curves yielding IC&lt;50&gt; values).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0223] Como se muestra en la FIG. 9A y FIG.9B, el CAF 162-46.2-SN-38 tenía valores de CI&lt;50&gt;similares en comparación con hRS7-SN-38. Cuando se ensayó contra la línea celular de adenocarcinoma de páncreas humano BxPC-3 (FIG. 9A), hRS7-SN-38 tenía una CI&lt;50&gt;de 5,8 nM, en comparación con 10,6 nM para 162-46.2-SN-38 y 1,6 nM para&lt;s&gt;N-38 libre. </span>[0223] As shown in FIG. 9A and FIG.9B, CAF 162-46.2-SN-38 had similar IC&lt;50&gt; values compared to hRS7-SN-38. When tested against the human pancreatic adenocarcinoma cell line BxPC-3 (FIG. 9A), hRS7-SN-38 had an IC&lt;50&gt; of 5.8 nM, compared to 10.6 nM for 162-46.2- SN-38 and 1.6 nM for free&lt;s&gt;N-38.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando se ensayó contra la línea celular de adenocarcinoma de mama humano MDAMB-468 (FIG. 9B), hRS7-SN-38 tuvo una CI&lt;50&gt;de 3,9 nM, en comparación con 6,1 nM para 162-46.2-SN-38 y 0,8 nM para SN-38 libre. Los anticuerpos libres por sí solos mostraron poca citotoxicidad para cualquiera de las líneas celulares cancerosas positivas para Trop-2. </span>When tested against the human breast adenocarcinoma cell line MDAMB-468 (FIG. 9B), hRS7-SN-38 had an IC&lt;50&gt; of 3.9 nM, compared to 6.1 nM for 162-46.2- SN-38 and 0.8 nM for free SN-38. Free antibodies alone showed little cytotoxicity to any of the Trop-2-positive cancer cell lines.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0224] En resumen, al comparar las eficaciasin vitrode tres anticuerpos anti-Trop-2 diferentes conjugados con el mismo fármaco citotóxico, los tres CAF exhibieron efectos citotóxicos equivalentes contra una variedad de líneas celulares cancerosas positivas para Trop-2. Estos datos respaldan que la clase de anticuerpos anti-Trop-2, incorporados en CAF conjugados con fármacos, son agentes terapéuticos anticancerígenos eficaces para tumores sólidos que expresan Trop-2. </span>[0224] In summary, when comparing the in vitro efficacies of three different anti-Trop-2 antibodies conjugated to the same cytotoxic drug, all three CAFs exhibited equivalent cytotoxic effects against a variety of Trop-2-positive cancer cell lines. These data support that the anti-Trop-2 class of antibodies, incorporated into drug-conjugated CAFs, are effective anticancer therapeutics for Trop-2-expressing solid tumors.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 8. Ensayos clínicos con CAF IMMU-132 Anti-Trop-2 que comprende anticuerpo hRS7 conjugado con SN-38 </span>Example 8. Clinical trials with CAF IMMU-132 Anti-Trop-2 comprising hRS7 antibody conjugated to SN-38</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resumen</span>Summary</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0225] El presente ejemplo informa los resultados de un ensayo clínico de fase I y la extensión en curso de fase II con IMMU-132, un CAF del anticuerpo anti-Trop-2 hRS7 humanizado internalizante conjugado mediante un conector sensible al pH a SN-38 (relación media de fármacos-anticuerpos = 7,6). Trop-2 es una proteína transmembrana de tipo I, transductora de calcio, expresada con alta densidad (~1 x 105), frecuencia y especificidad por muchos carcinomas humanos, con expresión limitada en el tejido normal. Los estudios preclínicos en ratones desnudos portadores de xenoinjertos de tumor pancreático humano Capan-1 han revelado que IMMU-132 es capaz de administrar hasta 120 veces más SN-38 al tumor que el derivado de una terapia con irinotecán máximamente tolerada. </span>[0225] The present example reports the results of a Phase I clinical trial and ongoing Phase II extension with IMMU-132, a CAF of internalizing humanized anti-Trop-2 hRS7 antibody conjugated via a pH-sensitive linker to SN -38 (mean drug-antibody ratio = 7.6). Trop-2 is a calcium-transducing type I transmembrane protein expressed with high density (~1 x 105), frequency and specificity by many human carcinomas, with limited expression in normal tissue. Preclinical studies in nude mice bearing Capan-1 human pancreatic tumor xenografts have revealed that IMMU-132 is capable of delivering up to 120 times more SN-38 to the tumor than that derived from a maximally tolerated irinotecan therapy.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0226] El presente Ejemplo informa el ensayo inicial de Fase I de 25 pacientes que habían fracasado en múltiples terapias previas (algunos incluían fármacos inhibidores de la topoisomerasa I/II), y la extensión en curso de Fase II que ahora informa sobre 69 pacientes, incluidos pacientes colorrectales (CCR), cánceres de pulmón de células pequeñas y de células no pequeñas (CPCP, CPCNP, respectivamente), de mama triple negativo (TNBC), de páncreas (PDC), de esófago y otros. </span>[0226] The present Example reports the initial Phase I trial of 25 patients who had failed multiple prior therapies (some including topoisomerase I/II inhibitor drugs), and the ongoing Phase II extension now reporting on 69 patients , including colorectal patients (CRC), small cell and non-small cell lung cancers (SCLC, NSCLC, respectively), triple negative breast (TNBC), pancreas (PDC), esophagus and others.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0227] Como se analiza en detalle a continuación, Trop-2 no se detectó en suero, pero se expresó fuertemente (&gt;2+) en la mayoría de los tumores archivados. En un diseño de ensayo 3+3, IMMU-132 se administró los días 1 y 8 en ciclos repetidos de 21 días, comenzando con 8 mg/kg/dosis, luego 12 y 18 mg/kg antes de la neutropenia limitante de la dosis. Para optimizar el tratamiento acumulativo con un mínimo retrasos, la fase II se centra en 8 y 10 mg/kg (n=30 y 14, respectivamente). En 49 pacientes que informaron EA relacionados en este momento, se produjo neutropenia &gt;G3 en el 28% (4% G4). Las toxicidades no hematológicas más comunes inicialmente en estos pacientes han sido fatiga (55%;&gt;G3 = 9%), náuseas (53%;&gt;G3=0%), diarrea (47%;&gt;G3 = 9%), alopecia (40%), y vómitos (32%;&gt;G3 = 2%). Se encontró UGT1A1 *28/*28 homocigótico en 6 pacientes, 2 de los cuales tenían toxicidades hematológicas y gastrointestinales más graves. En la Fase I y las fases de expansión, ahora hay 48 pacientes (excluyendo PDC) que son evaluables mediante RECIST/CT para obtener la mejor respuesta. Siete (15%) de los pacientes tuvieron una respuesta parcial (RP), incluidos pacientes con CCR (N = 1), t Nb C (N = 2), CPCP (N = 2), CPCNP (N = 1) y cánceres de esófago. (N = 1), y otros 27 pacientes (56%) tuvieron enfermedad estable (EE), para un total de 38 pacientes (79%) con respuesta a la enfermedad; 8 de 13 pacientes con PDC evaluables por TC (62%) tuvieron EE, con una mediana de tiempo hasta la progresión (TTP) de 12,7 semanas en comparación con 8,0 semanas en su último tratamiento previo. El TTP para los 48 pacientes restantes es de 12,6+ semanas(rango de 6,0 a 51,4 semanas).</span>[0227] As discussed in detail below, Trop-2 was not detected in serum, but was strongly expressed (&gt;2+) in the majority of archived tumors. In a 3+3 trial design, IMMU-132 was administered on days 1 and 8 in repeat 21-day cycles, starting at 8 mg/kg/dose, then 12 and 18 mg/kg before dose-limiting neutropenia. . To optimize cumulative treatment with minimal delays, phase II focuses on 8 and 10 mg/kg (n=30 and 14, respectively). In 49 patients reporting related AEs at this time, neutropenia &gt;G3 occurred in 28% (4% G4). The most common non-hematological toxicities initially in these patients have been fatigue (55%; &gt;G3 = 9%), nausea (53%; &gt;G3 = 0%), diarrhea (47%; &gt;G3 = 9%), alopecia ( 40%), and vomiting (32%;&gt;G3 = 2%). Homozygous UGT1A1 *28/*28 was found in 6 patients, 2 of whom had more severe hematologic and gastrointestinal toxicities. In Phase I and expansion phases, there are now 48 patients (excluding PDC) who are evaluable by RECIST/CT for best response. Seven (15%) patients had a partial response (PR), including patients with CRC (N = 1), t Nb C (N = 2), SCLC (N = 2), NSCLC (N = 1), and cancers of esophagus. (N = 1), and another 27 patients (56%) had stable disease (SE), for a total of 38 patients (79%) with disease response; 8 of 13 patients with CT-evaluable PDC (62%) had EE, with a median time to progression (TTP) of 12.7 weeks compared with 8.0 weeks at their last prior treatment. The TTP for the remaining 48 patients is 12.6+ weeks (range 6.0 to 51.4 weeks).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0228] CEA y CA19-9 en plasma se correlacionaron con las respuestas. No se detectaron anticuerpos anti-hRS7 o anti-SN-38 a pesar de la dosificación durante meses. El conjugado se eliminó del suero en 3 días, lo que coincide con estudiosin vivoen animales donde el 50% del SN-38 se liberó diariamente, con &gt;95% del SN-38 en el suero unido a la IgG en una forma no glucoronizada y en concentraciones hasta 100 veces superiores a las del SN-38 informadas en pacientes que recibieron irinotecán. Estos resultados muestran que el CAF que contiene hRS7-SN-38 es terapéuticamente activo en cánceres sólidos metastásicos, con diarrea y neutropenia manejables. </span>[0228] CEA and CA19-9 in plasma were correlated with responses. No anti-hRS7 or anti-SN-38 antibodies were detected despite dosing for months. The conjugate was cleared from serum within 3 days, consistent with in vivo animal studies where 50% of SN-38 was released daily, with &gt;95% of SN-38 in serum bound to IgG in a non-glucuronidated form and at concentrations up to 100 times higher than those of SN-38 reported in patients receiving irinotecan. These results show that CAF containing hRS7-SN-38 is therapeutically active in metastatic solid cancers, with manageable diarrhea and neutropenia.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Farmacocinética</span>Pharmacokinetics</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0229] Se utilizaron dos métodos ELISA para medir el aclaramiento de la IgG (captura con anticuerpo idiotipo anti-hRS7) y el conjugado intacto (captura con IgG anti-SN-38/sonda con anticuerpo idiotipo anti-hRS7). SN-38 se midió mediante HPLC. La fracción IMMU-132 total (conjugado intacto) se eliminó más rápidamente que la IgG (no se muestra), lo que refleja la liberación gradual conocida de SN-38 del conjugado. La determinación por HPLC de SN-38 (sin unir y TOTAL) mostró que &gt;95 % del SN-38 en el suero estaba unido a la IgG. Las concentraciones bajas de SN-38G sugieren que el SN-38 unido a la IgG está protegido de la glucuronidación. La comparación de ELISA para conjugado y HPLC SN-38 reveló que ambos se superponen, lo que sugiere que ELISA es un sustituto para monitorear la autorización del SN-38. </span>[0229] Two ELISA methods were used to measure clearance of the IgG (capture with anti-hRS7 idiotype antibody) and the intact conjugate (capture with anti-SN-38 IgG/probe with anti-hRS7 idiotype antibody). SN-38 was measured by HPLC. The total IMMU-132 fraction (intact conjugate) was cleared more rapidly than IgG (not shown), reflecting the known gradual release of SN-38 from the conjugate. HPLC determination of SN-38 (unbound and TOTAL) showed that &gt;95% of SN-38 in serum was bound to IgG. The low concentrations of SN-38G suggest that SN-38 bound to IgG is protected from glucuronidation. Comparison of ELISA for SN-38 conjugate and HPLC revealed that both overlap, suggesting that ELISA is a surrogate for monitoring SN-38 clearance.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0230] En la Tabla 3 se proporciona un resumen del régimen de dosificación y la encuesta de pacientes. </span>[0230] A summary of the dosing regimen and patient survey is provided in Table 3.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 3. Parámetros del ensayo clínico </span>Table 3. Parameters of the clinical trial</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
Estado del ensayo clínico</span>
Clinical trial status</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0231] Se informó sobre un total de 69 pacientes (incluidos 25 pacientes en la Fase I) con diversos cánceres metastásicos que tenían una mediana de 3 terapias previas. Ocho pacientes tuvieron progresión clínica y se retiraron antes de la evaluación por TC. Se informaron por separado trece pacientes con cáncer de páncreas evaluables por TC. La mediana de TTP (tiempo hasta la progresión) en pacientes con PDC fue de 11,9 semanas (rango de 2 a 21,4 semanas) en comparación con la mediana de TTP de 8 semanas para la última terapia anterior. </span>[0231] A total of 69 patients (including 25 patients in Phase I) with various metastatic cancers who had a median of 3 prior therapies were reported. Eight patients had clinical progression and withdrew before CT evaluation. Thirteen patients with pancreatic cancer evaluable by CT were reported separately. The median TTP (time to progression) in patients with PDC was 11.9 weeks (range, 2 to 21.4 weeks) compared with the median TTP of 8 weeks for the last prior therapy.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0232] Un total de 48 pacientes con diversos cánceres tuvieron al menos una evaluación por TC a partir de la cual se determinó la mejor respuesta (FIG. 10) y el tiempo hasta la progresión (TTP; FIG. 11). Para resumir los datos de Mejor Respuesta, de 8 pacientes evaluables con TNBC (cáncer de mama triple negativo), hubo 2 RP (respuesta parcial), 4 EE (enfermedad estable) y 2 EP (enfermedad progresiva) para una respuesta total [RP  EE] de 6/8 (75%). Para CPCP (cáncer de pulmón de células pequeñas), de 4 pacientes evaluables hubo 2 RP, 0 EE y 2 EP para una respuesta total de 2/4 (50%). Para CCR (cáncer colorrectal), de&lt;18&gt;pacientes evaluables hubo 1 RP, 11 Ee y 6 Ep para una respuesta total de 12/18 (67%). Para el cáncer de esófago, de 4 pacientes evaluables hubo 1 RP, 2 EE y 1 EP para una respuesta total de 3/4 (75%). Para CPCNP (cáncer de pulmón de células no pequeñas), de 5 pacientes evaluables hubo 1 RP, 3 EE y 1 EP para una respuesta total de 4/5 (80%). Sobre todos los pacientes tratados, de 48 pacientes evaluables hubo 7 RP, 27 EE y 14 EP para una respuesta total de 34/48 (71%). Estos resultados demuestran que el CAF anti-Trop-2 (hRS7-SN-38) mostró una eficacia clínica significativa contra una amplia gama de tumores sólidos en pacientes humanos. </span>[0232] A total of 48 patients with various cancers had at least one CT evaluation from which the best response (FIG. 10) and time to progression (TTP; FIG. 11) were determined. To summarize the Best Response data, of 8 evaluable patients with TNBC (triple negative breast cancer), there were 2 PR (partial response), 4 EE (stable disease), and 2 EP (progressive disease) for a complete response [PR EE ] of 6/8 (75%). For SCLC (small cell lung cancer), of 4 evaluable patients there were 2 PR, 0 EE, and 2 EP for a total response of 2/4 (50%). For CRC (colorectal cancer), of &lt;18&gt;evaluable patients there was 1 RP, 11 Ee, and 6 Ep for a total response of 12/18 (67%). For esophageal cancer, of 4 evaluable patients there was 1 PR, 2 EE, and 1 EP for a total response of 3/4 (75%). For NSCLC (non-small cell lung cancer), of 5 evaluable patients there was 1 PR, 3 EE, and 1 EP for an overall response of 4/5 (80%). Of all treated patients, of 48 evaluable patients there were 7 RP, 27 EE and 14 EP for a total response of 34/48 (71%). These results demonstrate that anti-Trop-2 CAF (hRS7-SN-38) showed significant clinical efficacy against a wide range of solid tumors in human patients.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0233] Los efectos secundarios informados de la terapia (eventos adversos) se resumen en la Tabla 4. Como se desprende de los datos de la Tabla 4, la eficacia terapéutica de hRS7-SN-38 se logró con dosis de CAF que mostraban un nivel aceptablemente bajo de efectos secundarios adversos. </span>[0233] The reported side effects of the therapy (adverse events) are summarized in Table 4. As evident from the data in Table 4, the therapeutic efficacy of hRS7-SN-38 was achieved with doses of CAF that showed a acceptably low level of adverse side effects.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 4. </span>Table 4.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">
[0234] Las respuestas parciales ejemplares al CAF anti-Trop-2 se confirmaron mediante datos de TC (no mostrados). Como RP ejemplar en CCR, una mujer de 62 años diagnosticada por primera vez con CCR se sometió a una hemicolectomía primaria. Cuatro meses después, se le realizó una resección hepática por metástasis hepáticas y recibió 7 meses de tratamiento con FOLFOX y 1 mes de 5FU. Presentó múltiples lesiones principalmente en el hígado (3+ Trop-2 según inmunohistología), por lo que ingresó al ensayo hRS7-SN-38 con una dosis inicial de 8 mg/kg aproximadamente 1 año después del diagnóstico inicial. En su primera evaluación por TC, se logró una RP, con una reducción del 37 % en las lesiones diana (no se muestra). El paciente continuó el tratamiento, logrando una reducción máxima del 65 % después de 10 meses de tratamiento (no mostrado) con una disminución del CEA de 781 ng/ml a 26,5 ng/ml), antes de progresar 3 meses después. </span>
[0234] Exemplary partial responses to anti-Trop-2 CAF were confirmed by CT data (not shown). As an exemplary RP in CRC, a 62-year-old woman first diagnosed with CRC underwent primary hemicolectomy. Four months later, he underwent liver resection for liver metastases and received 7 months of treatment with FOLFOX and 1 month of 5FU. He presented with multiple lesions mainly in the liver (3+ Trop-2 according to immunohistology), for which he was entered into the hRS7-SN-38 trial with a starting dose of 8 mg/kg approximately 1 year after the initial diagnosis. At his first CT evaluation, a PR was achieved, with a 37% reduction in target lesions (not shown). The patient continued treatment, achieving a maximum reduction of 65% after 10 months of treatment (not shown) with CEA decreasing from 781 ng/ml to 26.5 ng/ml), before progressing 3 months later.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0235] Como RP ejemplar en CPCNP, a un hombre de 65 años se le diagnosticó CPCNP en estadio IIIB (células cuadradas). El tratamiento inicial con carboplatino/etopósido (3 meses) junto con XRT de 7000 cGy dio como resultado una respuesta que duró 10 meses. Luego comenzó la terapia de mantenimiento con Tarceva, que continuó hasta que fue considerado para el ensayo IMMU-132, además de someterse a una laminectomía lumbar. Recibió primera dosis de IMMU-132 después de 5 meses de Tarceva, presentando en ese momento una lesión de 5,6 cm en pulmón derecho con abundante derrame pleural. Acababa de completar su sexta dosis dos meses después cuando la primera tomografía computarizada mostró que la lesión diana primaria se redujo a 3,2 cm (no se muestra). </span>[0235] As an exemplary RP in NSCLC, a 65-year-old man was diagnosed with stage IIIB NSCLC (square cells). Initial treatment with carboplatin/etoposide (3 months) along with 7000 cGy XRT resulted in a response lasting 10 months. He then began maintenance therapy with Tarceva, which continued until he was considered for the IMMU-132 trial, in addition to undergoing a lumbar laminectomy. He received his first dose of IMMU-132 after 5 months of Tarceva, presenting at that time a 5.6 cm lesion in the right lung with abundant pleural effusion. He had just completed his sixth dose two months later when the first CT scan showed that the primary target lesion was reduced to 3.2 cm (not shown).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0236] Como RP ejemplar en CPCP, a una mujer de 65 años se le diagnosticó CPCP pobremente diferenciado. Después de recibir carboplatino/etopósido (inhibidor de Topo-II) que terminó después de 2 meses sin respuesta, seguido de topotecán (inhibidor de Topo-I) que terminó después de 2 meses, también sin respuesta, recibió&lt;x&gt;R&lt;t&gt;local (3000 cGy) que terminó 1 mes después. Sin embargo, al mes siguiente la progresión había continuado. El paciente comenzó con IMMU-132 el mes siguiente (12 mg/kg; reducido a 6,8 mg/kg; expresión de Trop-23+), y después de dos meses de IMMU-132, se observó una reducción del 38% en las lesiones diana, incluida una reducción sustancial en la lesión pulmonar principal (no se muestra). El paciente evolucionó 3 meses después de recibir 12 dosis. </span>[0236] As an exemplary RP in SCLC, a 65-year-old woman was diagnosed with poorly differentiated SCLC. After receiving carboplatin/etoposide (Topo-II inhibitor) which ended after 2 months without response, followed by topotecan (Topo-I inhibitor) which ended after 2 months, also without response, he received&lt;x&gt;R&lt;t &gt;local (3000 cGy) which ended 1 month later. However, the following month the progression had continued. The patient was started on IMMU-132 the following month (12 mg/kg; reduced to 6.8 mg/kg; Trop-23+ expression), and after two months of IMMU-132, a 38% reduction was observed in the target lesions, including a substantial reduction in the primary lung lesion (not shown). The patient improved 3 months after receiving 12 doses.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0237] Estos resultados son significativos porque demuestran que el CAF anti-Trop-2 fue eficaz, incluso en pacientes que habían fracasado o progresado después de múltiples terapias previas. </span>[0237] These results are significant because they demonstrate that anti-Trop-2 CAF was effective, even in patients who had failed or progressed after multiple prior therapies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0238] En conclusión, en las dosis utilizadas, la toxicidad primaria fue una neutropenia manejable, con pocas toxicidades de Grado 3. IMMU-132 mostró evidencia de actividad (RP y EE duradera) en pacientes en recaída/refractarios con cáncer de mama triple negativo, cáncer de pulmón de células pequeñas, cáncer de pulmón de células no pequeñas, cáncer colorrectal y cáncer de esófago, incluidos pacientes con antecedentes de recaer en la terapia con inhibidores de la topoisomerasa-I. Estos resultados muestran la eficacia del CAF anti-Trop-2 en una amplia gama de cánceres que son resistentes a las terapias existentes. </span>[0238] In conclusion, at the doses used, the primary toxicity was manageable neutropenia, with few Grade 3 toxicities. IMMU-132 showed evidence of activity (PR and durable EE) in relapsed/refractory patients with triple breast cancer negative, small cell lung cancer, non-small cell lung cancer, colorectal cancer, and esophageal cancer, including patients with a history of relapse on topoisomerase-I inhibitor therapy. These results show the efficacy of anti-Trop-2 CAF in a wide range of cancers that are resistant to existing therapies.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 9. Conjugación de productos SN-38 bifuncionales con anticuerpos ligeramente reducidos </span>Example 9. Conjugation of bifunctional SN-38 products with slightly reduced antibodies</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0239] El MAb humanizado anti-CEACAM5, hMN-14 (también conocido como labetuzumab), el MAb humanizado anti-CD22, hLL2 (también conocido como epratuzumab), el MAb humanizado anti-CD20, hA20 (también conocido como veltuzumab), el MAb humanizado anti-CD20, hA20 (también conocido como veltuzumab), Se conjugaron MAb humanizado EGP-1, hRS7 y MAb humanizado antimucina, hPAM4 (también conocido como clivatuzumab), con SN-38 utilizando un conector CL2A. Cada anticuerpo se redujo con ditiotreitol (DTT), utilizado en un exceso molar de 50 a 70 veces, en PBS 40 mM, pH 7,4, que contenía EDTA 5,4 mM, a 37 °C (baño) durante 45 min. El producto reducido se purificó mediante cromatografía de exclusión por tamaño y/o diafiltración, y se intercambió el tampón por un tampón adecuado a pH 6,5. El contenido de tiol se determinó mediante el ensayo de Ellman y estuvo en el rango de 6,5 a 8,5 SH/IgG. Alternativamente, los anticuerpos se redujeron con Tris (2-carboxietil) fosfina (TCEP) en tampón fosfato a un pH en el rango de 5-7, seguido de conjugaciónin situ.El MAb reducido se hizo reaccionar con un exceso molar de aproximadamente 10 a 15 veces de CL2A-SN-38 usando DMSO al 7-15 % v/v como codisolvente y se incubó durante 20 minutos a temperatura ambiente. El conjugado se purificó mediante SEC centrifugada, paso a través de una columna hidrófoba y finalmente mediante ultrafiltración-diafiltración. Se analizó el producto para determinar SN-38 mediante absorbancia a 366 nm y correlacionándolo con valores estándar, mientras que la concentración de proteína se dedujo de la absorbancia a 280 nm, corregida por el desbordamiento de absorbancia de SN-38 a esta longitud de onda. De esta forma se determinaron las relaciones de sustitución SN-38/MAb. Los conjugados purificados se almacenaron como formulaciones liofilizadas en viales de vidrio, se taparon al vacío y se almacenaron en un congelador a -20 °C. Las relaciones de sustitución molar (MSR) de SN-38 obtenidas para estos conjugados estuvieron típicamente en el rango de 5 a 7. </span>[0239] The humanized anti-CEACAM5 MAb, hMN-14 (also known as labetuzumab), the humanized anti-CD22 MAb, hLL2 (also known as epratuzumab), the humanized anti-CD20 MAb, hA20 (also known as veltuzumab), The anti-CD20 humanized MAb, hA20 (also known as veltuzumab), EGP-1 humanized MAb, hRS7 and anti-mucin humanized MAb, hPAM4 (also known as clivatuzumab), were conjugated to SN-38 using a CL2A linker. Each antibody was reduced with dithiothreitol (DTT), used in a 50- to 70-fold molar excess, in 40 mM PBS, pH 7.4, containing 5.4 mM EDTA, at 37 °C (bath) for 45 min. The reduced product was purified by size exclusion chromatography and/or diafiltration, and the buffer was exchanged with a suitable buffer at pH 6.5. The thiol content was determined by the Ellman assay and was in the range of 6.5 to 8.5 SH/IgG. Alternatively, antibodies were reduced with Tris(2-carboxyethyl)phosphine (TCEP) in phosphate buffer at a pH in the range of 5-7, followed by in situ conjugation. The reduced MAb was reacted with a molar excess of approximately 10 to 15 times of CL2A-SN-38 using 7-15% v/v DMSO as cosolvent and incubated for 20 minutes at room temperature. The conjugate was purified by centrifuged SEC, passage through a hydrophobic column and finally by ultrafiltration-diafiltration. The product was analyzed for SN-38 by absorbance at 366 nm and correlating it with standard values, while the protein concentration was deduced from the absorbance at 280 nm, corrected for the absorbance spillover of SN-38 at this wavelength. . In this way, the SN-38/MAb substitution ratios were determined. The purified conjugates were stored as lyophilized formulations in glass vials, vacuum capped, and stored in a −20 °C freezer. The SN-38 molar substitution ratios (MSR) obtained for these conjugates were typically in the range of 5 to 7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 10. Terapia combinada con CAF anti-Trop-2 en CPCP </span>Example 10. Combined therapy with anti-Trop-2 CAF in SCLC</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0240] Dado que el cisplatino es uno de los principales quimioterapéuticos utilizados en combinación con irinotecán en el cáncer de pulmón de células pequeñas (CpCP) avanzado, se realizó un experimento para probar la combinación de cisplatino con IMMU-132 en ratones con tumores de CPCP humano (DMS 53). Además, se ensayó el carboplatino en este modelo de tumor, ya que también se utiliza clínicamente en CPCP. </span>[0240] Since cisplatin is one of the main chemotherapeutics used in combination with irinotecan in advanced small cell lung cancer (SCLC), an experiment was performed to test the combination of cisplatin with IMMU-132 in mice with tumors of Human SCLC (DMS 53). Furthermore, carboplatin was tested in this tumor model, as it is also used clinically in SCLC.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0241] A ratones hembra CB-17 SCID se les inyectó s.c. con una suspensión tumoral hecha de tumores madre DMS 53 (20% p/v) más células recolectadas de cultivo de tejidos (5x106 células por ratón) mezcladas 1:1 con matrigel. Una vez que los tumores alcanzaron un volumen tumoral medio de 0,270 ± 0,048 cm3, los animales se dividieron en nueve grupos de tratamiento diferentes de 9 ratones cada uno. Tres grupos de ratones recibieron IMMU-132 (500, 250 o 100 |jg i.p). mientras que un grupo de control recibió un conjugado anticuerpo-fármaco no dirigido a tumores elaborado con h679, un antihistamínico-succinil-glicina IgG humanizado (h679-SN-38; 500 jg i.p.). Todos fueron administrados dos veces por semana durante 4 semanas. Dos grupos recibieron sólo quimioterapia con cisplatino (5 mg/kg i.p). o carboplatino (50 mg/kg i.p). semanalmente durante 4 semanas. Dos grupos recibieron una combinación de IMMU-132 (250 jg i.v. semanamentex 4 semanas) más cisplatino o carboplatino. Un grupo de control final de ratones no tratados recibió solución salina (100 ml i.p. dos veces por semana durante 3,4 semanas). Se midieron los tumores y se pesaron los ratones dos veces por semana. </span>[0241] Female CB-17 SCID mice were injected s.c. with a tumor suspension made from DMS 53 stem tumors (20% w/v) plus cells harvested from tissue culture (5x106 cells per mouse) mixed 1:1 with matrigel. Once the tumors reached a mean tumor volume of 0.270 ± 0.048 cm3, the animals were divided into nine different treatment groups of 9 mice each. Three groups of mice received IMMU-132 (500, 250 or 100 |jg i.p). while a control group received a non-tumor-targeting antibody-drug conjugate made with h679, a humanized antihistamine-succinyl-glycine IgG (h679-SN-38; 500 jg i.p.). All were administered twice a week for 4 weeks. Two groups received only chemotherapy with cisplatin (5 mg/kg i.p). or carboplatin (50 mg/kg i.p). weekly for 4 weeks. Two groups received a combination of IMMU-132 (250 mg IV weekly x 4 weeks) plus cisplatin or carboplatin. A final control group of untreated mice received saline (100 ml i.p. twice a week for 3.4 weeks). Tumors were measured and mice were weighed twice a week.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RESULTADOS</span>RESULTS</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0242] Los volúmenes tumorales medios para los diversos grupos se muestran en la FIG. 12. Las tres dosis de IMMU-132 proporcionaron un efecto antitumoral significativo en comparación con los animales de control con solución salina(P&lt;0,0161; pruebatde una cola de AUC). La terapia con la dosis más alta de IMMU-132 (500 jg ) produjo regresiones tumorales significativamente mayores en ratones con tumores en comparación con todos los grupos de monoterapia, incluido el control h679-SN-38 (P &lt;0,0032; pruebatde dos colas de A&lt;u&gt;C). </span>[0242] The mean tumor volumes for the various groups are shown in FIG. 12. All three doses of IMMU-132 provided a significant antitumor effect compared to saline control animals (P&lt;0.0161; AUC one-tailed test). Therapy with the highest dose of IMMU-132 (500 μg) produced significantly greater tumor regressions in tumor-bearing mice compared with all monotherapy groups, including the h679-SN-38 control (P &lt; 0.0032; two-way test). A&lt;u&gt;C tails).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0243] Para los grupos de combinación, IMMU-132 (250 jg ) más carboplatino (FIG. 13) se acercaba a la importancia. (P = 0,0983; prueba t de dos colas de AUC) en el momento en que el primer ratón del grupo de control en monoterapia con carboplatino alcanzó su punto final de volumen tumoral &gt;1,0 cm3 el día 41 (día 14 de la terapia). Sin embargo, en términos de volúmenes tumorales medios absolutos, en este día la combinación de IMMU-132 (250 jg ) más carboplatino tuvo tumores significativamente más pequeños en comparación con la monoterapia con carboplatino (0,166 ± 0,019 cm3 frente a 0,602 ± 0,224 cm3, respectivamente;P= 0,0004, prueba t de dos colas). En comparación con los ratones tratados solo con IMMU-132 (250 jg dos veces por semana), los animales tratados con IMMU-132 (semanalmente) más carboplatino tuvieron tumores significativamente más pequeños a partir del día 73 (último día de comparación debido a que varios ratones alcanzaron el punto final; 0,745 ± 0,162 cm3 frente a 0,282 ± 0,153 cm3, respectivamente (P =0,0003,pruebatde dos colas AUC). </span>[0243] For the combination groups, IMMU-132 (250 jg) plus carboplatin (FIG. 13) approached significance. (P = 0.0983; AUC two-tailed t test) at the time point when the first mouse in the carboplatin monotherapy control group reached its end point of tumor volume &gt;1.0 cm3 on day 41 (day 14 of the therapy). However, in terms of absolute mean tumor volumes, on this day the combination of IMMU-132 (250 jg) plus carboplatin had significantly smaller tumors compared to carboplatin monotherapy (0.166 ± 0.019 cm3 vs. 0.602 ± 0.224 cm3, respectively;P= 0.0004, two-tailed t-test). Compared to mice treated with IMMU-132 alone (250 μg twice weekly), animals treated with IMMU-132 (weekly) plus carboplatin had significantly smaller tumors starting at day 73 (last day of comparison because several mice reached the end point; 0.745 ± 0.162 cm3 vs. 0.282 ± 0.153 cm3, respectively (P =0.0003, two-tailed AUC).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0244] Los ratones tratados con la combinación de IMMU-132 (250 jg ) más cisplatino (FIG. 14) exhibieron una inhibición significativa del crecimiento tumoral en comparación con la monoterapia con cisplatino (P = 0,0002, pruebatde dos colas de AUC). Cuando se compararon los volúmenes tumorales el día 73 (último día de comparación debido a que varios ratones del grupo de monoterapia con cisplatino alcanzaron el punto final), el grupo de combinación tenía tumores que eran aproximadamente 6,2 veces más pequeños que los del grupo de monoterapia con cisplatino (0,123 ± 0,040 cm3 vs. </span>[0244] Mice treated with the combination of IMMU-132 (250 μg) plus cisplatin (FIG. 14) exhibited significant inhibition of tumor growth compared to cisplatin monotherapy (P = 0.0002, two-tailed AUC test ). When tumor volumes were compared on day 73 (last day of comparison because several mice in the cisplatin monotherapy group reached the end point), the combination group had tumors that were approximately 6.2 times smaller than those in the cisplatin monotherapy group. monotherapy with cisplatin (0.123 ± 0.040 cm3 vs.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">0,758 ± 0,240 cm3, respectivamente (P &lt;0,0001, pruebatde dos colas). Asimismo, los ratones tratados con el esquema semanal de IMMU-132 (250 jg ) combinado con cisplatino tuvieron tumores significativamente más pequeños que los animales tratados solo con IMMU-132 (250 jg), aunque en el grupo de monoterapia IMMU-132 se administró dos veces por semana (P &lt;0,0001, pruebatde dos colas AUC). Finalmente, la combinación de IMMU-132 más cisplatino demostró ser superior a todos los demás grupos, incluidos los grupos de tratamiento en monoterapia con dosis altas de IMMU-132 más carboplatino y dosis altas de IMMU-132 (500 jg ) (P &lt;0,0066, pruebatde dos colas AUC). </span>0.758 ± 0.240 cm3, respectively (P &lt; 0.0001, two-tailed test). Likewise, mice treated with the weekly regimen of IMMU-132 (250 jg) combined with cisplatin had significantly smaller tumors than animals treated with IMMU-132 alone (250 jg), although in the monotherapy group IMMU-132 was administered twice a week (P &lt; 0.0001, two-tailed AUC). Finally, the combination of IMMU-132 plus cisplatin was shown to be superior to all other groups, including the monotherapy treatment groups with high-dose IMMU-132 plus carboplatin and high-dose IMMU-132 (500 jg) (P &lt; 0 .0066, two-tailed test (AUC).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0245] Tanto el tratamiento con IMMU-132 más carboplatino como el tratamiento con IMMU-132 más cisplatino fueron bien tolerados por los ratones. Un aspecto inusual de este modelo de tumor fue la observación de que los ratones que portaban tumores DMS 53 presentaban caquexia (FIG. 15) con una caída de peso en promedio superior al 15 % desde el principio. Por ejemplo, en los ratones de control con solución salina, a medida que la carga tumoral aumentó de 0,270 ± 0,053 cm3 el día 27 a 0,683 ± 0,185 cm3 el día 41, el peso corporal del animal disminuyó un 16,9% ± 3,4%. Sin embargo, a medida que los efectos antitumorales de la monoterapia IMMU-132 (500 |jg) o las combinaciones de IMMU-132 más carboplatino o cisplatino se hicieron evidentes, los ratones comenzaron a ganar peso nuevamente. Por ejemplo, en el grupo de IMMU-132 más carboplatino, los ratones perdieron su mayor peso hacia el día 38 (15,3% ± 5,6%), después de lo cual comenzaron a recuperar este peso perdido a medida que los tumores retrocedieron y los ratones regresaron al 100% de su peso. peso inicial el día 58. Durante ese tiempo, los tumores retrocedieron a 0,128 ± 0,0,018 cm3 desde un tamaño inicial de 0,270 ± 0,050 cm3 el día 27. Sin embargo, los animales comenzaron a perder peso nuevamente a medida que los tumores volvieron a crecer a un tamaño mayor que cuando comenzó la terapia (0,282 ± 0,153 cm3 el día 73). En resumen, a medida que estas terapias redujeron la carga tumoral, los efectos debilitantes de la caquexia se revirtieron en estos ratones, lo que indica aún más el beneficio de estas combinaciones en este modelo de enfermedad humana de CPCP. </span>[0245] Both IMMU-132 plus carboplatin treatment and IMMU-132 plus cisplatin treatment were well tolerated by the mice. An unusual aspect of this tumor model was the observation that mice carrying DMS 53 tumors exhibited cachexia (FIG. 15) with an average weight drop of more than 15% from the start. For example, in saline control mice, as the tumor burden increased from 0.270 ± 0.053 cm3 on day 27 to 0.683 ± 0.185 cm3 on day 41, the animal's body weight decreased by 16.9% ± 3.0%. 4%. However, as the antitumor effects of IMMU-132 monotherapy (500 μg) or combinations of IMMU-132 plus carboplatin or cisplatin became evident, the mice began to gain weight again. For example, in the IMMU-132 plus carboplatin group, mice lost their greatest weight by day 38 (15.3% ± 5.6%), after which they began to regain this lost weight as the tumors They regressed and the mice returned to 100% of their weight. initial weight on day 58. During that time, the tumors regressed to 0.128 ± 0.0.018 cm3 from an initial size of 0.270 ± 0.050 cm3 on day 27. However, the animals began to lose weight again as the tumors returned to grow to a larger size than when therapy began (0.282 ± 0.153 cm3 on day 73). In summary, as these therapies reduced tumor burden, the debilitating effects of cachexia were reversed in these mice, further indicating the benefit of these combinations in this human SCLC disease model.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 11. Terapia de pacientes con CPCPm humano con CAF Anti-Trop-2-SN-38 </span>Example 11. Therapy of patients with human mSCLC with CAF Anti-Trop-2-SN-38</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resumen</span>Summary</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0246] El topotecán, un inhibidor de la topoisomerasa I, está aprobado como terapia de segunda línea en pacientes sensibles a regímenes de primera línea que contienen platino, pero en veinte años no se ha aprobado ninguna nueva terapia para el tratamiento del cáncer de pulmón de células pequeñas metastásico (CPCPm). En este ejemplo, se estudió un nuevo conjugado anticuerpo-fármaco (CAF), sacituzumab govitecan, compuesto por un anticuerpo dirigido a Trop-2 y que contiene el metabolito activo del irinotecan, SN-38 (también un inhibidor de la topoisomerasa I). Los pacientes con una mediana de 2 terapias previas (rango 1-7) recibieron el CAF los días 1 y 8 de ciclos de 21 días, con una mediana de diez dosis (rango, 1 a 63). Las principales toxicidades de grado &gt;3 fueron neutropenia, fatiga y diarrea manejables. A pesar de recibir hasta 63 dosis repetidas, el CAF no fue inmunogénico. </span>[0246] Topotecan, a topoisomerase I inhibitor, is approved as second-line therapy in patients sensitive to first-line platinum-containing regimens, but no new therapy has been approved for the treatment of lung cancer in twenty years. metastatic small cell disease (mSCLC). In this example, a new antibody-drug conjugate (CAF), sacituzumab govitecan, was studied, composed of an antibody targeting Trop-2 and containing the active metabolite of irinotecan, SN-38 (also a topoisomerase I inhibitor). Patients with a median of 2 prior therapies (range, 1-7) received CAF on days 1 and 8 of 21-day cycles, with a median of ten doses (range, 1-63). The main grade &gt;3 toxicities were manageable neutropenia, fatigue, and diarrhea. Despite receiving up to 63 repeat doses, CAF was not immunogenic.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0247] El cuarenta y nueve por ciento de los 43 pacientes evaluables tuvieron una reducción del tamaño del tumor con respecto al valor inicial; la tasa de respuesta objetiva (respuestas parciales) fue del 16 % y se logró una enfermedad estable en el 49 % de los pacientes. La mediana de la supervivencia libre de progresión y la mediana de la supervivencia general fueron de 3,6 y 7,0 meses, respectivamente, según un análisis por intención de tratar (N = 53). Este CAF fue activo en pacientes quimiosensibles o quimiorresistentes a la quimioterapia de primera línea, y también en pacientes en los que fracasó la terapia de segunda línea con topotecán. Estos datos respaldan el uso de sacituzumab govitecan como un nuevo tratamiento para el CPCPm avanzado. </span>[0247] Forty-nine percent of the 43 evaluable patients had a reduction in tumor size from baseline; the objective response rate (partial responses) was 16%, and stable disease was achieved in 49% of patients. Median progression-free survival and median overall survival were 3.6 and 7.0 months, respectively, based on an intention-to-treat analysis (N = 53). This CAF was active in patients chemosensitive or chemoresistant to first-line chemotherapy, and also in patients who failed second-line therapy with topotecan. These data support the use of sacituzumab govitecan as a new treatment for advanced mSCLC.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Métodos</span>Methods</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0248] Se inscribieron pacientes &gt;18 años de edad con CPCPm que habían recaído o eran refractarios a al menos una línea de tratamiento estándar previa para la enfermedad metastásica en estadio IV y con tumores medibles mediante TC. Se les exigía que tuvieran un estado funcional de 0 o 1 del Eastern Cooperative Oncology Group (ECOG), función adecuada de médula ósea, función hepática y renal, y otros requisitos de elegibilidad como se describe en el ensayo de fase I (Starodub et al., 2015, Clin Cancer Res 21:3870-8). La terapia previa debía completarse al menos 4 semanas antes de la inscripción. </span>[0248] Patients &gt;18 years of age with mSCLC who had relapsed or were refractory to at least one prior standard line of treatment for stage IV metastatic disease and with CT-measurable tumors were enrolled. They were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, adequate bone marrow function, liver and kidney function, and other eligibility requirements as described in the phase I trial (Starodub et al ., 2015, Clin Cancer Res 21:3870-8). Prior therapy had to be completed at least 4 weeks before enrollment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0249] El objetivo general de esta parte del ensayo colectivo que se lleva a cabo para diversos cánceres (ClinicalTrials.gov, NCT01631552) fue evaluar la seguridad y la actividad antitumoral de sacituzumab govitecan en pacientes con CPCPm. Sacituzumab govitecan se administró por vía intravenosa a una velocidad de infusión inicial de 50 mg/h, que se completó en 3 h (las infusiones posteriores se completaron en 60-90 min). Opcionalmente se prescribieron premedicaciones (p. ej., difenhidramina, paracetamol y dexametasona) para reducir el riesgo de reacciones a la infusión. Se administraron dosis de 8 o 10 mg/kg los días 1 y 8 de un ciclo de 21 días, con contingencias de retraso (máximo de 2 semanas). Las toxicidades se controlaron mediante terapia de apoyo con factor de crecimiento hematopoyético para la reducción de células sanguíneas, retrasos y/o modificaciones de la dosis según lo especificado en el protocolo (p. ej., 25 % de la dosis anterior) o mediante la práctica médica estándar. El tratamiento continuó hasta la progresión de la enfermedad, el inicio de una terapia anticancerígena alternativa, la toxicidad inaceptable o la retirada del consentimiento. </span>[0249] The overall objective of this part of the collective trial being carried out for various cancers (ClinicalTrials.gov, NCT01631552) was to evaluate the safety and antitumor activity of sacituzumab govitecan in patients with mSCLC. Sacituzumab govitecan was administered intravenously at an initial infusion rate of 50 mg/h, which was completed within 3 h (subsequent infusions were completed within 60–90 min). Premedications (e.g., diphenhydramine, acetaminophen, and dexamethasone) were optionally prescribed to reduce the risk of infusion reactions. Doses of 8 or 10 mg/kg were administered on days 1 and 8 of a 21-day cycle, with delay contingencies (maximum of 2 weeks). Toxicities were managed by supportive therapy with hematopoietic growth factor for blood cell depletion, dose delays and/or modifications as specified in the protocol (e.g., 25% of the previous dose), or by standard medical practice. Treatment continued until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or withdrawal of consent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0250] Se inscribieron cincuenta y tres pacientes con CPCPm (30 mujeres, 23 hombres, con una mediana de edad de 63 años (rango, 44-82). La mediana de tiempo desde el diagnóstico inicial hasta el tratamiento con sacituzumab govitecan fue de 9,5 meses (rango, 3 a 53). La mayoría de los pacientes recibieron un tratamiento previo intensivo, con una mediana de 2 líneas de tratamiento previas (rango, 1 a 7). Todos recibieron cisplatino o carboplatino más etopósido. Veintidós (41%) pacientes tenían 1 línea de tratamiento previa, mientras que 14 (26%) y 17 (32%) recibieron 2 y &gt;3 regímenes de quimioterapia previos, respectivamente. Además, 18 (33%) recibieron topotecán y/o irinotecán, 9 (16%) recibieron un taxano y 5 (9%) recibieron un tratamiento con inhibidores de puntos de control inmunitarios, que incluía nivolumab (N=4) o atezolizumab (N=1). </span>[0250] Fifty-three mSCLC patients (30 women, 23 men, with a median age of 63 years (range, 44-82) were enrolled. The median time from initial diagnosis to treatment with sacituzumab govitecan was 9.5 months (range, 3 to 53). Most patients received intensive prior treatment, with a median of 2 prior lines of treatment (range, 1 to 7). 41%) patients had 1 prior line of treatment, while 14 (26%) and 17 (32%) received 2 and &gt;3 prior chemotherapy regimens, respectively. Additionally, 18 (33%) received topotecan and/or irinotecan, 9 (16%) received a taxane and 5 (9%) received immune checkpoint inhibitor therapy, including nivolumab (N=4) or atezolizumab (N=1).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0251] Según la duración de la respuesta a una terapia de primera línea que contiene platino mayor o menor de 3 meses, hubo 27 (51%) y 26 (49%) pacientes quimiosensibles y quimiorresistentes, respectivamente. La mayoría de los pacientes tenían enfermedad extensa, con metástasis a múltiples órganos, incluidos pulmones (66%), hígado (59%), ganglios linfáticos (76%), tórax (34%), glándulas suprarrenales (25%), huesos (23%), y pleura (6%). Otros sitios de enfermedad incluyeron páncreas (N = 4), cerebro (N = 2), piel (N = 2) y pared esofágica, ovario y seno (1 cada uno). </span>[0251] Based on duration of response to first-line platinum-containing therapy greater or less than 3 months, there were 27 (51%) and 26 (49%) chemosensitive and chemoresistant patients, respectively. Most patients had extensive disease, with metastases to multiple organs, including lungs (66%), liver (59%), lymph nodes (76%), chest (34%), adrenal glands (25%), bones ( 23%), and pleura (6%). Other disease sites included pancreas (N = 4), brain (N = 2), skin (N = 2), and esophageal wall, ovary, and sinus (1 each).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0252] El criterio de valoración principal fue la proporción de pacientes con una respuesta objetiva confirmada, evaluados aproximadamente cada 8 semanas hasta la progresión de la enfermedad, por el grupo de radiología de cada institución o un servicio de radiología local contratado. Las respuestas objetivas se evaluaron mediante los criterios de evaluación de respuesta en tumores sólidos, versión 1.1 (RECIST 1.1) (Eisenhauer et al., 2009, Eur J Cancer 45:228-47). Las respuestas parciales (RP) o completas (RC) requirieron confirmación dentro de 4 a 6 semanas después de la respuesta inicial. La tasa de beneficio clínico (TBC) se define como aquellos pacientes con una respuesta objetiva más enfermedad estable (EE) &gt;4 meses. La supervivencia se controló cada 3 meses hasta la muerte o la retirada del consentimiento. </span>[0252] The primary endpoint was the proportion of patients with a confirmed objective response, evaluated approximately every 8 weeks until disease progression, by the radiology group at each institution or a contracted local radiology service. Objective responses were evaluated using response evaluation criteria in solid tumors, version 1.1 (RECIST 1.1) (Eisenhauer et al., 2009, Eur J Cancer 45:228-47). Partial (PR) or complete (CR) responses required confirmation within 4 to 6 weeks after the initial response. The clinical benefit rate (CBT) is defined as those patients with an objective response plus stable disease (SE) &gt;4 months. Survival was monitored every 3 months until death or withdrawal of consent.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0253] Se realizaron evaluaciones de seguridad durante las visitas programadas o con mayor frecuencia si se justificaba. El recuento sanguíneo y la química sérica se comprobaron de forma rutinaria antes de la administración de sacituzumab govitecan y cuando estuviera clínicamente indicado. </span>[0253] Safety assessments were conducted during scheduled visits or more frequently if warranted. Blood counts and serum chemistry were routinely checked before administration of sacituzumab govitecan and when clinically indicated.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0254] Análisis estadísticos: los datos incluidos en los análisis se derivaron de pacientes inscritos desde noviembre de 2013 hasta junio de 2016, con seguimiento hasta el 31 de enero de 2017. La frecuencia y gravedad de los eventos adversos (EA) se definieron según el término preferido de MedDRA y la clasificación de órganos del sistema (SOC) versión 10, con gravedad evaluada por NCI-CTCA&lt;e&gt;v4.03. Se evaluó la toxicidad de todos los pacientes que recibieron sacituzumab govitecan. </span>[0254] Statistical Analyzes: Data included in the analyzes were derived from patients enrolled from November 2013 to June 2016, with follow-up through January 31, 2017. The frequency and severity of adverse events (AEs) were defined according to the MedDRA preferred term and system organ class (SOC) version 10, with severity assessed by NCI- CTCA&lt;e&gt;v4.03. All patients receiving sacituzumab govitecan were evaluated for toxicity.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0255] El protocolo disponía que se determinaran las tasas de respuesta objetiva (TRO) para los pacientes que recibieron &gt;2 dosis (1 ciclo) y tuvieron su evaluación CT inicial de 8 semanas. La duración de la respuesta se define de acuerdo con los criterios RECIST 1.1, y aquellos que tienen una respuesta objetiva se marcan desde el momento de la primera evidencia de respuesta hasta la progresión, mientras que la duración estable de la enfermedad se marca desde el inicio del tratamiento hasta la progresión. La SSP y la SG se definen desde el inicio del tratamiento hasta que se determina una evaluación objetiva de la progresión (SSP) o la muerte (SG). La duración de la respuesta, la SSP y la SG se estimaron mediante métodos de Kaplan-Meier, con intervalos de confianza (IC) del 95 %, utilizando el software estadístico MedCalc, versión 16.4.3 (Ostende, Bélgica). </span>[0255] The protocol provided that objective response rates (ORR) be determined for patients who received &gt;2 doses (1 cycle) and had their initial 8-week CT evaluation. Duration of response is defined according to RECIST 1.1 criteria, and those who have an objective response are marked from the time of first evidence of response to progression, while stable disease duration is marked from onset. from treatment to progression. PFS and OS are defined from the start of treatment until an objective assessment of progression (PFS) or death (OS) is determined. Duration of response, PFS, and OS were estimated by Kaplan-Meier methods, with 95% confidence intervals (CI), using MedCalc statistical software, version 16.4.3 (Ostend, Belgium).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0256] Inmunohistoquímica del tumor Trop-2 e inmunogenicidad de Sacituzumab Govitecan y sus componentes: las muestras tumorales de archivo para Trop-2 se tiñeron mediante IHC y se interpretaron como se informó anteriormente (Starodub et al., 2015, Clin Cancer Res 21:3870-8). La positividad requirió teñir al menos el 10% de las células tumorales, con una intensidad calificada como 1+ (débil), 2+ (moderada) y 3+ (fuerte). Las respuestas de los anticuerpos al sacituzumab govitecan, el anticuerpo IgG y el SN-38 se controlaron en muestras de suero tomadas al inicio del estudio y luego antes de cada ciclo par mediante ensayos inmunoabsorbentes ligados a enzimas realizados por el patrocinador (Starodub et al., 2015, Clin Cancer Res 21:3870-8). La sensibilidad del ensayo es de 50 ng/ml para el CAF y la IgG, y de 170 ng/ml para el anticuerpo anti-SN-38. </span>[0256] Trop-2 tumor immunohistochemistry and immunogenicity of Sacituzumab Govitecan and its components: Archival tumor samples for Trop-2 were stained by IHC and interpreted as previously reported (Starodub et al., 2015, Clin Cancer Res 21 :3870-8). Positivity required staining at least 10% of the tumor cells, with intensity graded as 1+ (weak), 2+ (moderate), and 3+ (strong). Antibody responses to sacituzumab govitecan, IgG antibody, and SN-38 were monitored in serum samples taken at baseline and then before each even cycle using enzyme-linked immunosorbent assays performed by the sponsor (Starodub et al. , 2015, Clin Cancer Res 21:3870-8). The sensitivity of the assay is 50 ng/ml for CAF and IgG, and 170 ng/ml for anti-SN-38 antibody.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 5. Datos demográficos iniciales y características de la enfermedad de todos los pacientes (N = 53) </span>Table 5. Baseline demographics and disease characteristics of all patients (N = 53).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Edad Años (mediana; rango) 63 (44 - 82) Sexo, N (%) Mujer 30 (56) </span>Age Years (median; range) 63 (44 - 82) Sex, N (%) Female 30 (56)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hombre 23 (44) Raza, N (%) Blanco 47(88) </span>Male 23 (44) Race, N (%) White 47(88)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Negro 3 (6) </span>Black 3 (6)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otro 3 (6) ECOG, N (%) 0 6 (11) </span>Other 3 (6) ECOG, N (%) 0 6 (11)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1 47(89) Sitios de metástasis, N (%) Pulmón 35 (66) </span>1 47(89) Metastasis sites, N (%) Lung 35 (66)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hígado 18 (59) Ganglios linfáticos 40 (76) Pecho 18 (34) Suprarrenales 13 (25) Hueso 12 (23) Derrame pleural 3 (5) Páncreas 4 (7) Pelvis 2 (3) Cerebro 2 (3) </span>Liver 18 (59) Lymph nodes 40 (76) Chest 18 (34) Adrenals 13 (25) Bone 12 (23) Pleural effusion 3 (5) Pancreas 4 (7) Pelvis 2 (3) Brain 2 (3)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Piel 2 (3) Otros 3 (5) Líneas anteriores de 1 22(41) Terapia 2 14 (26) N (%) &gt;3 17 (32) Sensibilidad a la quimioterapia de primera línea, N (%) Sensible 27(51) </span>Skin 2 (3) Other 3 (5) Previous lines of 1 22(41) Therapy 2 14 (26) N (%) &gt;3 17 (32) Sensitivity to first-line chemotherapy, N (%) Sensitive 27 (51) )</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resistente 26 (49) Terapia previa, N (%) Platino y etopósido 53 (100) </span>Resistant 26 (49) Previous therapy, N (%) Platinum and etoposide 53 (100)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Topotecán y/o irinotecán 18 (33) Taxanos 9 (16) Inhibidores de puntos de control (IPC) 5 (9)______ </span>Topotecan and/or irinotecan 18 (33) Taxanes 9 (16) Checkpoint inhibitors (CPI) 5 (9)______</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0257] Pacientes: desde noviembre de 2013 hasta junio de 2016, se inscribieron 53 pacientes con CPCPm (30 mujeres, 23 hombres, con una mediana de edad de 63 años (rango, 44-82) (Tabla 5). La mediana de tiempo desde el diagnóstico inicial hasta el tratamiento con sacituzumab govitecan fue de 9,5 meses (rango, 3 a 53). La mayoría de los pacientes recibieron un tratamiento previo intenso, con una mediana de 2 líneas de tratamiento previas (rango, 1 a 7). Todos recibieron cisplatino o carboplatino más etopósido. Veintidós (41%) pacientes tenían 1 línea de terapia previa, mientras que 14 (26%) y 17 (32%) recibieron 2 y &gt;3 regímenes de quimioterapia previos, respectivamente. Además, 18 (33%) recibieron topotecán y/o irinotecán, 9 (16 %) tenían un taxano y 5 (9 %) tenían una terapia con inhibidores de puntos de control inmunológico, que comprende nivolumab (N = 4) o atezolizumab (N = 1). Según una duración de la respuesta a una terapia de primera línea que contiene platino mayor o menor Durante más de 3 meses, hubo 27 (51%) y 26 (49%) pacientes quimiosensibles y quimiorresistentes, respectivamente. La mayoría de los pacientes tenían enfermedad extensa, con metástasis en múltiples órganos, incluidos pulmones (66%), hígado (59%), linfa ganglios (76%), tórax (34%), suprarrenales (25%), huesos (23%) y pleura (6%) (Tabla 5). Otros sitios de enfermedad incluyeron páncreas (N = 4), cerebro (N = 2), piel (N = 2) y pared esofágica, ovario y seno (1 cada uno). </span>[0257] Patients: From November 2013 to June 2016, 53 mSCLC patients (30 women, 23 men, with a median age of 63 years (range, 44-82) were enrolled (Table 5). Time from initial diagnosis to treatment with sacituzumab govitecan was 9.5 months (range, 3 to 53). Most patients were heavily pretreated, with a median of 2 prior lines of treatment (range, 1 to 53). 7) All received cisplatin or carboplatin plus etoposide. Twenty-two (41%) patients had 1 prior line of therapy, while 14 (26%) and 17 (32%) received 2 and &gt;3 prior chemotherapy regimens, respectively. , 18 (33%) received topotecan and/or irinotecan, 9 (16%) had a taxane, and 5 (9%) had immune checkpoint inhibitor therapy, comprising nivolumab (N = 4) or atezolizumab (N = 1). According to a duration of response to a first-line platinum-containing therapy greater or lesser than 3 months, there were 27 (51%) and 26 (49%) chemosensitive and chemoresistant patients, respectively. Most patients had extensive disease, with metastases to multiple organs, including lungs (66%), liver (59%), lymph nodes (76%), thorax (34%), adrenals (25%), bones (23%). %) and pleura (6%) (Table 5). Other disease sites included pancreas (N = 4), brain (N = 2), skin (N = 2), and esophageal wall, ovary, and sinus (1 each).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0258] Exposición, seguridad y tolerabilidad del tratamiento: de los 53 pacientes inscritos, dos tratados por primera vez en mayo de 2016 continuaban el tratamiento con sacituzumab govitecan en la fecha límite del 31 de enero de 2017. Todos los demás pacientes habían interrumpido el tratamiento y, por lo demás, estaban siendo monitoreados para determinar su supervivencia. Se han administrado más de 590 dosis (en 295 ciclos), con una mediana de 10 dosis (intervalo, 1-63) por paciente. No se informaron reacciones relacionadas con la perfusión. </span>[0258] Treatment Exposure, Safety, and Tolerability: Of the 53 patients enrolled, two treated for the first time in May 2016 were continuing treatment with sacituzumab govitecan as of the cut-off date of January 31, 2017. All other patients had discontinued treatment. treatment and were otherwise being monitored for survival. More than 590 doses have been administered (in 295 cycles), with a median of 10 doses (range, 1-63) per patient. No infusion-related reactions were reported.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0259] Las dosis iniciales en 15 pacientes se administraron a una dosis inicial de 8 mg/kg; 10 mg/kg fue la dosis inicial para los siguientes 38 pacientes. Entre los 2 grupos de dosis, 25 pacientes recibieron &gt; 10 dosis (&gt; 5 ciclos) y 2 recibieron 62 y 63 dosis (&gt;30 ciclos). La mediana de duración del tratamiento fue de 2,5 meses (rango, 1 a 23). La neutropenia (grado &gt; 2) fue la única indicación para la reducción de la dosis y se registró en el 29 % (11/38) de los pacientes con el nivel de dosis de 10 mg/kg después de una mediana de 2,5 dosis (rango, 1 a 9). Dos de los quince pacientes (13%) tratados con 8 mg/kg tuvieron reducciones, uno después de 2 dosis y otro después de 41 dosis (20 ciclos). Una vez reducidos, las reducciones adicionales fueron poco frecuentes. No se observaron muertes relacionadas con el tratamiento. </span>[0259] Starting doses in 15 patients were administered at a starting dose of 8 mg/kg; 10 mg/kg was the starting dose for the next 38 patients. Between the 2 dose groups, 25 patients received &gt;10 doses (&gt;5 cycles) and 2 received 62 and 63 doses (&gt;30 cycles). The median duration of treatment was 2.5 months (range, 1 to 23). Neutropenia (grade &gt; 2) was the only indication for dose reduction and occurred in 29% (11/38) of patients at the 10 mg/kg dose level after a median of 2.5 dose (range, 1 to 9). Two of the fifteen patients (13%) treated with 8 mg/kg had reductions, one after 2 doses and one after 41 doses (20 cycles). Once reduced, further reductions were rare. No treatment-related deaths were observed.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0260] En este ensayo, diez pacientes abandonaron antes de la primera evaluación de respuesta; cuatro recibieron 1 dosis, cinco recibieron 2 dosis y otro después de 4 dosis. Tres no fueron elegibles para la evaluación de respuesta después de recibir 1 o 2 dosis, porque uno tenía una histología mixta de CPCP y CPCNP, y los otros 2 fueron diagnosticados con metástasis cerebrales o de médula espinal antes del ensayo después de recibir la primera dosis de sacituzumab govitecan. </span>[0260] In this trial, ten patients dropped out before the first response evaluation; four received 1 dose, five received 2 doses and another after 4 doses. Three were not eligible for response evaluation after receiving 1 or 2 doses, because one had a mixed histology of SCLC and NSCLC, and the other 2 were diagnosed with brain or spinal cord metastases before the trial after receiving the first dose. of sacituzumab govitecan.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Dos pacientes que informaron eventos adversos de grado 3 CTCAE (neutropenia y fatiga) después de una dosis que no se recuperaron a tiempo para la segunda dosis fueron suspendidos según las pautas del protocolo. Cuatro pacientes se retiraron del estudio después de 2 dosis, 2 retiraron su consentimiento y 2 se retiraron debido a fatiga de grado 2. Un paciente adicional abandonó el estudio después de 4 tratamientos debido a múltiples comorbilidades concurrentes y murió repentinamente antes de la primera evaluación de respuesta. </span>Two patients who reported CTCAE grade 3 adverse events (neutropenia and fatigue) after one dose that did not recover in time for the second dose were discontinued per protocol guidelines. Four patients withdrew from the study after 2 doses, 2 withdrew consent, and 2 withdrew due to grade 2 fatigue. One additional patient withdrew from the study after 4 treatments due to multiple concurrent comorbidities and died suddenly before the first evaluation of answer.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0261] Los EA notificados con más frecuencia en los 53 pacientes que recibieron al menos una dosis de sacituzumab govitecan fueron náuseas, diarrea, fatiga, alopecia, neutropenia, vómitos y anemia (Tabla&lt;6&gt;). Se produjo neutropenia de grado 3 o 4 en el 34 % (18/53) de los pacientes, y solo un paciente tuvo neutropenia febril. Otros eventos adversos de grado 3 o 4 fueron pocos e incluyeron fatiga (13%), diarrea (9%), anemia (8%), aumento de la fosfatasa alcalina (8%) e hiponatremia (8%). Si bien hubo menos pacientes que requirieron una reducción de la dosis en el grupo de dosis de 8 mg/kg (13% frente a 28% en el grupo de 10 mg/kg), el nivel de dosis de 10 mg/kg fue igualmente bien tolerado, con modificación de la dosis y/o apoyo del factor de crecimiento en unos pocos pacientes. </span>[0261] The most frequently reported AEs in the 53 patients who received at least one dose of sacituzumab govitecan were nausea, diarrhea, fatigue, alopecia, neutropenia, vomiting, and anemia (Table&lt;6&gt;). Grade 3 or 4 neutropenia occurred in 34% (18/53) of patients, and only one patient had febrile neutropenia. Other grade 3 or 4 adverse events were few and included fatigue (13%), diarrhea (9%), anemia (8%), increased alkaline phosphatase (8%), and hyponatremia (8%). Although fewer patients required a dose reduction in the 8 mg/kg dose group (13% vs. 28% in the 10 mg/kg group), the 10 mg/kg dose level was equally well tolerated, with dose modification and/or growth factor support in a few patients.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla&lt;6&gt;. Frecuencia de eventos adversos (N = 53), independientemente de la causalidad, que ocurren en &gt;15 % (todos los grados) o &gt;2 % (grado &gt;3) de los pacientes (clasificados según todos los grados). </span>Table&lt;6&gt;. Frequency of adverse events (N = 53), regardless of causality, occurring in &gt;15% (all grades) or &gt;2% (grade &gt;3) of patients (classified according to all grades).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Todos los grados Grados 3 y 4 </span>All grades Grades 3 and 4</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Eventos adversos (N = 53)_________ N_______________ %___________________N___________________% Diarrea 28 52,8 5 9,4 Náuseas 27 50,9 7 -Fatiga 25 47,2 18 13, 2 Neutropenia 23 43,4 - 34, 0 Vómitos 18 34,0 - -Dolor abdominal 16 30,2 - -Anorexia 15 28,3 3 -Anemia 14 26,4 - 5,7 Alopecia 12 22,6 - -Estreñimiento 11 20,8 - -Hipomagnesemia 10 18,9 - -Deshidratación 9 17,0 - -Disnea 9 17,0 - -Tos 8 15,1 2 -Hipoxia 3 5,7 1 3,8 Neutropenia febril 1 1,9 1,9 </span>Adverse events (N = 53)_________ N_______________ %___________________N___________________% Diarrhea 28 52.8 5 9.4 Nausea 27 50.9 7 -Fatigue 25 47.2 18 13. 2 Neutropenia 23 43.4 - 34. 0 Vomiting 18 34. 0 - -Abdominal pain 16 30.2 - -Anorexia 15 28.3 3 -Anemia 14 26.4 - 5.7 Alopecia 12 22.6 - -Constipation 11 20.8 - -Hypomagnesemia 10 18.9 - -Dehydration 9 17.0 - -Dyspnea 9 17.0 - -Cough 8 15.1 2 -Hypoxia 3 5.7 1 3.8 Febrile neutropenia 1 1.9 1.9</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0262] Eficacia: como se describe, de los 53 pacientes con CPCNPm inscritos, diez interrumpieron el tratamiento antes de su primera evaluación de respuesta mediante TC, lo que dejó a 43 pacientes con la evaluación objetiva de respuesta requerida por el protocolo después de recibir al menos dos dosis de sacituzumab govitecan y al menos una exploración de seguimiento. FIG. 16 proporciona una serie de representaciones gráficas de las respuestas, incluyendo un diagrama en cascada del mejor cambio porcentual en la suma del diámetro de las lesiones diana para los 43 pacientes (FIG. 16A), un gráfico que muestra la duración de las respuestas para aquellos que lograron RP o estado de EE (FIG. 16B), y un gráfico que rastrea los cambios de respuesta de los pacientes con RP y EE a lo largo del tiempo (FIG.&lt;1 6&gt;C). </span>[0262] Efficacy: As described, of the 53 mNSCLC patients enrolled, ten discontinued treatment before their first CT response assessment, leaving 43 patients with protocol-required objective response assessment after receiving at least two doses of sacituzumab govitecan and at least one follow-up scan. FIG. 16 provides a series of graphical representations of the responses, including a waterfall diagram of the best percentage change in the sum of the diameter of the target lesions for the 43 patients (FIG. 16A), a graph showing the duration of the responses for those who achieved PR or EE status (FIG. 16B), and a graph that tracks the response changes of patients with PR and EE over time (FIG.&lt;1 6&gt;C).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0263] Veintiuno de los 43 pacientes evaluables por TC (49%) experimentaron una reducción del tamaño del tumor desde el inicio (FIG. 16A). Se produjeron respuestas parciales confirmadas (reducción &gt;30 %) en siete pacientes, lo que produjo una TRO del 16 % (Tabla 7). La mediana del tiempo de respuesta en estos pacientes fue de 2,0 meses (rango, 1,8 a 3,6 meses), con una mediana de duración de la respuesta estimada por Kaplan-Meier de 5,7 meses (IC del 95 %: 3,6, 19,9). Dos de los siete respondedores tuvieron respuestas continuas en el último seguimiento (es decir, los pacientes estaban vivos, sin progresión de la enfermedad y no habían iniciado tratamientos anticancerígenos alternativos), uno a los 7,2+ meses y el otro a los 8,7+ meses desde el inicio del tratamiento. (FIG. 1B, FIG. 1C). </span>[0263] Twenty-one of 43 CT-evaluable patients (49%) experienced a reduction in tumor size from baseline (FIG. 16A). Confirmed partial responses (&gt;30% reduction) occurred in seven patients, resulting in an ORR of 16% (Table 7). The median response time in these patients was 2.0 months (range, 1.8 to 3.6 months), with a Kaplan-Meier estimated median duration of response of 5.7 months (95% CI). %: 3.6, 19.9). Two of the seven responders had continuous responses at last follow-up (i.e., patients were alive, without disease progression, and had not initiated alternative anticancer treatments), one at 7.2+ months and the other at 8. 7+ months from the start of treatment. (FIG. 1B, FIG. 1C).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tabla 7. Resumen de respuesta de sacituzumab govitecan (IMMU-132) en pacientes con CPCP </span>Table 7. Summary of response to sacituzumab govitecan (IMMU-132) in patients with SCLC.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Mejor respuesta general, N (%) </span>Best overall response, N (%)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Total con evaluación de respuesta 43 </span>Total with response evaluation 43</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">RP (confirmado) 7 (16%) </span>PR (confirmed) 7 (16%)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PRu (sin confirmar; EE con &gt;30 % de contracción como mejor respuesta 6 (14%) </span>PRu (unconfirmed; EE with &gt;30% contraction as best response 6 (14%)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EE 15 (35%) </span>EE 15 (35%)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">EP 15 (35%) Tasa de beneficio clínico (RP+EE &gt;4 meses) N (%) 17/43 (40%) Duración de la respuesta objetiva confirmada, meses mediana (IC del 95 %) 5,7 (3,6, </span>EP 15 (35%) Clinical benefit rate (PR+EE &gt;4 months) N (%) 17/43 (40%) Duration of confirmed objective response, months median (95% CI) 5.7 (3, 6,</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19,9) Supervivencia libre de progresión, meses (N = 53), mediana (IC del 95%) 3,6 (2,0, 4,3) Supervivencia general, meses (N = 53), mediana (IC del 95 %) 7,0 (5,5; 8,3) Evaluación de la respuesta de IMMU-132 en pacientes sensibles (N = 24) a la 1.a línea. </span>19.9) Progression-free survival, months (N = 53), median (95% CI) 3.6 (2.0, 4.3) Overall survival, months (N = 53), median (95% CI) %) 7.0 (5.5, 8.3) Evaluation of the response of IMMU-132 in sensitive patients (N = 24) to the 1st line.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">PFS (mediana de meses; IC del 95 %) </span>PFS (median months; 95% CI)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SG (mediana de meses; IC del 95 %) 3,8 (2,8; 6,0) Tasa de beneficio clínico (RP+EE &gt;4 meses) N (%) 8,3 (7,0, </span>OS (median months; 95% CI) 3.8 (2.8, 6.0) Clinical benefit rate (PR+EE &gt;4 months) N (%) 8.3 (7.0, 6.0)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13,2) Evaluación de la respuesta de IMMU-132 en pacientes resistentes (N = 19) a ia línea. 12/24 (50%) </span>13.2) Evaluation of the response of IMMU-132 in patients resistant (N = 19) to the line. 12/24 (50%)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SSP (mediana de meses; IC del 95 %) 3.6 (1,8; 3,8) SG (mediana de meses; IC del 95 %) 6,2 (4,0; </span>PFS (median months; 95% CI) 3.6 (1.8, 3.8) OS (median months; 95% CI) 6.2 (4.0;</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10.5) </span>10.5)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tasa de beneficio clínico (RP+EE &gt;4 meses) N (%) 5/19 (26%) Pacientes que reciben IMMU-132 como segunda línea (N = 19) </span>Clinical benefit rate (PR+EE &gt;4 months) N (%) 5/19 (26%) Patients receiving IMMU-132 as second line (N = 19)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SSP, mediana de meses (IC del 95%) 3.6 (2,0, 5,3) SG (mediana de meses; IC del 95 %) 8,1 (7,5; </span>PFS, median months (95% CI) 3.6 (2.0, 5.3) OS (median months; 95% CI) 8.1 (7.5, 5.3)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10.5) </span>10.5)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tasa de beneficio clínico (RP+EE &gt;4 meses) N (%) 7/19 (37%) Pacientes que reciben IMMU-132 como línea &gt;3 (N = 24) </span>Clinical benefit rate (PR+EE &gt;4 months) N (%) 7/19 (37%) Patients receiving IMMU-132 as line &gt;3 (N = 24)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SLP, mediana de meses (IC del 95 %) 3,7 (1,8; 5,5) SG (mediana de meses; IC del 95 %) 7,0 (6,2; </span>PFS, median months (95% CI) 3.7 (1.8, 5.5) OS (median months, 95% CI) 7.0 (6.2, 5.5)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20,9) </span>20.9)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tasa de beneficio clínico (RP+EE &gt;4 meses) N (%) 9/24 (38%) IMMU-132 administrado como &gt;3 líneas y </span>Clinical benefit rate (PR+EE &gt;4 months) N (%) 9/24 (38%) IMMU-132 administered as &gt;3 lines and</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Topotecán/irinotecán previo (N = 15) </span>Prior topotecan/irinotecan (N = 15)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SSP, mediana de meses (IC del 95 %) 3.6 (3,3; 5,5) SG (mediana de meses; IC del 95 %) 8,8 (6,2; </span>PFS, median months (95% CI) 3.6 (3.3, 5.5) OS (median months, 95% CI) 8.8 (6.2, 5.5)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20,9) </span>20.9)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tasa de beneficio clínico (RP+EE &gt;4 meses) N (%) 6/15 (40%) Sin topotecán/irinotecán previo (N = 9) </span>Clinical benefit rate (PR+EE &gt;4 months) N (%) 6/15 (40%) No prior topotecan/irinotecan (N = 9)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SSP, mediana de meses (IC del 95 %) 3.7 (1,7; 4,3) SG (mediana de meses; IC del 95 %) 5,5 (3,2; 8,3) _______________ Tasa de beneficio clínico (RP+EE &gt;4 meses) N (%)__________________ 3/9 (33%) </span>PFS, median months (95% CI) 3.7 (1.7, 4.3) OS (median months, 95% CI) 5.5 (3.2, 8.3) _______________ Clinical benefit rate ( RP+EE &gt;4 months) N (%)__________________ 3/9 (33%)</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0264] La enfermedad estable (EE) se determinó en 21 pacientes (49%), e incluyó a seis (14%) que inicialmente tenían una reducción tumoral &gt;30% que no se mantuvo en la TC de confirmación posterior (RP o PRu no confirmada), y tres pacientes que tenían una reducción tumoral &gt;20%. Es importante señalar que diez pacientes tuvieron EE durante &gt;4 meses (mediana derivada de Kaplan-Meier = 5,6 meses, IC del 95 %: 5,2, 9,7), lo que no fue significativamente diferente de la mediana de SLP para el grupo de RP confirmada (7,9 meses, IC del 95%: 7,6, 21,9;P= 0,1620), y una tasa de beneficio clínico (TBC: Rp EE&gt;4 meses) del 40% (17/43). De hecho, incluso la SG para estos diez pacientes con EE no fue significativamente diferente de la de los siete pacientes con RP confirmada (8,3 meses, IC del 95 %: 7,5, 22,4 meses frente a 9,2 meses, IC del 95 %: 6,2, 20,9, respectivamente;P= 0,5599). Esto sugiere que mantener la EE durante un período adecuado (&gt;4 meses) debería ser un criterio de valoración de interés. Según la intención de tratar (ITT) (N = 53), la mediana de SSp fue de 3,6 meses (IC del 95 %: 2,0, 4,3) (FIG. 17 (A)), mientras que la mediana de S&lt;g&gt;fue de 7,0 meses (95 % IC: 5,5, 8,3), con 17 pacientes vivos y 5 perdidos durante el seguimiento (uno después de 1,8 meses, uno después de 5 meses y tres después de 11,4-12,8 meses) (FIG. 17 (B)). </span>[0264] Stable disease (SE) was determined in 21 patients (49%), and included six (14%) who initially had &gt;30% tumor shrinkage that was not maintained on subsequent confirmatory CT (RP or PRu not confirmed), and three patients who had &gt;20% tumor reduction. Importantly, 10 patients had EE for &gt;4 months (Kaplan-Meier derived median = 5.6 months, 95% CI: 5.2, 9.7), which was not significantly different from the median PFS for the confirmed PR group (7.9 months, 95% CI: 7.6, 21.9; P= 0.1620), and a clinical benefit rate (TBC: Rp EE&gt;4 months) of 40% (17/43). In fact, even the OS for these ten patients with EoE was not significantly different from that of the seven patients with confirmed PR (8.3 months, 95% CI: 7.5, 22.4 months vs. 9.2 months , 95% CI: 6.2, 20.9, respectively;P= 0.5599). This suggests that maintaining EE for an adequate period (&gt;4 months) should be an endpoint of interest. On an intention-to-treat (ITT) basis (N = 53), median pSS was 3.6 months (95% CI: 2.0, 4.3) (FIG. 17 (A)), while Median S&lt;g&gt;was 7.0 months (95% CI: 5.5, 8.3), with 17 patients alive and 5 lost to follow-up (one after 1.8 months, one after 5 months and three after 11.4-12.8 months) (FIG. 17 (B)).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0265] Trece de los 43 pacientes con una evaluación de respuesta objetiva fueron tratados con 8 mg/kg, uno confirmado (8%), uno RP no confirmado y tres EE. En el grupo de 10 mg/kg (N = 30), seis pacientes tuvieron RP confirmada (20%) y doce tuvieron EE, incluidos cinco con una TC que mostró una reducción &gt;30% (PRu). La TBC fue del 47 % (14/30), lo que sugiere que la dosis inicial de 10 mg/kg proporcionó una mejor respuesta general. </span>[0265] Thirteen of the 43 patients with an objective response evaluation were treated with 8 mg/kg, one confirmed (8%), one unconfirmed PR and three EE. In the 10 mg/kg group (N = 30) , six patients had confirmed PR (20%) and twelve had EE, including five with a CT scan showing &gt;30% reduction (PRu). The TBC was 47% (14/30), suggesting that the initial dose of 10 mg/kg provided a better overall response.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0266] Veinticuatro pacientes con una evaluación de respuesta fueron clasificados como sensibles a la primera línea de quimioterapia basada en platino (Tabla 7). Cuatro (17%) lograron una RP confirmada y nueve tuvieron EE, incluidos cuatro con una única exploración que mostró una reducción del tumor (PRu) &gt;30%. Diecinueve pacientes fueron resistentes, tres (16%) tenían RP confirmada y seis EE, incluidos dos con PRu. La mediana de SSP para los grupos quimiosensibles y quimiorresistentes fue de 3,8 meses (IC del 95 %: 2,8, 6,0) y 3,6 meses (IC del 95 %: 1,8, 3,8), respectivamente, mientras que la mediana de SG fue de 8,3 meses (IC del 95 %: 7,0, 13,2) y 6,2 meses (IC del 95%: 4,0, 10,5), respectivamente (Tabla 7). No se encontraron diferencias significativas en la SLP o la SG entre los grupos quimiosensibles y quimiorresistentes (P = 0,3981 y P = 0,3100, respectivamente). </span>[0266] Twenty-four patients with a response evaluation were classified as sensitive to first line platinum-based chemotherapy (Table 7). Four (17%) achieved confirmed PR and nine had EE, including four with a single scan showing tumor shrinkage (PRu) &gt;30%. Nineteen patients were resistant, three (16%) had confirmed PR and six EE, including two with PRu. The median PFS for the chemosensitive and chemoresistant groups was 3.8 months (95% CI: 2.8, 6.0) and 3.6 months (95% CI: 1.8, 3.8), respectively, while the median OS was 8.3 months (95% CI: 7.0, 13.2) and 6.2 months (95% CI: 4.0, 10.5), respectively ( Table 7). No significant differences in PFS or OS were found between the chemosensitive and chemoresistant groups (P = 0.3981 and P = 0.3100, respectively).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0267] Diecinueve de los 43 pacientes recibieron sacituzumab govitecan en segunda línea, y 3/19 (16%) tuvieron una RP y siete EE como mejor respuesta (dos de estos últimos tuvieron una reducción del tumor &gt;30%). La respuesta observada en estos pacientes fue la misma que la encontrada en los pacientes que recibieron sacituzumab govitecan como tercera o superior línea de tratamiento (N = 24), con cuatro RP confirmadas (16%) y 8 EE, incluidos cuatro pacientes con EE. con &gt;30% de reducción del tumor en una TC. No se encontraron diferencias significativas en la duración de la SSP o la SG(P= 0,9538 yP= 0,6853, respectivamente). Los análisis de respuesta se resumen en la Tabla 7. </span>[0267] Nineteen of the 43 patients received second-line sacituzumab govitecan, and 3/19 (16%) had a PR and seven SE as best response (two of the latter had &gt;30% tumor shrinkage). The response observed in these patients was the same as that found in patients who received sacituzumab govitecan as a third or higher line of treatment (N = 24), with four confirmed PRs (16%) and 8 SEs, including four patients with SEs. with &gt;30% tumor reduction on CT. No significant differences were found in the duration of PFS or OS (P= 0.9538 and P= 0.6853, respectively). The response analyzes are summarized in Table 7.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0268] Entre los cinco pacientes que recibieron tratamiento previo con un inhibidor de puntos de control inmunológico (IPC), uno experimentó una RP no confirmada (reducción del 54 % en la primera evaluación, retiró el consentimiento sin tratamiento o evaluaciones adicionales), dos lograron EE y uno tuvo una reducción del tumor del 17 % que duraba 8,7 meses y el otro sin cambios en el tamaño del tumor durante 3,7 meses, uno tenía enfermedad progresiva, mientras que el quinto paciente retiró su consentimiento después de un ciclo de sacituzumab govitecan. Todos los pacientes tratados con IPC no respondieron al IPC o progresaron antes de recibir sacituzumab govitecan, lo que indica que los pacientes pueden responder a IMMU-132 después de recibir el tratamiento con IPC. </span>[0268] Among the five patients who received prior treatment with an immune checkpoint inhibitor (CPI), one experienced an unconfirmed PR (54% reduction at first evaluation, withdrew consent without treatment or additional evaluations), two achieved EE and one had a 17% tumor shrinkage lasting 8.7 months and the other no change in tumor size for 3.7 months, one had progressive disease, while the fifth patient withdrew consent after a sacituzumab govitecan cycle. All patients treated with IPC did not respond to IPC or progressed before receiving sacituzumab govitecan, indicating that patients may respond to IMMU-132 after receiving IPC treatment.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0269] De los 24 pacientes que recibieron sacituzumab govitecan como terapia de tercera o última línea, quince habían recibido previamente topotecán y/o irinotecán, mientras que nueve nunca recibieron estos agentes. Las respuestas objetivas en estos dos grupos fueron similares, sin diferencias significativas en la SSP (3,8 frente a 3,7 meses;P= 0,7341). Sin embargo, aquellos tratados con sacituzumab govitecán que recibieron tratamiento previo con topotecán tuvieron una SG significativamente más larga que aquellos que no lo recibieron (8,8 meses, IC del 95 %: 6,2, 20,9 frente a 5,5 meses, IC del 95 %: 3,2, 8,3;P= 0,0357). La SG más prolongada en este grupo puede reflejar la actividad conocida del topotecán en pacientes sensibles al platino y, por lo tanto, puede tener un mejor resultado a largo plazo. </span>[0269] Of the 24 patients who received sacituzumab govitecan as third- or last-line therapy, fifteen had previously received topotecan and/or irinotecan, while nine had never received these agents. Objective responses in these two groups were similar, with no significant differences in PFS (3.8 vs. 3.7 months; P = 0.7341). However, those treated with sacituzumab govitecan who were previously treated with topotecan had a significantly longer OS than those who did not (8.8 months, 95% CI: 6.2, 20.9 vs 5.5 months , 95% CI: 3.2, 8.3;P= 0.0357). The longer OS in this group may reflect the known activity of topotecan in platinum-sensitive patients and therefore may have a better long-term outcome.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0270] Se presenta en la FIG. 18 un paciente que recibió sacituzumab govitecan después de una recaída al tratamiento de primera línea con carboplatino más etopósido. Otro ejemplo con una reducción considerable del tumor se muestra en la FIG. 19. </span>[0270] It is presented in FIG. 18 a patient who received sacituzumab govitecan after relapse to first-line treatment with carboplatin plus etoposide. Another example with considerable tumor reduction is shown in FIG. 19.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0271] Tinción inmunohistoquímica (IHC, por sus siglas en inglés) de muestras de tumores: se obtuvieron muestras de tumores de archivo de 29 pacientes, pero cuatro fueron inadecuadas para su revisión, lo que dejó 25 tumores evaluables, de los cuales el 92 % fueron positivos, y dos (8 %) tuvieron fuertes (3+) y trece (52%) tinción moderada (2+). Veintitrés de estos pacientes tuvieron una evaluación de respuesta objetiva. Hubo cinco con RP confirmada y dos RP no confirmadas en este grupo; cinco tenían tinción 2+, mientras que los otros dos tenían 1+ (no se muestra), lo que sugiere que una mayor expresión proporcionó mejores respuestas. Sin embargo, una evaluación de los valores de SSP y SG frente a la puntuación IHC no mostró una tendencia clara (no se muestra), y las estimaciones de Kaplan-Meier para SSP y SG para pacientes con puntuaciones IHC de 0 y 1+ combinadas (N = 10) frente a 2+ y 3+ combinadas (N = 13) no indicaron diferencias significativas (SSP,P= 0,2661; SG,P= 0,7186) según la puntuación IHC (no se muestra). </span>[0271] Immunohistochemical (IHC) staining of tumor samples: Archival tumor samples were obtained from 29 patients, but four were unsuitable for review, leaving 25 evaluable tumors, of which 92 % were positive, and two (8%) had strong (3+) and thirteen (52%) moderate (2+) staining. Twenty-three of these patients had an objective response evaluation. There were five with confirmed RP and two unconfirmed RP in this group; five had 2+ staining, while the other two had 1+ (not shown), suggesting that higher expression provided better responses. However, an evaluation of PFS and OS values against IHC score did not show a clear trend (not shown), and Kaplan-Meier estimates for PFS and OS for patients with IHC scores of 0 and 1+ combined (N = 10) vs 2+ and 3+ combined (N = 13) indicated no significant differences (PFS,P= 0.2661; OS,P= 0.7186) by IHC score (not shown).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0272] Inmunogenicidad del anticuerpo CAF, SN-38 o hRS7: no se detectaron anticuerpos neutralizantes contra sacituzumab govitecan, el anticuerpo o SN-38 en pacientes que mantuvieron el tratamiento incluso durante hasta 22 meses. </span>[0272] Immunogenicity of the CAF antibody, SN-38 or hRS7: No neutralizing antibodies against sacituzumab govitecan, the antibody or SN-38 were detected in patients who maintained treatment even for up to 22 months.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Discusión</span>Discussion</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0273] La recaída del CPCP a la quimioterapia de primera línea continúa dividiéndose en dos categorías: recaída resistente, que ocurre dentro de los tres meses posteriores a la primera terapia basada en platino, y recaída sensible, que ocurre después de al menos 3 meses después del tratamiento (O'Brien et al, 2006, J Clin Oncol 24:5441-7; Pérez-Soler et al., 1996, J Clin Oncol 14:2785-90). Aunque todavía existe cierta ambigüedad con respecto al mejor manejo del CPCP recurrente, el topotecán, un inhibidor de la topoisomerasa I similar al SN-38 utilizado en el CAF estudiado en este documento, es el único producto aprobado para la recaída quimiosensible, como lo respaldan numerosos ensayos (O'Brien et al., 2006, J Clin Oncol 24:5441-7; Horita et al., 2015, Sci Rep 5:15437). Sin embargo, la eficacia y los eventos adversos del topotecán han variado considerablemente en estudios anteriores, como lo demuestra un metanálisis de más de mil pacientes reportado en 14 artículos que el topotecán tuvo una tasa de respuesta objetiva del 5% en pacientes quimiorresistentes de primera línea y del 17% en pacientes quimiosensibles (Horita et al., 2015, Sci Rep 5: 15437). Hubo neutropenia, trombocitopenia y anemia de grado &gt;3 en el 69 %, 1 % y 24 % de los pacientes, respectivamente, y aproximadamente el 2 % de los pacientes murieron a causa de esta quimioterapia (Horita et al., 2015, Sci Rep 5:15437). Por lo tanto, el topotecán se muestra prometedor en este contexto de segunda línea en pacientes que recayeron después de mostrar sensibilidad a una quimioterapia basada en platino, pero con una toxicidad hematológica considerable. Sin embargo, incluso esta conclusión fue cuestionada recientemente por Lara et al. (2015, J Thorac Oncol 10:110-5), quienes afirmaron que la sensibilidad al platino no está fuertemente asociada con una mejor SSP y SG después del tratamiento con topotecán, que es su indicación actualmente aprobada. </span>[0273] SCLC relapse to first-line chemotherapy continues to be divided into two categories: resistant relapse, which occurs within three months of the first platinum-based therapy, and sensitive relapse, which occurs after at least 3 months after treatment (O'Brien et al, 2006, J Clin Oncol 24:5441-7; Pérez-Soler et al., 1996, J Clin Oncol 14:2785-90). Although there is still some ambiguity regarding the best management of recurrent SCLC, topotecan, a topoisomerase I inhibitor similar to SN-38 used in the CAF studied here, is the only product approved for chemosensitive relapse, as supported by numerous trials (O'Brien et al., 2006, J Clin Oncol 24:5441-7; Horita et al., 2015, Sci Rep 5:15437). However, the efficacy and adverse events of topotecan have varied considerably in previous studies, as demonstrated by a meta-analysis of more than a thousand patients reported in 14 articles that topotecan had an objective response rate of 5% in first-line chemoresistant patients. and 17% in chemosensitive patients (Horita et al., 2015, Sci Rep 5: 15437). Neutropenia, thrombocytopenia, and grade &gt;3 anemia occurred in 69%, 1%, and 24% of patients, respectively, and approximately 2% of patients died from this chemotherapy (Horita et al., 2015, Sci Rep 5:15437). Therefore, topotecan shows promise in this second-line setting in patients who relapsed after showing sensitivity to platinum-based chemotherapy, but with considerable hematological toxicity. However, even this conclusion was recently questioned by Lara et al. (2015, J Thorac Oncol 10:110-5), who stated that platinum sensitivity is not strongly associated with better PFS and OS after treatment with topotecan, which is its currently approved indication.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0274] Es en este contexto donde se presentan los resultados aquí presentados con sacituzumab govitecan en pacientes con enfermedad prolongada y avanzada. Los pacientes (estadio IV) que siguen una mediana de 2 (rango, 1 a 7) terapias previas son prometedores. Cuarenta y nueve por ciento de los pacientes mostró una reducción de las mediciones del tumor desde el inicio, según RECIST 1.1, con una TRO del 16% y una mediana duración de la respuesta de 5,7 meses (IC del 95%: 3,6, 19,9). Se encontró enfermedad estable en el 35% de los pacientes, donde el 14% de los estos pacientes con EE tuvieron una reducción del tumor &gt;30% como mejor respuesta, aunque no se mantuvieron en la segunda exploración. La tasa de beneficio clínico a &gt;4 meses fue del 40%. La mediana de SSP y SG fue de 3,6 y 7,0 meses, respectivamente. Es interesante que la mediana de SG para los diez pacientes con EE fue de 8,3 meses (IC del 95 %: 7,5, 22,4), lo que no es estadísticamente diferente a partir de la mediana de SG de 9,2 meses (IC del 95 %: 6,2, 20,9) para pacientes con RP(P= 0,5599). En el grupo que recibe 10 mg/kg como dosis inicial (N = 30), hubo una respuesta objetiva confirmada en seis (20%), y cinco pacientes adicionales tuvieron una única TC que mostró una reducción del tumor (PRu) &gt;30%. Además, la tasa de beneficio clínico para este grupo con la dosis de 10 mg/kg fue del 47%. Esto respalda la dosis preferida de 10 mg/kg. También es digna de mención la falta de selección de pacientes requerida en función de la tinción inmunohistoquímica del tumor Trop-2, aunque hubo una sugerencia de que una tinción más fuerte se correlacionaba con una mejor respuesta, pero no se encontraron diferencias significativas en la SSP o la SG con respecto a la puntuación IHC. </span>[0274] It is in this context that the results presented here with sacituzumab govitecan in patients with prolonged and advanced disease are presented. Patients (stage IV) following a median of 2 (range, 1 to 7) prior therapies are promising. Forty-nine percent of patients showed a reduction in tumor measurements from baseline, according to RECIST 1.1, with an ORR of 16% and a median duration of response of 5.7 months (95% CI: 3. 6, 19,9). Stable disease was found in 35% of patients, where 14% of these patients with EE had &gt;30% tumor reduction as the best response, although they were not maintained in the second examination. The clinical benefit rate at &gt;4 months was 40%. Median PFS and OS were 3.6 and 7.0 months, respectively. Interestingly, the median OS for the ten EoE patients was 8.3 months (95% CI: 7.5, 22.4), which is not statistically different from the median OS of 9. 2 months (95% CI: 6.2, 20.9) for patients with RP(P= 0.5599). In the group receiving 10 mg/kg as a starting dose (N = 30), there was a confirmed objective response in six (20%), and an additional five patients had a single CT scan showing &gt;30% tumor shrinkage (PRu). . Furthermore, the clinical benefit rate for this group with the 10 mg/kg dose was 47%. This supports the preferred dose of 10 mg/kg. Also noteworthy is the lack of patient selection required based on immunohistochemical staining of the Trop-2 tumor, although there was a suggestion that stronger staining correlated with a better response, but no significant differences in PFS were found. or OS with respect to IHC score.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0275] Como se mencionó, la SSP y la SG no difirieron sustancialmente entre pacientes con EE &gt;4 meses o RP. Los pacientes con RP no confirmada (es decir, &gt;30% de reducción del tumor en una TC) o con EE generalmente no se consideran en la mayoría de las evaluaciones de TRO. Sin embargo, los resultados aquí no indican diferencias en la duración de la respuesta entre pacientes con RP o EE confirmada que dura más de 4 meses (FIG. 16B). De hecho, el seguimiento dinámico de las respuestas individuales de los pacientes para RP o EE (especialmente cuando la EE dura &gt; 4 meses, que es un marco de tiempo similar para confirmar la RP) sugiere un beneficio clínico para ambos grupos al permanecer por debajo del tamaño inicial del tumor durante varios meses (FIG. 16C). Aunque hubo una tendencia a que la SSP de los pacientes con RP confirmada fuera más larga que la del grupo de pacientes con EE que duró &gt;4 meses (P = 0,1620), la SG para estos 2 grupos no fue significativamente diferente (P = 0,5599). Por lo tanto, si bien el número de pacientes en este análisis inicial es relativamente pequeño, los datos sugieren que se debe dar más consideración a la estabilización de la enfermedad como un indicador importante de la actividad clínica cuando se logra una duración adecuada, similar al seguimiento de los pacientes que reciben tratamiento inmunológico. inhibidores de puntos de control. </span>[0275] As mentioned, PFS and OS did not differ substantially between patients with EE &gt;4 months or PR. Patients with unconfirmed PR (i.e., &gt;30% tumor shrinkage on CT) or EE are generally not considered in most ORR evaluations. However, the results here indicate no differences in duration of response between patients with confirmed PR or EE lasting more than 4 months (FIG. 16B). Indeed, dynamic monitoring of individual patient responses to RP or EE (especially when EE lasts &gt; 4 months, which is a similar time frame for confirming RP) suggests clinical benefit for both groups in remaining below of the initial size of the tumor for several months (FIG. 16C). Although there was a trend for the PFS of patients with confirmed PR to be longer than that of the group of patients with EE lasting &gt;4 months (P = 0.1620), the OS for these 2 groups was not significantly different (P = 0.5599). Therefore, although the number of patients in this initial analysis is relatively small, the data suggest that more consideration should be given to disease stabilization as an important indicator of clinical activity when an adequate duration is achieved, similar to monitoring of patients receiving immunological treatment. checkpoint inhibitors.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0276] La evaluación de los pacientes según la quimiosensibilidad previa (N = 24) o la quimiorresistencia (N = 19) no muestra diferencias en la respuesta con el tratamiento con sacituzumab govitecan (Tabla 7). Los resultados de SSP y SG fueron de 3,8 y 8,3 meses para los pacientes quimiosensibles en primera línea, en comparación con una SSP y SG de 3,6 meses y 6,2 meses, respectivamente, para el grupo quimiorresistente. Sin diferencia estadística, parece que sacituzumab govitecan se puede administrar a pacientes en terapias de segunda o última línea, independientemente de que los pacientes sean quimiosensibles o quimiorresistentes a la quimioterapia de primera línea. Esto difiere del topotecán, que está indicado sólo en aquellos pacientes con CPCP que mostraron una respuesta de &gt;3 meses a la quimioterapia de primera línea con cisplatino y etopósido ((O'Brien et al., 2006, J Clin Oncol 24:5441-7; Pérez-Soler et al., 1996, J Clin Oncol 14:2785-90). De 28 pacientes estudiados por Pérez-Solar et al. (1996, J Clin Oncol 14:2785-90), el 11% tuvo una RP, con una mediana de supervivencia de 5 meses y una supervivencia a un año del 3,5%. </span>[0276] Evaluation of patients according to previous chemosensitivity (N = 24) or chemoresistance (N = 19) shows no difference in response with treatment with sacituzumab govitecan (Table 7). PFS and OS results were 3.8 and 8.3 months for chemosensitive patients in first-line, compared with PFS and OS of 3.6 months and 6.2 months, respectively, for the chemoresistant group. Without statistical difference, it appears that sacituzumab govitecan can be administered to patients on second- or last-line therapies, regardless of whether patients are chemosensitive or chemoresistant to first-line chemotherapy. This differs from topotecan, which is indicated only in those patients with SCLC who showed a response of &gt;3 months to first-line chemotherapy with cisplatin and etoposide ((O'Brien et al., 2006, J Clin Oncol 24:5441- 7; Pérez-Soler et al., 1996, J Clin Oncol 14:2785-90). PR, with a median survival of 5 months and a one-year survival of 3.5%.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0277] Aunque tanto el topotecán como el SN-38 son inhibidores de la enzima ADN topoisomerasa I, que es responsable de relajar una hélice de ADN superenrollada cuando el ADN se sintetiza mediante la estabilización del complejo de ADN, provocando la acumulación de roturas de ADN de una sola cadena (Takimoto &amp; Arbuck, 1966, Camptothecins (En: Chabner &amp; Long (Eds.), Cancer Chemotherapy and Biotherapy. Segunda ed. Filadelfia: Lippincott-Raven; p. 463-84), sacituzumab govitecan mostró actividad en pacientes que recayeron después de la terapia con topotecán. Por lo tanto, la resistencia o recaída al topotecán puede no ser una contraindicación para la administración de sacituzumab govitecan y, debido a que es igualmente activo en pacientes que eran quimiorresistentes al cisplatino y al etopósido, puede ser de particular valor como tratamiento de segunda línea en pacientes con CPCP metastásico independientemente de estado de quimiosensibilidad. </span>[0277] Although both topotecan and SN-38 are inhibitors of the enzyme DNA topoisomerase I, which is responsible for relaxing a supercoiled DNA helix when DNA is synthesized by stabilizing the DNA complex, causing the accumulation of DNA breaks. single-stranded DNA (Takimoto &amp; Arbuck, 1966, Camptothecins (In: Chabner &amp; Long (Eds.), Cancer Chemotherapy and Biotherapy. Second ed. Philadelphia: Lippincott-Raven; p. 463-84), sacituzumab govitecan showed activity in patients who relapsed after topotecan therapy Therefore, resistance or relapse to topotecan may not be a contraindication to the administration of sacituzumab govitecan and, because it is equally active in patients who were chemoresistant to cisplatin and etoposide, may be of particular value as a second-line treatment in patients with metastatic SCLC regardless of chemosensitivity status.</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0278] En los veinte años transcurridos desde la aprobación del topotecán en segunda línea, no se ha autorizado ningún agente nuevo para el tratamiento del CPCP metastásico en segunda línea o en tratamientos posteriores. Sin embargo, más recientemente ha habido avances con inhibidores de la proteína de muerte celular programada (EP-1) de los receptores de puntos de control de células T y la proteína 4 asociada a linfocitos T citotóxicos (CTLA-4) (Antonia et al.,&lt;2 0 1 6&gt;, Lancet Oncol 17:883-95). Estos autores realizaron un ensayo de fase I-II de nivolumab con o sin ipilimumab del anticuerpo CTLA-4 en pacientes con CPCP recurrente. Nivolumab solo logró una tasa de respuesta del 10 %, mientras que la combinación tuvo tasas de respuesta del 19 al 23 % y una tasa de control de la enfermedad del 32 % (Antonia et al., 2016, Lancet Oncol 17:883-95). Sin embargo, un estudio reciente de ipilimumab con o sin quimioterapia en CPCP no pudo confirmar estos resultados (Reck et al., 2016, J Clin Oncol 34:3740-48). Dado que observamos que sacituzumab govitecan puede tener actividad en pacientes que fracasan en la terapia con inhibidores de puntos de control inmunológico, estamos estudiando esto más a fondo, especialmente debido a la evidencia que muestra tales respuestas después de la terapia con un inhibidor de puntos de control inmunológico en pacientes con otros tipos de cáncer (Bardia et al., 2017, J Clin Oncol 35:2141-48; Faltas et al., 2016, Clin Genitourin Cancer 14:e75-9; Heist et al., 2017, J Clin Oncol 35:2790-97; Tagawa et al., 2017, J Clin Oncol 35: resumen 327). </span>[0278] In the twenty years since the approval of topotecan in second line, no new agent has been approved for the treatment of metastatic SCLC in second line or subsequent treatments. However, more recently there have been advances with inhibitors of the T cell checkpoint receptor programmed cell death protein (EP-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) (Antonia et al .,&lt;2 0 1 6&gt;, Lancet Oncol 17:883-95). These authors conducted a phase I-II trial of nivolumab with or without the CTLA-4 antibody ipilimumab in patients with recurrent SCLC. Nivolumab alone achieved a 10% response rate, while the combination had response rates of 19 to 23% and a disease control rate of 32% (Antonia et al., 2016, Lancet Oncol 17:883-95 ). However, a recent study of ipilimumab with or without chemotherapy in SCLC failed to confirm these results (Reck et al., 2016, J Clin Oncol 34:3740-48). Since we observed that sacituzumab govitecan may have activity in patients who fail immune checkpoint inhibitor therapy, we are studying this further, especially given the evidence showing such responses after therapy with a checkpoint inhibitor. immune control in patients with other types of cancer (Bardia et al., 2017, J Clin Oncol 35:2141-48; Faltas et al., 2016, Clin Genitourin Cancer 14:e75-9; Heist et al., 2017, J Clin Oncol 35:2790-97; Tagawa et al., 2017, J Clin Oncol 35: abstract 327).</span>
  </p>
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[0279] A pesar de los recientes avances en inmunoterapia y la identificación de otros objetivos novedosos para el CPCP (Rudin et al., 2017, Lancet Oncol 18:42-51), esta sigue siendo una enfermedad letal, especialmente en la población quimiorresistente a la terapia de primera línea. Los resultados actuales de sacituzumab govitecan en pacientes muy pretratados con CPCP en estadio IV avanzado y recidivante sugieren que este CAF es útil en el tratamiento de pacientes con CPCP quimiosensible y quimiorresistente, tanto antes como después de topotecan. </span>[0279] Despite recent advances in immunotherapy and the identification of other novel targets for SCLC (Rudin et al., 2017, Lancet Oncol 18:42-51), it remains a lethal disease, especially in the chemoresistant population. to first-line therapy. The current results of sacituzumab govitecan in heavily pretreated patients with advanced and relapsed stage IV SCLC suggest that this CAF is useful in the treatment of patients with chemosensitive and chemoresistant SCLC, both before and after topotecan.</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(15)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Spanish</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM458424069" lang="EN" load-source="google" class="style-scope patent-text">
  <claim num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REIVINDICACIONES
1. Un conjugado de fármaco-anticuerpo anti-Trop-2 (CAF) que comprende SN-38 conjugado con un anticuerpo anti-Trop-2, para usar en un método para tratar el cáncer de pulmón de células pequeñas (CPCP), en donde el método comprende administrar a un paciente humano con CPCP (i) el conjugado anticuerpo-fármaco (CAF) anti-Trop-2 y (ii) cisplatino o carboplatino, en el que el CAF se administra como terapia de segunda línea o posterior a pacientes que han recibido tratamiento previo contra el cáncer para el CPCP, en el que el anticuerpo anti-Trop-2 es un anticuerpo RS7 humanizado que comprende las secuencias CDR de cadena ligera CDR1 (KASQDVSIAVA, SEQ ID NO:1); Cd R2 (SASYRYT, SEQ ID NO:2); y CDR3 (QQHYITPLT, SEQ ID NO:3) y las secuencias de CDR de cadena pesada CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) y CDR3 (GGFGSSYWYFDV, SEQ ID NO:6), y en donde hay un conector CL2A entre el SN-38 y el anticuerpo y la estructura del CAF es MAb-CL2A-SN-38. </span>CLAIMS
1. An anti-Trop-2 antibody-drug conjugate (CAF) comprising SN-38 conjugated to an anti-Trop-2 antibody, for use in a method of treating small cell lung cancer (SCLC), in wherein the method comprises administering to a human SCLC patient (i) the anti-Trop-2 antibody-drug conjugate (CAF) and (ii) cisplatin or carboplatin, wherein the CAF is administered as second-line or subsequent therapy. patients who have received prior anti-cancer treatment for SCLC, wherein the anti-Trop-2 antibody is a humanized RS7 antibody comprising the CDR1 light chain CDR sequences (KASQDVSIAVA, SEQ ID NO:1); Cd R2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6), and where there is a CL2A linker between SN-38 and the antibody and the structure of the CAF is MAb-CL2A-SN-38 .</span>
    </claim-text>
  </claim>
  <claim num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Cisplatino o carboplatino para usar en un método para tratar el cáncer de pulmón de células pequeñas (CPCP), en donde el método comprende administrar a un paciente humano con CPCP (i) un conjugado de anticuerpo-fármaco (CAF) anti-Trop-2 que comprende SN-38 conjugado con un anticuerpo anti-Trop-2 y (ii) cisplatino o carboplatino, en donde el CAF se administra como terapia de segunda línea o posterior a pacientes que han recibido tratamiento oncológico previo para el CPCP, en donde el anticuerpo anti-Trop-2 es un anticuerpo RS7 humanizado que comprende las secuencias CDR de cadena ligera CDR1 (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); y CDR3 (QQHYITPLT, SEQ ID NO:3) y las secuencias de CDR de cadena pesada CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5) y CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6), y en donde hay un conector CL2A entre el SN-38 y el anticuerpo y la estructura del CAF es MAb-CL2A-SN-38. </span>2. Cisplatin or carboplatin for use in a method of treating small cell lung cancer (SCLC), wherein the method comprises administering to a human patient with SCLC (i) an anti-Trop antibody-drug conjugate (CAF). -2 comprising SN-38 conjugated to an anti-Trop-2 antibody and (ii) cisplatin or carboplatin, wherein CAF is administered as second-line or subsequent therapy to patients who have received prior oncological treatment for SCLC, in wherein the anti-Trop-2 antibody is a humanized RS7 antibody comprising the CDR1 light chain CDR sequences (KASQDVSIAVA, SEQ ID NO:1); CDR2 (SASYRYT, SEQ ID NO:2); and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO: 6), and where there is a CL2A linker between SN-38 and the antibody and the structure of the CAF is MAb-CL2A-SN-38 .</span>
    </claim-text>
  </claim>
  <claim num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para el uso de la reivindicación 1, o cisplatino o carboplatino para el uso de la reivindicación 2, en el que el cáncer es metastásico (CPCPm).
</span>3. The anti-Trop-2 antibody-drug conjugate (CAF) for the use of claim 1, or cisplatin or carboplatin for the use of claim 2, wherein the cancer is metastatic (mSCLC).
</span>
    </claim-text>
  </claim>
  <claim num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para el uso de la reivindicación 1, o cisplatino o carboplatino para el uso de la reivindicación 2, en el que el CAF se administra como terapia de segunda línea o posterior a pacientes que han recaído previamente. o han sido resistentes al tratamiento con un agente anticancerígeno estándar.
</span>4. The anti-Trop-2 antibody-drug conjugate (CAF) for the use of claim 1, or cisplatin or carboplatin for the use of claim 2, wherein the CAF is administered as second-line or subsequent therapy. patients who have previously relapsed. or have been resistant to treatment with a standard anticancer agent.
</span>
    </claim-text>
  </claim>
  <claim num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para el uso de la reivindicación 1, o cisplatino o carboplatino para el uso de la reivindicación 2, en el que el paciente ha recaído previamente o ha sido resistente al tratamiento con topotecán o irinotecán.
</span>5. The anti-Trop-2 antibody-drug conjugate (CAF) for the use of claim 1, or cisplatin or carboplatin for the use of claim 2, wherein the patient has previously relapsed or been resistant to treatment with topotecan or irinotecan.
</span>
    </claim-text>
  </claim>
  <claim num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para el uso de la reivindicación 5, o cisplatino o carboplatino para el uso de la reivindicación 5, en el que el CPCP es resistente a la quimioterapia con agentes que contienen platino.
</span>6. The anti-Trop-2 antibody-drug conjugate (CAF) for the use of claim 5, or cisplatin or carboplatin for the use of claim 5, wherein the SCLC is resistant to chemotherapy with platinum-containing agents .
</span>
    </claim-text>
  </claim>
  <claim num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para el uso de la reivindicación 5, o cisplatino o carboplatino para el uso de la reivindicación 5, en el que el CPCP es sensible a la quimioterapia con agentes que contienen platino.
</span>7. The anti-Trop-2 antibody-drug conjugate (CAF) for the use of claim 5, or cisplatin or carboplatin for the use of claim 5, wherein the SCLC is sensitive to chemotherapy with platinum-containing agents .
</span>
    </claim-text>
  </claim>
  <claim num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para el uso de la reivindicación 1, o cisplatino o carboplatino para el uso de la reivindicación 2, en el que el CAF se administra en una dosis de entre 6 mg/kg y 12 mg/kg.
</span>8. The anti-Trop-2 antibody-drug conjugate (CAF) for the use of claim 1, or cisplatin or carboplatin for the use of claim 2, wherein the CAF is administered in a dose between 6 mg/ kg and 12 mg/kg.
</span>
    </claim-text>
  </claim>
  <claim num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para uso de la reivindicación 8, o cisplatino o carboplatino para uso de la reivindicación 8, en el que la dosis está entre 8 mg/kg y 10 mg/kg.
</span>9. The anti-Trop-2 antibody-drug conjugate (CAF) for use in claim 8, or cisplatin or carboplatin for use in claim 8, wherein the dose is between 8 mg/kg and 10 mg/kg.
</span>
    </claim-text>
  </claim>
  <claim num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para el uso de la reivindicación 1, o cisplatino o carboplatino para el uso de la reivindicación 2, en el que el tratamiento da como resultado una reducción del tamaño del tumor de al menos un 15 %, al menos un 20 %, al menos el 30% o al menos el 40%.
</span>10. The anti-Trop-2 antibody-drug conjugate (CAF) for the use of claim 1, or cisplatin or carboplatin for the use of claim 2, wherein the treatment results in a reduction in the size of the tumor of at least 15%, at least 20%, at least 30% or at least 40%.
</span>
    </claim-text>
  </claim>
  <claim num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para uso de la reivindicación 3, o cisplatino o carboplatino para uso de la reivindicación 3, en el que el método comprende además reducir el tamaño o eliminar las metástasis.
</span>11. The anti-Trop-2 antibody-drug conjugate (CAF) for use in claim 3, or cisplatin or carboplatin for use in claim 3, wherein the method further comprises reducing the size or eliminating metastases.
</span>
    </claim-text>
  </claim>
  <claim num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para uso de la reivindicación 1, o cisplatino o carboplatino para uso de la reivindicación 2, en el que hay 7-8 moléculas de SN-38 unidas a cada molécula de anticuerpo.
</span>12. The anti-Trop-2 antibody-drug conjugate (CAF) for use in claim 1, or cisplatin or carboplatin for use in claim 2, wherein there are 7-8 molecules of SN-38 attached to each molecule of antibody.
</span>
    </claim-text>
  </claim>
  <claim num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para uso de la reivindicación 1, o cisplatino o carboplatino para uso de la reivindicación 2, en el que la dosis de CAF se administra al sujeto humano una o dos veces por semana según un horario con un ciclo seleccionado del grupo compuesto por: (i) semanalmente; (ii) cada dos semanas; (iii) una semana de terapia seguida de dos, tres o cuatro semanas de descanso; (iv) dos semanas de terapia seguidas de una, dos, tres o cuatro semanas de descanso; (v) tres semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; (vi) cuatro semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; (vii) cinco semanas de terapia seguidas de una, dos, tres, cuatro o cinco semanas de descanso; y (viii) mensualmente; preferiblemente el ciclo se repite 4, 6, 8, 10, 12, 16 o 20 veces.
</span>13. The anti-Trop-2 antibody-drug conjugate (CAF) for use in claim 1, or cisplatin or carboplatin for use in claim 2, wherein the dose of CAF is administered to the human subject once or twice per week according to a schedule with a cycle selected from the group consisting of: (i) weekly; (ii) every two weeks; (iii) one week of therapy followed by two, three, or four weeks of rest; (iv) two weeks of therapy followed by one, two, three, or four weeks of rest; (v) three weeks of therapy followed by one, two, three, four, or five weeks of rest; (vi) four weeks of therapy followed by one, two, three, four, or five weeks of rest; (vii) five weeks of therapy followed by one, two, three, four, or five weeks of rest; and (viii) monthly; preferably the cycle is repeated 4, 6, 8, 10, 12, 16 or 20 times.
</span>
    </claim-text>
  </claim>
  <claim num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para uso de la reivindicación 1, o cisplatino o carboplatino para uso de la reivindicación 2, en el que el CAF se administra en combinación con una o más modalidades terapéuticas seleccionadas del grupo que consiste en un anticuerpo no conjugado, un inmunoconjugado, terapia génica, quimioterapia, un péptido terapéutico, terapia con citocinas, radioterapia localizada, terapia con ARN de interferencia, un fármaco, una toxina y una citocina, preferiblemente el fármaco, toxina o agente quimioterapéutico se selecciona del grupo que consiste de 5-fluorouracilo, afatinib, aplidina, azaribina, anastrozol, antraciclinas, axitinib, AVL-101, AVL-291, bendamustina, bleomicina, bortezomib, bosutinib, briostatina-1, busulfán, caliqueamicina, camptotecina, 10-hidroxicamptotecina, carmustina, celebrex, clorambucilo, inhibidores de la Cox-2, irinotecán (CPT-11), SN-38, cladribina, camptotecanos, ciclofosfamida, crizotinib, citarabina, dacarbazina, dasatinib, dinaciclib, docetaxel, dactinomicina, daunorrubicina, doxorrubicina, 2-pirrolinodoxorrubicina (2P-DOX), cianomorfolino doxorrubicina, glucurónido de doxorrubicina, glucurónido de epirrubicina, erlotinib, estramustina, epidofilotoxina, erlotinib, entinostat, agentes fijadores de receptores de estrógeno, etopósido (VP16), glucurónido de etopósido, fosfato de etopósido, exemestano, fingolimod, flavopiridol, floxuridina (FUdR), 3',5'-O-dioleoil-FudR (FUdR-dO), fludarabina, flutamida, inhibidores de farnesil-proteína transferasa, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabina, hidroxiurea, ibrutinib, idarrubicina, idelalisib, ifosfamida, imatinib, L-asparaginasa, lapatinib, lenolidamida, leucovorina, LFM-A13, lomustina, mecloretamina, melfalán, mercaptopurina, 6-mercaptopurina, metotrexato, mitoxantrona, mitramicina, mitomicina, mitotano, navelbina, neratinib, nilotinib, nitrosurea, olaparib, plicomicina, procarbazina, paclitaxel, PCI-32765, pentostatina, PSI-341, raloxifeno, semustina, sorafenib, estreptozocina, SU11248, sunitinib, tamoxifeno, temazolomida (una forma acuosa de DTIC), transplatino, talidomida, tioguanina, tiotepa, teniposida, topotecán, mostaza de uracilo, vatalanib, vinorelbina, vinblastina, vincristina, alcaloides de la vinca y ZD1839.
</span>14. The anti-Trop-2 antibody-drug conjugate (CAF) for use in claim 1, or cisplatin or carboplatin for use in claim 2, wherein the CAF is administered in combination with one or more therapeutic modalities selected from the group consisting of an unconjugated antibody, an immunoconjugate, gene therapy, chemotherapy, a therapeutic peptide, cytokine therapy, localized radiotherapy, RNA interference therapy, a drug, a toxin and a cytokine, preferably the drug, toxin or agent chemotherapeutic is selected from the group consisting of 5-fluorouracil, afatinib, aplidine,azaribin, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan, calicheamicin, camptothecin, 10-hydroxycamptothecin, carmustine, celebrex, chlorambucil, Cox-2 inhibitors, irinotecan (CPT-11), SN-38, cladribine, camptothecans, cyclophosphamide, crizotinib, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicin (2P-DOX), cyanomorpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, erlotinib, estramustine, epidophyllotoxin, erlotinib, entinostat, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, phosphate etoposide, exemestane, fingolimod, flavopiridol, floxuridine (FUdR), 3',5'-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, fostamatinib, ganatespib, GDC-0834, GS -1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, L-asparaginase, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin , mitomycin, mitotane, navelbine, neratinib, nilotinib, nitrosurea, olaparib, plicomycin, procarbazine, paclitaxel, PCI-32765, pentostatin, PSI-341, raloxifene, semustine, sorafenib, streptozocin, SU11248, sunitinib, tamoxifen, temazolomide (an aqueous form of DTIC), transplatin, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine, vinca alkaloids and ZD1839.
</span>
    </claim-text>
  </claim>
  <claim num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. El conjugado anticuerpo-fármaco (CAF) anti-Trop-2 para el uso de la reivindicación 1, o cisplatino o carboplatino para el uso de la reivindicación 2, en el que el CAF se administra al paciente humano que se ha sometido a una cirugía o que está programado para una cirugía.</span>15. The anti-Trop-2 antibody-drug conjugate (CAF) for the use of claim 1, or cisplatin or carboplatin for the use of claim 2, wherein the CAF is administered to the human patient who has undergone having surgery or who is scheduled for surgery.</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (6)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9770517B2/en"><a id="link" href="#" class="style-scope state-modifier">US9770517B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-03-01</span>
                    <span class="td style-scope patent-result">2017-09-26</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Anti-Trop-2 antibody-drug conjugates and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20130029909A1/en"><a id="link" href="#" class="style-scope state-modifier">US20130029909A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2009-09-15</span>
                    <span class="td style-scope patent-result">2013-01-31</span>
                    <span class="td style-scope patent-result">John Ryan</span>
                    <span class="td style-scope patent-result">Treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10137196B2/en"><a id="link" href="#" class="style-scope state-modifier">US10137196B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2018-11-27</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9492566B2/en"><a id="link" href="#" class="style-scope state-modifier">US9492566B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-12-13</span>
                    <span class="td style-scope patent-result">2016-11-15</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Antibody-drug conjugates and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2981543A1/en"><a id="link" href="#" class="style-scope state-modifier">CA2981543A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-04-22</span>
                    <span class="td style-scope patent-result">2016-10-27</span>
                    <span class="td style-scope patent-result">Immunomedics, Inc.</span>
                    <span class="td style-scope patent-result">Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6980980B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6980980B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-06-25</span>
                    <span class="td style-scope patent-result">2021-12-15</span>
                    <span class="td style-scope patent-result">イミューノメディクス、インコーポレイテッドImmunomedics, Inc.</span>
                    <span class="td style-scope patent-result">
  The combination of anti-HLA-DR or anti-TROP-2 antibodies with microtubule inhibitors, PARP inhibitors, Breton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves the therapeutic effect of cancer.
 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (2)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2021143741A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2021143741A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-01-15</span>
                    <span class="td style-scope patent-result">2021-07-22</span>
                    <span class="td style-scope patent-result">北京海步医药科技有限公司</span>
                    <span class="td style-scope patent-result">Targeting polypeptide-drug conjugate and use thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2023208341A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2023208341A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-04-27</span>
                    <span class="td style-scope patent-result">2023-11-02</span>
                    <span class="td style-scope patent-result">ITM Isotope Technologies Munich SE</span>
                    <span class="td style-scope patent-result">Combination treatment of small-cell lung cancer 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party, ‡ Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RU2758234C2/en"><a id="link" href="#" class="style-scope state-modifier">RU2758234C2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-10-26</span>
                    <span class="td style-scope patent-result">TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER CHARACTERIZED BY Trop-2 EXPRESSION USING SATSITUZUMAB GOVITECAN AND Rad51 INHIBITOR 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11192955B2/en"><a id="link" href="#" class="style-scope state-modifier">US11192955B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-12-07</span>
                    <span class="td style-scope patent-result">Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10954305B2/en"><a id="link" href="#" class="style-scope state-modifier">US10954305B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-03-23</span>
                    <span class="td style-scope patent-result">Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10744129B2/en"><a id="link" href="#" class="style-scope state-modifier">US10744129B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-08-18</span>
                    <span class="td style-scope patent-result">Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2953441T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2953441T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-11-13</span>
                    <span class="td style-scope patent-result">
  Combination of anti-hla-dr or anti-Trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10799597B2/en"><a id="link" href="#" class="style-scope state-modifier">US10799597B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-10-13</span>
                    <span class="td style-scope patent-result">Subcutaneous administration of antibody-drug conjugates for cancer therapy 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210046185A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210046185A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-02-18</span>
                    <span class="td style-scope patent-result">Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2892525T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2892525T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-02-04</span>
                    <span class="td style-scope patent-result">
  Neoadjuvant use of antibody-drug conjugates
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2966466T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2966466T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-04-22</span>
                    <span class="td style-scope patent-result">
  Small cell lung cancer (SCLC) therapy with a topoisomerase-I inhibitor antibody-drug conjugate (ADC) targeting trop-2
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20240148873A1/en"><a id="link" href="#" class="style-scope state-modifier">US20240148873A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2024-05-09</span>
                    <span class="td style-scope patent-result">Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (3)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        US201762463316P<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-02-24</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10413539B2/en"><a id="link" href="#" class="style-scope state-modifier">US15/820,708</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2017-11-22</span>
                    <span class="td style-scope patent-result">Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018156634A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/US2018/019025</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-02-21</span>
                    <span class="td style-scope patent-result">Therapy of small-cell lung cancer (sclc) with a topoisomerase-i inhibiting antibody-drug conjugate (adc) targeting trop-2 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu">·</span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Anatomy</div>
          
            <div class="item style-scope dropdown-menu">Chemical class</div>
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          
            <div class="item style-scope dropdown-menu">Chemical group</div>
          
            <div class="item style-scope dropdown-menu">Diseases</div>
          
            <div class="item style-scope dropdown-menu">Drugs</div>
          
            <div class="item style-scope dropdown-menu">Effects</div>
          
            <div class="item style-scope dropdown-menu">Human genes</div>
          
            <div class="item style-scope dropdown-menu">Inorganic materials</div>
          
            <div class="item style-scope dropdown-menu">Methods</div>
          
            <div class="item style-scope dropdown-menu">Natural products</div>
          
            <div class="item style-scope dropdown-menu">Nutrition</div>
          
            <div class="item style-scope dropdown-menu">Polymers</div>
          
            <div class="item style-scope dropdown-menu">Proteins</div>
          
            <div class="item style-scope dropdown-menu">Species</div>
          
            <div class="item style-scope dropdown-menu">Substances</div>
          
            <div class="item style-scope dropdown-menu">Toxicity</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Small cell lung cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">64</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antibody-drug conjugate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">40</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">therapeutic procedure</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">83</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">small cell lung carcinoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">63</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antibody drug conjugate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,description</span>
                        <span class="td nowrap style-scope patent-result">34</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">targeting</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">DNA topoisomerase I inhibitor</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Topoisomerase I Inhibitor</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">244</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">treatment</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">99</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drug</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">80</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drug</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">56</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">therapeutic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">53</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">irinotecan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">52</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">irinotecan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">51</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">carboplatin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">48</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cisplatin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">45</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cisplatin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">45</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">topotecan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">36</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">topotecan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">36</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chemotherapy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Metastases</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">radiotherapy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">anticancer treatment</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">carboplatin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Homo sapiens</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">126</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">method</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">98</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">82</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">anthracyclines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">58</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">platinum</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">33</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">immunoconjugate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">31</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">reduction</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cerebellar degeneration-related antigen 1</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chemical substances by application</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">camptothecin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">18</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">paclitaxel</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">18</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Inorganic materials style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">platinum</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Doxorubicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">16</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Homo sapiens Cerebellar degeneration-related antigen 1</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">16</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">etoposide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">16</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">processed proteins &amp; peptides</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">16</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">dl-camptothecin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">15</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">metastatic neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">13</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">weekly effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">13</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">(7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Paclitaxel</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antineoplastic agent</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">etoposide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mercaptopurine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">taxol</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">12</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">metastastic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">11</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytokines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytokines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE03 - Erlotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">erlotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">toxin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Toxicity style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">toxin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Camptothecin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">camptothecin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">actinomycin D</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">doxorubicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">erlotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">floxuridine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">gefitinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">gefitinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">ibrutinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">idelalisib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mercaptopurine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">surgical procedure</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">teniposide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">(E)-dacarbazine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE27 - Ibrutinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">ibrutinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">10-Hydroxycamptothecin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">CPT-OH</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L-methotrexate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Vinca alkaloid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">anthracyclines and related substance</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">gemcitabine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">gemcitabine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">methotrexate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">sunitinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vinorelbine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vinorelbine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">6</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Fluorouracil</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">LFM-A13</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Vinblastine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">calicheamicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">calicheamicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chemotherapeutic effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">coxibs</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cyclooxygenase 2 inhibitor</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">docetaxel</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mechlorethamine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mechlorethamine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">n-[3-[6-[4-[(2r)-1,4-dimethyl-3-oxopiperazin-2-yl]anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vinblastine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vincaleukoblastine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vincristine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vincristine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vincristine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">5</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">(2S,3S,4S,5R,6R)-6-[(2S,3R,4S,6R)-4-amino-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">(2s,3s,4s,5r,6s)-6-[4-[(5s,5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenoxy]-3,4,5-trihydrox</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">1-oxidanylurea</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">2-[(2S)-1-[3-ethyl-7-[(1-oxido-3-pyridin-1-iumyl)methylamino]-5-pyrazolo[1,5-a]pyrimidinyl]-2-piperidinyl]ethanol</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">5-[bis(2-chloroethyl)amino]uracil</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">6-Mercaptoguanine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">6S-folinic acid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">7-Cyan-hept-2t-en-4,6-diinsaeure</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Aromasine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Bleomycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Busulfan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Carmustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Chloditan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cladribine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cyclophosphamide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytarabine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Dactinomycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Dasatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Idarubicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Idarubicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE01 - Imatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE02 - Gefitinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE06 - Dasatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE07 - Lapatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE14 - Bosutinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE16 - Crizotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lomustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Mitomycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Mytomycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Tamoxifen</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Thiotepa</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">actinomycin D</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">afatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">afatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">alvocidib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">alvocidib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">ammonia dichloroplatinum(2+)</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">anastrozole</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">anastrozole</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">axitinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">axitinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">azaribine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">azaribine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bendamustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bendamustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bleomycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bleomycin A2</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bortezomib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bortezomib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bosutinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bosutinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bryostatin 1</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bryostatin 1</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">busulfan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">carmustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">celecoxib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chlorambucil</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chlorambucil</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cladribine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">crizotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">crizotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cyclophosphamide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cytarabine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">dacarbazine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">dactinomycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">dasatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">daunorubicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">daunorubicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">deoliosyl-3C-alpha-L-digitoxosyl-MTM</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">dinaciclib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">entinostat</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">entinostat</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">estramustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">estramustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">estrogen receptors</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">exemestane</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fingolimod</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fingolimod</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">floxuridine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fludarabine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fludarabine phosphate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fluorouracil</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">flutamide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">flutamide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">folinic acid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Nutrition style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">folinic acid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">folinic acid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fostamatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">fostamatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">gene silencing by RNA</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">idarubicin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">ifosfamide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">ifosfamide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">imatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">imatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">lapatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">lapatinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">leucovorin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">lomustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">melphalan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">melphalan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mithramycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mitomycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mitotane</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mitoxantrone</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mitoxantrone</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">olaparib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">olaparib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">plicamycin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">plitidepsin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">plitidepsin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">plitidepsin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">teniposide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">thalidomide</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">thiotepa</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">tioguanine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">tioguanine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">uracil mustard</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vatalanib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vatalanib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">4</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">(2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[4-[[(2s,3s,4s,6r)-3-hydroxy-2-methyl-6-[[(1s,3s)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]oxan-4-yl]carbamoyloxymethyl]-2-nitrophenoxy]oxane-2-carboxylic acid</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Natural products style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">(8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">1-alkyl-2-acetylglycerophosphocholine esterase</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Asparaginase</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">BAY-43-9006</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE04 - Sunitinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE05 - Sorafenib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">L01XE08 - Nilotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">binding agent</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">gene therapy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">navelbine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">neratinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">nilotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">nilotinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pentostatin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pentostatin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">procarbazine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">procarbazine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">protein farnesyltransferase inhibitor</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">raloxifene</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">raloxifene</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">semustine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">sorafenib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">streptozocin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">streptozocin</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">sunitinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vinorelbine ditartrate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">RNA interference-mediated gene silencing</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">celebrex</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">oncological effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">tamoxifen</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Inorganic materials style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">PO4</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims</span>
                        <span class="td nowrap style-scope patent-result">1</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">estrogen receptors</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims</span>
                        <span class="td nowrap style-scope patent-result">1</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">idelalisib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims</span>
                        <span class="td nowrap style-scope patent-result">1</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">neratinib</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims</span>
                        <span class="td nowrap style-scope patent-result">1</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">phosphate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims</span>
                        <span class="td nowrap style-scope patent-result">1</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">phosphate</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims</span>
                        <span class="td nowrap style-scope patent-result">1</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Chemical compound style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">sacituzumab govitecan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">137</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">sacituzumab govitecan</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">133</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigen</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">61</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigens</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">61</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigens</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">61</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">binding</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">40</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Immunoglobulin Fragments</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Immunoglobulin Fragments</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">combination therapy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">immunotherapy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">standard therapy</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">abstract,description</span>
                        <span class="td nowrap style-scope patent-result">2</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1696434382" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.1696434382" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=2114384481" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>